false 2024 --12-31 Q2 0001178670 0.0034941 365 382 xbrli:shares iso4217:USD iso4217:USD xbrli:shares alny:product xbrli:pure alny:performance_obligation alny:target alny:day iso4217:USD alny:Unit alny:patent alny:lawsuit alny:disputed_term alny:case 0001178670 2024-01-01 2024-06-30 0001178670 2024-07-26 0001178670 2024-06-30 0001178670 2023-12-31 0001178670 us-gaap:ProductMember 2024-04-01 2024-06-30 0001178670 us-gaap:ProductMember 2023-04-01 2023-06-30 0001178670 us-gaap:ProductMember 2024-01-01 2024-06-30 0001178670 us-gaap:ProductMember 2023-01-01 2023-06-30 0001178670 alny:CollaborationsMember 2024-04-01 2024-06-30 0001178670 alny:CollaborationsMember 2023-04-01 2023-06-30 0001178670 alny:CollaborationsMember 2024-01-01 2024-06-30 0001178670 alny:CollaborationsMember 2023-01-01 2023-06-30 0001178670 us-gaap:RoyaltyMember 2024-04-01 2024-06-30 0001178670 us-gaap:RoyaltyMember 2023-04-01 2023-06-30 0001178670 us-gaap:RoyaltyMember 2024-01-01 2024-06-30 0001178670 us-gaap:RoyaltyMember 2023-01-01 2023-06-30 0001178670 2024-04-01 2024-06-30 0001178670 2023-04-01 2023-06-30 0001178670 2023-01-01 2023-06-30 0001178670 us-gaap:CommonStockMember 2023-12-31 0001178670 us-gaap:AdditionalPaidInCapitalMember 2023-12-31 0001178670 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2023-12-31 0001178670 us-gaap:RetainedEarningsMember 2023-12-31 0001178670 us-gaap:CommonStockMember 2024-01-01 2024-03-31 0001178670 us-gaap:AdditionalPaidInCapitalMember 2024-01-01 2024-03-31 0001178670 2024-01-01 2024-03-31 0001178670 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2024-01-01 2024-03-31 0001178670 us-gaap:RetainedEarningsMember 2024-01-01 2024-03-31 0001178670 us-gaap:CommonStockMember 2024-03-31 0001178670 us-gaap:AdditionalPaidInCapitalMember 2024-03-31 0001178670 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2024-03-31 0001178670 us-gaap:RetainedEarningsMember 2024-03-31 0001178670 2024-03-31 0001178670 us-gaap:CommonStockMember 2024-04-01 2024-06-30 0001178670 us-gaap:AdditionalPaidInCapitalMember 2024-04-01 2024-06-30 0001178670 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2024-04-01 2024-06-30 0001178670 us-gaap:RetainedEarningsMember 2024-04-01 2024-06-30 0001178670 us-gaap:CommonStockMember 2024-06-30 0001178670 us-gaap:AdditionalPaidInCapitalMember 2024-06-30 0001178670 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2024-06-30 0001178670 us-gaap:RetainedEarningsMember 2024-06-30 0001178670 us-gaap:CommonStockMember 2022-12-31 0001178670 us-gaap:AdditionalPaidInCapitalMember 2022-12-31 0001178670 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2022-12-31 0001178670 us-gaap:RetainedEarningsMember 2022-12-31 0001178670 2022-12-31 0001178670 us-gaap:CommonStockMember 2023-01-01 2023-03-31 0001178670 us-gaap:AdditionalPaidInCapitalMember 2023-01-01 2023-03-31 0001178670 2023-01-01 2023-03-31 0001178670 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2023-01-01 2023-03-31 0001178670 us-gaap:RetainedEarningsMember 2023-01-01 2023-03-31 0001178670 us-gaap:CommonStockMember 2023-03-31 0001178670 us-gaap:AdditionalPaidInCapitalMember 2023-03-31 0001178670 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2023-03-31 0001178670 us-gaap:RetainedEarningsMember 2023-03-31 0001178670 2023-03-31 0001178670 us-gaap:CommonStockMember 2023-04-01 2023-06-30 0001178670 us-gaap:AdditionalPaidInCapitalMember 2023-04-01 2023-06-30 0001178670 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2023-04-01 2023-06-30 0001178670 us-gaap:RetainedEarningsMember 2023-04-01 2023-06-30 0001178670 us-gaap:CommonStockMember 2023-06-30 0001178670 us-gaap:AdditionalPaidInCapitalMember 2023-06-30 0001178670 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2023-06-30 0001178670 us-gaap:RetainedEarningsMember 2023-06-30 0001178670 2023-06-30 0001178670 alny:ONPATTROMember country:US 2024-04-01 2024-06-30 0001178670 alny:ONPATTROMember country:US 2023-04-01 2023-06-30 0001178670 alny:ONPATTROMember country:US 2024-01-01 2024-06-30 0001178670 alny:ONPATTROMember country:US 2023-01-01 2023-06-30 0001178670 srt:EuropeMember alny:ONPATTROMember 2024-04-01 2024-06-30 0001178670 srt:EuropeMember alny:ONPATTROMember 2023-04-01 2023-06-30 0001178670 srt:EuropeMember alny:ONPATTROMember 2024-01-01 2024-06-30 0001178670 srt:EuropeMember alny:ONPATTROMember 2023-01-01 2023-06-30 0001178670 alny:NonUSOrEuropeMember alny:ONPATTROMember 2024-04-01 2024-06-30 0001178670 alny:NonUSOrEuropeMember alny:ONPATTROMember 2023-04-01 2023-06-30 0001178670 alny:NonUSOrEuropeMember alny:ONPATTROMember 2024-01-01 2024-06-30 0001178670 alny:NonUSOrEuropeMember alny:ONPATTROMember 2023-01-01 2023-06-30 0001178670 alny:ONPATTROMember 2024-04-01 2024-06-30 0001178670 alny:ONPATTROMember 2023-04-01 2023-06-30 0001178670 alny:ONPATTROMember 2024-01-01 2024-06-30 0001178670 alny:ONPATTROMember 2023-01-01 2023-06-30 0001178670 alny:AmvuttraMember country:US 2024-04-01 2024-06-30 0001178670 alny:AmvuttraMember country:US 2023-04-01 2023-06-30 0001178670 alny:AmvuttraMember country:US 2024-01-01 2024-06-30 0001178670 alny:AmvuttraMember country:US 2023-01-01 2023-06-30 0001178670 alny:AmvuttraMember srt:EuropeMember 2024-04-01 2024-06-30 0001178670 alny:AmvuttraMember srt:EuropeMember 2023-04-01 2023-06-30 0001178670 alny:AmvuttraMember srt:EuropeMember 2024-01-01 2024-06-30 0001178670 alny:AmvuttraMember srt:EuropeMember 2023-01-01 2023-06-30 0001178670 alny:NonUSOrEuropeMember alny:AmvuttraMember 2024-04-01 2024-06-30 0001178670 alny:NonUSOrEuropeMember alny:AmvuttraMember 2023-04-01 2023-06-30 0001178670 alny:NonUSOrEuropeMember alny:AmvuttraMember 2024-01-01 2024-06-30 0001178670 alny:NonUSOrEuropeMember alny:AmvuttraMember 2023-01-01 2023-06-30 0001178670 alny:AmvuttraMember 2024-04-01 2024-06-30 0001178670 alny:AmvuttraMember 2023-04-01 2023-06-30 0001178670 alny:AmvuttraMember 2024-01-01 2024-06-30 0001178670 alny:AmvuttraMember 2023-01-01 2023-06-30 0001178670 alny:GIVLAARIMember country:US 2024-04-01 2024-06-30 0001178670 alny:GIVLAARIMember country:US 2023-04-01 2023-06-30 0001178670 alny:GIVLAARIMember country:US 2024-01-01 2024-06-30 0001178670 alny:GIVLAARIMember country:US 2023-01-01 2023-06-30 0001178670 srt:EuropeMember alny:GIVLAARIMember 2024-04-01 2024-06-30 0001178670 srt:EuropeMember alny:GIVLAARIMember 2023-04-01 2023-06-30 0001178670 srt:EuropeMember alny:GIVLAARIMember 2024-01-01 2024-06-30 0001178670 srt:EuropeMember alny:GIVLAARIMember 2023-01-01 2023-06-30 0001178670 alny:NonUSOrEuropeMember alny:GIVLAARIMember 2024-04-01 2024-06-30 0001178670 alny:NonUSOrEuropeMember alny:GIVLAARIMember 2023-04-01 2023-06-30 0001178670 alny:NonUSOrEuropeMember alny:GIVLAARIMember 2024-01-01 2024-06-30 0001178670 alny:NonUSOrEuropeMember alny:GIVLAARIMember 2023-01-01 2023-06-30 0001178670 alny:GIVLAARIMember 2024-04-01 2024-06-30 0001178670 alny:GIVLAARIMember 2023-04-01 2023-06-30 0001178670 alny:GIVLAARIMember 2024-01-01 2024-06-30 0001178670 alny:GIVLAARIMember 2023-01-01 2023-06-30 0001178670 alny:OXLUMOMember country:US 2024-04-01 2024-06-30 0001178670 alny:OXLUMOMember country:US 2023-04-01 2023-06-30 0001178670 alny:OXLUMOMember country:US 2024-01-01 2024-06-30 0001178670 alny:OXLUMOMember country:US 2023-01-01 2023-06-30 0001178670 srt:EuropeMember alny:OXLUMOMember 2024-04-01 2024-06-30 0001178670 srt:EuropeMember alny:OXLUMOMember 2023-04-01 2023-06-30 0001178670 srt:EuropeMember alny:OXLUMOMember 2024-01-01 2024-06-30 0001178670 srt:EuropeMember alny:OXLUMOMember 2023-01-01 2023-06-30 0001178670 alny:NonUSOrEuropeMember alny:OXLUMOMember 2024-04-01 2024-06-30 0001178670 alny:NonUSOrEuropeMember alny:OXLUMOMember 2023-04-01 2023-06-30 0001178670 alny:NonUSOrEuropeMember alny:OXLUMOMember 2024-01-01 2024-06-30 0001178670 alny:NonUSOrEuropeMember alny:OXLUMOMember 2023-01-01 2023-06-30 0001178670 alny:OXLUMOMember 2024-04-01 2024-06-30 0001178670 alny:OXLUMOMember 2023-04-01 2023-06-30 0001178670 alny:OXLUMOMember 2024-01-01 2024-06-30 0001178670 alny:OXLUMOMember 2023-01-01 2023-06-30 0001178670 us-gaap:ProductMember 2024-06-30 0001178670 us-gaap:ProductMember 2023-12-31 0001178670 alny:RocheMember us-gaap:CollaborativeArrangementMember 2024-04-01 2024-06-30 0001178670 alny:RocheMember us-gaap:CollaborativeArrangementMember 2023-04-01 2023-06-30 0001178670 alny:RocheMember us-gaap:CollaborativeArrangementMember 2024-01-01 2024-06-30 0001178670 alny:RocheMember us-gaap:CollaborativeArrangementMember 2023-01-01 2023-06-30 0001178670 us-gaap:CollaborativeArrangementMember alny:RegeneronPharmaceuticalsIncorporationMember 2024-04-01 2024-06-30 0001178670 us-gaap:CollaborativeArrangementMember alny:RegeneronPharmaceuticalsIncorporationMember 2023-04-01 2023-06-30 0001178670 us-gaap:CollaborativeArrangementMember alny:RegeneronPharmaceuticalsIncorporationMember 2024-01-01 2024-06-30 0001178670 us-gaap:CollaborativeArrangementMember alny:RegeneronPharmaceuticalsIncorporationMember 2023-01-01 2023-06-30 0001178670 us-gaap:CollaborativeArrangementMember alny:NovartisMember 2024-04-01 2024-06-30 0001178670 us-gaap:CollaborativeArrangementMember alny:NovartisMember 2023-04-01 2023-06-30 0001178670 us-gaap:CollaborativeArrangementMember alny:NovartisMember 2024-01-01 2024-06-30 0001178670 us-gaap:CollaborativeArrangementMember alny:NovartisMember 2023-01-01 2023-06-30 0001178670 us-gaap:CollaborativeArrangementMember alny:OtherCollaborationsMember 2024-04-01 2024-06-30 0001178670 us-gaap:CollaborativeArrangementMember alny:OtherCollaborationsMember 2023-04-01 2023-06-30 0001178670 us-gaap:CollaborativeArrangementMember alny:OtherCollaborationsMember 2024-01-01 2024-06-30 0001178670 us-gaap:CollaborativeArrangementMember alny:OtherCollaborationsMember 2023-01-01 2023-06-30 0001178670 us-gaap:CollaborativeArrangementMember 2024-04-01 2024-06-30 0001178670 us-gaap:CollaborativeArrangementMember 2023-04-01 2023-06-30 0001178670 us-gaap:CollaborativeArrangementMember 2024-01-01 2024-06-30 0001178670 us-gaap:CollaborativeArrangementMember 2023-01-01 2023-06-30 0001178670 us-gaap:CollaborativeArrangementMember 2024-06-30 0001178670 us-gaap:CollaborativeArrangementMember 2023-12-31 0001178670 alny:RocheMember alny:ClinicalTrialAndManufacturingMember 2024-04-01 2024-06-30 0001178670 alny:RocheMember alny:ExternalServicesMember 2024-04-01 2024-06-30 0001178670 alny:RocheMember alny:OtherMember 2024-04-01 2024-06-30 0001178670 alny:RocheMember alny:ClinicalTrialAndManufacturingMember 2023-04-01 2023-06-30 0001178670 alny:RocheMember alny:ExternalServicesMember 2023-04-01 2023-06-30 0001178670 alny:RocheMember alny:OtherMember 2023-04-01 2023-06-30 0001178670 alny:RegeneronPharmaceuticalsIncorporationMember alny:ClinicalTrialAndManufacturingMember 2024-04-01 2024-06-30 0001178670 alny:RegeneronPharmaceuticalsIncorporationMember alny:ExternalServicesMember 2024-04-01 2024-06-30 0001178670 alny:OtherMember alny:RegeneronPharmaceuticalsIncorporationMember 2024-04-01 2024-06-30 0001178670 alny:RegeneronPharmaceuticalsIncorporationMember alny:ClinicalTrialAndManufacturingMember 2023-04-01 2023-06-30 0001178670 alny:RegeneronPharmaceuticalsIncorporationMember alny:ExternalServicesMember 2023-04-01 2023-06-30 0001178670 alny:OtherMember alny:RegeneronPharmaceuticalsIncorporationMember 2023-04-01 2023-06-30 0001178670 alny:OtherCollaborationsMember alny:ClinicalTrialAndManufacturingMember 2024-04-01 2024-06-30 0001178670 alny:OtherCollaborationsMember alny:ExternalServicesMember 2024-04-01 2024-06-30 0001178670 alny:OtherMember alny:OtherCollaborationsMember 2024-04-01 2024-06-30 0001178670 alny:OtherCollaborationsMember alny:ClinicalTrialAndManufacturingMember 2023-04-01 2023-06-30 0001178670 alny:OtherCollaborationsMember alny:ExternalServicesMember 2023-04-01 2023-06-30 0001178670 alny:OtherMember alny:OtherCollaborationsMember 2023-04-01 2023-06-30 0001178670 alny:ClinicalTrialAndManufacturingMember 2024-04-01 2024-06-30 0001178670 alny:ExternalServicesMember 2024-04-01 2024-06-30 0001178670 alny:OtherMember 2024-04-01 2024-06-30 0001178670 alny:ClinicalTrialAndManufacturingMember 2023-04-01 2023-06-30 0001178670 alny:ExternalServicesMember 2023-04-01 2023-06-30 0001178670 alny:OtherMember 2023-04-01 2023-06-30 0001178670 alny:RocheMember alny:ClinicalTrialAndManufacturingMember 2024-01-01 2024-06-30 0001178670 alny:RocheMember alny:ExternalServicesMember 2024-01-01 2024-06-30 0001178670 alny:RocheMember alny:OtherMember 2024-01-01 2024-06-30 0001178670 alny:RocheMember alny:ClinicalTrialAndManufacturingMember 2023-01-01 2023-06-30 0001178670 alny:RocheMember alny:ExternalServicesMember 2023-01-01 2023-06-30 0001178670 alny:RocheMember alny:OtherMember 2023-01-01 2023-06-30 0001178670 alny:RegeneronPharmaceuticalsIncorporationMember alny:ClinicalTrialAndManufacturingMember 2024-01-01 2024-06-30 0001178670 alny:RegeneronPharmaceuticalsIncorporationMember alny:ExternalServicesMember 2024-01-01 2024-06-30 0001178670 alny:OtherMember alny:RegeneronPharmaceuticalsIncorporationMember 2024-01-01 2024-06-30 0001178670 alny:RegeneronPharmaceuticalsIncorporationMember alny:ClinicalTrialAndManufacturingMember 2023-01-01 2023-06-30 0001178670 alny:RegeneronPharmaceuticalsIncorporationMember alny:ExternalServicesMember 2023-01-01 2023-06-30 0001178670 alny:OtherMember alny:RegeneronPharmaceuticalsIncorporationMember 2023-01-01 2023-06-30 0001178670 alny:OtherCollaborationsMember alny:ClinicalTrialAndManufacturingMember 2024-01-01 2024-06-30 0001178670 alny:OtherCollaborationsMember alny:ExternalServicesMember 2024-01-01 2024-06-30 0001178670 alny:OtherMember alny:OtherCollaborationsMember 2024-01-01 2024-06-30 0001178670 alny:OtherCollaborationsMember alny:ClinicalTrialAndManufacturingMember 2023-01-01 2023-06-30 0001178670 alny:OtherCollaborationsMember alny:ExternalServicesMember 2023-01-01 2023-06-30 0001178670 alny:OtherMember alny:OtherCollaborationsMember 2023-01-01 2023-06-30 0001178670 alny:ClinicalTrialAndManufacturingMember 2024-01-01 2024-06-30 0001178670 alny:ExternalServicesMember 2024-01-01 2024-06-30 0001178670 alny:OtherMember 2024-01-01 2024-06-30 0001178670 alny:ClinicalTrialAndManufacturingMember 2023-01-01 2023-06-30 0001178670 alny:ExternalServicesMember 2023-01-01 2023-06-30 0001178670 alny:OtherMember 2023-01-01 2023-06-30 0001178670 alny:RocheMember alny:RocheCollaborationAndLicenseAgreementMember 2023-07-21 2023-07-21 0001178670 alny:RocheCollaborationAndLicenseAgreementMember 2023-07-21 2023-07-21 0001178670 alny:RocheCollaborationAndLicenseAgreementMember 2023-07-21 0001178670 alny:RocheMember alny:RocheCollaborationAndLicenseAgreementMember 2024-06-30 0001178670 alny:RocheMember alny:MilestoneMember alny:RocheCollaborationAndLicenseAgreementMember 2024-01-01 2024-06-30 0001178670 alny:RocheMember alny:RocheCollaborationAndLicenseAgreementMember alny:LicenseObligationMember 2024-06-30 0001178670 alny:RocheMember alny:RocheCollaborationAndLicenseAgreementMember alny:LicenseObligationMember 2024-04-01 2024-06-30 0001178670 alny:RocheMember alny:RocheCollaborationAndLicenseAgreementMember alny:LicenseObligationMember 2023-04-01 2023-06-30 0001178670 alny:RocheMember alny:RocheCollaborationAndLicenseAgreementMember alny:LicenseObligationMember 2024-01-01 2024-06-30 0001178670 alny:RocheMember alny:RocheCollaborationAndLicenseAgreementMember alny:LicenseObligationMember 2023-01-01 2023-06-30 0001178670 alny:RocheMember alny:RocheCollaborationAndLicenseAgreementMember alny:DevelopmentServicesObligationMember 2024-06-30 0001178670 alny:RocheMember alny:RocheCollaborationAndLicenseAgreementMember alny:DevelopmentServicesObligationMember 2024-04-01 2024-06-30 0001178670 alny:RocheMember alny:RocheCollaborationAndLicenseAgreementMember alny:DevelopmentServicesObligationMember 2023-04-01 2023-06-30 0001178670 alny:RocheMember alny:RocheCollaborationAndLicenseAgreementMember alny:DevelopmentServicesObligationMember 2024-01-01 2024-06-30 0001178670 alny:RocheMember alny:RocheCollaborationAndLicenseAgreementMember alny:DevelopmentServicesObligationMember 2023-01-01 2023-06-30 0001178670 alny:RocheMember alny:TechnologyTransferObligationMember alny:RocheCollaborationAndLicenseAgreementMember 2024-06-30 0001178670 alny:RocheMember alny:TechnologyTransferObligationMember alny:RocheCollaborationAndLicenseAgreementMember 2024-04-01 2024-06-30 0001178670 alny:RocheMember alny:TechnologyTransferObligationMember alny:RocheCollaborationAndLicenseAgreementMember 2023-04-01 2023-06-30 0001178670 alny:RocheMember alny:TechnologyTransferObligationMember alny:RocheCollaborationAndLicenseAgreementMember 2024-01-01 2024-06-30 0001178670 alny:RocheMember alny:TechnologyTransferObligationMember alny:RocheCollaborationAndLicenseAgreementMember 2023-01-01 2023-06-30 0001178670 alny:RocheMember alny:RocheCollaborationAndLicenseAgreementMember 2024-04-01 2024-06-30 0001178670 alny:RocheMember alny:RocheCollaborationAndLicenseAgreementMember 2023-04-01 2023-06-30 0001178670 alny:RocheMember alny:RocheCollaborationAndLicenseAgreementMember 2024-01-01 2024-06-30 0001178670 alny:RocheMember alny:RocheCollaborationAndLicenseAgreementMember 2023-01-01 2023-06-30 0001178670 alny:RegeneronPharmaceuticalsIncorporationMember alny:GlobalStrategicCollaborationMember 2024-06-01 2024-06-30 0001178670 alny:RegeneronPharmaceuticalsIncorporationMember alny:GlobalStrategicCollaborationMember 2019-01-01 2019-12-31 0001178670 alny:RegeneronPharmaceuticalsIncorporationMember alny:FundingAtProgramInitiationMember alny:GlobalStrategicCollaborationMember 2019-12-31 0001178670 alny:FundingAtLeadCandidateIdentificationMember alny:RegeneronPharmaceuticalsIncorporationMember alny:GlobalStrategicCollaborationMember 2019-12-31 0001178670 srt:MaximumMember alny:RegeneronPharmaceuticalsIncorporationMember alny:GlobalStrategicCollaborationMember 2019-01-01 2019-12-31 0001178670 srt:MaximumMember alny:RegeneronPharmaceuticalsIncorporationMember alny:GlobalStrategicCollaborationMember 2019-12-31 0001178670 alny:RegeneronPharmaceuticalsIncorporationMember alny:GlobalStrategicCollaborationMember 2024-06-30 0001178670 alny:RegeneronPharmaceuticalsIncorporationMember alny:GlobalStrategicCollaborationMember 2024-06-05 0001178670 alny:RegeneronPharmaceuticalsIncorporationMember alny:GlobalStrategicCollaborationMember 2024-06-05 2024-06-05 0001178670 alny:RegeneronPharmaceuticalsIncorporationMember 2024-06-05 2024-06-05 0001178670 alny:RegeneronPharmaceuticalsIncorporationMember alny:GlobalStrategicCollaborationMember alny:ResearchServicesObligationMember 2024-06-05 0001178670 alny:RegeneronPharmaceuticalsIncorporationMember alny:GlobalStrategicCollaborationMember alny:C5LicenseObligationMember 2024-06-05 0001178670 alny:RegeneronPharmaceuticalsIncorporationMember alny:C5MonotherapyObligationMember alny:GlobalStrategicCollaborationMember 2024-06-05 0001178670 alny:RegeneronTechnologyTransferObligationMember alny:RegeneronPharmaceuticalsIncorporationMember alny:GlobalStrategicCollaborationMember 2024-06-05 0001178670 alny:RegeneronPharmaceuticalsIncorporationMember alny:GlobalStrategicCollaborationMember alny:ResearchServicesObligationMember 2024-06-30 0001178670 alny:RegeneronPharmaceuticalsIncorporationMember alny:GlobalStrategicCollaborationMember alny:ResearchServicesObligationMember 2023-12-31 0001178670 alny:RegeneronPharmaceuticalsIncorporationMember alny:GlobalStrategicCollaborationMember alny:C5LicenseObligationMember 2024-06-30 0001178670 alny:RegeneronPharmaceuticalsIncorporationMember alny:GlobalStrategicCollaborationMember alny:C5LicenseObligationMember 2023-12-31 0001178670 alny:RegeneronTechnologyTransferObligationMember alny:RegeneronPharmaceuticalsIncorporationMember alny:GlobalStrategicCollaborationMember 2024-06-30 0001178670 alny:RegeneronTechnologyTransferObligationMember alny:RegeneronPharmaceuticalsIncorporationMember alny:GlobalStrategicCollaborationMember 2023-12-31 0001178670 alny:RegeneronPharmaceuticalsIncorporationMember alny:GlobalStrategicCollaborationMember 2023-12-31 0001178670 alny:RegeneronPharmaceuticalsIncorporationMember alny:GlobalStrategicCollaborationMember alny:ResearchServicesObligationMember 2024-04-01 2024-06-30 0001178670 alny:RegeneronPharmaceuticalsIncorporationMember alny:GlobalStrategicCollaborationMember alny:ResearchServicesObligationMember 2023-04-01 2023-06-30 0001178670 alny:RegeneronPharmaceuticalsIncorporationMember alny:GlobalStrategicCollaborationMember alny:ResearchServicesObligationMember 2024-01-01 2024-06-30 0001178670 alny:RegeneronPharmaceuticalsIncorporationMember alny:GlobalStrategicCollaborationMember alny:ResearchServicesObligationMember 2023-01-01 2023-06-30 0001178670 alny:RegeneronPharmaceuticalsIncorporationMember alny:GlobalStrategicCollaborationMember alny:C5LicenseObligationMember 2024-04-01 2024-06-30 0001178670 alny:RegeneronPharmaceuticalsIncorporationMember alny:GlobalStrategicCollaborationMember alny:C5LicenseObligationMember 2023-04-01 2023-06-30 0001178670 alny:RegeneronPharmaceuticalsIncorporationMember alny:GlobalStrategicCollaborationMember alny:C5LicenseObligationMember 2024-01-01 2024-06-30 0001178670 alny:RegeneronPharmaceuticalsIncorporationMember alny:GlobalStrategicCollaborationMember alny:C5LicenseObligationMember 2023-01-01 2023-06-30 0001178670 alny:RegeneronPharmaceuticalsIncorporationMember alny:GlobalStrategicCollaborationMember 2024-04-01 2024-06-30 0001178670 alny:RegeneronPharmaceuticalsIncorporationMember alny:GlobalStrategicCollaborationMember 2023-04-01 2023-06-30 0001178670 alny:RegeneronPharmaceuticalsIncorporationMember alny:GlobalStrategicCollaborationMember 2024-01-01 2024-06-30 0001178670 alny:RegeneronPharmaceuticalsIncorporationMember alny:GlobalStrategicCollaborationMember 2023-01-01 2023-06-30 0001178670 alny:A2013TheMedicinesCompanyCollaborationMember alny:ProductAlliancesMember alny:NovartisAGMember 2013-02-01 2024-06-30 0001178670 srt:MinimumMember alny:A2013TheMedicinesCompanyCollaborationMember alny:ProductAlliancesMember alny:NovartisAGMember 2024-06-30 0001178670 alny:A2013TheMedicinesCompanyCollaborationMember srt:MaximumMember alny:ProductAlliancesMember alny:NovartisAGMember 2024-06-30 0001178670 us-gaap:FairValueMeasurementsRecurringMember us-gaap:MoneyMarketFundsMember 2024-06-30 0001178670 us-gaap:FairValueMeasurementsRecurringMember us-gaap:MoneyMarketFundsMember us-gaap:FairValueInputsLevel1Member 2024-06-30 0001178670 us-gaap:FairValueMeasurementsRecurringMember us-gaap:MoneyMarketFundsMember us-gaap:FairValueInputsLevel2Member 2024-06-30 0001178670 us-gaap:FairValueMeasurementsRecurringMember us-gaap:MoneyMarketFundsMember us-gaap:FairValueInputsLevel3Member 2024-06-30 0001178670 us-gaap:FairValueMeasurementsRecurringMember us-gaap:USTreasurySecuritiesMember 2024-06-30 0001178670 us-gaap:FairValueMeasurementsRecurringMember us-gaap:USTreasurySecuritiesMember us-gaap:FairValueInputsLevel1Member 2024-06-30 0001178670 us-gaap:FairValueMeasurementsRecurringMember us-gaap:USTreasurySecuritiesMember us-gaap:FairValueInputsLevel2Member 2024-06-30 0001178670 us-gaap:FairValueMeasurementsRecurringMember us-gaap:USTreasurySecuritiesMember us-gaap:FairValueInputsLevel3Member 2024-06-30 0001178670 us-gaap:FairValueMeasurementsRecurringMember us-gaap:CommercialPaperMember 2024-06-30 0001178670 us-gaap:FairValueMeasurementsRecurringMember us-gaap:CommercialPaperMember us-gaap:FairValueInputsLevel1Member 2024-06-30 0001178670 us-gaap:FairValueMeasurementsRecurringMember us-gaap:FairValueInputsLevel2Member us-gaap:CommercialPaperMember 2024-06-30 0001178670 us-gaap:FairValueMeasurementsRecurringMember us-gaap:CommercialPaperMember us-gaap:FairValueInputsLevel3Member 2024-06-30 0001178670 us-gaap:FairValueMeasurementsRecurringMember us-gaap:USGovernmentSponsoredEnterprisesDebtSecuritiesMember 2024-06-30 0001178670 us-gaap:FairValueMeasurementsRecurringMember us-gaap:FairValueInputsLevel1Member us-gaap:USGovernmentSponsoredEnterprisesDebtSecuritiesMember 2024-06-30 0001178670 us-gaap:FairValueMeasurementsRecurringMember us-gaap:FairValueInputsLevel2Member us-gaap:USGovernmentSponsoredEnterprisesDebtSecuritiesMember 2024-06-30 0001178670 us-gaap:FairValueMeasurementsRecurringMember us-gaap:FairValueInputsLevel3Member us-gaap:USGovernmentSponsoredEnterprisesDebtSecuritiesMember 2024-06-30 0001178670 us-gaap:FairValueMeasurementsRecurringMember us-gaap:CorporateDebtSecuritiesMember 2024-06-30 0001178670 us-gaap:FairValueMeasurementsRecurringMember us-gaap:FairValueInputsLevel1Member us-gaap:CorporateDebtSecuritiesMember 2024-06-30 0001178670 us-gaap:FairValueMeasurementsRecurringMember us-gaap:FairValueInputsLevel2Member us-gaap:CorporateDebtSecuritiesMember 2024-06-30 0001178670 us-gaap:FairValueMeasurementsRecurringMember us-gaap:FairValueInputsLevel3Member us-gaap:CorporateDebtSecuritiesMember 2024-06-30 0001178670 us-gaap:FairValueMeasurementsRecurringMember us-gaap:MunicipalNotesMember 2024-06-30 0001178670 us-gaap:FairValueMeasurementsRecurringMember us-gaap:FairValueInputsLevel1Member us-gaap:MunicipalNotesMember 2024-06-30 0001178670 us-gaap:FairValueMeasurementsRecurringMember us-gaap:FairValueInputsLevel2Member us-gaap:MunicipalNotesMember 2024-06-30 0001178670 us-gaap:FairValueMeasurementsRecurringMember us-gaap:FairValueInputsLevel3Member us-gaap:MunicipalNotesMember 2024-06-30 0001178670 us-gaap:FairValueMeasurementsRecurringMember 2024-06-30 0001178670 us-gaap:FairValueMeasurementsRecurringMember us-gaap:FairValueInputsLevel1Member 2024-06-30 0001178670 us-gaap:FairValueMeasurementsRecurringMember us-gaap:FairValueInputsLevel2Member 2024-06-30 0001178670 us-gaap:FairValueMeasurementsRecurringMember us-gaap:FairValueInputsLevel3Member 2024-06-30 0001178670 us-gaap:FairValueMeasurementsRecurringMember us-gaap:MoneyMarketFundsMember 2023-12-31 0001178670 us-gaap:FairValueMeasurementsRecurringMember us-gaap:MoneyMarketFundsMember us-gaap:FairValueInputsLevel1Member 2023-12-31 0001178670 us-gaap:FairValueMeasurementsRecurringMember us-gaap:MoneyMarketFundsMember us-gaap:FairValueInputsLevel2Member 2023-12-31 0001178670 us-gaap:FairValueMeasurementsRecurringMember us-gaap:MoneyMarketFundsMember us-gaap:FairValueInputsLevel3Member 2023-12-31 0001178670 us-gaap:FairValueMeasurementsRecurringMember us-gaap:USTreasurySecuritiesMember 2023-12-31 0001178670 us-gaap:FairValueMeasurementsRecurringMember us-gaap:USTreasurySecuritiesMember us-gaap:FairValueInputsLevel1Member 2023-12-31 0001178670 us-gaap:FairValueMeasurementsRecurringMember us-gaap:USTreasurySecuritiesMember us-gaap:FairValueInputsLevel2Member 2023-12-31 0001178670 us-gaap:FairValueMeasurementsRecurringMember us-gaap:USTreasurySecuritiesMember us-gaap:FairValueInputsLevel3Member 2023-12-31 0001178670 us-gaap:FairValueMeasurementsRecurringMember us-gaap:CommercialPaperMember 2023-12-31 0001178670 us-gaap:FairValueMeasurementsRecurringMember us-gaap:CommercialPaperMember us-gaap:FairValueInputsLevel1Member 2023-12-31 0001178670 us-gaap:FairValueMeasurementsRecurringMember us-gaap:FairValueInputsLevel2Member us-gaap:CommercialPaperMember 2023-12-31 0001178670 us-gaap:FairValueMeasurementsRecurringMember us-gaap:CommercialPaperMember us-gaap:FairValueInputsLevel3Member 2023-12-31 0001178670 us-gaap:FairValueMeasurementsRecurringMember us-gaap:CorporateDebtSecuritiesMember 2023-12-31 0001178670 us-gaap:FairValueMeasurementsRecurringMember us-gaap:FairValueInputsLevel1Member us-gaap:CorporateDebtSecuritiesMember 2023-12-31 0001178670 us-gaap:FairValueMeasurementsRecurringMember us-gaap:FairValueInputsLevel2Member us-gaap:CorporateDebtSecuritiesMember 2023-12-31 0001178670 us-gaap:FairValueMeasurementsRecurringMember us-gaap:FairValueInputsLevel3Member us-gaap:CorporateDebtSecuritiesMember 2023-12-31 0001178670 us-gaap:FairValueMeasurementsRecurringMember us-gaap:USGovernmentSponsoredEnterprisesDebtSecuritiesMember 2023-12-31 0001178670 us-gaap:FairValueMeasurementsRecurringMember us-gaap:FairValueInputsLevel1Member us-gaap:USGovernmentSponsoredEnterprisesDebtSecuritiesMember 2023-12-31 0001178670 us-gaap:FairValueMeasurementsRecurringMember us-gaap:FairValueInputsLevel2Member us-gaap:USGovernmentSponsoredEnterprisesDebtSecuritiesMember 2023-12-31 0001178670 us-gaap:FairValueMeasurementsRecurringMember us-gaap:FairValueInputsLevel3Member us-gaap:USGovernmentSponsoredEnterprisesDebtSecuritiesMember 2023-12-31 0001178670 us-gaap:FairValueMeasurementsRecurringMember us-gaap:CertificatesOfDepositMember 2023-12-31 0001178670 us-gaap:FairValueMeasurementsRecurringMember us-gaap:CertificatesOfDepositMember us-gaap:FairValueInputsLevel1Member 2023-12-31 0001178670 us-gaap:FairValueMeasurementsRecurringMember us-gaap:FairValueInputsLevel2Member us-gaap:CertificatesOfDepositMember 2023-12-31 0001178670 us-gaap:FairValueMeasurementsRecurringMember us-gaap:CertificatesOfDepositMember us-gaap:FairValueInputsLevel3Member 2023-12-31 0001178670 us-gaap:FairValueMeasurementsRecurringMember 2023-12-31 0001178670 us-gaap:FairValueMeasurementsRecurringMember us-gaap:FairValueInputsLevel1Member 2023-12-31 0001178670 us-gaap:FairValueMeasurementsRecurringMember us-gaap:FairValueInputsLevel2Member 2023-12-31 0001178670 us-gaap:FairValueMeasurementsRecurringMember us-gaap:FairValueInputsLevel3Member 2023-12-31 0001178670 us-gaap:USTreasurySecuritiesMember 2024-06-30 0001178670 us-gaap:USGovernmentSponsoredEnterprisesDebtSecuritiesMember 2024-06-30 0001178670 us-gaap:CorporateDebtSecuritiesMember 2024-06-30 0001178670 us-gaap:CommercialPaperMember 2024-06-30 0001178670 us-gaap:MunicipalNotesMember 2024-06-30 0001178670 us-gaap:USTreasurySecuritiesMember 2023-12-31 0001178670 us-gaap:USGovernmentSponsoredEnterprisesDebtSecuritiesMember 2023-12-31 0001178670 us-gaap:CorporateDebtSecuritiesMember 2023-12-31 0001178670 us-gaap:CommercialPaperMember 2023-12-31 0001178670 us-gaap:CertificatesOfDepositMember 2023-12-31 0001178670 us-gaap:OtherAssetsMember 2024-06-30 0001178670 us-gaap:OtherAssetsMember 2023-12-31 0001178670 alny:AccumulatedLossOnInvestmentInJointVentureMember 2023-12-31 0001178670 us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember 2023-12-31 0001178670 us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember 2023-12-31 0001178670 us-gaap:AccumulatedTranslationAdjustmentMember 2023-12-31 0001178670 alny:AccumulatedLossOnInvestmentInJointVentureMember 2024-01-01 2024-06-30 0001178670 us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember 2024-01-01 2024-06-30 0001178670 us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember 2024-01-01 2024-06-30 0001178670 us-gaap:AccumulatedTranslationAdjustmentMember 2024-01-01 2024-06-30 0001178670 alny:AccumulatedLossOnInvestmentInJointVentureMember 2024-06-30 0001178670 us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember 2024-06-30 0001178670 us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember 2024-06-30 0001178670 us-gaap:AccumulatedTranslationAdjustmentMember 2024-06-30 0001178670 alny:AccumulatedLossOnInvestmentInJointVentureMember 2022-12-31 0001178670 us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember 2022-12-31 0001178670 us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember 2022-12-31 0001178670 us-gaap:AccumulatedTranslationAdjustmentMember 2022-12-31 0001178670 alny:AccumulatedLossOnInvestmentInJointVentureMember 2023-01-01 2023-06-30 0001178670 us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember 2023-01-01 2023-06-30 0001178670 us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember 2023-01-01 2023-06-30 0001178670 us-gaap:AccumulatedTranslationAdjustmentMember 2023-01-01 2023-06-30 0001178670 alny:AccumulatedLossOnInvestmentInJointVentureMember 2023-06-30 0001178670 us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember 2023-06-30 0001178670 us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember 2023-06-30 0001178670 us-gaap:AccumulatedTranslationAdjustmentMember 2023-06-30 0001178670 alny:ConvertibleSeniorNotesInitialAmountMember us-gaap:ConvertibleDebtMember 2022-12-31 0001178670 alny:ConvertibleSeniorNotesMember us-gaap:ConvertibleDebtMember 2022-01-01 2022-12-31 0001178670 alny:ConvertibleSeniorNotesAdditionalAmountMember us-gaap:ConvertibleDebtMember 2022-09-13 0001178670 alny:ConvertibleSeniorNotesMember us-gaap:ConvertibleDebtMember 2022-09-13 2022-09-13 0001178670 alny:ConvertibleSeniorNotesMember us-gaap:ConvertibleDebtMember 2022-09-13 0001178670 alny:ConvertibleSeniorNotesMember us-gaap:ConvertibleDebtMember 2022-09-15 2022-09-15 0001178670 alny:ConvertibleSeniorNotesMember alny:DebtConversionTermsOneMember us-gaap:ConvertibleDebtMember 2022-09-15 2022-09-15 0001178670 alny:ConvertibleSeniorNotesMember us-gaap:ConvertibleDebtMember alny:DebtConversionTermsTwoMember 2022-09-15 2022-09-15 0001178670 alny:ConvertibleSeniorNotesMember us-gaap:ConvertibleDebtMember 2022-09-12 0001178670 alny:ConvertibleSeniorNotesMember alny:DebtConversionTermsThreeMember us-gaap:ConvertibleDebtMember 2022-09-15 2022-09-15 0001178670 alny:ConvertibleSeniorNotesMember us-gaap:ConvertibleDebtMember 2024-06-30 0001178670 alny:ConvertibleSeniorNotesMember us-gaap:ConvertibleDebtMember 2024-01-01 2024-06-30 0001178670 us-gaap:CallOptionMember us-gaap:ConvertibleDebtMember 2022-09-12 0001178670 alny:ConvertibleSeniorNotesMember us-gaap:ConvertibleDebtMember 2022-09-12 2022-09-12 0001178670 us-gaap:CollaborativeArrangementMember alny:BlackstoneGroupIncMember 2020-04-30 0001178670 us-gaap:CollaborativeArrangementMember alny:BlackstoneGroupIncMember 2020-04-01 2020-04-30 0001178670 us-gaap:CollaborativeArrangementMember alny:BlackstoneGroupIncMember srt:ScenarioForecastMember 2030-01-01 0001178670 us-gaap:CollaborativeArrangementMember alny:BlackstoneGroupIncMember 2024-06-30 0001178670 us-gaap:CollaborativeArrangementMember alny:BlackstoneGroupIncMember 2023-12-31 0001178670 us-gaap:CollaborativeArrangementMember alny:BlackstoneGroupIncMember 2024-01-01 2024-06-30 0001178670 us-gaap:CollaborativeArrangementMember alny:VutrisiranAndZilebesiranMember alny:BlackstoneLifeSciencesMember 2020-08-01 2020-08-31 0001178670 us-gaap:CollaborativeArrangementMember alny:HELIOSBPhase3ClinicalTrialMember alny:BlackstoneLifeSciencesMember 2020-08-01 2020-08-31 0001178670 us-gaap:CollaborativeArrangementMember alny:ALNAGTPhase2ClinicalTrialMember alny:BlackstoneLifeSciencesMember 2020-08-01 2020-08-31 0001178670 us-gaap:CollaborativeArrangementMember alny:ALNAGTPhase3ClinicalTrialMember alny:BlackstoneLifeSciencesMember 2020-08-01 2020-08-31 0001178670 us-gaap:CollaborativeArrangementMember alny:VutrisiranMember alny:BlackstoneLifeSciencesMember 2020-08-01 2020-08-31 0001178670 alny:DevelopmentMilestoneMember alny:BlackstoneLifeSciencesMember 2023-09-01 2023-09-30 0001178670 us-gaap:CollaborativeArrangementMember alny:ALNAGTPhase2ClinicalTrialMember alny:BlackstoneLifeSciencesMember 2023-09-01 2023-09-30 0001178670 alny:BlackstoneLifeSciencesMember 2024-06-30 0001178670 us-gaap:DerivativeMember 2023-12-31 0001178670 us-gaap:DerivativeMember 2024-01-01 2024-06-30 0001178670 us-gaap:DerivativeMember 2024-06-30 0001178670 us-gaap:ResearchAndDevelopmentExpenseMember 2024-04-01 2024-06-30 0001178670 us-gaap:ResearchAndDevelopmentExpenseMember 2023-04-01 2023-06-30 0001178670 us-gaap:ResearchAndDevelopmentExpenseMember 2024-01-01 2024-06-30 0001178670 us-gaap:ResearchAndDevelopmentExpenseMember 2023-01-01 2023-06-30 0001178670 us-gaap:SellingGeneralAndAdministrativeExpensesMember 2024-04-01 2024-06-30 0001178670 us-gaap:SellingGeneralAndAdministrativeExpensesMember 2023-04-01 2023-06-30 0001178670 us-gaap:SellingGeneralAndAdministrativeExpensesMember 2024-01-01 2024-06-30 0001178670 us-gaap:SellingGeneralAndAdministrativeExpensesMember 2023-01-01 2023-06-30 0001178670 us-gaap:EmployeeStockOptionMember 2024-01-01 2024-06-30 0001178670 us-gaap:EmployeeStockOptionMember 2023-01-01 2023-06-30 0001178670 us-gaap:RestrictedStockMember 2024-01-01 2024-06-30 0001178670 us-gaap:RestrictedStockMember 2023-01-01 2023-06-30 0001178670 us-gaap:ConvertibleDebtMember 2024-01-01 2024-06-30 0001178670 us-gaap:ConvertibleDebtMember 2023-01-01 2023-06-30 0001178670 2022-07-12 0001178670 2023-08-09 0001178670 2023-08-21 0001178670 2023-08-30 2023-08-30 0001178670 2023-05-26 0001178670 2023-09-30 0001178670 alny:KevinFitzgeraldMember 2024-04-01 2024-06-30 0001178670 alny:KevinFitzgeraldMember 2024-01-01 2024-06-30 0001178670 alny:KevinFitzgeraldMember 2024-06-30 0001178670 alny:DennisA.AusielloMember 2024-04-01 2024-06-30 0001178670 alny:DennisA.AusielloMember 2024-01-01 2024-06-30 0001178670 alny:DennisA.AusielloMember 2024-06-30
ã¢ã¡ãªã«åè¡åœ
蚌åžååŒå§å¡äŒ
ã¯ã·ã³ãã³DC 20549
____________________________________________
FORM 10-Q
____________________________________________ â 蚌åžååŒæ³ç¬¬13æ¡ãŸãã¯15(d)æ¡ã«åºã¥ãååæå ±åæž
å ±åæéãçµäºãã2023幎6æ30æ¥ããã£ãŠ2024幎6æ30æ¥
OR â 移è¡æéïŒÂ            ãã             ãŸã§
移è¡æé: ___________ãã ___________ãŸã§
å§å¡äŒãã¡ã€ã«çªå· 001-36407
__________________________________________
ã¢ã«ãã©ã ãã¡ãŒãã·ã¥ãŒãã£ã«ã«ãºç€Ÿ
ïŒèŠçŽã§æå®ãããæ£ç¢ºãªç»é²è
åïŒ
__________________________________________ ãã©ãŠã§ã¢
ïŒèšç«å°ã®å·ãŸãã¯ãã®ä»ã®ç®¡èœåºåïŒ
ïŒèšç«ãŸãã¯çµç¹ïŒ
ïŒI.R.S.éçšè
èå¥çªå·ïŒ
ïŒæ¬ç€Ÿæåšå°ã®äœæïŒ
ïŒéµäŸ¿çªå·ïŒ
ïŒRegistrantã®é»è©±çªå·ãåžå€å±çªãå«ãïŒ
77-0602661
ïŒI.R.S. éçšäž»èå¥çªå·ïŒ
èå¥çªå·ïŒ
675ãŠãšã¹ãã»ã±ã³ãã«ã»ã¹ããªãŒãã
ãã³ãªã»Aã»ãã«ãã¢ã»ã¹ã¯ãŠã§ã¢
ã±ã³ããªããž , MA
ïŒæ¬ç€Ÿæåšå°ïŒ
02142
ïŒéµäŸ¿çªå·ïŒ
(617 ) 551-8200
ïŒç»é²è
ã®é»è©±çªå·ãåžå€å±çªãå«ãïŒ
__________________________________________
æ³ç¬¬12(b)æ¡ã«åºã¥ãç»é²ããã蚌åž:
蚌åžã®çš®é¡ ãã¬ãŒãã£ã³ã°ã·ã³ãã« ç»é²ãããŠããååŒæã®å称 æ®éæ ªåŒã1æ ªãããã®ååŒéé¡ã¯$0.01 ALNY The Nasdaq Stock Market LLC
ç»é²è
ãïŒ1ïŒ1934幎ã®èšŒåžååŒæ³ã®ã»ã¯ã·ã§ã³13ãŸãã¯15ïŒdïŒã«ãã£ãŠæåºã矩åä»ããããŠãããã¹ãŠã®å ±åãéå»12ãæéïŒãŸãã¯ç»é²è
ããã®ãããªå ±åãæåºããå¿
èŠããã£ãã»ã©çãæéïŒæåºãããã©ãããããã³ïŒ2ïŒéå»90æ¥éã«ãã®ãããªæåºèŠä»¶ã®å¯Ÿè±¡ã§ãã£ããã©ããããã§ãã¯ããŒã¯ã§ç€ºããŠãã ãããã¯ã   x ããã â
ç»é²è
ããéå»12ãæéïŒãŸãã¯ç»é²è
ããã®ãããªãã¡ã€ã«ãæåºããå¿
èŠããã£ãã»ã©çãæéïŒã«ãèŠåS-Tã®èŠå405ïŒãã®ç« ã®Â§232.405ïŒã«åŸã£ãŠæåºããå¿
èŠã®ãããã¹ãŠã®ã€ã³ã¿ã©ã¯ãã£ãããŒã¿ãã¡ã€ã«ãé»åçã«æåºãããã©ããããã§ãã¯ããŒã¯ã§ç€ºããŠãã ãããã¯ã   x ããã â
ç»é²è
ã倧éå éæåºè
ãå éæåºè
ãéå éæåºè
ãå ±åæžæåºèŠæš¡ã®å°ããäŒæ¥ããŸãã¯æ°èæé·äŒæ¥ã®ãããã§ãããããã§ãã¯ããŒã¯ã§ç€ºããŠãã ããã ã倧éå éæåºè
ãããå éæåºè
ãããå ±åæžæåºèŠæš¡ã®å°ããäŒæ¥ãããæ°èæé·äŒæ¥ãã®å®çŸ©ã«ã€ããŠã¯ãExchange Actã®èŠå120å2ãåç
§ããŠãã ããã
倧åå éãã¡ã€ã©ãŒ x å é床ãã¡ã€ã©ãŒ â éå éãã¡ã€ã©ãŒ â å°èŠæš¡å ±åäŒç€Ÿ â æ°èæé·äŒæ¥ â
ã¢ã€ãã 2ãæ ªåŒã®æªç»é²è²©å£²ãè³é䜿çšãçºè¡è
ã«ããæ ªåŒã®è³Œå
¥
ç»é²è
ãã·ã§ã«äŒç€ŸïŒèšŒåžååŒæ³ã®èŠå12b-2ã§å®çŸ©ãããŠããïŒãã©ããããã§ãã¯ããŒã¯ã§ç€ºããŠãã ãããã¯ãâ ããã x
2024幎7æ26æ¥æç¹ã§ãç»é²è
ã¯æ®éæ ªåŒ$0.01ã®å²åã§128,380,513æ ªãææããŠããŸãã æ®éæ ªåŒ$0.01ã®å²åã§çºè¡æžã¿ã®æ ªåŒæ°ã¯128,380,513æ ªã§ãã
ã¢ã«ãã©ã ãã¡ãŒãã·ã¥ãŒãã£ã«ã«ãºç€Ÿ
第10-Qãã©ãŒã ã§ã®ååæå ±åæž
ããªã³ãããããšããååã®ã¢ã«ãã©ã 瀟ã®åååã§ãã ® ãã¢ã ããã©ããšããååã®åååã§ãã ® ãã®ãã©ãŒãªããšããååã®åååã§ãã ® ããªãã·ã¥ãŒã«ã¢ããšããååã®åååã§ãã ® IKARIAâ¢ãå«ãAlnylam Pharmaceuticals, Inc.ã®åæšããã³ç»é²åæšã¯ãã¹ãŠAlnylamã®è²¡ç£ã§ããããã®ååæå ±åæžã§èšåãããŠãããã®ä»ã®åæšãŸãã¯ãµãŒãã¹ããŒã¯ã¯åææè
ã®è²¡ç£ã§ãã
å°æ¥ã®èŠéãã«é¢ãã泚æäºé
æ¬ååæå ±åæž10-Qã«ã¯ã1933幎蚌åžæ³ç¬¬27Aæ¡ãæ¹æ£åŸã®é
ç®27Aãããã³1934幎蚌åžååŒæ³ç¬¬21Eæ¡ãæ¹æ£åŸã®é
ç®21Eã®æå³ã§ååããªå£°æãå«ãŸããŠããŸããç§ãã¡ã¯ããããã®ååããªå£°æãã1995幎ã®ç§ç蚌åžèšŽèšæ¹é©æ³ã«å«ãŸããååããªå£°æã«é¢ããå®å
šãªæž¯æ¹ŸèŠå®ã«ã«ããŒããããã®ãšèããŠããããããã®å®å
šãªæž¯æ¹ŸèŠå®ã®éµå®ã®ããã«ãã®å£°æãå«ããŠããŸããæ¬ååæå ±åæž10-Qã«å«ãŸããæŽå²çäºå®ä»¥å€ã®ãã¹ãŠã®å£°æã¯ãååããªå£°æã§ããå Žåã«ãã£ãŠã¯ããå¯èœæ§ãããããããããšãã§ããããæåŸ
ãããããèšç»ãããŠããããæå³ããŠããããäºæž¬ãããŠããããç¶ç¶ããããè² ã®åœ±é¿ããšãã£ãçšèªã§ååããªå£°æãèå¥ã§ããŸãããããã®ååããªå£°æã«ã¯ã次ã®ãããªãã®ãå«ãŸããŸãã
⢠æ¿èªãããåã³ç 究段éã®RNAiæ²»çè¬ïŒONPATTROãAMIVUTTRAãGIVLAARIãOXLUMOãLeqvioïŒã«å¯Ÿããç§ãã¡ã®èŠè§£ã ® ïŒã€ã³ã¯ãªã·ã©ã³ïŒããã£ãã·ã©ã³ããžã¬ãã·ã©ã³ã
⢠ONPATTROãAMVUTTRAãGIVLAARIãOXLUMOã®ç¶ç¶çãªè£œåçºå£²ãšãLeqvioãšfitusiranã«é¢ããåœç€Ÿã®å
±åéçºè
ã®èšç»ã«å ããŠãè¿œå ã®ã°ããŒãã«èŠå¶ç³è«ã®èšç»ããããŸãã
⢠AMVUTTRAïŒvutrisiranïŒãATTRã¢ããã€ããŒã·ã¹ã«å¯Ÿããå¿ççæ²»çãšããŠèŠå¶åœå±ã®æ¿èªãååŸããèœåïŒ
⢠ãONPATTROãããAMVUTTRAãããGIVLAARIãããOXLUMOãããLeqvioããããã¯å°æ¥ã®è£œåã®ãåžå ŽèŠæš¡ã®æœåšæ§ã«é¢ããç§ãã¡ã®æåŸ
ãåã³åæ¥åã®æåã«é¢ããç§ãã¡ã®æåŸ
ãã
⢠ONPATTROãAMVUTTRAãGIVLAARIãOXLUMOããŸãã¯å°æ¥ã®è£œåã«é¢ããèŠå¶æ¿èªã®ååŸãšç¶æã䞊ã³ã«äŸ¡æ Œèšå®ããã³è£åã®ç²åŸèœåãããã³Leqvioããã³fitusiranã«é¢ããå
±åç 究è
ã®èœåã
⢠ç§ãã¡ã®ç 究éçºããã°ã©ã ã®é²æç¶æ³ãçšãªç
æ°ãšäžè¬çãªç
æ°ã®äž¡æ¹ã®ããã°ã©ã ãå«ã;
⢠ç§ãã¡ã®æ°ããæè¡ãç¹ã«ç§ãã¡ã®IKARIAãã©ãããã©ãŒã ã補åãšã³ãžã³ãæ¡åŒµããŠå€èèçµç¹ãå«ããèœåããåäžãã補åãããã¡ã€ã«ãåºçŸããå¯èœæ§ãããã
⢠çŸåšããã³äºå®ãããŠããèšåºè©Šéšããã³ãããã®è©Šéšããã®ããŒã¿ã®å ±åã«é¢ããæåŸ
ïŒ
⢠èšåºè©Šéšã®èšèšãéå§ãã¿ã€ãã³ã°ãç¶ç¶ãé²è¡ã«åœ±é¿ããå¯èœæ§ãããèŠå¶ç³è«ã®ã¿ã€ãã³ã°ãèŠå¶åœå±ãšã®çžäºäœçšãã¢ããã€ã¹ããŸãã¯è¡åããŸãã¯è¿œå ã®åèšåºããã³/ãŸãã¯èšåºè©Šéšã®å¿
èŠæ§ãåŒãèµ·ããå¯èœæ§ããããŸã;ãŸãã¯èŠå¶åœå±ã®æ¿èªã®ã¿ã€ãã³ã°ãå¯èœæ§ã圱é¿ãåããå¯èœæ§ããããŸãã
⢠åœç€Ÿã®è£œé æ¥åã®ç¶æ³ãONPATTROãAMVUTTRAãGIVLAARIãOXLUMOããŸãã¯åœç€ŸãŸãã¯åœç€Ÿã®å
±åç 究è
ã«ãã£ãŠéçºããã³åæ¥åããããã®ä»ã®è£œåãŸãã¯è£œååè£ããŸãã¯å¥çŽã¡ãŒã«ãŒã«ããé
延ãäžæããŸãã¯å€±æã«é¢ããç¶æ³ïŒ
⢠å°æ¥ã®ãã³ãããã¯ãå
¬è¡è¡çäžã®ç·æ¥äºæ
ããç§ãã¡ã®è²¡åããã©ãŒãã³ã¹ãããžãã¹ããã³ãªãã¬ãŒã·ã§ã³ã補é ããµãã©ã€ãã§ãŒã³ãç 究éçºæŽ»åããã³ãã€ãã©ã€ã³ããã°ã©ã ã«åãŒã圱é¿ãããã³ãã®ä»ã®ããžãã¹ãžã®æœåšçãªåœ±é¿ãªã©ããããŸãã補é æ¥ããµãã©ã€ãã§ãŒã³ãç 究éçºæŽ»åããã³ãã€ãã©ã€ã³ããã°ã©ã ãªã©ãå«ãŸããŸãã
⢠ç§ãã¡ã®é²æã¯ãã°ããŒãã«ãªåæ¥ã€ã³ãã©ã¹ãã©ã¯ãã£ãæ§ç¯ãã掻çšãç¶ããŠããŸãã
⢠ONPATTROãAMVUTTRAãGIVLAARIãOXLUMOãããã³Leqvioã®åæ¥çæåã«ç«¶åããå¯èœæ§ã®ãã補åã®åœ±é¿ãããã³åœç€Ÿã®è£œååè£ãLeqvioãŸãã¯fitusiranã«é¢ããŠåœç€Ÿããã³/ãŸãã¯åœç€Ÿã®å
±åç 究è
ããã®ãããªè£œåã«å¯Ÿæããèœåã
⢠æé·ãšå¶æ¥è²»çšã®ç®¡çèœå
⢠ããããã®5幎èšç»ã«ã€ããŠã®èãæ¹ãšæŠç¥ã2025幎ãŸã§ã«ãããã¯ã©ã¹ã®ãã€ãªãã¯ãããžãŒäŒæ¥ã«ãªãããšãªã©ããã®æŠç¥ã«é¢é£ããã¡ããªãã¯ãéæããããã®æå³ãããã³ãããããæŠç¥ãæåè£ã«å®è¡ã§ããèœåïŒ ãAlnylam P x25ãæŠç¥ã¯ãæç¶å¯èœãªé©æ°ãšåªãã財åæ¥çžŸãéããŠãçããç
æ°ããäžè¬çãªç
æ°ã«å€é©çãªè¬å€ãæäŸããããšã§ãã 5 ãAlnylam P x25ãæŠç¥ã¯ãæç¶å¯èœãªé©æ°ãšåªãã財åæ¥çžŸãéããŠãçããç
æ°ããäžè¬çãªç
æ°ã«å€é©çãªè¬å€ãæäŸããããšã§ãã æŠç¥ãå®è¡ããããšãã§ããèœåãå«ãããã®æŠç¥ã«é¢é£ããã¡ããªãã¯ãéæããæåã2025幎ãŸã§ã«ãããã¯ã©ã¹ã®ãã€ãªãã¯ãããžãŒäŒæ¥ã«ãªãããšãªã©ãããããã®æŠç¥ãšç®æšïŒ ãAlnylam P x25ãæŠç¥ã¯ãæç¶å¯èœãªé©æ°ãšåªãã財åæ¥çžŸãéããŠãçããç
æ°ããäžè¬çãªç
æ°ã«å€é©çãªè¬å€ãæäŸããããšã§ãã 5 ãAlnylam P x25ãæŠç¥ã¯ãæç¶å¯èœãªé©æ°ãšåªãã財åæ¥çžŸãéããŠãçããç
æ°ããäžè¬çãªç
æ°ã«å€é©çãªè¬å€ãæäŸããããšã§ãã æŠç¥ïŒ
⢠ç§ãã¡ã¯çŸåšã®çŸéæ®é«ã«ãã£ãŠãå°æ¥ã®æ ªåŒèª¿éã®å¿
èŠãªãã«èªå·±æç¶å¯èœãªãããã¡ã€ã«ãéæã§ãããšãã信念ãæã£ãŠããŸãã
⢠çŸè¡ã®éå¶èšç»ã«åºã¥ããŠãçŸéãçŸéåçç©ããã³åžå Žã§æµéããŠããæ ªåŒããã³åµåžã»åµå蚌åžããåœç€Ÿã®éå¶ãæ¯ããæéã«ã€ããŠã®åœç€Ÿã®æåŸ
ã
⢠補åã®éçºã補é ãæµéã«ç¬¬äžè
ãžã®äŸåããããŸãã
⢠åœç€Ÿãšã®äŒæ¥ååã«é¢ããŠãæ¢åãŸãã¯å°æ¥ã®å¥çŽã«åºã¥ãæœåšçãªã©ã€ã»ã³ã¹æããã€ã«ã¹ããŒã³ããã³ãã€ã€ãªãã£æ¯æãã«é¢ããç§ãã¡ã®æåŸ
;
⢠åœç€Ÿã®ç¥ç財ç£ã®ååŸãç¶æããã³ä¿è·ãããèœåïŒ
⢠é©æ Œãªäž»èŠç®¡çè·ãç§åŠè
ãéçºãå»çãåæ¥ã¹ã¿ãããã³ã³ãµã«ã¿ã³ããã¢ããã€ã¶ãŒãåžåããã³ä¿æããèœåïŒ
⢠蚎èšã®çµæãPfizer瀟ããã€ãªã³ããã¯ç€ŸãModerna瀟ãžã®ç¹èš±äŸµå®³èšŽèšããã®ä»ã®æ³çæç¶ãããŸãã¯æ¿åºã®èª¿æ»ã®ããããã«ã€ããŠã®çµæïŒ
⢠米åœãå€åœã«ãããèŠå¶äžã®ååïŒ
⢠æ³åŸããã³èŠå¶ã®åœ±é¿
⢠競åä»ç€Ÿãšæ¥çã«é¢é£ããçºå±ã
⢠åœç€Ÿã®æ¯æ矩åãæºãããåœç€Ÿã®åµåãã€ãŸã転æåµåžãå«ããå©æ¯ã®æ¯æããåèè³ããŸã転æåµåžã®æéã«å¿
èŠãªçŸéã®æ¯æããè¡ãèœåã«ã€ããŠã
⢠ã³ãŒã«äº€æååŒã®å¹æã«é¢ããç§ãã¡ã®æåŸ
ãšããªãã·ã§ã³ã®çžææ¹ãŸãã¯ãã®é¢é£äŒç€Ÿã®äºæ³ãããåžå ŽæŽ»åã«ã€ããŠã
ãããã®å
èŠçãªå£°æã¯ãçµå¶é£ãå°æ¥ã®äºè±¡ãããžãã¹ãããã³å°æ¥ã®è²¡åããã©ãŒãã³ã¹ã«é¢ããŠçŸåšæã£ãŠããèŠè§£ãåæ ããŠãããæ¢ç¥ãŸãã¯æªç¥ã®ãªã¹ã¯ãäžç¢ºå®æ§ãããã³ãã®ä»ã®èŠå ãå«ãŸããŠããããããã®å
èŠçãªå£°æã«ãã£ãŠæ瀺ãŸãã¯æ瀺ãããå°æ¥ã®çµæãããã©ãŒãã³ã¹ããŸãã¯æ¥çžŸãšå®éã®çµæãããã©ãŒãã³ã¹ããŸãã¯æ¥çžŸã倧ããç°ãªãåå ãšãªãå¯èœæ§ããããŸããå®éã®çµæãçŸåšã®äºæ³ããèããç°ãªãèŠå ã«ã¯ããã®ä»ã«ãæ¬ååæå ±åæžã®éšåIIãé
ç®1Aãããªã¹ã¯ãã¡ã¯ã¿ãŒãããã³ãã®ä»ã®å Žæã§èª¬æãããèŠå ãå«ãŸããŸããæ¬ååæå ±åæžã®ä»ã®ã»ã¯ã·ã§ã³ã«ã¯ãåœç€Ÿã®ããžãã¹ããã³è²¡åæ¥çžŸã«äžå©ã«åœ±é¿ãäžããå¯èœæ§ã®ããè¿œå çèŠå ãå«ãŸããå ŽåããããŸãããŸããç§ãã¡ã¯éåžžã«ç«¶äºãæ¿ãããæ¥éã«å€åããç°å¢ã§éå¶ããŠããŸããæ°ãããªã¹ã¯èŠå ãææåºçŸãã管çé£ããã¹ãŠã®ãªã¹ã¯èŠå ãäºæž¬ããããšã¯ã§ããããã¹ãŠã®ãªã¹ã¯èŠå ã®åœ±é¿ãè©äŸ¡ããããšã¯ã§ããŸããããŸããã©ã®èŠå ããŸãã¯èŠå ã®çµã¿åãããããããªãå
èŠçãªå£°æã«å«ãŸãããã®ãšç°ãªãå®éã®çµæãåŒãèµ·ããå¯èœæ§ãããããèŠç©ããããšãã§ããŸããããããã®äžç¢ºå®æ§ãèžãŸãããšããããã®å
èŠçãªå£°æã«é床ã«äŸåããªãããã«ããŠãã ãããæ³åŸã«ããå¿
èŠãšãããªãéããç§ãã¡ã¯å°æ¥ã«ãããŠæ°ããæ
å ±ãæäŸãããå Žåã§ããäœããã®çç±ã§ãããã®å
èŠçãªå£°æãæŽæ°ãŸãã¯ä¿®æ£ãã矩åã¯ãªããã®ãšããŸãããã ãã米蚌åžååŒå§å¡äŒïŒSECïŒã«æåºããåœç€Ÿã®å ±åæžã«ãããŠè¡ããããããªãé瀺ãåç
§ããããšããå§ãããŸãã
第Iéš è²¡åæ
å ±
ã¢ã«ãã©ã ãã¡ãŒãã·ã¥ãŒãã£ã«ã«ãºç€Ÿ
é£çµç°¡æ貞å察ç
§è¡š
(åãã«åäœã1æ ªåœããéé¡ä»¥å€)
ïŒæªç¢ºå®ïŒ
2024幎6æ30æ¥ã« 2023幎12æ31æ¥ è³ç£ æµåè³ç£ïŒ çŸéããã³çŸéåçç© $ 968,492  $ 812,688ã§ã  åžå Žæ§ã®ããåµåèšŒåž 1,646,268  1,615,516  åžå Žæ§ã®ããæ ªåŒèšŒåž 9,889  11,178  売æéãçŽé¡ 309,481  327,787  ã€ã³ãã³ã㪠83,981  89,146  åæè²»çšããã³ãã®ä»ã®æµåè³ç£ 154,745  126,382  æµåè³ç£åèš 3,172,856  2,982,697  äžåç£ããã©ã³ããèšåãçŽé¡ 517,159  526,057  ãªãã¬ãŒãã£ã³ã°ãªãŒã¹ã®äœ¿çšæš©è³ç£ 198,303  199,732  å¶éä»ãæè³ 49,391  49,391  ãã®ä»ã®è³ç£ 71,925ã§ã  72,003  ç·è³ç£ $ 4,009,634  $ 3,829,880 Â è² åµãšæ ªäž»ã®èµ€å çŸåšã®è² åµ: è²·æé $ 73,980  $ 55,519  æªæè²»çš 808,643  713,013  ãªãã¬ãŒãã£ã³ã°ã»ãªãŒã¹ã®è² åµ 41,656ã§ã  41,510  繰延åç 69,009  102,753  å°æ¥ã®ãã€ã€ãªãã£ã®å£²åŽã«é¢é£ãã責任 61,963  54,991  æµåè² åµåèš 1,055,251  967,786  ãªãã¬ãŒãã£ã³ã°ã»ãªãŒã¹ã®è² åµãåœæåãå·®ãåŒãããã®
239,352  243,101ã§ã  繰延åçãåœæåãå·®ãåŒãããã® 2,402  188,175  転æç€Ÿåµ 1,022,688ã§ã  1,020,776  å°æ¥ã®ãã€ã€ãªãã£ã®å£²åŽã«é¢é£ããè² åµïŒçŸåšã®éšåãå·®ãåŒãããã®ïŒ 1,342,580  1,322,248  ãã®ä»ã®è² åµ 350,428  308,438 Â è² åµç·é¡ 4,012,701  4,050,524  ã³ãããã¡ã³ããšäžæž¬ã®äºæ
ïŒæ³š13ïŒ
æ ªäž»èµ€å: åªå
æ ªåŒã$0.01 1æ ªãããã®é¡é¢äŸ¡é¡ã 5,000 æ¿èªãããæ ªåŒãš ããã 2024幎6æ30æ¥ããã³2023幎12æ31æ¥çŸåšã®çºè¡æžæ ªåŒæ°
â  â  æ®éæ ªåŒã$0.01 1æ ªãããã®é¡é¢äŸ¡é¡ã 250,000 æ¿èªãããæ ªåŒ; 128,021 2024幎6æ30æ¥çŸåšã®çºè¡æžæ ªåŒæ° 125,794 2023幎12æ31æ¥çŸåšã®çºè¡æžæ ªåŒæ°
1,281  1,259  ãã®ä»ã®æ蟌è³æ¬ 7,122,704ã§ã  6,811,063  ãã®ä»ã®å
æ¬æ倱ã®çŽ¯èš (34,637 ) (23,375 ) 环ç©èµ€å (7,092,415 ) (7,009,591 ) æ ªäž»ç·èµ€å (3,067 ) (220,644ã§ã ) è² åµç·é¡ãšæ ªäž»èµ€å $ 4,009,634  $ 3,829,880 Â
æ·»ä»ã®æ³šèšã¯ããããã®èŠçŽãããé£çµè²¡åè«žè¡šã®äžéšãæ§æããŠããŸãã
ã¢ã«ãã©ã ãã¡ãŒãã·ã¥ãŒãã£ã«ã«ãºç€Ÿ
é£çµæçèšç®æžïŒæç²ïŒ
ç·æ倱
(åãã«åäœã1æ ªåœããéé¡ä»¥å€)
ïŒæªç¢ºå®ïŒ
3 ãæãçµäº 6æ30æ¥ 6 ãæéçµäº 6æ30æ¥ 2024 2023 2024 2023 éçšæçŽ°æž åç: çŽè£œååå
¥ $ 410,088  $ 305,705  $ 775,251  $ 582,033  ã³ã©ãã¬ãŒã·ã§ã³ã«ããçŽåå
¥ 227,338  5,844  345,886  42,306  ãã€ã€ãªãã£åå
¥ 22,399% Â 7,205 Â 33,021 Â 13,705 Â ç·åå
¥ 659,825  318,754  1,154,158  638,044  éçšã³ã¹ããšçµè²»: 売äžå䟡 67,271  75,336  121,884  116,768  ã³ã©ãã¬ãŒã·ã§ã³ã®è²»çšãšãã€ã€ãªã㣠1,401  10,034  12,764  23,471  ç 究éçº 294,142  248,526  555,137  479,095  販売ãäžè¬ããã³ç®¡ç 248,397  214,689  459,194  398,348  éçšã³ã¹ããšçµè²»ã®åèš 611,211ã§ã  548,585  1,148,979  1,017,682  äºæ¥ããã®åçïŒæ倱ïŒ
48,614  (229,831 ) 5,179  (379,638 ) ãã®ä» (è²»çš) åå
¥: æ¯æå©æ¯ (33,258 ) (30,035 ) (68,511ã§ã ) (58,990ã§ã ) å©æ¯åå
¥ 29,182  21,075%  58,827  39,730  ãã®ä»ã®è²»çšãçŽé¡ (55,705 ) (35,418 ) (70,249 ) (47,673 ) ãã®ä»ã®è²»çšåèšãçŽé¡ (59,781 ) (44,378 ) (79,933 ) (66,933% ) çšåŒåæ倱
(11,167 ) (274,209 ) (74,754ã§ã ) (446,571 ) æåŸçšåŒåœé
(5,722 ) (1,815 ) (8,070 ) (3,554 ) çŽæ倱
$ (16,889 ) $ (276,024 ) $ (82,824 ) $ (450,125 ) æ®éæ ªåŒ1æ ªãããã®çŽæ倱-åºæ¬ããã³åžèååŸ
$ (0.13 ) $ (2.21 ) $ (0.66 ) $ (3.62 ) æ®éæ ªåŒ1æ ªãããã®åºæ¬ããã³åžèååŸã®çŽæ倱ã®èšç®ã«äœ¿çšãããå éå¹³åæ®éæ ªåŒ
126,733 Â 124,659 Â 126,435 Â 124,387 Â å
æ¬æ倱èšç®æž
çŽæ倱
$ (16,889 ) $ (276,024 ) $ (82,824 ) $ (450,125 ) ãã®ä»ã®å
æ¬çïŒæ倱ïŒåå
¥ïŒ
åžå Žæ§ã®ããæ䟡蚌åžã®æªå®çŸå©çïŒæ倱ïŒ
(727 ) (2,025 ) (4,295 ) 2,100  å€è²šæç®ïŒæ倱ïŒå©ç
(6,952 ) 4,073  (7,030 ) 5,483  確å®çµŠä»å¹Žéå¶åºŠãçšåŒåŸ 30  (4 ) 63  (9 ) ãã®ä»ã®å
æ¬å©çïŒæ倱ïŒç·é¡
(7,649 ) 2,044 Â (11,262 ) 7,574 Â å
æ¬çæ倱
$ (24,538 ) $ (273,980 ) $ (94,086 ) $ (442,551 )
æ·»ä»ã®æ³šèšã¯ããããã®èŠçŽãããé£çµè²¡åè«žè¡šã®äžéšãæ§æããŠããŸãã
ã¢ã«ãã©ã ãã¡ãŒãã·ã¥ãŒãã£ã«ã«ãºç€Ÿ
æ ªäž»ã®èµ€åã®ç°¡ç¥åé£çµè²¡åè«žè¡š
å¶æ¥æŽ»åã«ãããã£ãã·ã¥ãããŒïŒ
ïŒæªç¢ºå®ïŒ
æ®éæ ªåŒ [è¿œå ] æ¯æãæžã¿ è³æ¬ çŽ¯ç© ãã®ä» å
æ¬ç æ倱 çŽ¯ç© èµ€å åèš æ ªäž»ã® èµ€å æ ªåŒ éé¡ 2023幎12æ31æ¥çŸåšã®æ®é« 125,794  $ 1,259  $ 6,811,063  $ (23,375 ) $ (7,009,591 ) $ (220,644ã§ã ) æºæ³åŸŽåçšæ§é€åŸã®æ®éã¹ããã¯ãªãã·ã§ã³ã®è¡äœ¿ 223  2  24,763  â â 24,765 Â æ ªåŒãã©ã³ã«åºã¥ãæ®éæ ªåŒã®çºè¡ 446  4  (4 ) â â â Â æ ªåŒããŒã¹ã®å ±é
¬ææ°æ â â 46,155  â â 46,155  ãã®ä»ã®å
æ¬æ倱
â â â (3,613 ) â (3,613 ) çŽæ倱 â â â â (65,935 ) (65,935 ) 2024幎3æ31æ¥çŸåšã®æ®é« 126,463  1,265  6,881,977  (26,988 ) (7,075,526 ) (219,272 ) æºæ³åŸŽåçšæ§é€åŸã®æ®éã¹ããã¯ãªãã·ã§ã³ã®è¡äœ¿ 1,264ã§ã  13  140,273  â â 140,286 Â æ ªåŒãã©ã³ã«åºã¥ãæ®éæ ªåŒã®çºè¡ 294  3  10,358  â â 10,361 Â æ ªåŒããŒã¹ã®å ±é
¬ææ°æ â â 90,096  â â 90,096  ãã®ä»ã®å
æ¬æ倱
â â â (7,649 ) â (7,649 ) çŽæ倱 â â â â (16,889 ) (16,889 ) 2024幎6æ30æ¥çŸåšã®æ®é« 128,021  $ 1,281  $ 7,122,704ã§ã  $ (34,637 ) $ (7,092,415 ) $ (3,067 )
æ·»ä»ã®æ³šèšã¯ããããã®èŠçŽãããé£çµè²¡åè«žè¡šã®äžéšãæ§æããŠããŸãã
ã¢ã«ãã©ã ãã¡ãŒãã·ã¥ãŒãã£ã«ã«ãºç€Ÿ
æ ªäž»ã®èµ€åã®ç°¡ç¥åé£çµè²¡åè«žè¡š
å¶æ¥æŽ»åã«ãããã£ãã·ã¥ãããŒïŒ
ïŒæªç¢ºå®ïŒ
æ®éæ ªåŒ [è¿œå ] æ¯æãæžã¿ è³æ¬ 环ç©
ãã®ä»
å
æ¬ç
æ倱
çŽ¯ç© èµ€å åèš
æ ªäž»ã®
èµ€å
æ ªåŒ éé¡ 2022幎12æ31æ¥çŸåšã®æ®é« 123,925ã§ã  $ 1,240  $ 6,454,540  $ (44,654 ) $ (6,569,349 ) $ (158,223 ) æºæ³åŸŽåçšæ§é€åŸã®æ®éã¹ããã¯ãªãã·ã§ã³ã®è¡äœ¿ 269  3  26,415ã§ã  â â 26,418 Â æ ªåŒãã©ã³ã«åºã¥ãæ®éæ ªåŒã®çºè¡ 47  â â â â â æ ªåŒããŒã¹ã®å ±é
¬ææ°æ â â 41,136  â â 41,136  ãã®ä»ã®å
æ¬å©ç
â â â 5,530  â 5,530  çŽæ倱 â â â â (174,101ã§ã ) (174,101ã§ã ) 2023幎3æ31æ¥çŸåšã®æ®é« 124,241  1,243  6,522,091  (39,124 ) (6,743,450ã§ã ) (259,240ã§ã ) æºæ³åŸŽåçšæ§é€åŸã®æ®éã¹ããã¯ãªãã·ã§ã³ã®è¡äœ¿ 372  4  38,111  â â 38,115% Â æ ªåŒãã©ã³ã«åºã¥ãæ®éæ ªåŒã®çºè¡ 288  3  9,981  â â 9,984 Â æ ªåŒããŒã¹ã®å ±é
¬ææ°æ â â 76,990ã§ã  â â 76,990ã§ã  ãã®ä»ã®å
æ¬å©ç
â â â 2,044  â 2,044  çŽæ倱 â â â â (276,024 ) (276,024 ) 2023幎6æ30æ¥çŸåšã®æ®é« 124,901  $ 1,250%  $ 6,647,173%  $ (37,080 ) $ (7,019,474ã§ã ) $ (408,131 )
æ·»ä»ã®æ³šèšã¯ããããã®èŠçŽãããé£çµè²¡åè«žè¡šã®äžéšãæ§æããŠããŸãã
ã¢ã«ãã©ã ãã¡ãŒãã·ã¥ãŒãã£ã«ã«ãºç€Ÿ
ãã£ãã·ã¥ãããŒã®æŠèŠ
å¶æ¥æŽ»åã«ãããã£ãã·ã¥ãããŒïŒ
ïŒæªç¢ºå®ïŒ
6æ30æ¥ãŸã§ã®6ãæé 2024 2023 ïŒåååäœïŒ çŽæ倱 $ (82,824 ) $ (450,125 ) å¶æ¥æŽ»åã«ãããçŽæ倱ã調æŽããããã®éçŸé調æŽïŒ æžäŸ¡ååŽè²»ããã³ååŽè²» 28,520  27,244  é転ãªãŒã¹ã«é¢é£ããååŽè²»ããã³å©æ¯èªè å°æ¥ã®ãã€ã€ãªãã£è²©å£²ã«é¢é£ããåµåã®éçŸéå©æ¯è²»çš  22,282  å°æ¥ã®ãã€ã€ã«ãã£ãŒè²©å£²ã«é¢é£ããè² åµã«å¯ŸããéçŸéå©åè²»çš 61,103  51,647 Â æ ªåŒå ±é
¬è²»çš
134,635  115,749  äžå Žæ ªåŒèšŒåžã®å®çŸããã³æªå®çŸæ倱
1,289  867  éçºããªããã£ãåµåã®å
¬æ£äŸ¡å€å€å 64,228  36,686 Â ä» (15,365 ) (8,252 ) å¶æ¥è³ç£ããã³è² åµã®å€å: 売æéã®çŽé¡ 10,050  16,053  åšåº« 6,816  1,582  åæè²»çšããã³ãã®ä»ã®è³ç£ (13,775 ) (29,109 ) æ¯æ調æŽ, æªæè²»çšããã³ãã®ä»ã®è² åµ 69,605  766  皌åãªãŒã¹è² åµ (23,791 ) (23,847 ) åæåç (219,506 ) 12,866  å¶æ¥æŽ»åã«ããæ£å³çŸéæµå
¥éé¡
42,643  (225,461 ) æè³æŽ»åã«ãããã£ãã·ã¥ãããŒïŒ åºå®è³ç£ã®è³Œå
¥ (20,991 ) (29,810 ) 売買å¯èœæ䟡蚌åžã®è³Œå
¥ (717,826 ) (812,887 ) æ䟡蚌åžã®å£²åŽçåã¯åéç 705,137  å¶éä»ãæè³ã®æºæã«ããåç  å¶éä»ãæè³ã®è³Œå
¥ 57,875  58,475  å¶éä»ãæè³ã®è³Œå
¥ (57,875 ) (58,475 ) æè³æŽ»åã«ãããã£ãã·ã¥ãããŒã®çŽæµåº
(33,680 ) (ã¹ããã¯ãªãã·ã§ã³ããã®ä»ã®çš®é¡ã®æ ªåŒã®è¡äœ¿ã«ããåçïŒçŽé¡ ) 財å掻åããã®ãã£ãã·ã¥ãããŒ: æ ªåŒãªãã·ã§ã³ã®è¡äœ¿ãªã©ã«ããååéé¡åèš éçºããªããã£ãã«ããåçïŒçŽé¡  91,765  éçºããªããã£ãã«ããåçïŒçŽé¡
2020幎12æ31æ¥ã«åœç€Ÿã®æ®éæ ªåŒã«100ãã«ãæè³ããããšãåæãšããèšæž¬æéã®çµãããšå§ãã®Common Stockã®æ ªäŸ¡ã®å·®é¡ã«åºã¥ããŠèšç®ããããã¹ãŠã®é
åœãåæè³ãããã®ãšä»®å®ããŠããŸãã  8,000  財å掻åã«ããçŽçŸéæµå
¥é¡ 160,407  99,765  çºæ¿ã¬ãŒãã®å€åãçŸéãçŸéåçç©åã³ææãããçŸéã«åãŒãåœ±é¿ (13,061
) 2,046  çŸéãçŸéåçç©åã³ææãããçŸéã®çŽå¢æž
156,309  (208,580 ) æéŠæ®é«ã®çŸéãçŸéåçç©åã³å¶éä»ãçŸé 814,884  868,556  ææ«æ®é«ã®çŸéãçŸéåçç©åã³å¶éä»ãçŸé $ 971,193  $ 659,976  ãã£ãã·ã¥ãããŒã®è£è¶³éç€ºïŒ æ¯æå©æ¯ã®çŸé $ 39,101  $ 17,128 Â
æ·»ä»ã®æ³šèšã¯ããããã®èŠçŽãããé£çµè²¡åè«žè¡šã®äžéšãæ§æããŠããŸãã
ã¢ã«ãã©ã ãã¡ãŒãã·ã¥ãŒãã£ã«ã«ãºç€Ÿ
ã³ã³ãã³ã¹ãé£çµè²¡åè«žè¡šã«é¢ãã泚èš
ïŒæªç¢ºå®ïŒ
1. ããžãã¹ã®æ§è³ª
Alnylam PharmaceuticalsãInc.ïŒä»¥äžAlnylamãå瀟ãç§ãã¡ãåœç€ŸãŸãã¯ç§ãã¡ïŒã¯ããªãæ žé
žå¹²æžïŒRNAiïŒã«åºã¥ããç»æçãªæ²»çè¬ã®éçºã»åæ¥åãç®æããã€ãªè£œè¬äŒç€ŸãšããŠã2002幎6æ14æ¥ã«äºæ¥ãéå§ããŸãããç§ãã¡ã¯ãå°æ¥ã®æé·ã®ããã®RNAiæ²»çè¬ã®æç¶å¯èœãªèšåºãã€ãã©ã€ã³ãšãæç¶çãªã€ãããŒã·ã§ã³ãšæ£è
ãžã®ããã³ã·ã£ã«ãæã€å
ç¢ãªææ©çç 究ãšã³ãžã³ãæ§ç¯ããã°ããŒãã«ã§åæ¥åãããå€åç®ã®ãã€ãªè£œè¬äŒç€Ÿãæ§ç¯ããããã®åœç€Ÿã®æŠç¥ãé²ããŠããŸããèšç«ä»¥æ¥ãRNAiåéã§ã®åŒ·åãªç¥ç財ç£æš©ã確ç«ããäž»èŠãªè£œè¬ããã³çåœç§åŠäŒæ¥ãšã®æŠç¥çãªååé¢ä¿ãç¯ããã©ã€ã»ã³ã¹å¥çŽã«ããåçãçã¿åºããæçµçã«ã¯åœç€Ÿã®æŠç¥çãªååè
ãšååããŠã°ããŒãã«ã«RNAiæ²»çè¬ãéçºããåæ¥åããããšã«çŠç¹ãåœãŠãŠããŸãããç§ãã¡ã¯ãäºæ¥èšç»ãç 究ãéçºã補é ãåæ¥åã®ããã»ãšãã©ã®åªåãåŸããç¥ç財ç£æš©ã®ååŸãç³è«ãæ¡å€§ããããžã¡ã³ãããã³æè¡ã¹ã¿ããã®æ¡çšãè³é調éã«åãå
¥ããŸããã
2021幎åãç§ãã¡ã¯ç§ãã¡ã®æŠç¥ãéå§ããŸããã ãAlnylam P x25ãæŠç¥ã¯ãæç¶å¯èœãªé©æ°ãšåªãã財åæ¥çžŸãéããŠãçããç
æ°ããäžè¬çãªç
æ°ã«å€é©çãªè¬å€ãæäŸããããšã§ãã 5 x25 ããã«ããã2025幎æ«ãŸã§ã«ããããã£ã¢ã®ãã€ãªãã¯ãããžãŒäŒæ¥ãžã®èšç»çãªç§»è¡ãç®æããæç¶å¯èœãªã€ãããŒã·ã§ã³ã«ããäžçäžã®æ£è
ã«å€é©çãªåžå°çŸæ£ãšäžè¬çŸæ£ã®æ²»çè¬ãæäŸããäžæ¹ãåªãã財åæ瞟ãå®çŸããããšãç®æããŠããŸãã ãAlnylam P x25ãæŠç¥ã¯ãæç¶å¯èœãªé©æ°ãšåªãã財åæ¥çžŸãéããŠãçããç
æ°ããäžè¬çãªç
æ°ã«å€é©çãªè¬å€ãæäŸããããšã§ãã 5 ãAlnylam P x25ãæŠç¥ã¯ãæç¶å¯èœãªé©æ°ãšåªãã財åæ¥çžŸãéããŠãçããç
æ°ããäžè¬çãªç
æ°ã«å€é©çãªè¬å€ãæäŸããããšã§ãã ããã«ãããæç¶å¯èœãªã€ãããŒã·ã§ã³ã«ããäžçäžã®æ£è
ã«å€é©çãªåžå°çŸæ£ããã³äžè¬çŸæ£ã®æ²»çè¬ãæäŸããåªãã財åæ瞟ãå®çŸããããšãç®æããŠããŸãã
2024幎6æ30æ¥æç¹ã§ãç§ãã¡ã¯è£œåã販売ããŠããããã®äžã«ã¯ååè
ã«ãã£ãŠåæ¥åããã補åãå«ãŸããŠããŸããããã«ãåæ¥åã«åããŠé²è¡äžã®åŸæè©Šéšäžã®ããã°ã©ã ãè€æ°ãããŸããçŸåšãäž»ã«ç±³åœããã³ãšãŒãããã§ãONPATTROãAMVUTTRAãGIVLAARIããã³OXLUMOã®åæ¥å補åããäžççãªè£œååçãçæããŠããŸãã 5æ¥é ããŒã±ãã£ã³ã°è£œåãå«ãè€æ°ã®è£œå oneworldã¢ã©ã€ã¢ã³ã¹ã®ã¡ã³ããŒãšè¿œå ã®ã°ããŒãã«ããŒãããŒãšãšãã«ãã客æ§ã¯alaskaair.comã§30以äžã®èªç©ºäŒç€Ÿãšäžçäžã®1,000以äžã®ç®çå°ã§è³Œå
¥ãç²åŸããŸãã¯äº€æããéžæè¢ãä»ãŸã§ä»¥äžã«ãããŸãã ååè
ã«ãã£ãŠåæ¥åããã1ã€ã®è£œåãããã³çŸåšåæ¥åã«åããŠé²è¡äžã®è€æ°ã®åŸæè©Šéšäžã®ããã°ã©ã "4人" ONPATTROãAMVUTTRAãGIVLAARIããã³OXLUMOãšããåæ¥åæžã¿ååããäž»ã«ç±³åœããã³ãšãŒãããã§äžççãªè£œååçãçã¿åºããŠããŸãã
2. æ瀺äºé
ããã³é£çµã®åå
ã¢ã«ãã©ã ã®æ·»ä»ã®ç°¡ç¥ãªé£çµè²¡åè«žè¡šã¯æªç£æ»ã§ãç±³åœã®äžè¬çã«åãå
¥ããããŠããäŒèšååïŒGAAPïŒã«åºã¥ããŠäžéæéã«é©çšããããŸãã管çè
ã®æèŠã«ãããšãå ±åæéã®æ¥çžŸãå
¬æ£ã«è¡šãã®ã«å¿
èŠãªéåžžã®ããã³ç¶ç¶çãªèª¿æŽããã¹ãŠå«ãã§ããŸããåœç€Ÿã®ç°¡ç¥ãªé£çµè²¡åè«žè¡šã¯ããŸãã2023幎12æ31æ¥ã®å¹Žæ¬¡å ±åæžã«å«ãŸããŠãã蚌åžååŒå§å¡äŒãžã®ç³è«æž10-kã«èšèŒãããŠããç£æ»æžã¿é£çµè²¡åè«žè¡šãšå€§å¹
ã«äžèŽããåºç€ã§äœæãããŠãããããããšãšãã«èªãŸããå¿
èŠããããŸãã幎æ«ã®ç°¡ç¥ãªé£çµãã©ã³ã¹ã·ãŒãããŒã¿ã¯ãç£æ»æžã¿è²¡åè«žè¡šããå°ãããŸããããGAAPã§å¿
èŠãšããããã¹ãŠã®é瀺ãå«ã¿ãŸãããä»»æã®äžéæéã®æ¥çžŸã¯ãå¿
ãããä»ã®äžéæéãŸãã¯å®å
šãªè²¡æ¿å¹ŽåºŠã®æ¥çžŸã瀺ããã®ã§ã¯ãããŸããã
ä»éããèŠçŽãããåç®è²¡åè«žè¡šã¯ãã¢ã«ãã©ã åã³å®å
šåäŒç€Ÿã®äºæ¥ãåæ ããŠããŸããå
šã»ã¯ã¿ãŒã®å£åº§åã³ååŒãé€å»ãããŠããŸãã
åœç€Ÿã®éèŠãªäŒèšæ¹éã¯ã2023幎12æ31æ¥ã«çµäºããå¹Žæ¬¡å ±åæžã®ä»å±ã®é£çµè²¡åè«žè¡šã®æ³šé2ã«èšèŒãããŠããŸãã2024幎6æ30æ¥çµäºæç¹ãŸã§ã«åœç€Ÿã®éèŠãªäŒèšæ¹éã«é倧ãªå€æŽã¯ãããŸããã§ããã
èŠç©ããã®äœ¿çš
GAAPã«æºæ ãã財åè«žè¡šã®äœæã«ã¯ã財åè«žè¡šã®ç°¡çŽåãããé£çµæ¥æç¹ã®è³ç£ãè² åµãæœåšçãªè³ç£åã³è² åµã®é瀺ã®å ±åé¡ãå ±åæéäžã®å£²äžé«åã³è²»çšã®å ±åé¡ã«åœ±é¿ããèŠç©ãããšä»®å®ã管çè·ãè¡ãå¿
èŠããããŸããç§ãã¡ã¯åœç€Ÿç°¡çŽåãããé£çµè²¡åè«žè¡šã«ãããŠãåšåº«ã®è©äŸ¡åã³é¢é£è²»çšãå°æ¥ã®ãã€ã€ãªãã£è²©å£²ã«é¢ãã責任ãéçºå¥çŽã«åºã¥ã責任ãæåŸçšã繰延çšéè³ç£è©äŸ¡ã®åŒåœéã売äžèªèãç 究éçºè²»çšãæ ªåŒå ±é
¬ã«é¢ããèŠç©ããåã³ä»®å®ã䜿çšããŠããŸããç§ãã¡ã¯ããããã®èŠç©ãããæŽå²ççµéšãšãåççã ãšä¿¡ããããæ§ã
ãªä»®å®ã«åºã¥ããŠè¡ã£ãŠããŸããå®éã®çµæã¯èŠç©ãããšã¯ç°ãªãå¯èœæ§ããããŸããèŠç©ããã®å€æŽã¯å€æããæéã«å ±åãããçµæã«åæ ãããŸãã
æµåæ§
çŸåšã®éå¶èšç»ã«åºã¥ãããã®ååæå ±åæž10-Qã®ç³è«æ¥ããå°ãªããšã次ã®12ãæéã«ãããé転è³éããã³éçšããŒãºãæºããããã«ã2024幎6æ30æ¥æç¹ã§ã®çŸéãçŸéåçç©ããã³æ䟡蚌åžã¯ååã§ãããšèããŠããŸãã
ã¢ã«ãã©ã ãã¡ãŒãã·ã¥ãŒãã£ã«ã«ãºç€Ÿ
ã³ã³ãã³ã¹ãé£çµè²¡åè«žè¡šã«é¢ãã泚èš
ïŒæªç¢ºå®ïŒ
æè¿ã®äŒèšåå
2023幎12æã財åäŒèšåºæºå§å¡äŒïŒãŸãã¯FASbïŒã¯ãæå¹çšç調æŽã«é¢ããå解ãããæ
å ±ã®é瀺ãããã³ç®¡èœåºåããšã«æ¯æãããæåŸçšã«é¢ããæ¡åŒµæ
å ±ã®é瀺ãæ±ããäŒèšåºæºã¢ããããŒã2023-09ãçºè¡ããŸãããé瀺èŠä»¶ã¯ã远溯çã«é©çšããããšãã§ããŸãããå°æ¥çãªããŒã¹ã§é©çšãããŸãããã®åºæºã¯ã2024幎12æ15æ¥ä»¥éã«éå§ãããäºæ¥å¹ŽåºŠã«é©çšãããæ©ææ¡çšãèš±å¯ãããŠããŸããç§ãã¡ã¯ããã®æ°ããåºæºã«é¢é£ããé瀺èŠä»¶ãè©äŸ¡äžã§ãã
2023幎11æãFASBã¯äŒèšåºæºæ¹æ£å£°æ2023-07ãåºåå ±åïŒTopic 280ïŒïŒå ±å察象åºåé瀺ã®æ¹åããçºè¡ããéèŠãªéšéè²»çšã«é¢ããè¿œå é瀺ãéããŠå ±å察象åºåé瀺èŠä»¶ã®æ¹åãæå³ããŠããŸãããã®åºæºã¯2023幎12æ15æ¥ä»¥éã®è²¡å幎床ããã³2024幎12æ15æ¥ä»¥éã®è²¡å幎床ã®éã®äžéæããé©çšãããæ©ææ¡çšãèš±å¯ãããŠããŸããä¿®æ£å
容ã¯è²¡åè«žè¡šã®éå»ã®ãã¹ãŠã®æéã«å¯ŸããŠåŸæ¹é©çšãããã¹ãã§ããåœç€Ÿã§ã¯ããã®æ°ããåºæºã«é¢é£ããé瀺èŠä»¶ãè©äŸ¡ããŠããŸãã
3. ããã補åã®åç
補åã販売ãããå°åã«åºã¥ããŠåé¡ãããããã補ååçã¯ã次ã®ããã«æ§æãããŠããŸãã
3 ãæãçµäº 6æ30æ¥ 6 ãæéçµäº 6æ30æ¥ (ååäœ) 2024 2023 2024 2023 ãªã³ããããŒ ç±³åœ $ 22,112  $ 25,560  $ 38,651  $ 55,377ã§ã  ãšãŒããã 37,074  56,393  81,764  116,071  ãã®ä»ã®å°å 18,058  9,505  26,046  22,503  åèš 77,244  91,458  146,461  193,951  ã¢ã ãããã© ç±³åœ 148,463  96,469  278,701  175,482  ãšãŒããã 56,760  14,405  100,493  21,173  ãã®ä»ã®å°å 24,886  21,262  46,156ã§ã  37,249  åèš 230,109  132,136  425,350  233,904  ã®ãã©ãªãã ç±³åœ 41,225  35,196  79,956  65,487  ãšãŒããã 16,314  14,051  31,629  28,522  ãã®ä»ã®å°å 4,588  8,652  8,598  11,796  åèš 62,127ã§ã  57,899  120,183  105,805  ãªã¯ã¹ã«ã¢ãã ç±³åœ 15,744ã§ã  8,794  29,076  17,851  ãšãŒããã 20,503  12,216  41,930  25,525  ãã®ä»ã®å°å 4,361  3,202  12,251  4,997  åèš 40,608  24,212  83,257  48,373  補åã®ç·çŽåå
¥ $ 410,088 Â $ 305,705 Â $ 775,251 Â $ 582,033 Â
ã¢ã«ãã©ã ãã¡ãŒãã·ã¥ãŒãã£ã«ã«ãºç€Ÿ
ã³ã³ãã³ã¹ãé£çµè²¡åè«žè¡šã«é¢ãã泚èš
ïŒæªç¢ºå®ïŒ
次ã®è¡šã¯ãåœç€Ÿã®çŽè£œååçã«é¢é£ããåµæš©ã®ãã©ã³ã¹ã瀺ããŠããŸãã
å¶æ¥æŽ»åã«ãããã£ãã·ã¥ãããŒïŒ 2021幎6æ30æ¥çŸåš 2024
2023幎12æ31æ¥çŸåš 2023 ã売æéãçŽé¡ãã«å«ãŸããåµæš© $ 248,654  $ 210,097 Â
4. ã³ã©ãã¬ãŒã·ã§ã³ããã®çŽåç
ã³ã©ãã¬ãŒã·ã§ã³ããã®æ£å³åå
¥ã¯ä»¥äžã®ãšããã§ãïŒ
6æ30æ¥ã«çµäºãã3ãæé 6æ30æ¥ã«çµäºãã6ãæé (ååäœ) 2024 2023 2024 2023 ããã·ã¥
$ 16,506  $ â  $ 91,186  $ â  ãªãžã§ããã³ãã¡ãŒãã·ã¥ãŒãã£ã«ã«ãº 207,429  (2,837 ) 234,193  17,153  ããã«ãã£ã¹AG 2,304ã§ã  8,627  16,820  23,560  ãã®ä» 1,099  54  3,687  1,593  åèš $ 227,338  $ 5,844  $ 345,886  $ 42,306 Â
    次ã®è¡šã¯ãåœç€Ÿã®åæ¥å¥çŽã«é¢é£ããåµæš©ããã³å¥çŽåµåã®åæ¯ã瀺ããŠããŸãã
å¶æ¥æŽ»åã«ãããã£ãã·ã¥ãããŒïŒ 2024幎6æ30æ¥çŸåš 2023幎12æ31æ¥çŸåš ã売æéãçŽé¡ãã«å«ãŸããåµæš© $ 39,497  $ 99,576  ãæªæ売äžé«ãã«å«ãŸããå¥çŽè² åµ $ 71,176  $ 290,763 Â
2024幎6æ30æ¥çµäºæç¹ããã³2024幎6æ30æ¥çµäºæç¹ã«ãããŠã売äžé«ã¯ãããã2å2870äžãã«ã3å9440äžãã«ãšèªèããã2023幎6æ30æ¥çµäºæç¹ããã³2023幎6æ30æ¥çµäºæç¹ã«ãããŠãå¥çŽåµåã®æ®é«ã«å«ãŸããŠãã売äžé«ã¯ãããã1åãã«ã1å7100äžãã«ãšãªããŸããã200.0 çŸäžãã«ãš$2å2870äžãã«ã®å£²äžé«ãèªèããŸããã 2024幎6æ30æ¥çµäºæç¹ããã³2024幎6æ30æ¥çµäºæç¹ã«ãããŠã売äžé«ã¯ãããã2å2870äžãã«ã3å9440äžãã«ãšèªèããã2023幎6æ30æ¥çµäºæç¹ããã³2023幎6æ30æ¥çµäºæç¹ã«ãããŠãå¥çŽåµåã®æ®é«ã«å«ãŸããŠãã売äžé«ã¯ãããã1åãã«ã1å7100äžãã«ãšãªããŸããã4.8 çŸäžãã«ãš$10.3 1åãã«ã®å£²äžé«ãèªèããŸããã
売äžé«ãå€æããã«ã¯ããŸãæéŠã®å¥çŽåµåæ®é«ã«å£²äžé«ãå²ãåœãŠã売äžé«ããã®æ®é«ãäžåããŸã§é²å±ãããŸãã次ã®æã«ãããŠããããã®å¥çŽã«è¿œå å ±é
¬ãåŸãããå Žåãå ±åæã«ãããèªèããããã¹ãŠã®å£²äžé«ã¯ãæ°ããªå ±é
¬ã®äžéšã«é©çšããã代ããã«ãå¥çŽåµåã®éå§æã«é©çšããããšä»®å®ããŠããŸãã
以äžã®è¡šã¯ãå
±åç 究å¥çŽã«çŽæ¥åž°å±ããåœç€ŸãèªèããçŽå£²äžé«ã«å¯Ÿããç 究éçºè²»çšã®ã¿ã€ãå¥è²»çšã瀺ããŠããŸãã
6æ30æ¥ãŸã§ã®3ãæé 2024 2023 å¶æ¥æŽ»åã«ãããã£ãã·ã¥ãããŒïŒ èšåºããã³è£œé æ¥
å€éšãµãŒãã¹ ä» èšåºããã³è£œé æ¥
å€éšãµãŒãã¹ ä» ãã·ã¥
$ 22,503  $ 2,499  $ 1234  $ â  $ â  $ â  ãªãžã§ããã³ãã¡ãŒãã·ã¥ãŒãã£ã«ã«ãº 6,006  3,492  4,786  9,956  910  9,330 Â ä» 1,485  89  242  85  58  405  ç·èš $ 29,994  $ 6,080  $ 6,262  $ 10,041  $ 968  $ 9,735 Â
ã¢ã«ãã©ã ãã¡ãŒãã·ã¥ãŒãã£ã«ã«ãºç€Ÿ
ã³ã³ãã³ã¹ãé£çµè²¡åè«žè¡šã«é¢ãã泚èš
ïŒæªç¢ºå®ïŒ
6æ30æ¥ãŸã§ã®6ãæé 2024 2023 å¶æ¥æŽ»åã«ãããã£ãã·ã¥ãããŒïŒ èšåºããã³è£œé æ¥
å€éšãµãŒãã¹ ä» èšåºããã³è£œé æ¥
å€éšãµãŒãã¹ ä» ãã·ã¥
$ 36,638  $ 6,111  $ 1,568  $ â  $ â  $ â  ãªãžã§ããã³ãã¡ãŒãã·ã¥ãŒãã£ã«ã«ãº 16,795  7,233  8,959  18,472  2,150  18,693 Â ä» 3,591  89  949  397  184  765  ç·èš $ 57,024  $ 13,433  $ 11,476  $ 18,869  $ 2,334  $ 19,458 Â
äžèšè¡šã«å«ãŸããå¥çŽã«é¢é£ããç 究éçºè²»çšã¯ã(i)èšåºããã³èšåºåè²»çšïŒèšåºããã³èšåºå補åã®è£œé ãå«ãïŒã(ii)ã³ã³ãµã«ãã£ã³ã°ãµãŒãã¹ãå®éšçšåã»ãµãŒãã¹ãªã©ã®å€éšãµãŒãã¹ããã㊠(iii)ãã®ä»ã®è²»çšïŒãããã§ãã·ã§ãã«ãµãŒãã¹ãæœèšããã³äžéšã®éæ¥è²»çšãªã©ïŒãåœäºæ¥è
ã«è«æ±ããã劥åœãªå ±é
¬åã³é¢é£è²»çšã«å¯Ÿããåæ¥åçããååŽãããé¡ãå«ãã§ããŸãã2024幎6æ30æ¥ããã³2023幎6æ30æ¥ã«çµäºãã3ãæããã³6ãæã«ã€ããŠããåœç€Ÿã®åæ¥å¥çŽã«é¢é£ããéèŠãªè²©å£²ãäžè¬ç®¡çè²»çšã¯çºçããŠããŸããã§ãããã
補åã®ã³ã©ãã¬ãŒã·ã§ã³
ãã·ã¥
2023幎7æ21æ¥ãã€ãŸãæå¹æ¥ã«ãç§ãã¡ã¯Fã»ãããã³ - ã©ã»ãã·ã¥æ ªåŒäŒç€Ÿãããã³ãžã§ãã³ããã¯ç€Ÿãã€ãŸãå
šäœçã«ã¯ãã·ã¥ç€Ÿãšããžã¬ãã·ã©ã³ã®å
±åéçºã®ããã®äžçæŠç¥çææºã確ç«ããã³ã©ãã¬ãŒã·ã§ã³ã»ã©ã€ã»ã³ã¹å¥çŽãã€ãŸããã·ã¥å¥çŽã«èª¿å°ããŸããããžã¬ãã·ã©ã³ã¯ãçŸåšé«è¡å§ã®æ²»çã«ãããŠç¬¬2çžèšåºè©Šéšäžã§ãããèèçºçŸæ§ã¢ã³ã®ãªãã³ã·ããŒã²ã³ãã¿ãŒã²ããã«ããç§ãã¡ã®å¹²æžæ§å°RNAïŒsiRNAïŒæ²»çè¬ã§ãã
Rocheå¥çŽã«ãããåœç€Ÿã¯zilebesiranãäžçäžã§å
±åéçºããæš©å©ïŒCo-Commercialization TerritoryãšåŒã°ããïŒãšãç±³åœã§zilebesiranãåæ¥åããç¬å çãªæš©å©ïŒRoche TerritoryãšåŒã°ããïŒãRocheã«ä»äžããRoche Territoryã§ã®zilebesiranã®éçºãšåæ¥åã®ããã«zilebesiranã補é ããããã®éç¬å çãªæš©å©ãRocheã«ãäžãããRocheå¥çŽã«åºã¥ããRocheã¯åœç€Ÿã«å¯ŸããŠéè¿éåæãéãšããŠ$ãæ¯æã£ãã310.0 ïŒcïŒçŽ$ã®éæ¯é
çå©çã«åž°å±ããåœæçŽå©çãå«ã¿ãŸããéæ¯é
çå©çã«åž°å±ããæåŸçšè²»çšã¯ãçŽ$ãäžåããŸãã
ç§ãã¡ã¯zilebesiranã®ã°ããŒãã«ãªèšåºéçºããªãŒãããŠããŸããç§ãã¡ã¯40%ãæ
åœããRocheã¯ã°ããŒãã«ãªèŠå¶æ¿èªã®ããã«éçºæŽ»åãè¡ãäžã§çºçãã60%ã®éçºè²»çšãè² æ
ããŠããŸããCo-Commercialization Territoryã§ã®zilebesiranã®èŠå¶æ¿èªãæ¯æŽããããã«å®æœãããéçºæŽ»åã«é¢é£ããŠçºçãããã¹ãŠã®è²»çšã¯ãç§ãã¡ãšRocheãåçã«è² æ
ããè¿œå çãªéçºæŽ»åãå¿
èŠãªå Žåã«ã®ã¿è² æ
ããŸããRocheã¯Roche Territoryã§ã®èŠå¶æ¿èªãæ¯æŽããããã«äž»ã«è¡ããããã¹ãŠã®éçºæŽ»åã«ã€ããŠåç¬ã§è² æ
ããŸããèŠå¶æ¿èªãåŸãããå ŽåãRocheã¯Roche Territoryã§ã®zilebesiranã®æä»çãªåæ¥åæš©ãæã¡ãåœè©²ãã€ã€ãªãã£æéäžã®zilebesiranã®çŽå£²äžé«ã«å¿ãããã£ã¢ããå°æ°ã®ãã€ã€ãªãã£ãåœããšã«ç§ãã¡ã«æ¯æããŸããç§ãã¡ãšRocheã¯ãCo-Commercialization Territoryã§zilebesiranãå
±ååæ¥åããå©çãšæ倱ïŒå«ãåæ¥åã³ã¹ãïŒãåçã«åæ
ããŸãã40 Co-Commercialization Territoryã§ã®zilebesiranã®èŠå¶æ¿èªãæ¯æŽããããã«å®æœãããéçºæŽ»åã«é¢é£ããŠçºçãããã¹ãŠã®è²»çšã¯ãç§ãã¡ãšRocheãåçã«è² æ
ããè¿œå çãªéçºæŽ»åãå¿
èŠãªå Žåã«ã®ã¿è² æ
ããŸãã60 Co-Commercialization Territoryã§ã®zilebesiranã®èŠå¶æ¿èªãæ¯æŽããããã«äž»ã«è¡ãããéçºæŽ»åã«é¢é£ããŠçºçãããã¹ãŠã®è²»çšã¯ãRocheãåç¬ã§è² æ
ããŸãã50 /50 Co-Commercialization Territoryã§ã®èŠå¶æ¿èªãæ¯æŽããããã«å®æœãããéçºæŽ»åã«é¢é£ããŠçºçãããã¹ãŠã®è²»çšã¯ãç§ãã¡ãšRocheãåçã«è² æ
ããè¿œå çãªéçºæŽ»åãå¿
èŠãªå Žåã«ã®ã¿è² æ
ããŸãã50 /50 ç§ãã¡ãšRocheã¯Co-Commercialization Territoryã§zilebesiranãå
±ååæ¥åããå©çãšæ倱ïŒå«ãåæ¥åã³ã¹ãïŒãåçã«åæ
ããŸãã
ãã·ã¥ã¯ãäºåã®æžé¢ã«ããéç¥ã«ãããçç±ã®åŠäœãåããããŸãã¯ãŸã£ããçç±ãªãã«ãã·ã¥å¥çŽãçµäºããæš©å©ãæããŸãããã ããçµäºéç¥ãæåã®éçºãã€ã«ã¹ããŒã³ã®éæåŸã3çªç®ã®éçºãã€ã«ã¹ããŒã³ã®éæåã«è¡ãããå Žåããã·ã¥ã¯åœç€Ÿã«$ã®è§£çŽææ°æãæ¯æãå¿
èŠããããŸã50.0 çŸäžãããã«ããããã®åœäºè
ããçžææ¹åœäºè
ã«ããé倧ãªéåãŸãã¯ç Žç£ãçç±ã«ãæ¯æ£æéãæ¡ä»¶ãšããŠãã·ã¥å¥çŽãçµäºããããšãã§ããŸãããã·ã¥å¥çŽã¯ããã®æ¡ä»¶ã«åŸã£ãŠæ©æã«çµäºããªãéãã(a) ãã·ã¥æºå·ã§ã¯è©²åœããåœã§é©çšããããã€ã€ã«ãã£æéã®æºäºæã«ã(b) å
±ååæ¥åã®åãçµã¿æéã®æºäºæã«ã(b) å
±ååæ¥åå°åã§ã¯ãåœããšã«å€±å¹ãããŸã§æå¹ã§ãã
ç§ãã¡ã¯ãã·ã¥ã®å¥çŽãè©äŸ¡ãããã®å¥çŽã«ã¯äŒèšåºæºã³ãŒãã£ããŒã·ã§ã³ïŒASCïŒ606ããã³ASC 808ã®ç¯å²å
ã«ããèŠçŽ ãå«ãŸããŠãããšçµè«ã¥ããŸããã å¥çŽã«åºã¥ãåç ãããŠãå
±åååé¢ä¿ã§ããASC 808ãè©äŸ¡ããŸããã ã³ã©ãã¬ãŒã·ã§ã³ç· çµ .
æå¹æ¥æç¹ã§ãASC 606ã®ç¯å²å
ã§è©äŸ¡ãããRocheå¥çŽã®ä»¥äžã®çŽæãç¹å®ãããŸããïŒ(i) Co-Commercializationé åå
ã§zilebesiranãéçºããåæ¥åããããã®å
±ææä»çã©ã€ã»ã³ã¹ãRocheé åå
ã§zilebesiranã補é ããããã®éæä»çã©ã€ã»ã³ã¹ (Rocheé åå
ã§zilebesiranãéçºããã³åæ¥åããããã«éå®çã«äœ¿çšããã) ãããã³Rocheé åå
ã§zilebesiranãåæ¥åããããã®æä»çã©ã€ã»ã³ã¹ (Rocheã©ã€ã»ã³ã¹çŸ©åãšããŠéåçã«èšåããã)ã(ii) 補é ãå«ãéçºãµãŒãã¹
ã¢ã«ãã©ã ãã¡ãŒãã·ã¥ãŒãã£ã«ã«ãºç€Ÿ
ã³ã³ãã³ã¹ãé£çµè²¡åè«žè¡šã«é¢ãã泚èš
ïŒæªç¢ºå®ïŒ
ãã·ã¥éçºãµãŒãã¹ã®çŸ©åã§ãããžã¬ãã·ã©ã³ã®èŠå¶æ¿èªããµããŒãããèšåºäŸçµŠåã®æäŸãããã³ïŒiiiïŒãžã¬ãã·ã©ã³ã®æ¢åã®è£œé ããã»ã¹ã®æè¡ç§»è»¢ã§ãããã·ã¥ãã¯ãããžãŒãã©ã³ã¹ãã¡ãŒçŸ©åã ãã·ã¥åæã®å±¥è¡çŸ©åããã·ã¥å±¥è¡çŸ©åãšåŒã³ãŸãã éå»1é±éã¯æ ªäž»ã«ãšã£ãŠå€§å€ãªæéã§ãã£ããããåºæ¬çãªãã¡ã³ãã¡ã³ã¿ã«åæãè¡ããäœãåŠã¶ããšãã§ãããã調ã¹ãŠã¿ãŸãããã ãã·ã¥åæã®å±¥è¡çŸ©åã¯ããã·ã¥å±¥è¡çŸ©åãšããŠç·ç§°ãããŸãã
ãã·ã¥å¥çŽã§æŠèª¬ããããªãã·ã§ã³ããå®è¡çŸ©åãçããããéèŠãªæš©å©ãæã€ãã©ãããè©äŸ¡ãããªãã·ã§ã³ã¯ãããããã·ã¥ã«éèŠãªæš©å©ãäžããªãããããã·ã¥å¥çŽå
ã§ç¬ç«ããå±¥è¡çŸ©åãšããŠèæ
®ãããŸããã§ããã
äžèšã®çŽæãè©äŸ¡ããRocheã©ã€ã»ã³ã¹çŸ©åãRocheéçºãµãŒãã¹çŸ©åãRocheãã¯ãããžãŒãã©ã³ã¹ãã¡ãŒçŸ©åã¯ãã³ããŒãšã客æ§ã®é¢ä¿ãåæ ããŠãããããASC 606ã®ç¯å²å
ã®å±¥è¡çŸ©åãè¡šããŸããRocheã©ã€ã»ã³ã¹çŸ©åã¯ãæ©èœçãªç¥ç財ç£ãšèŠãªãããä»ã®å¥çŽäžã®çŽæãšã¯åºå¥ãããŸããRocheã¯ããããã®ã©ã€ã»ã³ã¹ãç¬èªã«ãŸãã¯ä»ã®å©çšå¯èœãªãªãœãŒã¹ãšãšãã«å©çšããããšãã§ããããã§ããã©ã€ã»ã³ã¹ã¯åæã«æäŸããããããå¥çŽç· çµæã«ã¯1ã€ã®å±¥è¡çŸ©åãšèŠãªãããŸããRocheéçºãµãŒãã¹çŸ©åã¯ãRocheãåææç«æã«ç§ãã¡ã移転ããã©ã€ã»ã³ã¹ãšå
±ã«éçºãµãŒãã¹ãå©çšã§ããããšãã§ãããããåºå¥ãããŸããzilebesiranã¯å¥çŽç· çµæã«ç¬¬2çžèšåºè©Šéšäžã§ãããããéçºãµãŒãã¹ã¯åæã®ç¥ç財ç£ãé倧ã«å€æŽãŸãã¯ã«ã¹ã¿ãã€ãºããããšã¯äºæ³ãããŸãããRocheãã¯ãããžãŒãã©ã³ã¹ãã¡ãŒçŸ©åã¯ãç§ãã¡ã®RNAiãã©ãããã©ãŒã ã®é²æ©ãšã第äžè
å¥çŽè£œé çµç¹ãå©çšããŠzilebesiranã補é ããããã«å©çšããããããåºå¥ãããŸãããããã£ãŠããããã顧客ãšã®å¥çŽã«ãããŠç¬ç«ããå±¥è¡çŸ©åã瀺ããŸãã
ç§ãã¡ã¯ãç§ãã¡ãšãã·ã¥ãäž¡æ¹ãšãåæ¥å掻åã«ç©æ¥µçãªåå è
ã§ãããååŒã®åæ¥çæåã«äŸåããéèŠãªãªã¹ã¯ãšå ±é
¬ã«ãããããŠãããããç±³åœã«ããããžã¬ãã·ã©ã³ã®å
±ååååã«é¢é£ããååçãªæŽ»åãASC 808ã®ç¯å²å
ã§å¥åã®å£åº§ãŠããããšèŠãªããŠããŸãã
ãã·ã¥åå®ã®éå§æã«ãASC 606ã«åºã¥ãååŒäŸ¡æ Œã¯$ã§ãããšå€æããŸãã857.0 çŸäžãåèšã¯310.0 çŸäžã®åæããš $547.0 ãã·ã¥ã®å±¥è¡çŸ©åã«é¢é£ããéçºã»è£œé ãµãŒãã¹ããã³æè¡ç§»è»¢ã«ããè²»çšåéã«ããå€å察䟡ã100äžä»¶è¿œå ãããŸãããç§ãã¡ã¯ãèªèããã环ç©åçé¡ã®å€§å¹
ãªé転ã¯èµ·ããããããªããšæèšã§ããªããšå€æããããããããã®æœåšçãªæ¯æãã«ã¯é«ãäžç¢ºå®æ§ãšãªã¹ã¯ããããããéçºãèŠå¶äžã®ãã€ã«ã¹ããŒã³ã«é¢é£ããå€å察䟡ã¯ãéå§æã«å®å
šã«å¶çŽãããåœåã®ååŒäŸ¡æ Œããé€å€ããããšå€æããŸããããŸãããã€ã€ã«ãã£ãšè²©å£²ãã€ã«ã¹ããŒã³ã¯ç¥ç財ç£ã®ã©ã€ã»ã³ã¹ã®ã¿ã«é¢ä¿ãããããASC 606ã®è²©å£²ãŸãã¯äœ¿çšéããŒã¹ã®ãã€ã€ã«ãã£ã®äŸå€ã«åºã¥ããååŒäŸ¡æ Œããé€å€ãããŠããããšãããããŸããã
Rocheã®ããã©ãŒãã³ã¹çŸ©åããšã«éå§æã®æšå®ã¹ã¿ã³ãã¢ãã³è²©å£²äŸ¡æ Œãéçºããåç¬åºæºã§å®æçã«è²©å£²ãããå Žåã®äŸ¡æ Œã決å®ããããšãç®çãšããŸãããRocheã©ã€ã»ã³ã¹çŸ©åã«å¯Ÿããæšå®ã®ã¹ã¿ã³ãã¢ããŒã³è²©å£²äŸ¡æ Œã¯ãäž»ã«ãåã¢ã³ããŒã©ã€ã»ã³ã¹ãŸãã¯ã¢ã¯ãã£ããã£ã«é¢é£ããå°æ¥ã®çŸéåçã®ç¢ºçéã¿çŸåšäŸ¡å€ã«åºã¥ããŠéçºããŸããããã®ãããªèŠç©ãããéçºããéã«ã¯ãé©çšãããåžæ³ãšé¢é£ãããšã³ãã£ãã£åºæã®èŠå ãæåã®ç¢ºçãzilebesiranãéçºããããã«å¿
èŠãªæéãå²åŒçãèæ
®ããŠãäºæž¬ãããåçã決å®ããããã«å€æãé©çšããŸãããRocheéçºãµãŒãã¹çŸ©åããã³Rocheãã¯ãããžãŒç§»è»¢çŸ©åã«å«ãŸãããµãŒãã¹ããã³èšåºäŸçµŠã®æšå®ã¹ã¿ã³ãã¢ãã³è²©å£²äŸ¡æ Œã¯ããµãŒãã¹ãå®è¡ããããã«å¿
èŠãªäœæ¥ã®ã¬ãã«ãšããã«ã¿ã€ã ã®åçåŸæ¥å¡ãšäºæ³ããããªãœãŒã¹ãã³ãããããããã®ã³ã¹ãã«å ããŠãåççãªããŒãžã³ãäž»ã«èæ
®ããŠéçºãããŸããã
ãã·ã¥éçºå¥çŽã®çŸ©åããã³ãã·ã¥æè¡ç§»è»¢ã®çŸ©åã«é¢é£ããèŠç©ããã«åºã¥ãæãæ»ãã«é¢é£ããå€æ°ã®é
åããå€æ°ã®æ¯æãæ¡ä»¶ãéæããããã®åªåã«é¢é£ããŠããåå±¥è¡çŸ©åã«å²ãåœãŠãååã®å±¥è¡çŸ©åã«å¯ŸããŠå€æ°ã®éšåãå®å
šã«å²ãåœãŠãããšã¯ãå¥çŽã®å
šãŠã®å±¥è¡çŸ©åããã³æ¯ææ¡ä»¶ãèæ
®ããASC606ã®å²ãåœãŠç®æšã«äžèŽããŠããŸãã ASC606ã®å²ãåœãŠç®æšãèæ
®ãããšãåºå®åæãã®èæ
®é¡105çŸäžãã«ãå®å
šã«ãã·ã¥ã©ã€ã»ã³ã¹çŸ©åã«å²ãåœãŠãåºå®èæ
®ã®å€ãšãéçºããã³èŠå¶åœå±ã®ãã€ã«ã¹ããŒã³ã販売ããŒã¹ã®ãã€ã«ã¹ããŒã³ãããã³ãã€ã€ãªãã£ã®æ®é«ãæåŸ
å€ã§åç®ããããšã§ã¹ã¿ã³ãã¢ãã³è²©å£²äŸ¡æ Œã«è¿ã¥ããããšãã§ããŸãããããã£ãŠãåºå®åæãã®èæ
®é¡ãå®å
šã«Rocheã©ã€ã»ã³ã¹çŸ©åã«å²ãåœãŠãããšã¯ãå¥çŽã®å
šãŠã®å±¥è¡çŸ©åããã³æ¯ææ¡ä»¶ãèæ
®ããASC 606ã®å²ãåœãŠç®æšã«äžèŽããŠããŸãã310.0 105çŸäžãã«ã®åºå®åæãã®èæ
®é¡ãå®å
šã«ãã·ã¥ã©ã€ã»ã³ã¹çŸ©åã«å²ãåœãŠãæ®ãéçºããã³èŠå¶åœå±ã®ãã€ã«ã¹ããŒã³ã販売ããŒã¹ã®ãã€ã«ã¹ããŒã³ãããã³ãã€ã€ãªãã£ã®æåŸ
å€ã®çŸåšã®èæ
®ã®å¶éã解æ¶ãããããã¯è²©å£²ãããã¯äœ¿çšããŒã¹ã®ãã€ã€ã«ãã£äŸå€ãæž¡ããã®ãšããå Žåããããã®å€ã®åèšããRocheã©ã€ã»ã³ã¹çŸ©åã®ã¹ã¿ã³ãã¢ãã³è²©å£²äŸ¡æ Œã«è¿ã¥ããŸãã
ãã·ã¥ã®ã©ã€ã»ã³ã¹çŸ©åã¯ãã©ã€ã»ã³ã¹ããã·ã¥ã«è²æž¡ããããšã§äžå®æç¹ã§æºããããŸããã ã©ã€ã»ã³ã¹ã®ç®¡çã¯å¹åçºçæ¥ã«ç§»è»¢ããããã·ã¥ã¯ã©ã€ã»ã³ã¹ãå©çšããæ©æµãåããããšãã§ããŸããã ãã·ã¥éçºã®ããã«
ã¢ã«ãã©ã ãã¡ãŒãã·ã¥ãŒãã£ã«ã«ãºç€Ÿ
ã³ã³ãã³ã¹ãé£çµè²¡åè«žè¡šã«é¢ãã泚èš
ïŒæªç¢ºå®ïŒ
ãµãŒãã¹çŸ©åã«ã€ããŠã¯ãè²»çšã«åºã¥ãå
¥åæ¹æ³ãçšããŠã矩åã®ç·äºæ³è²»çšã«å¯Ÿããè²»çšãæ
å ±ãåºæºã«ååæããšã«æ¯äŸããããã©ãŒãã³ã¹ã枬å®ããŸããæåŸ
ãããå
šäœçãªåªåã®å²åã決å®ããŸãããã®æ¯çã¯ã矩åã«å²ãåœãŠãããååŒäŸ¡æ Œã«é©çšãããŸããèŠç©ãããéçºããããã»ã¹ã«ãããŠãåœç€Ÿã®ç®¡çéšéã¯éèŠãªå€æãäžããŠããŸããåå ±åææ«ã«ãããŠãååŒäŸ¡æ Œãåè©äŸ¡ããŸãã
2024幎6æ30æ¥æç¹ã§ãç·ååŒäŸ¡æ Œã¯922.0çŸäžãã«ãšæ±ºå®ããã2023幎12æ31æ¥ããã®å¢å é¡ã¯$çŸäžã§ããå¢å ã¯ãKARDIA-3ãã§ãŒãº2ç 究ã®æåã®æ£è
æäžã®éçºãã€ã«ã¹ããŒã³ã®éæã«ãããã®ã§ãã922.0 1000äžãã«å¢å ããŸãã65.0 KARDIA-3ãã§ãŒãº2ç 究ã§æåã®æ£è
ãæäžãããéçºã®ãã€ã«ã¹ããŒã³ãéæããããããå¢å é¡ã¯$çŸäžã§ãã
äžèšã®è¡šã¯ãæéäžã«ããã売äžé«æŽ»åã«å ããŠãåæ¥çžŸçŸ©åã«å²ãåœãŠãããååŒäŸ¡æ Œã®æŠèŠããååäœã§æäŸããŸãã
売äžé«ã¯èªèãããŠãã ååŒäŸ¡æ Œãå²ãåœãŠããã 6æ30æ¥ãŸã§ã®3ãæé 6æ30æ¥ãŸã§ã®6ãæé å±¥è¡ã®çŸ©å 2024幎6æ30æ¥çŸåš 2024 2023 2024 2023 ãã·ã¥ã©ã€ã»ã³ã¹çŸ©å
$ 375,000  $ â  $ â  $ 65,000  $ â  ãã·ã¥éçºãµãŒãã¹çŸ©å
545,000  12,797  â  19,948  â  ãã·ã¥æè¡ç§»è»¢çŸ©å
2,000 Â â Â â Â â Â â Â $ 922,000 Â $ 12,797 Â $ â Â $ 84,948 Â $ â Â
2024幎6æ30æ¥æç¹ã§ãæºããããŠããªããã·ã¥ã®å±¥è¡çŸ©åã«å²ãåœãŠãããååŒäŸ¡æ Œã®åèšé¡ã¯$ã§ãããã®ååŒäŸ¡æ Œã¯ããµãŒãã¹ãå®æœãããã«ã€ãããã·ã¥å¥çŽã®æéäžã«èªèãããèŠèŸŒã¿ã§ãã503.1 çŸäžãã«ã§ãã
ãªãžã§ããã³ãã¡ãŒãã·ã¥ãŒãã£ã«ã«ãºç€Ÿãæè¿äºæ³éãã«åŒ·ã第2ååæãå ±åãããããå€ãã®ã¢ããªã¹ãã¯ããã®äŒæ¥ãèµèããæ²»çã®é åã§æãèå³æ·±ãäŒæ¥ã®1ã€ã§ãããšäž»åŒµããŠããŸãã
æŠèŠ
2019幎ãç§ãã¡ã¯Regeneronãšã®ã°ããŒãã«ãªæŠç¥çææºãç· çµããçŒãšäžæ¢ç¥çµç³»ããŸãã¯CNSã§çºçŸããæ²»çæšçã«å¯ŸåŠããããšã«ãããåºç¯ãªçŸæ£ã®RNAiæ²»çæ³ã®çºèŠãéçºãåæ¥åãè¡ãããšãšãªããŸããããã®ææºã¯Regeneronåæ¥ãšåŒã°ããRegeneron Master Agreementãšãããã¹ã¿ãŒå¥çŽã«ãã管çãããŠããŸããRegeneron Master Agreementã«åºã¥ããç§ãã¡ã¯Regeneronãš(i)ãC5è£äœåªä»çŸæ£ã®C5 siRNAãšããŠçŸåšéçºäžã®cemdisiranã®åå€çæ³ã®ç¶ç¶çãªéçºãã«ããŒããå
±åååå¥çŽïŒC5 Co-Coåæ¥å¥çŽïŒãç· çµãã(ii)ãRegeneronã®pozelimabãšcemdisiranã®æC5æäœ-siRNAã®äœµçšãè©äŸ¡ããããã®ã©ã€ã»ã³ã¹å¥çŽïŒC5 License AgreementïŒãç· çµããŸããããããã®å¥çŽã¯äžç·ã«äº€æžãããããããã¹ã¿ãŒå¥çŽãC5 Co-Coåæ¥å¥çŽãC5 License Agreementã¯äžæ¬ããŠåãæ±ãããŸããã
2022幎11æãRegeneronã¯C5 Co-Coã³ã©ãã¬ãŒã·ã§ã³å¥çŽã«åºã¥ãæš©å©ãè¡äœ¿ããŠãã»ã ãã·ã©ã³åå€ã®ãããªãéçºããã³åååããã®è±éãéžæããŸãããRegeneronãè±éã決å®ããçµæãC5 Co-Coã³ã©ãã¬ãŒã·ã§ã³å¥çŽã«åºã¥ã蚱諟ã¯ç§ãã¡ã«æ»ããã»ã ãã·ã©ã³åå€ã®éçºããã³åååã«ç¬å çãªæš©å©ãæã¡ãRegeneronã¯ã¢ãã»ã©ããŒã®ããã°ã©ã ã«ãããè²»çšã«å
±åã§è² æ
ããªããªããŸãããRegeneronã¯ãã»ã ãã·ã©ã³ã®ã¢ãã»ã©ããŒã®çŽå£²äžé«ã«éå±€åŒã®äºæ¡ã®ãã€ã€ã«ãã£ãåŒãç¶ãåãåãè³æ ŒããããŸããã
2024幎6æãåœç€Ÿã¯ä¿®æ£ããå調æŽãããC5ã©ã€ã»ã³ã¹å¥çŽããä¿®æ£ãããC5ã©ã€ã»ã³ã¹å¥çŽããšç· çµããC5 Co-Coã³ã©ãã¬ãŒã·ã§ã³å¥çŽãçµäºããRegeneronã«åå€ãšããŠã®cemdisiranã®äžççãªã©ã€ã»ã³ã¹ã«å ããæC5æäœãšã®äœµçšã«ããcemdisiranã®äœ¿çšèš±è«Ÿãä»äžããŸãããä¿®æ£ãããC5ã©ã€ã»ã³ã¹å¥çŽã«ãããRegeneronã¯åå€ãšæC5æäœãšã®äœµçšã«ããcemdisiranã®éçºã補é ãåæ¥åã«é¢ããŠè²¬ä»»ãè² ãããšãšãªããŸããåœç€Ÿã¯ãä¿®æ£ãããC5ã©ã€ã»ã³ã¹å¥çŽã®äžç°ãšããŠãcemdisiranã®è£œé æè¡ç§»è»¢ãµãŒãã¹ãRegeneronã«æäŸããŸããRegeneronã¯ãåœç€Ÿã«åæéãšããŠ$ millionãæ¯æããåå€ãšããŠã®cemdisiranã«å¯ŸããèŠå¶æ¿èªãåããå Žåã«ã¯äžå®ã®ãã€ã«ã¹ããŒã³å ±é
¬ããçŽå£²äžé«ã«å¿ããäºæ¡å°ã®ãã€ã€ã«ãã£ãŒãæ¯æããŸããä¿®æ£ãããC5ã©ã€ã»ã³ã¹å¥çŽã«ãããcemdisiranã䜵çšè£œåã®äžéšãšããŠäœ¿çšãããå Žåã«ãåœç€Ÿã¯äœäºæ¡ã®ãã€ã€ã«ãã£ãŒããã³æ倧ã§$ millionã®åæ¥çãã€ã«ã¹ããŒã³ãåãåãæš©å©ã¯å€æŽãããŸããã§ããã10.0 $millionãåæããšããŠRegeneronãæäŸããåå€ãšããŠã®cemdisiranãèŠå¶æ¿èªãåããå Žåã«ã¯ãäžå®ã®ãã€ã«ã¹ããŒã³å ±é
¬ããçŽå£²äžé«ã«å¿ãã段éçãªäºæ¡ã®ãã€ã€ã«ãã£ãŒãåãåãããšã«ãªããŸãã325.0 cemdisiranã䜵çšè£œåã®äžéšãšããŠäœ¿çšãããå Žåã«ãåœç€Ÿã¯äœäºæ¡ã®ãã€ã€ã«ãã£ãŒããã³æ倧ã§$ millionã®åæ¥çãã€ã«ã¹ããŒã³ãåãåãæš©å©ã¯ãä¿®æ£ãããC5ã©ã€ã»ã³ã¹å¥çŽã«ããå€æŽãããŸããã§ããã
Regeneronã³ã©ãã¬ãŒã·ã§ã³ã®èŠå®ã«åŸããåœç€Ÿã¯åæç 究æéãšããŠæ倧ãŸã§RNAiæ²»çè¬ãçºèŠããããã«Regeneronãšç¬å çã«ååããŠçŒããã³CNSçŸæ£ã«å¯Ÿããç 究ãè¡ã£ãŠããŸãã äžå¹Ž ïŒã€ãã·ã£ã«ãªãµãŒãã¿ãŒã ãšåŒã°ããïŒæéå
ã«ãRegeneronã¯ãåæç 究æéã®å»¶é·ïŒãªãµãŒãã¿ãŒã ãšã¯ã¹ãã³ã·ã§ã³ãšåŒã°ããïŒã®ãªãã·ã§ã³ãæã£ãŠããŸãã
ã¢ã«ãã©ã ãã¡ãŒãã·ã¥ãŒãã£ã«ã«ãºç€Ÿ
ã³ã³ãã³ã¹ãé£çµè²¡åè«žè¡šã«é¢ãã泚èš
ïŒæªç¢ºå®ïŒ
æŽã«æåã®ç 究æéã»ç 究æéãšãã«ãè¿œå æéãæ¯æãããšã«ãããæ倧ã§â¡å¹Žé延é·ããããšãã§ããŸãã 5幎 è¿œå ã®ç 究æé延é·æ$â¡çŸäžãã«ãããããŸããæªäœ¿çšã®èè³é¡ã¯3åãã«ã§ãã Regeneronãšã®ååã¯ãèèã«çºçŸããéºäŒåãã¿ãŒã²ããã«ããRNAiæ²»çæ³ã®äžéšãã«ããŒããŸãã
ãªãžã§ããã³ã¯ãéå®çãªäŸå€ãé€ããç®ã®çŸæ£ã察象ãšããå
šããã°ã©ã ã®éçºããã³åæ¥åã®ãªãŒããè¡ããåœç€Ÿã¯ã©ã€ã»ã³ã¹å¥çŽã®æ¡ä»¶ã«åŸã£ãŠãç¹å®ã®æœåšçãªãã€ã«ã¹ããŒã³ããã³ãã€ã€ã«ãã£æ¯æãã®æš©å©ãæããŸããåœç€Ÿãšãªãžã§ããã³ã¯ãCNSããã³èèããã°ã©ã ã«é¢ããŠãªãŒããŒã·ããã亀äºã«æ
åœããŠããããªãŒãããŒãã£ãŒã¯ã°ããŒãã«éçºããã³åæ¥è²¬ä»»ãä¿æããŸãããã®ãããªCNSããã³èèããã°ã©ã ã«ã€ããŠã¯ããªãŒãåè£è
ã®éžææã«ã䞡瀟ã¯åæãã圢åŒã®å
±åã³ã©ãã¬ãŒã·ã§ã³å¥çŽã«åå ãããªãã·ã§ã³ãæãã䞡瀟ã¯ããã°ã©ã ã®ãã¹ãŠã®éçºããã³åæ¥å掻åã®ã³ã¹ããšå©çãå¹³çã«å
±æããŸããéãªãŒãããŒãã£ãŒããç¹å®ã®CNSãŸãã¯èèããã°ã©ã ã«é¢ããŠå
±åã³ã©ãã¬ãŒã·ã§ã³å¥çŽã«åå ããªãããšãéžæããå Žåãåœç€Ÿãšãªãžã§ããã³ã¯ããã®ãããªããã°ã©ã ã«é¢ããŠã©ã€ã»ã³ã¹å¥çŽãç· çµãããªãŒãããŒãã£ãŒã¯ã©ã€ã»ã³ã¹å¥çŽã®ç®çã®ããã®ãã©ã€ã»ã³ã·ãŒããšãªããŸããCNSãŸãã¯èèããã°ã©ã ã®ãªãŒãããŒãã£ãŒãå
±åã³ã©ãã¬ãŒã·ã§ã³å¥çŽã«åå ããªãããšãéžæããå Žåãåœç€Ÿãšãªãžã§ããã³ã¯ãã®ãããªããã°ã©ã ã«é¢ããŠã©ã€ã»ã³ã¹å¥çŽãç· çµããããã°ã©ã ã®ãªãŒããŒã·ããã¯ä»ã®ããŒãã£ãŒã«ç§»è¡ãã以åã®éãªãŒãããŒãã£ãŒã¯ã©ã€ã»ã³ã¹å¥çŽã®ç®çã®ããã®ãã©ã€ã»ã³ã·ãŒããšãªããŸãã
Regeneron ãã¹ã¿ãŒã¢ã°ãªãŒã¡ã³ãã«é¢é£ããŠãçŒã®ããã°ã©ã ã«ãããŠæ©æã®èšåºéçºã«ãããç¹å®ã®åºæºãéæããå Žåãããã«5çŸäžãã«ãåãåãè³æ ŒããããŸãããŸããåæç 究æéäžã«æåãããããã°ã©ã ãåŒãç¶ãé²ããŠãããRegeneron ã¯ãã®æéäžã«1幎ã«ã€ãè¿œå ã®ã¿ãŒã²ãããæåããæš©å©ãæã¡ãŸãããããåããã°ã©ã ã«å¯ŸããRegeneron ã¯ããã°ã©ã éå§æã«5çŸäžãã«ã®è³éãæäŸãããªãŒãåè£ã®åå®æã«ã¯ããã«5çŸäžãã«ã®è³éãæäŸããŸããRegeneron ãç 究æéã®å»¶é·ã®ãªãã·ã§ã³ãè¡äœ¿ããå ŽåãRegeneron ã¯1幎ã«ã€ãè¿œå ã®ã¿ãŒã²ãããæåããæš©å©ãä¿æããç§ãã¡ã¯Extensionæéäžã«ãåããã°ã©ã éå§æã«5çŸäžãã«ã®è³éãåãåãè³æ ŒãããããªãŒãåè£åå®æã«ã¯ããã«5çŸäžãã«ãåãåãããšãã§ããŸãã100.0 åæèšåºéçºã«ãããç¹å®ã®åºæºãéæããå ŽåãçŒã®ããã°ã©ã ã«é¢ããŠãã€ã«ã¹ããŒã³æ¯æããšããŠããã«5çŸäžãã«ãåãåãè³æ ŒããããŸãã ã«ããŽãªãŒ6ã®6ã€ã®èšé²ãç ŽããŠã©ãŒã¿ãŒã¹ã©ã€ããŒããæµ·ãã154ãã£ãŒãäžç©ºã«ããã¯ã©ãŠã³ãºãšããžäœéšãªã©ãæŒãå€ã楜ããã8ã€ã®ç®çå°ã«ã¯ããããã楜ãããã¢ãã¬ããªã³ããã¯ãã¯ãããããããããªåããŠã®ãã®ã次ã®ã¬ãã«ã®ãæ°ã«å
¥ãããããŸãããããŠã1é±éã®ãã¡ã®1æ¥çšã®7ã€ã®ããŒã«ããããæµ·äžåã®åãäžãåŒç¡éããŒã«ãªã©ããã€ããã®æ¹æ³ã¯æ¯é¡ãããŸããã ãã®æéäžãRegeneron ã¯1幎ã«ã€ãè¿œå ã®ã¿ãŒã²ãããæåããæš©å©ãæã¡ãŸãã2.5 åæç 究ã«ãããŠãRegeneron ã¯åããã°ã©ã éå§æã«5çŸäžãã«ã®è³éãæäŸããŸãã2.5 åæç 究ã«ãããŠãRegeneron ã¯ãªãŒãåè£åå®æã«ããã«5çŸäžãã«ãæäŸããŸãã ã«ããŽãªãŒ6ã®6ã€ã®èšé²ãç ŽããŠã©ãŒã¿ãŒã¹ã©ã€ããŒããæµ·ãã154ãã£ãŒãäžç©ºã«ããã¯ã©ãŠã³ãºãšããžäœéšãªã©ãæŒãå€ã楜ããã8ã€ã®ç®çå°ã«ã¯ããããã楜ãããã¢ãã¬ããªã³ããã¯ãã¯ãããããããããªåããŠã®ãã®ã次ã®ã¬ãã«ã®ãæ°ã«å
¥ãããããŸãããããŠã1é±éã®ãã¡ã®1æ¥çšã®7ã€ã®ããŒã«ããããæµ·äžåã®åãäžãåŒç¡éããŒã«ãªã©ããã€ããã®æ¹æ³ã¯æ¯é¡ãããŸããã ç 究æéã®å»¶é·æéäžã¯ãRegeneron ã¯1幎ã«ã€ãè¿œå ã®ã¿ãŒã²ãããæåããæš©å©ãä¿æããç§ãã¡ã¯åããã°ã©ã éå§æã«5çŸäžãã«ã®è³éãåãåãè³æ ŒãããããªãŒãåè£åå®æã«ã¯ããã«5çŸäžãã«ãåãåãããšãã§ããŸãã2.5 ç 究æéã®å»¶é·æéäžãåããã°ã©ã éå§æã«5çŸäžãã«ããªãŒãåè£åå®æã«ã¯ããã«5çŸäžãã«ãåãåãããšãã§ããŸãã2.5 ç 究æéã®å»¶é·æéäžãåããã°ã©ã éå§æã«5çŸäžãã«ããªãŒãåè£åå®æã«ã¯ããã«5çŸäžãã«ãåãåãè³æ ŒããããŸãã
ãã®åŸç· çµãããä»»æã®ã©ã€ã»ã³ã¹å¥çŽã«ã€ããŠã¯ãã©ã€ã»ã³ã·ãŒã¯åå補åã®éçºããã³åååã«é¢é£ããŠçºçããèªå·±ã®è²»çšããã³çµè²»ã«äžè¬çã«è²¬ä»»ãè² ãããšã«ãªããŸãããŸããã©ã€ã»ã³ã·ãŒã¯ãååæ¥è£œåã«ã€ããŠç·é¡$äžãã«ãŸã§ã®éçºããã³/ãŸãã¯åååã®ãã€ã«ã¹ããŒã³ãã€ã¡ã³ããæ¯æãããšã«ãªããŸããããã«ãã©ã€ã»ã³ã¹å¥çŽã®äžã§è©²åœããåæ¥è£œåãåããŠåæ¥è²©å£²ãããåŸãã©ã€ã»ã³ã·ãŒã¯éåžžã®åæžãåããåå補åã®å¹ŽéçŽå£²äžé«ã«åºã¥ããäœäºæ¡ãã%ãŸã§ã®æ®µéçãªãã€ã€ã«ãã£ãã€ã¡ã³ããæ¯æãå¿
èŠããããŸãã150.0 ååæ¥è£œåã«ã€ããŠãã©ã€ã»ã³ã·ãŒã¯ç·é¡$çŸäžãã«ãæ¯æãããšã«ãªããåååã®ãã€ã«ã¹ããŒã³ãã€ã¡ã³ããå«ãŸããŸãããã®åŸãã©ã€ã»ã³ã¹å¥çŽã®äžã§è©²åœããåæ¥è£œåãåããŠåæ¥è²©å£²ãããå Žåãã©ã€ã»ã³ã·ãŒã¯éåžžã®åæžãåããåå補åã®å¹ŽéçŽå£²äžé«ã«åºã¥ã段éçãªãã€ã€ã«ãã£ãã€ã¡ã³ããæ¯æãå¿
èŠããããŸãããã€ã€ã«ãã£ãã€ã¡ã³ãçã¯äœäœäºæ¡ãã%ãŸã§ãšãªã£ãŠããŸãã 20 åæ¥è£œåã®ç·å¹Žéããã売äžé«ã«åºã¥ããã©ã€ã»ã³ã·ãŒã¯éåžžã®åæžãåããäžå®ã®æ®µéçãªãã€ã€ã«ãã£ãã€ã¡ã³ããæ¯æãå¿
èŠããããŸãããã€ã€ã«ãã£çã¯äœäºæ¡ãã%ãŸã§ãšãªã£ãŠããŸãã
ãã®åŸç· çµãããååçµåå¥çŽã«ã€ããŠã¯ãéçºããã³ååå掻åã®ãã¹ãŠã®è²»çšãšå©çãç§ãã¡ãšãªãžã§ããã³ãå¹³çã«åæ
ããŸããåœç€Ÿã®è²»çšã®æãæ»ãã¯ãèŠçŽãããé£çµæçèšç®æžã§ç 究éçºè²»ã®åæžãšå
æ¬æ倱ãšããŠèšäžãããŸããããåœäºè
ããªããã¢ãŠãæš©ãè¡äœ¿ããå Žåã該åœããco-coã³ã©ãã¬ãŒã·ã§ã³å¥çŽã«åºã¥ãã³ã©ãã¬ãŒã·ã§ã³è£œåã®éçºãšåååã«é¢é£ããŠçºçãããã¹ãŠã®è²»çšãšçµè²»ã¯ãå®ãããããã€ã³ããéããŠç¶ç¶çã«è²»çšãåæ
ããããšãæ¡ä»¶ãšããŠãäž»å°åœäºè
ãè² æ
ããŸããååçµåå¥çŽã«åºã¥ããŠè©²åœããã³ã©ãã¬ãŒã·ã§ã³è£œåãåããŠåæ¥çã«è²©å£²ããåŸã«ãããåœäºè
ããªããã¢ãŠãæš©ãè¡äœ¿ããå Žåãäž»å°åœäºè
ã¯äžå®ã®æ®µéçãªãã€ã€ãªãã£ã®æ¯æããè¡ãå¿
èŠããããŸãããã€ã€ãªãã£ã®æ¯æãã¯ã2æ¡å°ãšããäœãéé¡ãã 20 %ãã³ã©ãã¬ãŒã·ã§ã³è£œåã®å¹Žéç·å£²äžé«ãšãªããã¢ãŠãæš©ã®è¡äœ¿ã®ã¿ã€ãã³ã°ã«åºã¥ããŠãçžææ¹ã«ãæ
£ç¿çãªåæžãšãªããã¢ãŠã移è¡è²»çšã®åæžãæ¡ä»¶ãšããŸãã
å¥çŽå€æŽ
ASC 606ã«åºã¥ããŠãå¥çŽã®ä¿®æ£ãåç¬ã®å¥çŽãšããŠèªèããããã«å¿
èŠãªèŠä»¶ãæºãããªããããè¿œå ã®ç¬ç«ãã財貚ããµãŒãã¹ã«äº€æããã察䟡ã¯åç¬ã®è²©å£²äŸ¡æ Œãåæ ããŠããŸããããã®ãããç§ãã¡ã¯C5ã©ã€ã»ã³ã¹å¥çŽããã³Regeneronãã¹ã¿ãŒå¥çŽã1ã€ã®çµåå¥çŽãšããŠèªèããŠããŸããä¿®æ£æ¥ã¯ãC5ã©ã€ã»ã³ã¹å¥çŽã®2024幎6æã®å¹åçºçæ¥ãšãããŸããã
å¥çŽå€æŽã«äŒŽãç§ãã¡ã®å±¥è¡çŸ©åã«ã¯ã(i) ç 究ã©ã€ã»ã³ã¹ããã³ç 究ãµãŒãã¹ãå«ãŸããå
±åã§ç 究ãµãŒãã¹å±¥è¡çŸ©åãšããŠèšåããã(ii) çµã¿åããçæ³çšã®ã»ã ãã·ã©ã³ã®äžçã©ã€ã»ã³ã¹ãããã³è£œé ããã³éçºãµãŒãã¹å±¥è¡çŸ©åãå«ãŸããå
±åã§C5ã©ã€ã»ã³ã¹å±¥è¡çŸ©åãšããŠèšåããã(iii) åå€çæ³çšã®ã»ã ãã·ã©ã³ã®äžçã©ã€ã»ã³ã¹ã§ããC5 Monotherapyå±¥è¡çŸ©åãããã³(iv) ã»ã ãã·ã©ã³ã®æ¢å補é ããã»ã¹ã®æè¡ç§»è»¢ã§ããRegeneron Technology Transferå±¥è¡çŸ©åãå«ãŸããŸãã
ä¿®æ£ãããC5ã©ã€ã»ã³ã¹å¥çŽã¯ãå¥çŽä¿®æ£åã«ãªãžã§ããã³ãšã®ã°ããŒãã«ã§æŠç¥çã³ã©ãã¬ãŒã·ã§ã³ãéå§ããæç¹ã§ã®å±¥è¡çŸ©åã§ãã£ãç 究ãµãŒãã¹çŸ©åãŸãã¯C5ã©ã€ã»ã³ã¹çŸ©åãå€æŽããŸããã§ãããä¿®æ£ãããC5ã©ã€ã»ã³ã¹å¥çŽã®çµæ äº C5åå€çæ³çŸ©åãšãªãžã§ããã³æè¡ç§»è»¢çŸ©åãªã©ã®è¿œå ã®å±¥è¡çŸ©åãC5åå€çæ³ã®çŸ©åãèæ
®ãããŸã
ã¢ã«ãã©ã ãã¡ãŒãã·ã¥ãŒãã£ã«ã«ãºç€Ÿ
ã³ã³ãã³ã¹ãé£çµè²¡åè«žè¡šã«é¢ãã泚èš
ïŒæªç¢ºå®ïŒ
Regeneronã¯ãcemdisiranåå€ã©ã€ã»ã³ã¹ãç¬èªãŸãã¯ä»ã®å®¹æã«å©çšå¯èœãªãªãœãŒã¹ãšå
±ã«å©çšã§ãããã®ã©ã€ã»ã³ã¹ã¯å¥çŽã®ä»ã®çŽæãšã¯å¥åã«èå¥ã§ããŸããRegeneronã®ãã¯ãããžãŒãã©ã³ã¹ãã¡ãŒçŸ©åã¯ãcemdisiranãèšåºéçºã®é«åºŠãªæ®µéã«ããããµãŒãããŒãã£ã®å¥çŽè£œé çµç¹ãå©çšããŠcemdisiranã補é ããŠãããããæè¡ç§»è»¢ããªããŠããåœç€Ÿãã移転ãããcemdisiranåå€ã©ã€ã»ã³ã¹ã«ãã£ãŠå©çãåŸãããšãã§ããŸãããããã£ãŠãC5 Monotherapy矩åãšRegeneron Technology Transfer矩åã¯ãããããåå¥ã®å±¥è¡çŸ©åãè¡šããŸãã
å€æŽæ¥çŸåšã$ã§æ°ããååŒäŸ¡æ Œãèšå®ããŸããã329.7 çºçæ¥çŸåšã®æ®ãã®å
æãåç$ãè¡šãã$çŸäžã®å¢äŸ¡èšç®ã«åºã¥ãååŒäŸ¡æ Œãæ°ãã確ç«ããŸããã260.3 Research Services ObligationãC5 License ObligationãRegeneron Technology Transfer Obligationããã³Amended C5 License Agreementã«é¢ããèŠç©ãã®è¿éããã³ãã€ã«ã¹ãã³ã«é¢é£ãã$çŸäžã®å€æ°èšç®ããã³$çŸäžã®äºåæ¯æãã«ã€ããŠã$çŸäžã®å€æ°èšç®ãç¬èªã®å±¥è¡çŸ©åã«å²ãåœãŠãŸãããå€æ°æ¯æãã®æ¡ä»¶ãå±¥è¡çŸ©åã®å±¥è¡ã«å¯æ¥ã«é¢é£ããŠãããããå
šãŠã®å±¥è¡çŸ©åãšæ¯ææ¡ä»¶ãèæ
®ãããšãäœãã®å€æ°æ¯æé¡ãå®å
šã«å±¥è¡çŸ©åã«å²ãåœãŠãããšã¯ãå¥çŽã«ãããæ©çãŸãã®ç®çã«é¢ããŠASC 606ã«æºæ ããŠããŸãã59.4 Research Services ObligationãC5 License ObligationãRegeneron Technology Transfer Obligationã«é¢ããèŠç©ããã®è¿éããã³ãã€ã«ã¹ãã³ãããã³Amended C5 License Agreementã«é¢ãã$çŸäžã®åæãã«ã€ããŠãå€æŽæ¥çŸåšã®å®è¡å¯èœãªè²¬ä»»ã®å±¥è¡ãšé£åããå€æ°å ±é
¬ã«ã€ããŠã®å²ãåœãŠãèæ
®ããŠããã®$çŸäžãå
šãŠã®å±¥è¡çŸ©åãšæ¯ææ¡ä»¶ãèæ
®ããŠãããããã®å±¥è¡çŸ©åã«å¯ŸããŠå®å
šã«å²ãåœãŠãŸããã10.0 Amended C5 License Agreementã«é¢é£ãã$çŸäžã®åæãã«ã€ããŠããããæåã®å±¥è¡çŸ©åã«å²ãåœãŠãŸããã59.4 å€æ°æ¯æé¡ã®$çŸäžããå€æ°æ¯æãã®æ¡ä»¶ãå±¥è¡çŸ©åã®å±¥è¡ã«å¯æ¥ã«é¢é£ããŠãããããå
šãŠã®å±¥è¡çŸ©åãšæ¯ææ¡ä»¶ãå¥çŽã«èæ
®ããŠãããããã®å±¥è¡çŸ©åã«å¯ŸããŠå®å
šã«å²ãåœãŠãããšã¯ASC 606ã®å²ãåœãŠç®çã«äžèŽããŠããŸãã
èŠå¶äžã®ãã€ã«ã¹ããŒã³ã«é¢é£ããå€æ°å ±é
¬ã«ã€ããŠã¯ãäžç¢ºå®æ§ãšãªã¹ã¯ãé«ããããå®å
šã«å¶çŽãããååŒäŸ¡æ Œããé€å€ããããšã決å®ããŸããããŸãã环ç©èªèé¡ã«å¯ŸããŠå€§å¹
ãªé転ãçºçããããšã確å®ã§ã¯ãªããšå€æã§ããªãã£ãããããããã®æœåšçãªæ¯æããååŒäŸ¡æ Œããé€å€ããããšã決å®ããŸããããã€ã€ã«ãã£ãšè²©å£²ããŒã¹ã®ãã€ã«ã¹ããŒã³ã¯ãç¥ç財ç£ã®ã©ã€ã»ã³ã¹ã«ã®ã¿é¢ä¿ããŠãããããASC 606ã®è²©å£²ãŸãã¯äœ¿çšããŒã¹ã®ãã€ã€ã«ãã£äŸå€ã®äžã§ååŒäŸ¡æ Œããé€å€ãããŸããã
æŽæ°æ¥æç¹ã§ãåæ¥çžŸçŸ©åã«å¯ŸããååŒäŸ¡æ Œã¯ä»¥äžã®éãã§ãïŒåäœïŒååïŒïŒ
å±¥è¡ã®çŸ©å åç¬è²©å£²äŸ¡æ Œ åºå®å¯ŸäŸ¡
å²ãåœãŠãããå¯å€å¯ŸäŸ¡
ååŒå
šäœäŸ¡æ Œ
ç 究ãµãŒãã¹å¥çŽ $ 78,820  $ 45,469  $ 30,000  $ 75,469  C5ã©ã€ã»ã³ã¹å¥çŽçŸ©å $ 53,745  31,004  25,386  56,390  C5åå€å¥çŽçŸ©å
$ 332,000  191,520  â  191,520  ãªãžã§ããã³ãã¯ãããžãŒç§»è»¢å¥çŽçŸ©å
$ 4,000 Â 2,307 Â 4,000 Â 6,307 Â $ 270,300 Â $ 59,386 Â $ 329,686 Â
調æŽåŸãåºå®ã®èæ
®ã¯ã管çãéèŠãªå€æãè¡ã£ãå矩åã®çžå¯ŸçãªèŠèŸŒã¿åç¬è²©å£²äŸ¡æ Œã«åºã¥ããŠãããããã®çŸ©åã«å²ãåœãŠãããŸãããç§ãã¡ã¯ãæ®ãã®ç 究ãµãŒãã¹ã®çŸ©åãæ®ãã®C5ã©ã€ã»ã³ã¹ã®çŸ©åãããã³æ°ããRegeneron Technology Transferã®çŸ©åã®èŠèŸŒã¿åç¬è²©å£²äŸ¡æ ŒãããµãŒãã¹ãå®è¡ããããã«å¿
èŠãªåªåã®ã¬ãã«ããã«ã¿ã€ã åœããã®åŸæ¥å¡ã®ã³ã¹ããããã³è² æ
ãããäºå®ã®ã¬ãœãŒã¹ã«åççãªããŒãžã³ãå ãããã®ãäž»ã«ããŒã¹ã«ããŠèŠç©ãããŸãããC5åå€çæ³çŸ©åã®äžã§ä»äžãããcemdisiranåå€çæ³ã©ã€ã»ã³ã¹ã®èŠèŸŒã¿åç¬è²©å£²äŸ¡æ Œã¯ãcemdisiranã®åæ¥æéã«ãããäºæž¬åçã確ç«ããæå確çã«åºã¥ããŠèª¿æŽãããå²åŒãã£ãã·ã¥ãããŒã¢ãã«ã«åºã¥ããŠèª¿æŽåžå Žè©äŸ¡ææ³ã䜿çšããŠæšå®ããŸããã
$ã®ååŒäŸ¡æ Œ191.50 C5åå€çŸ©åããã©ãŒãã³ã¹çŸ©åã«å
åœããã$çŸäžã®ååŒäŸ¡æ Œã¯ããã®çŸ©åãRegeneronã«ã©ã€ã»ã³ã¹ãè²æž¡ãããæç¹ã§æºãããããããããã«èªèãããŸãããã©ã€ã»ã³ã¹ã®ç®¡çæš©ã¯2024幎6æã«ç§»è»¢ãããRegeneronã¯ã©ã€ã»ã³ã¹ã䜿çšããŠå©çãåŸãããšãã§ããŸããã
å¥çŽå€æŽæ¥æç¹ã§æ®ãã®èª¿æ»ãµãŒãã¹ããã³æ®ãã®C5ã©ã€ã»ã³ã¹çŸ©åã®çŽ¯ç©è¿œãã€ã調æŽãé²æç¶æ³ããã³å€æŽåŸã®ååŒäŸ¡æ Œãåæ ããããèªèãããŸãããæ®ãã®èª¿æ»ãµãŒãã¹ããã³æ®ãã®C5ã©ã€ã»ã³ã¹çŸ©åã®çŽ¯ç©è¿œãã€ã調æŽã¯ãç¡èŠã§ããçšåºŠã§ããã
ãªãµãŒããµãŒãã¹å¥çŽãC5ã©ã€ã»ã³ã¹å¥çŽãåã³Regeneronãã¯ãããžãŒç§»è»¢å¥çŽã«ã€ããŠãèå¥ãããå矩åæ¯ã«ãå
šäœã®èŠèŸŒã¿è²»çšã«å¯Ÿããè²»çšçºçã«åºã¥ããå
¥åæ¹æ³ã䜿çšããæéçµéã«å¯Ÿããæ¯äŸããã©ãŒãã³ã¹ãèšæž¬ããŸããæåŸ
ããç·äœæ¥éã«å¯Ÿããå®çŸäœæ¥éã®æ¯çã決å®ããããšã§ããã®æ¯çãå矩åã«å²ãåœãŠãããååŒäŸ¡æ Œã«é©çšãããŸããèŠç©ãéçºããããã»ã¹ã§ããããžã¡ã³ãã¯éèŠãªèŠè§£ãæ¡çšããŠããŸãããããã®èŠç©ã«å€æŽãããã°ã环ç©çã«åãæ»ãããäŒæ¥ã®æéã§èªèãããŸããæ¯åã®å ±åæéã®çµäºæã«ååŒäŸ¡æ Œãåè©äŸ¡ããŸãã2024幎6æ30æ¥çŸåšã®æªå®äºã®å¥çŽã«é¢é£ããååŒäŸ¡æ Œã¯ãå¥çŽéé¡ããå¢å ããŸããã31.6 ãã®å¥çŽã«é¢é£ããæªå®äºã®ããã©ãŒãã³ã¹çŸ©åã«å¯Ÿããæ®é«ã¯ã2024幎6æ30æ¥çŸåšã§å¥çŽãããç·é¡ãå¢å ãã$ millionã§ãã
ã¢ã«ãã©ã ãã¡ãŒãã·ã¥ãŒãã£ã«ã«ãºç€Ÿ
ã³ã³ãã³ã¹ãé£çµè²¡åè«žè¡šã«é¢ãã泚èš
ïŒæªç¢ºå®ïŒ
åœç€Ÿã®ç 究ãµãŒãã¹åµåã«äž»ã«é¢é£ããä¿®æ£æ¥ãå¥çŽã®ä¿®æ£æ¥ä»¥éãåœç€Ÿã®åµåãå®äºããããã«å¿
èŠãªç 究掻åã®èŠç©ããã®ã¿ã€ãã³ã°ãšãåœç€ŸãéæããããšãæåŸ
ããçµæçãªãã€ã«ã¹ããŒã³ãå€æŽãããŸããããã®åæã«åºã¥ãåçã¯ãå
±åç 究åçãšããŠèšäžãããŸãã
以äžã®è¡šã¯ããã©ã³ã¹ã·ãŒãæ¥æç¹ã§å²ãåœãŠãããååŒäŸ¡æ Œã®æŠèŠãæªè§£æ¶ã®å¥çŽå±¥è¡çŸ©åæ®é«æç¹ã§ã®åæåçãããã³æéäžã«èªèããã売äžé«ããåã®åäœã§æäŸããŠããŸãã
ååŒäŸ¡æ Œãå²ãåœãŠããã åååå
¥ å±¥è¡ã®çŸ©å 2021幎6æ30æ¥çŸåš 2024 2021幎6æ30æ¥çŸåš 2024
2023幎12æ31æ¥çŸåš 2023 ç 究ãµãŒãã¹ã®çŸ©å $ 102,969  $ 41,469  $ 63,400  C5ã©ã€ã»ã³ã¹ã®çŸ©å 60,484  27,400  27,500  ãªãžã§ããã³ã®æè¡ç§»è»¢çŸ©å
6,307 Â 2,307 Â â Â $ 169,760 Â $ 71,176 Â $ 90,900 Â
売äžé«ã¯èªèãããŠãã 6æ30æ¥ãŸã§ã®3ãæé 6æ30æ¥ãŸã§ã®6ãæé å±¥è¡ã®çŸ©å 2024 2023 2024 2023 ç 究ãµãŒãã¹ã®çŸ©å $ 4,000  $ (17,000 ) $ 18,700  $ (6,300 ) C5ã©ã€ã»ã³ã¹ã®çŸ©å 8,800  3,100  10,500  5,300  $ 12,800  $ (13,900 ) $ 29,200  $ (1,000 )
2024幎6æ30æ¥çŸåšãæªæãã®ç 究ãµãŒãã¹ã®çŸ©åãC5ã©ã€ã»ã³ã¹ã®çŸ©åãããã³Regeneronãã¯ãããžãŒç§»è»¢ã®çŸ©åã«å²ãåœãŠãããååŒäŸ¡æ Œã®ç·é¡ã¯$ã§ãã152.2 ãµãŒãã¹ãå®æœãããæéã«å¿ããŠãRegeneronã³ã©ãã¬ãŒã·ã§ã³ã®æéäžã«èªèãããããšãäºæ³ããã$äžã«åé¡ãããRegeneronã³ã©ãã¬ãŒã·ã§ã³ã«é¢é£ããå
éãåçã¯ãåçãèªèãããæéã«åºã¥ããç·è³ç£åèšè² åµèšç®æžã«çŸåšãŸãã¯éæµéè³ç£ãšããŠåé¡ãããŸãã
ããã«ãã£ã¹
2013幎ãã¶ã»ã¡ãã£ã·ã³ãºã»ã«ã³ãããŒãšã®ã³ã©ãã¬ãŒã·ã§ã³
2013幎2æãç§ãã¡ã¯ã¡ãã£ã·ã³ãºã«ã³ãããŒïŒMDCOïŒãšã©ã€ã»ã³ã¹ããã³å
±åéçºå¥çŽãç· çµããMDCOã«å¯ŸããŠããããããã€ã³ã³ã³ããŒããŒãŒãµãããªã·ã³/ã¿ã€ã9ãæšçãšããRNAiæ²»çè¬ã®éçºã補é ãåæ¥åã®ç¬å çãªäžççãªã©ã€ã»ã³ã¹ãä»äžããäœã³ã¬ã¹ãããŒã«è¡çããã³ãã®ä»ã®äººéã®çŸæ£ãinclisiranãæ²»çããããã«äœ¿çšããããšãèš±å¯ããŸãããç§ãã¡ã¯ãæ¬æ¥ãŸã§ã«æ¹æ£ãããMDCOã©ã€ã»ã³ã¹å¥çŽãšããŠãã®å¥çŽãåç
§ããŠããŸãã2020幎ãNovartis AGãŸãã¯Novartisã¯ãMDCOã®å
šæš©å©ããã³åµåãåŒãç¶ããMDCOã©ã€ã»ã³ã¹å¥çŽã®ãã¹ãŠã®æš©å©ãšçŸ©åãåŒãç¶ããŸããã
2024幎6æ30æ¥çŸåšãç§ãã¡ã¯ãã€ã«ã¹ããŒã³ã§ç²åŸããäžåäžãã«ã皌ãåºããããã«åæ¥åãã€ã«ã¹ããŒã³ã§1,000äžãã«ä»¥äžãåãåãæš©å©ããããŸããããã«ãããã«ãã£ã¹ããã®é¢é£äŒç€Ÿããã³ãµãã©ã€ã»ã³ã·ãŒã«ããã©ã€ã»ã³ã¹è£œåã®å¹ŽéäžççŽå£²äžé«ã«åºã¥ããŠã0%ãã5%ã®ç¯å²å
ã®ãã€ã€ã«ãã£ãæ¯æãããŸãããç¹å®ã®ç¶æ³äžã§åæžãããããšããããŸãã120.0 ãã€ã«ã¹ããŒã³ã§äžåäžãã«ã皌ãåºããããã«åæ¥åãã€ã«ã¹ããŒã³ã§1,000äžãã«ä»¥äžãåãåãæš©å©ããããŸãã60.0 ããã«ãã£ã¹ããã®é¢é£äŒç€Ÿããã³ãµãã©ã€ã»ã³ã·ãŒã«ããã©ã€ã»ã³ã¹è£œåã®å¹ŽéäžççŽå£²äžé«ã«åºã¥ããŠã0%ãã5%ã®ç¯å²å
ã®ãã€ã€ã«ãã£ãæ¯æãããŸãããç¹å®ã®ç¶æ³äžã§åæžãããããšããããŸãã 10 0%ãã5%ãŸã§ã®ãã€ã€ã«ãã£ãæ¯æãããŸãã 20 ããã«ãã£ã¹ããã®é¢é£äŒç€Ÿããã³ãµãã©ã€ã»ã³ã·ãŒã«ããã©ã€ã»ã³ã¹è£œåã®å¹ŽéäžççŽå£²äžé«ãåºã«ã0%ãã5%ãŸã§ã®ãã€ã€ã«ãã£ãæ¯æããŸãããç¹å®ã®ç¶æ³äžã§åæžãããããšããããŸãã
ä»
äžèšã®åæ¥å¥çŽã«å ããŠãç§ãã¡ã¯åœæåœç€Ÿã®æ¥çžŸã財åç¶æ³ã«åå¥ã«åœ±é¿ãäžããããã§ã¯ãªãæ§ã
ãªä»ã®åæ¥å¥çŽãæã£ãŠããŸãããããã®å¥çŽã®èŠå®ã«åºã¥ããç§ãã¡ã¯ãæ§ã
ãªå°æ¥çãªäºè±¡ïŒäŸãã°ãæ§ã
ãªéçºãåæ¥çãªãã€ã«ã¹ããŒã³ã®éæãªã©ïŒã®çºçã«äŒŽããè¿œå æéãæ¯æãããšãå¿
èŠã§ããå ŽåããããŸããæã
ã¯ãŸããèšå€§ãªç 究éçºè²»ãè² æ
ããããšããããããŸãã¯ããã«å¯ŸããŠè«æ±æžãåé ããå ŽåããããŸããããã«ããããã®åæ¥é¢é£ã®è£œåãæ¿èªãããå Žåãç§ãã¡ã¯å°æ¥ã®è²©å£²ã«å¯Ÿãããã€ã€ã«ãã£ãæ¯æãå¿
èŠãããå ŽåãããããŸãã¯ãããåãåãããšããããŸããããããªããããããã®é¡ã®æ¯æããŸãã¯åé ã¯ãããŸããŸãªå°æ¥ã®äºè±¡ã®çºçã«äŸåããŠããŸããå»è¬åéçºã®äžç¢ºå®æ§ããäžè¬ã«è¬å€éçºãåæ¥åã«å€±æããé«ãæŽå²ç倱æçã®ãããçŸåšã®ãã¹ãŠã®åæ¥å¥çŽããã³ã©ã€ã»ã³ã¹å¥çŽããã®ã³ã¡ã³ãã§èª¬æããŠããå¥çŽãå«ãããã®ãããªæ¯æããåããä¿èšŒã¯ãªãå¯èœæ§ããããŸãã
ã¢ã«ãã©ã ãã¡ãŒãã·ã¥ãŒãã£ã«ã«ãºç€Ÿ
ã³ã³ãã³ã¹ãé£çµè²¡åè«žè¡šã«é¢ãã泚èš
ïŒæªç¢ºå®ïŒ
5. ãã®äŒç€Ÿã®éèè³ç£ããã³è² åµã®å
¬æ£äŸ¡å€ã®èŠç©ããã¯ãå
¬æ£äŸ¡å€äŒèšåºæºã«åºã¥ãæ çµã¿ã«åºã¥ããŠããŸãããã®æ çµã¿ã¯ãè©äŸ¡ã«äœ¿çšãããå
¥åã«åºã¥ããŠãããèœåçåžå Žã§ã®åŒçšäŸ¡æ Œãæåªå
ãã芳å¯å¯èœãªå
¥åãå©çšå¯èœãªå Žåã¯èŠ³å¯å¯èœãªå
¥åã䜿çšããããšãèŠæ±ããŸããå
¬æ£äŸ¡å€äŒèšåºæºéå±€ã§ã®å
¬æ£äŸ¡å€è©äŸ¡ã®é瀺ã¯ãè©äŸ¡ã«ãããéèŠãªå
¥åã芳å¯å¯èœãã©ããã«åºã¥ããŠããŸããè©äŸ¡ãé瀺ãããéå±€ã®ã¬ãã«ã¯ãèœåçåžå Žã§ã®æªèª¿æŽåŒçšäŸ¡æ Œã«æåªå
ãäžãããããã®äŒç€Ÿã®éèŠãªåžå Žä»®å®ãåæ ãã芳å¯å¯èœãªå
¥åã«æäœéåªå
ãããŸããå
¬æ£äŸ¡å€è©äŸ¡ãå ±åãããå
¬æ£äŸ¡å€éå±€ã¯ã枬å®å
šäœã«éèŠãªå
¥åã®æãäœãã¬ãã«ã«åºã¥ããŠããŸããéå±€ã¯ä»¥äžã®3ã€ã§ãã
以äžã®è¡šã¯ãå®æçã«è©äŸ¡ãããå
¬æ£äŸ¡å€ã§èšæž¬ãããè³ç£ããã³è² åµã«é¢ããæ
å ±ãæ瀺ãããã®å
¬æ£äŸ¡å€ã決å®ããããã«äœ¿çšããè©äŸ¡æè¡ã®å
¬æ£äŸ¡å€éå±€ã瀺ããŠããŸãã
(ååäœ) 2024幎6æ30æ¥çŸåš 掻çºãªåžå Žã§ã®çžå ŽäŸ¡æ Œ (ã¬ãã« 1) éèŠãªèŠ³å¯å¯èœãªå
¥å (ã¬ãã« 2) 芳å¯ã§ããªãéèŠãªã€ã³ããã (ã¬ãã« 3) éèè³ç£ çŸéåçç©: ãããŒã»ããŒã±ããã»ãã¡ã³ã $ 158,467  $ 158,467  $ â  $ â  米åœè²¡åçèšŒåž 36,315%  â  36,315%  â  ã³ããŒã·ã£ã«ã»ããŒã㌠6,300人  â  6,300人  â  åžå Žæ§ã®ããåµåžïŒ ç±³åœè²¡åçèšŒåž 882,671  â  882,671  â  米åœæ¿åºãåŸæŽããäŒæ¥èšŒåž 383,501  â  383,501  â  ã³ãŒãã¬ãŒãããŒã 305,003  â  305,003  â  ã³ããŒã·ã£ã«ã»ããŒã㌠70,079  â  70,079  â  å°æ¹èšŒåž 5,014  â  5,014  â  åžå Žæ§ã®ããæ ªåŒèšŒåž 9,889  9,889  â  â  å¶éä»çŸéïŒãããŒããŒã±ãããã¡ã³ãïŒ 1,217  1,217  â  â  éèè³ç£ç·é¡ $ 1,858,456  $ 169,573  $ 1,688,883  $ â  éèè² åµ éçºããªããã£ãè³ å責任 $ 390,939  $ â  $ â  $ 390,939 Â
å¶æ¥æŽ»åã«ãããã£ãã·ã¥ãããŒïŒ 2023幎12æ31æ¥çŸåš 掻çºãªåžå Žã§ã®åŒçšäŸ¡æ Œ ïŒã¬ãã«1ïŒ éèŠãªèŠ³æž¬å¯èœãªå
¥å: ïŒã¬ãã«2ïŒ èããäžå¯èŠãªå
¥å ïŒã¬ãã«3ïŒ éèè³ç£ çŸéåçç©ïŒ ãã¹ãŠæä¿¡ $ 166,059  $ 166,059  $ â  $ â  ã¢ã¡ãªã«è²¡åçèšŒåž 30,712  â  30,712  â  ã³ããŒã·ã£ã«ããŒã㌠2,685  â  2,685  â  äŒæ¥ããŒã 762  â  762  â  売åŽå¯èœãªåµåžã»åµå蚌åž: ã¢ã¡ãªã«è²¡åçèšŒåž 862,022  â  862,022  â  ã¢ã¡ãªã«æ¿åºã¹ãã³ãµãŒã«ããäŒæ¥åµèšŒåž 441,341  â  441,341  â  äŒæ¥ããŒã 252,350  â  252,350  â  ã³ããŒã·ã£ã«ããŒã㌠56,216  â  56,216  â  é éèšŒæž 3,587  â  3,587  â  æµååžå Žæ§èšŒåž 11,178  11,178  â  â  å¶éä»ãçŸéïŒãããŒããŒã±ãããã¡ã³ãïŒ 1,210  1,210  â  â  ç·è³ç£ $ 1,828,122  $ 178,447  $ 1,649,675  $ â  財åè² åµ éçºããªããã£ãè² åµ $ 324,941  $ â  $ â  $ 324,941 Â
2024幎ããã³2023幎6æ30æ¥ã«çµäºãã6ãæéã«ã¯ã ããã ã¬ãã«3ã®éèè³ç£ãŸãã¯è² åµãžã®è»¢éããŸãã¯ã¬ãã«3ã®éèè² åµããã®ééãçŸéã売æéãçŽè³ç£ããã®ä»ã®æµåè³ç£ãè²·æéããã³æªæè²»çšã®èŠçŽé£çµè²žå察ç
§è¡šã«åæ ãããŠãã垳簿䟡é¡ã¯ãçææºæã«ããå
¬æ£äŸ¡å€ã«è¿ããã®ã§ãã
ã¢ã«ãã©ã ãã¡ãŒãã·ã¥ãŒãã£ã«ã«ãºç€Ÿ
ã³ã³ãã³ã¹ãé£çµè²¡åè«žè¡šã«é¢ãã泚èš
ïŒæªç¢ºå®ïŒ
6. æµåçãªåµåžã»åµå蚌åž
åœç€Ÿã¯äœå°çŸéæ®é«ãæµåçãªåµåžæè³ã«æè³ããæ瀺ãããåãã©ã³ã¹ã·ãŒãæ¥ã«ãããŠãå
šãŠã®åµåžæè³ã売åŽå¯èœã§ãããçŸåšã®è³ç£ãšããŠåé¡ããŠããŸãããããã¯ãçŸåšã®æ¥åã«å©çšå¯èœãªãã¡ã³ãã®æè³ã瀺ããŠããŸãã2024幎6æ30æ¥ãŸãã¯2023幎6æ30æ¥çµäºã®3ãæãŸãã¯6ãæã«ããã£ãŠãæµåçãªåµåžæè³ã«é¢é£ããæžå°ååŽè²»çšãèšé²ããŠããŸããã§ããã
以äžã®è¡šã¯ãç§ãã¡ã®å£²åŽå¯èœãªåµåžã»åµå蚌åžããŸãšãããã®ã§ãïŒ
2024幎6æ30æ¥çŸåš (ååäœ) ååŽæžã¿ è²»çš æªå®çŸç·å©ç
æªå®çŸæ倱ç·é¡
å
¬æ£äŸ¡å€ ç±³åœè²¡åçèšŒåž $ 920,578  $ 79  $ (1,671ã§ã ) $ 918,986  米åœæ¿åºãåŸæŽããäŒæ¥èšŒåž 384,165  63  (727 ) 383,501  ã³ãŒãã¬ãŒãããŒã 305,491  39  (527 ) 305,003  ã³ããŒã·ã£ã«ã»ããŒã㌠76,379  â  â  76,379  å°æ¹èšŒåž 5,017  â  (3 ) 5,014  åèš $ 1,691,630  $ 181  $ (2,928 ) $ 1,688,883 Â
2023幎12æ31æ¥çŸåš (ååäœ) ååŽæžã¿ è²»çš æªå®çŸç·å©ç
æªå®çŸæ倱ç·é¡
å
¬æ£äŸ¡å€ ç±³åœè²¡åçèšŒåž $ 892,237  $ 1,085  $ (588 ) $ 892,734  米åœæ¿åºãåŸæŽããäŒæ¥èšŒåž 440,915  1,000  (574 ) 441,341  ã³ãŒãã¬ãŒãããŒã 252,487  945  (320 ) 253,112  ã³ããŒã·ã£ã«ã»ããŒã㌠58,901  â  â  58,901  é éèšŒæž 3,587  â  â  3,587  åèš $ 1,648,127  $ 3,030  $ (1,482 ) $ 1,649,675% Â
åœç€Ÿã®å£²è²·å¯èœãªåµåžã»åµå蚌åžã®å
¬æ£äŸ¡å€ã¯ã財åè«žè¡šå
ã®åé¡ã«ãã£ãŠä»¥äžã®ããã«èšèŒãããŠããŸãã
(ååäœ) 2024幎6æ30æ¥çŸåš 2023幎12æ31æ¥çŸåš åžå Žæ§ã®ããåµåèšŒåž $ 1,646,268  $ 1,615,516  çŸéããã³çŸéåçç© 42,615%  34,159  åèš $ 1,688,883  $ 1,649,675% Â
7. ãã®ä»ã®è²žå察ç
§è¡šã®è©³çŽ°
åšåº«
åšåº«ã®éšåã¯ä»¥äžã®éãã«ãŸãšããããŠããŸãã
(ååäœ) 2024幎6æ30æ¥çŸåš 2023幎12æ31æ¥çŸåš åææ $ 26,021  $ 23,346  äœæ¥äž
66,535  76,963  å®æå 27,855%  25,123  åšåº«åèš
$ 120,411ã§ã  $ 125,432 Â
2024幎6æ30æ¥ããã³2023幎12æ31æ¥æç¹ã§ãç§ãã¡ã¯ãããããã®ä»ã®è³ç£ã®äžã«å«ãŸããŠããé·æåšåº«è³ç£ããããããã¯éåžžã®é転ãµã€ã¯ã«ãè¶
ããŠæ¶è²»ãããããšãäºæ³ããŠããŸãã36.4 çŸäžãã«ãš$36.3 ãã®åšåº«ã¯ãéåžžã®é転ãµã€ã¯ã«ãè¶
ããŠæ¶è²»ãããããšãäºæ³ããŠããããããã®ä»ã®è³ç£ã®äžã«å«ãŸããŠããŸãã
ã¢ã«ãã©ã ãã¡ãŒãã·ã¥ãŒãã£ã«ã«ãºç€Ÿ
ã³ã³ãã³ã¹ãé£çµè²¡åè«žè¡šã«é¢ãã泚èš
ïŒæªç¢ºå®ïŒ
çŸéãçŸéåçç©ããã³ææãããçŸé
次ã®è¡šã¯ãåœç€Ÿã®èŠçŽãããé£çµè²žå察ç
§è¡šå
ã«å ±åãããçŸéãçŸéåçç©åã³å¶éä»ãçŸéã®èª¿æŽãæäŸããŠããããããã®éé¡ã瀺ãåœç€Ÿã®èŠçŽãããé£çµãã£ãã·ã¥ã»ãããŒèšç®æžå
ã®ç·é¡ãšåèšãããŠããŸãã
2021幎6æ30æ¥çŸåš å¶æ¥æŽ»åã«ãããã£ãã·ã¥ãããŒïŒ 2024 2023 çŸéåã³çŸéåçç© $ 968,492  $ 657,800  ãã®ä»ã®è³ç£ã«å«ãŸããå¶éä»ãçŸéã®åèš 2,701  2,176  çŸéãçŸéåçç©ãããã³å¶éä»ãçŸéã®åèšã¯ãæŠç¥ãããé£çµçŸéãããŒèšç®æžã«è¡šç€ºãããŸãã
$ 971,193 Â $ 659,976 Â
ãã®ä»å
æ¬å©ç(æ倱)
以äžã®è¡šã¯ãåèŠçŽ å¥ã«çŽ¯ç©ã®ãã®ä»å
æ¬æçã®å€åããŸãšãããã®ã§ãïŒ
å¶æ¥æŽ»åã«ãããã£ãã·ã¥ãããŒïŒ Joint Venture ã«ãããæè³æ倱 確å®çµŠä»å¹Žé èšç» åµåã«å¯Ÿããæªå®çŸã®(æ倱)å©ç
蚌åž
å€è²šç¿»èš³ èª¿æŽ ãã®ä»çŽ¯ç©åèš
å
æ¬æ倱
2023幎12æ31æ¥çŸåšæ®é« $ (32,792 ) $ (2,753 ) $ 1,548  $ 10,622  $ (23,375 ) ååé¡åç·ç¶æ倱ïŒãã®ä»ïŒ
â  â  (4 ) (7,030 ) (7,034 ) ãã®ä»å
æ¬å©çããååé¡ãããéé¡
â  63  (4,291 ) â  (4,228 ) ãã®ä»ã®ç¶åæççŽæ倱
â  63  (4,295 ) (7,030 ) (11,262 ) 2024幎6æ30æ¥æç¹ã®æ®é« $ (32,792 ) $ (ãã®ä»ã®å°åïŒ2ïŒ ) $ (2,747 ) $ 3,592  $ (34,637 )
å¶æ¥æŽ»åã«ãããã£ãã·ã¥ãããŒïŒ ãã³ãã£ãŒãžã®æè³æ倱 確å®çµŠä»å¹Žé èšç» åµåããã®æªå®çŸ(æ倱)å©ç
蚌åž
å€è²šç¿»èš³ èª¿æŽ ãã®ä»ã®å
æ¬å©ç环ç©é¡
2022幎12æ31æ¥ã®æ®é« $ (32,792 ) $ (1,092 ) $ (9,470 ) $ (1,300 ) $ (44,654 ) ååé¡åãã®ä»å
æ¬çå©çã®é
åœå
â  â  (11 ) 5,483  5,472  ãã®ä»ã®å
æ¬å©çããååé¡ãããéé¡
â  (9 ) 2,111  â  2,102  ãã®ä»å
æ¬å©ççŽé¡
â  (9 ) 2,100æ ªã劻ã«ãã  5,483  7,574  2023幎6æ30æ¥çŸåšã®æ®é« $ (32,792 ) $ (1,101 ) $ (7,370 ) $
4,183 Â $ (37,080 )
环ç©ãã®ä»å
æ¬å©çïŒæ倱ïŒããååé¡ãããéé¡ã¯ãåžå Žå¯èœãªåµå蚌åžã®è§£æ±ºãšç§ãã¡ã®å¹Žé矩åã®ååŽã«é¢é£ããŠãããç·è³ç£è² åµèšç®æžãšå
æ¬æçèšç®æžã®ãã®ä»ã®è²»çšã®äžã«èšé²ãããŸãã
8. 転æ瀟åµ
2027幎å°æã®è»¢æå¯èœãªåªå
åµ
2022幎ã«ãç§ãã¡ã¯ã·ãã¢åµã®åªå
å
¬éãéå§ãã$900.0 ã®åµåç·é¡ã§ããïŒ
ã®ã³ã³ããŒããã«ç€Ÿåµã2027幎ãŸã§ã«çºè¡ããŸããããã®æç¹ã§ãåæ賌å
¥è
ã¯ãè¿œå ã®$ 1 ã®åµåç·é¡ã§ããïŒ
ã®ã³ã³ããŒããã«ç€Ÿåµãè¿œå 瀟åµã賌å
¥ãããªãã·ã§ã³ãè¡äœ¿ããåæ賌å
¥è
ãšãšãã«åãããŠåµåžãšããŠçºè¡ããã瀟åµãã€ãŸãåµåžã®ç·çºè¡é¡ã$135.0 ãšããŸããããããã®åµåžã¯ã2022幎9æ15æ¥ä»ãã®åµåžå¥çŽæžããŸãã¯ãå¥çŽæžãã«åºã¥ããŠçºè¡ãããŸãããå¥çŽæžã«ã¯ãéåžžã®å¥çŽæ¡é
ãå«ãŸããŠãããäžå®ã®ããã©ã«ãã€ãã³ããèŠå®ãããŠããŸããããã©ã«ãã€ãã³ããçºçããå Žåãåµåžã®æ¯ææºåãã§ããäžå®ã®çš®é¡ã®ç Žç£ãŸãã¯åç£ã€ãã³ããçºçããå Žåãèªåçã«åµåžãæ¯æãææ¥ãšãªããŸãã 1 $1.04 10åãã«ã®åµåžãçºè¡ãããŸããã
ã¢ã«ãã©ã ãã¡ãŒãã·ã¥ãŒãã£ã«ã«ãºç€Ÿ
ã³ã³ãã³ã¹ãé£çµè²¡åè«žè¡šã«é¢ãã泚èš
ïŒæªç¢ºå®ïŒ
çŽå¹£ã¯ã以åã«æç®ãåéããŸãã¯è²·ãæ»ãããªãéãã2027幎9æ15æ¥ã«æºæã«ãªããŸããçŽå¹£ã«ã¯ã以äžã®å©çã§å©æ¯ãããããŸã 1 2023幎3æ15æ¥ãããæ¯å¹Ž3æ15æ¥ãš9æ15æ¥ã«å幎ããšã«å»¶æ»ããŠæ¯æããã幎éã®å²åãçŽå¹£ã¯ã2027幎6æ15æ¥ä»¥éãããŒããã«ããŒã®éžæã«ãã転æå¯èœã§ãã2027幎6æ15æ¥ããåã®åµåžã¯ã以äžã®ç¶æ³ã§ã®ã¿è»¢æå¯èœã§ãã(1) 2022幎12æ31æ¥ã«çµäºããæŠååæ以éã«å§ãŸãä»»æã®æŠååæäžïŒããã³åœè©²æŠååæäžã®ã¿ïŒãããæåŸã«å ±åãããåœç€Ÿã®æ®éæ ªåŒã®å£²åŽäŸ¡æ Œã 20 æéäžã®ååŒæ¥æ°ïŒé£ç¶ããŠãããã©ããã«ãããããïŒ 30 çŽåã®æŠååæã®æçµååŒæ¥ã«çµäºããé£ç¶ååŒæ¥ãã以äžãšåçããã以äžã§ãã 130 該åœããåååŒæ¥ã®è»¢æäŸ¡æ Œã®ïŒ
ãïŒ2ïŒãã®é äº ããšã¯å¶æ¥æ¥ã®æé å ãã®æ¥ã®åååŒæ¥ã®åµåžã®å
æ¬1,000ãã«ãããã®ååŒäŸ¡æ Œã瀺ãé£ç¶ååŒæ¥æé å é£ç¶ããååŒæ¥ã®æé㯠98 ååå ±åãããåœç€Ÿã®æ®éæ ªåŒã®å£²åŽäŸ¡æ Œãšãã®ååŒæ¥ã®åµåžã®æç®ã¬ãŒãã®ç©ã®å²åãïŒ3ïŒåµåžã®äžéšãŸãã¯å
šéšãåé察象ãšãããã©ããããŸãã¯ïŒ4ïŒåµåžã管çããã€ã³ãã³ãã£ãŒã«å®ããããŠããç¹å®ã®äŒæ¥ã€ãã³ãã®çºçæãåœç€Ÿã¯ãåœç€Ÿã®éžææã«ãå¿
èŠã«å¿ããŠãçŸéãåœç€Ÿã®æ®éæ ªåŒããŸãã¯çŸéãšæ®éæ ªåŒã®çµã¿åãããæ¯æããŸãã¯åŒãæž¡ãããšã§ãåµåžã®è»¢æã決æžããŸãã
ããŒãã®æç®ã¬ãŒãã¯ãåæå€ã§1,000ãã«ã®å
æ¬é¡ããã3.4941æ ªã®æ®éæ ªåŒã«çžåœããåææç®äŸ¡æ Œã¯çŽ$ã«çžåœããŸãã1,000ãã«ã®åè³æéã«ã€ããæ®éæ ªåŒ3.4941æ ªã§ããæç®ã¬ãŒããåãã«é©çšãããŸããããã¯åææç®äŸ¡æ Œãããã286.20ãã«ã®æ®éæ ªåŒ1æ ªã«çžåœããããšãæå³ããŸããããŒãã®åææç®äŸ¡æ Œã¯ã2022幎9æ12æ¥ã«å ±åãããæ®éæ ªåŒã®1æ ªåœãã212.00ãã«ã®äŸ¡æ Œã«å¯ŸããŠçŽ%ã®ãã¬ãã¢ã ãæå³ããŸããåµåå¥çŽæžã®æ¡é
ã«åŸããæç®ã¬ãŒãã¯ç¹å®ã®ç¶æ³ã«å¿ããŠèª¿æŽãããå ŽåããããŸãã ããŒãã®åææç®äŸ¡æ Œã¯ã2022幎9æ12æ¥ã«å ±åãããæ®éæ ªåŒã®1æ ªããã212.00ãã«ã®äŸ¡æ Œã«å¯ŸããŠçŽ%ã®ãã¬ãã¢ã ãæå³ããŸãã 35 ïŒ
äžã§ã$212.00ãäžåããŸãã212.00 å¥çŽæžã®æ¡é
ã«åŸããæç®ã¬ãŒãã¯ç¹å®ã®ç¶æ³ã«å¿ããŠèª¿æŽãããå ŽåããããŸãã
2025幎9æ20æ¥ä»¥åã«ã¯ããŒããåéããããšã¯ã§ããŸããã2025幎9æ20æ¥ä»¥éã«ãåŒç€Ÿã®æ®éæ ªåŒã®æçµå ±å売åŽäŸ¡æ Œãå°ãªããšãé£ç¶çã« 100 ååŒæéäžã®å
¬èšŒéèååã®å
æ¬éã® 130 åœç€Ÿã®æ®éæ ªåŒã®æåŸã«å ±åããã売åŽäŸ¡æ Œããæäœ15æ¥éïŒé£ç¶ããŠããªããŠãããããã¯çŽåã®ååŒæ¥ãå«ããé£ç¶ããååŒæ¥æéãå«ãïŒè»¢æäŸ¡æ Œã«å¯ŸããŠå°ãªããšã$1ã®å²åã§å£²è²·ãããå Žåãåœç€Ÿã¯2024幎11æ20æ¥ä»¥éãå¶éãããããä»»æã®éšåãŸãã¯å
šéšãçŸéã§åéããããšãã§ãããåéé¡ã«ã¯ãåéæ¥ãŸã§ã®å©æ¯ãå«ãŸããªãã20 æäœ15æ¥éãïŒé£ç¶ããŠããªããŠãããããã¯çŽåã®ååŒæ¥ãå«ããé£ç¶ããååŒæ¥æéãå«ãïŒãåœç€Ÿã®æ®éæ ªåŒã«å¯Ÿãã転æäŸ¡æ Œã«å¯ŸããŠ$1以äžã®å²åã§å£²è²·ãããå Žåã«é©çšãããã30 æªåéã®å©æ¯ãå ããé¡ã«çããçŸéã§ãããŒãã®äžéšãŸãã¯å
šãŠãåŒç€Ÿã®éžæã«ããåéããããšãã§ããŸããããŒãã«ã¯ã·ã³ãã³ã°ãã¡ã³ãã¯çšæãããŠãããããããã£ãŠå®æçã«ããŒããåéãŸãã¯ååããããšã¯çŸ©åä»ããããŠããŸããã
ã€ã³ãã³ã蚌æžã«å®ããããåºæ¬çãªå€æŽãåããå Žåãäžéšã®æ¡ä»¶ã«åŸããä¿æè
ã¯çŸéã§ããŒãã®ãã¹ãŠãŸãã¯äžéšãåºæ¬çãªå€æŽè²·ãåãäŸ¡æ Œã«ããè¿æžãèŠæ±ããããšãã§ãããã®è¿æžéé¡ã¯ã®ããªã³ã·ãã«éé¡ã®ïŒ
ã«å ããŠæªæãã®å©æ¯ãšãªããŸããããã«ãæºææ¥ä»¥åã«ç¹å®ã®äŒæ¥ã€ãã³ããçºçããå ŽåããŸãã¯åéã®éç¥ãçºè¡ããå ŽåãããŒããå€æããããšãéžæããä¿æè
ã®å€æã¬ãŒããäºãå®çŸ©ãããéé¡ã«å¢ãããŸãããã ããããŒãã®ä¿æè
ãå€æããããšãèš±å¯ããæ¡ä»¶ã¯ãä»ååæã§ã¯æºããããŸããã§ããã 100 åµåžã®å
æ¬éé¡ã®ïŒ
ãã©ã¹æªæãå©æ¯ã«çããåºæ¬å€æŽè²·æ»ãäŸ¡æ Œã§ãä¿æè
ã¯ããŒãã®ãã¹ãŠãŸãã¯äžéšãçŸéã§è²·ãæ»ããŠãããããšãã§ããŸãããŸããæºæåã«ç¹å®ã®äŒç€Ÿè¡äºãçºçããå Žåãåééç¥ãåºããå Žåã«ã¯ã泚æã«åºã¥ããŠæè³å®¶ãããŒããå€æããŠå€æçãå¢ããããšãã§ããããããããããå®çŸ©ãããæ°éãå¢ããããšãã§ããŸãããã ããããŒããå€æããããã®æ¡ä»¶ãä»ååæã«æºããããŠããªããããããŒãä¿æè
ãå€æããããšãèš±å¯ãããŠããŸããã
2024幎6æ30æ¥æç¹ã§ãçºè¡è²»çšæªååŽé¡$ââçŸäžãã«ãå·®ãåŒããåéæéãé·ãè² åµã«åé¡ãããŠããŸãã12.3 2024幎6æ30æ¥æç¹ã§ãããŒãã®èŠç©ããããå
¬æ£äŸ¡å€ã¯çŽ$ââååãã«ã§ãããå
¬æ£äŸ¡å€ã¯ã2024幎6æ30æ¥ãŸã§ã®æåŸã®ã¢ã¯ãã£ãã«ååŒãããããŒãã®$100ãããã®äŸ¡æ Œã«åºã¥ããŠæ±ºå®ãããŸãã(Level 2)ã1.11 ããŒãã¯å²é¢çºè¡ãããããŒãã®å¥çŽæéäžã«çºè¡ã«é¢é£ããè²»çšã¯å©æ¯è²»çšã«ååŽãããŸãã2024幎6æ30æ¥çŸåšãããŒãã®å®è³ªå©çã¯1 %.
ã³ãŒã«ã¿ã€ãã®ååŒäžéãã
2022幎ã«ã¯ãã€ãã·ã£ã«ã»ããŒãã®äŸ¡æ Œèšå®ããã³åæããŒãžã£ãŒã«ããè¿œå ããŒãã®è³Œå
¥ãªãã·ã§ã³ã®è¡äœ¿ã«é¢é£ããŠããã©ã€ããŒããªäº€æžã«ãããã£ããã»ã³ãŒã«ã»ãã©ã³ã¶ã¯ã·ã§ã³ããŸãã¯ãã£ããã»ã³ãŒã«ã»ãã©ã³ã¶ã¯ã·ã§ã³ã«åå ããŸããããã£ããã»ã³ãŒã«ã»ãã©ã³ã¶ã¯ã·ã§ã³ã§ã¯ãéåžžã®åžèæ ªåŒèª¿æŽãå«ããããŒãã«åºã¥ãæ®éæ ªåŒã®æ°éãåæçã«ã«ããŒãããŸãããã£ããã»ã³ãŒã«ã»ãã©ã³ã¶ã¯ã·ã§ã³ã®ãã£ããäŸ¡æ Œã¯ãåæã«ã¯1æ ªããã424.00ãã«ã§ãããããã¯2022幎9æ12æ¥ã«å ±åãããæ®éæ ªåŒã®çŽè¿ã®å£²åŽäŸ¡æ Œã§ãã1æ ªããã212.00ãã«ã«å¯ŸããŠ%ã®ãã¬ãã¢ã ãè¡šãããã£ããã»ã³ãŒã«ã»ãã©ã³ã¶ã¯ã·ã§ã³ã®æ¡ä»¶ã«åºã¥ããŠç¹å®ã®èª¿æŽãå ããããŸãã424.00ãã«/æ ªã§ã1æ ªãããã®æåŸã®å ±åãããæ®éæ ªäŸ¡æ Œã§ãã2022幎9æ12æ¥ã®1æ ªããã212.00ãã«ã«å¯ŸããŠ%ã®ãã¬ãã¢ã ãè¡šããŸãã ãã£ããã»ã³ãŒã«ã»ãã©ã³ã¶ã¯ã·ã§ã³ã®æ¡ä»¶ã«åºã¥ããç¹å®ã®èª¿æŽãå ããããŸãã 100 æ®éæ ªåŒã®å ±åãããå£²äŸ¡æ Œã«å¯ŸããŠïŒ
äžæãã2022幎9æ12æ¥ã®æ ªäŸ¡1æ ª212ãã«ã«åºã¥ããäžéä»ãã³ãŒã«ååŒã®æ¡ä»¶äžã§äžå®ã®èª¿æŽãå¿
èŠã§ãã212.00 äžéä»ãã³ãŒã«ååŒã®æ¡é
ã«åŸã£ãŠãäžå®ã®èª¿æŽãå¿
èŠã§ãã
9. å°æ¥ã®ãã€ã€ãªãã£è²©å£²ã«é¢é£ãã責任
2020幎4æãç§ãã¡ã¯BX Bodyguard Royalties L.P.ïŒThe Blackstone Group Inc.ã®é¢é£äŒç€ŸïŒãŸãã¯Blackstone Royaltiesãšè²·åå¥çŽããŸãã¯è²·åå¥çŽã«çœ²åããŸãããBlackstone Royaltiesã¯ãå
ã
ã¯èšå®ããããã€ã€ã«ãã£éæ¯æå¯èœãªå²åãŸãã¯ãã€ã€ãªãã£å©çãååŸããŸããã 50 MDCOããã®é¢é£äŒç€ŸãŸãã¯ãµãã©ã€ã»ã³ã·ãŒãå«ãããããã®ã©ã€ã»ã³ã¹è£œåã®ããã売äžã«é¢é£ããinclisiranïŒãŸãã¯ãã©ã³ãå»è¬åLeqvioïŒããã³ãã®ä»ãã¹ãŠã®ã©ã€ã»ã³ã¹è£œåã«ã€ããŠã®åæã«èšå®ããããã€ã€ã«ãã£ãŒéé¡ã«ã€ããŠãïŒ
ãå«ãåæ¥çãªãã€ã«ã¹ããŒã³ã®æ¯æå¯èœéé¡ã®ïŒ
ãšäžç·ã«ãRoyalty Interestã賌å
¥ããŸããã 75 MDCO License Agreementã«åºã¥ãRoyalty Interestå
.eè²·åãããå©çã«å¯Ÿãã2029幎12æ31æ¥ãŸã§ã®æ¯æãããå°ãªããšã10åãã«ã«çžåœããªãå ŽåãBlackstone Royaltiesã¯ã2030幎1æ1æ¥ä»¥éã«ïŒ
ã§Royalty InterestãåãåããŸãã賌å
¥ãããå©çã®å£²åŽã«å¯ŸããèŠè¿ããšããŠãBlackstone Royaltiesã¯ç§ãã¡ã«$ãæ¯æããŸããã1.00 ãã©ãã¯ã¹ããŒã³ã»ãã€ã€ã«ãã£ã¯ããã®ä»ã®ãã€ã€ã«ãã£å©çãåãåããŸãã 55 ïŒ
ã«å§ãŸãRoyalty Interestãåãåãããšã«ãªããŸãã1.00 10Kãã©ãŒã ãå
ã«ããCallon Petroleum Companyã®äŒèšå¹ŽåºŠã2023幎12æ31æ¥ã«çµäºãã幎床ã«ã€ããŠãçºè¡æžã¿ã®æ®éæ ªåŒã¯66508277æ ªã§ããã
BXããã£ãŒã¬ãŒãã»ãã€ã€ãªãã£ãºLPãžã®è¿æžçŸ©åãšç¶ç¶çãªé¢äžã«ããããã®ååŒã®ååé¡ãåœç€Ÿã®ç°¡ç¥å䜵貞å察ç
§è¡šäžã®ææ°ææ§é€åŸã®åµåãšããŠèšé²ããŸãããŸãããã¹ãŠã®ãã€ã€ã«ãã£ãå£åº§ã§åŠçããŸãã
ã¢ã«ãã©ã ãã¡ãŒãã·ã¥ãŒãã£ã«ã«ãºç€Ÿ
ã³ã³ãã³ã¹ãé£çµè²¡åè«žè¡šã«é¢ãã泚èš
ïŒæªç¢ºå®ïŒ
MDCOã©ã€ã»ã³ã¹å¥çŽã«ããç§ãã¡ãžã®åæ¥çãªãã€ã«ã¹ããŒã³ããåœç€Ÿã®ç°¡æå䜵æçèšç®æžãšå
æ¬çæ倱èšç®æžã®å£²äžé«ãšããŠåŠçããã
å°æ¥ã®ãã€ã€ã«ãã£ãŒè²©å£²ã«é¢é£ããåµåã®ååŽã決å®ããããã«ããã©ãã¯ã¹ããŒã³ã»ãã€ã€ã«ãã£ãŒãžã®å°æ¥ã®æ¯æç·é¡ãèŠç©ããå¿
èŠããããŸããåæç· çµæã«èšé²ããã10åãã«ã®åµåã¯ã賌å
¥å¥çŽã®æå¹æéäžããã€ã€ã«ãã£ãŒããã³åæ¥çãã€ã«ã¹ããŒã³ã»ãã€ã¡ã³ãã®åèšé¡ã«å©æ¯è²»çšãšããŠå ç®ãããŸãã2024幎6æ30æ¥æç¹ã§ããã®å©æ¯è²»çšã®æšå®é¡ã¯ãæå¹å¹Žå©çã«æç®ããŠïŒ
ã«ãªããŸãããããã®æšå®ã«ã¯ãåæç· çµæã«èšé²ãããéé¡ãšå°æ¥æéã§èªèãããå©æ¯è²»çšã®äž¡æ¹ã«åœ±é¿ãåãŒãæ§ã
ãªä»®å®ãå«ãŸããŠããŸãã1.00 賌å
¥å¥çŽã®æå¹æéäžãåæç· çµæã«èšé²ããã10åãã«ã®åµåã¯ããããã®ãã€ã€ã«ãã£ãŒããã³åæ¥çãã€ã«ã¹ããŒã³ã»ãã€ã¡ã³ãã®åèšé¡ã«å©æ¯è²»çšãšããŠå ç®ãããŸãã2024幎6æ30æ¥æç¹ã§ããã®å©æ¯è²»çšã®ç·é¡ã¯ã幎å©çïŒ
ã«çžåœãããšèŠç©ããããŠããŸãã 9 ãããã®æšå®ã«ã¯ãåæç· çµæã«èšé²ãããéé¡ãšå°æ¥æéã§èªèãããå©æ¯è²»çšã®äž¡æ¹ã«åœ±é¿ãåãŒãä»®å®ãå«ãŸããŠããŸãã
ãã©ãã¯ã¹ããŒã³ã»ãã€ã€ã«ãã£ãžã®æ¯æããè¡ããããã³ã«ã賌å
¥å¥çŽã®æå¹æéäžã«è² åµã®æ®é«ãè¿æžãããŸããè¿æžã®æ£ç¢ºãªã¿ã€ãã³ã°ãšéé¡ã¯ãåå ±åæéããšã«å€æŽãããå¯èœæ§ããããŸããLeqvioã®ã°ããŒãã«å£²äžé«ã倧å¹
ã«å¢æžãããšãå°æ¥ã®ãã€ã€ã«ãã£å£²åŽã«é¢é£ããè² åµãå©æ¯è²»çšãããã³è¿æžæéã«é倧ãªåœ±é¿ãäžããŸããå®æçã«ãã©ãã¯ã¹ããŒã³ã»ãã€ã€ã«ãã£ãžã®äºå®ãããæ¯æããè©äŸ¡ãããã®æ¯æãã®éé¡ãã¿ã€ãã³ã°ãåœåã®èŠç©ãããšå®è³ªçã«ç°ãªãå Žåãå°æ¥ã®ãã€ã€ã«ãã£ã®å£²åŽã«é¢é£ããè² åµã®ååŽããã³é¢é£ããå©æ¯è²»çšãèŠéãè¯ã調æŽããŸãã
2024幎6æ30æ¥çŸåšãå°æ¥ã®ãã€ã€ãªãã£ãŒå£²åŽã«é¢é£ããåµåã®åž³ç°¿äŸ¡é¡ã¯$ã§ã1.40 10åãã«ãææ°æ$çŸäžãå·®ãåŒããçŽé¡ã§ãã2024幎6æ30æ¥çŸåšã®å°æ¥é
åœã«é¢é£ããåµåã®åž³ç°¿äŸ¡é¡ã¯ãåœç€Ÿããã©ãã¯ã¹ããŒã³ã»ãã€ã€ã«ãã£ãŒãºã«æ¯æãããå°æ¥ã®ãã€ã€ãªãã£ãŒãšåæ¥çãªãã€ã«ã¹ããŒã³ã®èŠç©ããã«åºã¥ããçŸåšã®èŠç©ããã§ãã¬ãã«ïŒã®å
¥åãšèŠãªãããŸãã9.5 å°æ¥ãã©ãã¯ã¹ããŒã³ã»ãã€ã€ã«ãã£ãŒãºãæ¯æãåæ¥çãªãã€ã«ã¹ããŒã³ãå«ãå°æ¥ã®ãã€ã€ãªãã£ãŒã®èŠç©ããã«åºã¥ãã2024幎6æ30æ¥çŸåšã®å°æ¥ã®ãã€ã€ãªãã£ãŒã®å£²åŽã«é¢é£ããè² åµã®åž³ç°¿äŸ¡é¡ã¯ãå
¬æ£äŸ¡å€ã«è¿äŒŒããŠããŸãããããã¯ã¬ãã«ïŒã®å
¥åãšèŠãªãããŸãã
以äžã®è¡šã¯ãå°æ¥ã®ãã€ã€ã«ãã£è²©å£²ã«é¢é£ãã責任ã«å¯Ÿãã掻åãååäœã§ç€ºããŠããŸãïŒ
2023幎12æ31æ¥æç¹ã®åž³ç°¿äŸ¡é¡
$ 1,377,239  èªèãããå©æ¯è²»çš 61,103  æ¯æã (33,799
) 2024幎6æ30æ¥æç¹ã®åž³ç°¿äŸ¡é¡
$ 1,404,543 Â
10ã éçºããªããã£ãè³ å責任
2020幎8æãæã
ã¯BXLS Vããã£ãŒã¬ãŒã-PCP L.P.ããã³BXLS Family Investment Partnership V-ESC L.P.ïŒä»¥äžããã©ãã¯ã¹ããŒã³ ã©ã€ã ãµã€ãšã³ã·ãºãšç·ç§°ãããïŒãšã®å
±åéçºå¥çŽïŒè³éæäŸå¥çŽãšãåŒç§°ãããïŒã«èª¿å°ããŸããããã®å¥çŽã«ããããã©ãã¯ã¹ããŒã³ ã©ã€ã ãµã€ãšã³ã·ãºã¯ç§ãã¡ã®2ã€ã®å¿è¡ç®¡çŸæ£ããã°ã©ã ã®ãã¡ããŽããªã·ã©ã³ããã³ãžã¬ãã·ã©ã³ã®èšåºéçºã«åããæé«ïŒ150.0 çŸäžãã«ã®åºè³ãæäŸããŠããã ãããšãšãªããŸããã2024幎6æ30æ¥çŸåšããã©ãã¯ã¹ããŒã³ ã©ã€ã ãµã€ãšã³ã·ãºã¯HELIOS-b第3çžèšåºè©Šéšã«é¢é£ãããŽããªã·ã©ã³ã®éçºè²»çšã«å¯ŸããŠïŒ70.0 çŸäžãã«ããžã¬ãã·ã©ã³ã®ç¬¬2çžèšåºè©Šéšã®ããã®ïŒ26.0 çŸäžãã«ã®åºè³ãè¡ã£ãŠããŸããããã«ããã©ãã¯ã¹ããŒã³ ã©ã€ã ãµã€ãšã³ã·ãºã¯ããžã¬ãã·ã©ã³ã®ç¬¬3çžèšåºè©Šéšã«é¢é£ããéçºè²»çšã«ã€ããŠãæ倧ïŒ54.0 çŸäžãã«ãŸã§åºè³ããæš©å©ãä¿æããŠããŸãããããã¯çŸ©åã§ã¯ãããŸããããã©ãã¯ã¹ããŒã³ ã©ã€ã ãµã€ãšã³ã·ãºãæäŸãã第3çžèšåºè©Šéšã«å¿
èŠãªæçµçãªè³éé¡ã¯ãç§ãã¡ãç¹å®ã®éçºãã€ã«ã¹ããŒã³ãéæããããšã«ãã£ãŠæ±ºå®ãããŸãããã©ãã¯ã¹ããŒã³ ã©ã€ã ãµã€ãšã³ã·ãºãšç§ãã¡ã®éã§ã¯ããŽããªã·ã©ã³ãšãžã¬ãã·ã©ã³ã®éçºããã³åæ¥åã®è²¬ä»»ã¯ç¬å çã«ç§ãã¡ã«ãããŸãã
ãã©ãã¯ã¹ããŒã³ã»ã©ã€ããµã€ãšã³ã¹ãvutrisiranã®èšåºéçºè²»çšã«å¯Ÿããæ¯æŽãè¡ã代ããã«ãvutrisiranãATTRå¿ççã®èŠå¶æ¿èªãåããŠæåã®åæ¥è²©å£²ãè¡ãããåŸã®æéã«ãAMVUTTRAïŒvutrisiranïŒã®çŽå£²äžé«ã«å¯ŸããŠãã€ã€ã«ãã£ãŒã%æ¯æãããšã«åæããæå®ãããåœã§ATTRå¿ççã®èŠå¶æ¿èªãåããå Žåã¯ã匷å¶ååã«ç¶ããŠvutrisiranãåžå Žããæ€åãããªãéãããã®æè³é¡ã®æ倧å¢é¡æ¯æããè¡ãããšã«åæããŠããŸãã 1 vutrisiranã®çŽå£²äžé«ã«å¯Ÿãã%ãã€ã€ã«ãã£ãŒãæ¯æããvutrisiranãATTRå¿ççã®èŠå¶æ¿èªãåããŠæåã®åæ¥è²©å£²ãè¡ãããåŸã®æéã«æå®ãããåœã§vutrisiranã®èŠå¶æ¿èªãåŸãå Žåãæè³é¡ã®æ倧å¢é¡æ¯æããè¡ããŸãããvutrisiranã匷å¶ååã«ç¶ããŠåžå Žããæ€åãããå Žåã¯ããã®ãããªæ¯æããè¡ããŸããã 10幎é zilebesiranã®ç¬¬2çžèšåºè©Šéšã®éçºè²»ã«å¯ŸããBlackstone Life Sciencesã®è³éæäŸã«å¯ŸããèŠè¿ããšããŠãzilebesiranã®ç¬¬2çžèšåºè©Šéšã®æåè£ã«å®äºããå Žåã«ãBlackstone Life Sciencesã«ã圌ãã®ç¬¬2çžã®æè³é¡ã®æ倧å¢é¡æ¯æãããç¹å®ã®èŠå¶äžã®ã€ãã³ããçºçããªãéããæè³é¡ã®æ倧å¢é¡æ¯æããããããšã«åæããŠããŸãã 2.5 Blackstone Life Sciencesã«ãæå®ãããåœã§ã®zilebesiranã®èŠå¶æ¿èªãè¡ãããå Žåãæè³é¡ã®æ倧å¢é¡æ¯æããæ倧åæ°ãŸã§è¡ãããšã«åæããvutrisiranã匷å¶ååã«ç¶ããŠåžå Žããæ€åãããªãéããèŠå¶æ¿èªãããæéäžã«æè³é¡ã®æ倧å¢é¡æ¯æããå®æœããŸãã 2幎 æå®ãããæéã®æè³ã®æ倧åæ°ã«å¿ããŠãvutrisiranãATTRå¿ççã®èŠå¶æ¿èªãåããå ŽåãBlackstone Life Sciencesã«æè³é¡ã®æ倧å¢é¡æ¯æããããããšã«åæããŠããŸãããvutrisiranã匷å¶ååã«ç¶ããŠåžå Žããæ€åãããå Žåã¯ããã®ãããªæ¯æãã¯è¡ããŸããã 3.25 zilebesiranã®ç¬¬2çžèšåºè©Šéšã®éçºè²»ã«å¯ŸããBlackstone Life Sciencesã®è³éæäŸã«å¯ŸããèŠè¿ããšããŠãzilebesiranã®ç¬¬2çžèšåºè©Šéšãæåè£ã«å®äºããå Žåã«ã圌ãã®ç¬¬2çžã®æè³é¡ã®æ倧å¢é¡æ¯æããããããšã«åæããŠããŸãããäžå®ã®èŠå¶äžã®ã€ãã³ããzilebesiranã®ç¶ç¶çãªéçºã«åœ±é¿ãäžããå Žåã¯ããã®ãããªæ¯æãã¯è¡ããŸããã ä»äžæ¥ãã4幎åŸã®åšå¹Ž æè³é¡ã®æ倧å¢é¡æ¯æãããã€ã€ãBlackstone Life Sciencesã«ãæå®ãããæéã«ãzilebesiranã®ç¬¬2çžèšåºè©Šéšãæåè£ã«å®äºããå Žåã«ã圌ãã®ç¬¬2çžã®æè³é¡ã®æ倧å¢é¡æ¯æããè¡ãããšã«åæããŠããŸãã84.5 2023幎9æãzilebesiranã®KARDIA-1第2çžèšåºè©Šéšã®ãããã©ã€ã³çµæãçºè¡šããã$5000äžã®éçºãã€ã«ã¹ããŒã³éæãçºçãã16åã®åçãªååææ¯æãã§Blackstone Life Sciencesã«æ¯æãããŸãã 4幎 4.5 Blackstone Life Sciencesã«ãæå®ãããåœã§ã®zilebesiranã®èŠå¶æ¿èªãè¡ãããå Žåããã®æéäžã«ã圌ãã®ç¬¬3çžã®æè³é¡ã®æ倧å¢é¡æ¯æããããŸãããzilebesiranã匷å¶ååã«ç¶ããŠåžå Žããæ€åãããå Žåã¯ããã®ãããªæ¯æãã¯è¡ããŸããã ä»äžæ¥ãã4幎åŸã®åšå¹Ž æè³é¡ã®æ倧å¢é¡æ¯æãããã€ã€ãBlackstone Life Sciencesã«ãæå®ãããæéã«ãzilebesiranã®ç¬¬3çžèšåºè©Šéšã§ã®èŠå¶æ¿èªãåããå Žåã«ã圌ãã®ç¬¬3çžã®æè³é¡ã®æ倧å¢é¡æ¯æããè¡ãããšã«åæããŠããŸãã
ã¢ã«ãã©ã ãã¡ãŒãã·ã¥ãŒãã£ã«ã«ãºç€Ÿ
ã³ã³ãã³ã¹ãé£çµè²¡åè«žè¡šã«é¢ãã泚èš
ïŒæªç¢ºå®ïŒ
è³éæäŸå¥çŽã«åºã¥ãæ¯æ矩åã¯ãvutrisiranåã³zilebesiranã«é¢ããç¥ç財ç£æš©ã«å¯Ÿããæ
ä¿æš©ãè³éé ãå
¥ãå£åº§ã«å¯Ÿããæ
ä¿æš©ãé€ããæ
ä¿ãããäºå®ã§ãã
ç§ãã¡ããã©ãã¯ã¹ããŒã³ã©ã€ããµã€ãšã³ã¹ã¯ãä»ã®æ¹ããã®ç Žç£ãåæ§ã®æç¶ãããªãããå Žåãåã
ãè³éæäŸå¥çŽãå
šé¢çã«è§£é€ããæš©å©ãæããŠããŸããç§ãã¡ããã©ãã¯ã¹ããŒã³ã©ã€ããµã€ãšã³ã¹ã¯ãçžææ¹ã®é倧ãªéåãæ¯æ£ãããªãã£ãå Žåããããã¯è£œåã®ç¹å®ã®æ£è
ã®å¥åº·ããã³å®å
šçç±ããããã¯è£œåã®èšåºè©ŠéšãçµäºããåŸã«è£œåãç¹å®ã®äž»èŠåœã®èŠå¶æ¿èªãåããããªãã£ãå Žåã補åå
šè¬ãŸãã¯è£œåã«é¢ããŠãè³éæäŸå¥çŽãå
šé¢çãŸãã¯éšåçã«è§£é€ããããšãã§ããŸãããŸãããã©ãã¯ã¹ããŒã³ã©ã€ããµã€ãšã³ã¹ã«ã¯ãæ¯æããããã¯è£œåã®éçºãåååèœåã«åœ±é¿ããç¹å®ã®ã€ãã³ããçºçããå ŽåããŸãã¯ç§ãã¡ã®æ¯é
æš©ãå€æŽãããå Žåãè³éæäŸå¥çŽãå
šé¢çã«è§£é€ããæš©å©ããããŸãããã©ãã¯ã¹ããŒã³ã©ã€ããµã€ãšã³ã¹ã¯ãç¹å®ã®è£œåã«é¢ããŠãå
±åæå°å§å¡äŒããã®è£œåã®éçºããã°ã©ã ãå
šé¢çã«è§£é€ããããšãéžæããå Žåããã®è£œåã«é¢ããŠç¹å®ã®èšåºè©Šéšã®çµæãåŸãããªãã£ãå Žåããããã¯vutrisiranã«é¢ããŠã®ã¿ãç¹å®ã®äž»èŠåžå Žã§ç¹èš±äŸµå®³ã®èšŽèšã«ãã£ãŠvutrisiranã®éçºãŸãã¯åååã®æš©å©ãçŠæ¢ãããå Žåã補åã«é¢ããŠè³éæäŸå¥çŽã解é€ããããšãã§ããŸããäžéšã®è§£é€ã®ç¶æ³ã§ã¯ãç§ãã¡ã¯ãã©ãã¯ã¹ããŒã³ã©ã€ããµã€ãšã³ã¹ã«å¯ŸããŠããã©ãã¯ã¹ããŒã³ã©ã€ããµã€ãšã³ã¹ããåãåã£ãéçºè³éãšåé¡ããããã¯ãã®åé¡ã®éé¡ãæ¯æãããšãæ±ããããç§ãã¡ã¯ãzilebesiranãŸãã¯vutrisiranãATTRã¢ããã€ããŒã·ã¹ããã³å¿ççã«å¯ŸããèŠå¶æ¿èªãåããå Žåãäžèšã§èª¬æãããŠããæ¯æãããŸãã¯AMVUTTRAã®å Žåã¯äžèšã®ãã€ã€ãªãã£ãã解é€åŸãåŒãç¶ãæ¯æã矩åããããŸãã
åœç€Ÿã¯ãASC 815ããããªããã£ãããã³ãããžã³ã°ãã«åºã¥ãããã©ãã¯ã¹ããŒã³ã»ã©ã€ããµã€ãšã³ã¹ãžã®æ¯æãã®ã¿ã€ãã³ã°ã«å¿ããŠåœç€Ÿã®è²žå察ç
§è¡šã®æªæè²»çšãŸãã¯ãã®ä»ã®è² åµã«èšé²ããããå
¬æ£äŸ¡å€ã«èšæž¬ãããããªããã£ãåµåãšããŠããã¡ã³ãã£ã³ã°å¥çŽãèšäžããŠããŸããéçºããªããã£ãåµåã®åè©äŸ¡ã«ããå
¬æ£äŸ¡å€ã®å€åã¯ãåœç€Ÿã®é£çµè²¡åè«žè¡šã«ããããã®ä»ã®è²»çšãšããŠèšäžãããŸãã
2024幎6æ30æ¥çŸåšãããªããã£ãè² åµã¯å
¬æ£äŸ¡å€éå±€ã®ã¬ãã«3ã®éèè² åµã«åé¡ãããŠããŸããè©äŸ¡æ¹æ³ã«ã¯ãïŒiïŒãã©ãã¯ã¹ããŒã³ã»ã©ã€ããµã€ãšã³ã¹ããæ¯æããåããããã«å®ããããéçºãã€ã«ã¹ããŒã³ãéæãã確çãšææãïŒiiïŒèŠå¶åœå±ã®æ¿èªãšãã©ãã¯ã¹ããŒã³ã»ã©ã€ããµã€ãšã³ã¹ãžã®æ¯æããåŸããã確çãšææãïŒiiiïŒATTRã¢ããã€ãã€ãã®èŠå¶åœå±ã®æ¿èªãåæãšããŠãAMVUTTRAã®çŽå£²äžé«ã«å¯ŸããŠæ¯æããããã€ã€ã«ãã£ã®éé¡ãšææã®èŠç©ãããªã©ã芳å¯äžå¯èœãªã¬ãã«3ã®äž»èŠãªã€ã³ããããçµã¿èŸŒãŸããŠããŸããå¿ççã®äººãïŒivïŒç§ãã¡ã®åå
¥è²»çšïŒ11 %)ãããã³ (v) ãã©ãã¯ã¹ããŒã³ã»ã©ã€ããµã€ãšã³ã¹ã®åå
¥è²»çš (6 %).
以äžã®è¡šã¯ãéçºæŽŸçè² åµã«é¢ãã掻åãåãã«åäœã§ç€ºããŠããŸãã
2023幎12æ31æ¥æç¹ã®åž³ç°¿äŸ¡é¡
$ 324,941  è³éæäŸå¥çŽã®äžã§åãåã£ãéé¡ 12,333  è³éæäŸå¥çŽã®äžã§æ¯æãããéé¡ (10,563 ) éçºããªããã£ãåµåã®å
¬æ£äŸ¡å€å€å 64,228  2024幎6æ30æ¥æç¹ã®åž³ç°¿äŸ¡é¡
$ 390,939 Â
11. æ ªåŒå ±é
¬
以äžã®è¡šã¯ããªãã¬ãŒãã£ã³ã°ã³ã¹ããè²»çšã«å«ãŸããæ ªåŒå ±é
¬è²»çšãããã³æ ªäž»è³æ¬å°äœéã«å«ãŸããæ ªåŒå ±é
¬è² æ
ããåœç€Ÿã®ç°¡æå䜵æçèšç®æžããã³æ ªäž»è³æ¬æ¬ æã®ç°¡æå䜵èšç®æžã«ãŸãšãããã®ã§ãã
 6æ30æ¥ãŸã§ã®3ãæé 6æ30æ¥ãŸã§ã®6ãæé å¶æ¥æŽ»åã«ãããã£ãã·ã¥ãããŒïŒ 2024 2023 2024 2023 ç 究éçº $ 48,115  $ 32,801  $ 67,330  $ 49,033  販売ã»äžè¬ç®¡çè²»çš 41,173  43,001  67,305  66,716  åšåº«ããŒã¹ã®å ±é
¬è²»çšã®åèš
89,288  75,802  134,635  115,749 Â æ ªåŒããŒã¹ã®å ±é
¬è²»çšïŒå€§æåïŒ
808  1,188  1,616  2,377  ç·æ ªåŒå ±é
¬è²»çšãã£ãŒãž
$ 90,096 Â $ 76,990 Â $ 136,251 Â $ 118,126 Â
ã¢ã«ãã©ã ãã¡ãŒãã·ã¥ãŒãã£ã«ã«ãºç€Ÿ
ã³ã³ãã³ã¹ãé£çµè²¡åè«žè¡šã«é¢ãã泚èš
ïŒæªç¢ºå®ïŒ
12. 1æ ªãããã®çŽæ倱ïŒ
åºæ¬çãªäžæ ªåœããã®çŽæ倱ã¯ãçºè¡æžã¿ã®æ®éæ ªåŒã®å éå¹³åæ°ã§çŽæ倱ãå²ã£ãŠèšç®ããŸããåžèååŸã®äžæ ªåœããã®çŽæ倱ã¯ãåžèåããã³ã·ã£ã«äžæ ªåœããã®çŽæ倱ãšçºçæéäžã«æªã ä¿æããŠããçºè¡æžã¿æ®éæ ªåŒãšåžèåéšåãå å³ããŠçŽæ倱ãå²ã£ãŠèšç®ãããŸããåžèååŸã®äžæ ªåœããã®çŽæ倱ã®èšç®ã§ã¯ã転æ瀟åµã®å©åè²»çšãæé€ããããã«çŽæ倱ã調æŽããŸããããã³ã·ã£ã«äžæ ªåœããã®æ®éæ ªåŒã«ã¯ãå¶éä»ãæ ªåŒãŠãããã®çºè¡ãæ ªåŒãªãã·ã§ã³ã®è¡äœ¿ïŒãã®åçã財åæ¡ä»¶ã®åæ ã«ããèªå·±æ ªåŒåŠçæ³ã«åºã¥ããŠå賌å
¥ãããæªæãæ ªè³Œå
¥å¥çŽã«äœ¿çšããããšä»®å®ããå ŽåïŒããã³æéäžã«æªã çºçããŠãã転æ瀟åµã®æ ªåŒãžã®è»¢æãå«ãŸããŸãïŒçºè¡æ¥åã¯å ±åãããæåã®æéã«ãããŠè»¢æ瀟åµã®æç®æ¹æ³ãé©çšãããšä»®å®ïŒçŽæ倱ãçºçããæéã«ãããŠããã³ã·ã£ã«äžè¬æ ªã®è¿œå ãååžèåã«ãªãå ŽåãåžèååŸã®äžæ ªåœããã®çŽæ倱ã¯åºæ¬çãªäžæ ªåœããã®çŽæ倱ãšåãã§ãã
以äžã®è¡šã¯ãåžèåé²æ¢ã®ããã«é€å€ãããæœåšçãªæ®éæ ªåŒïŒè²¡åäŒèšåŠçãæç®èª¿æŽé¡ãèæ
®ããåïŒã瀺ããŠããŸãã
2021幎6æ30æ¥çŸåš å¶æ¥æŽ»åã«ãããã£ãã·ã¥ãããŒïŒ 2024 2023 ããã©ãŒãã³ã¹ã«åºã¥ãã¹ããã¯ãªãã·ã§ã³ãå«ãæ®éæ ªåŒè³Œå
¥ãªãã·ã§ã³ 売æéã¢ã»ããåæœèšããååã£ãè³é(çŽé¡)  8,023  éãã¹ããªã¹ããªã¯ãããã¹ã¿ãã¯ãŠããããããã©ãŒãã³ã¹ã«åºã¥ãå¶éä»ãã¹ããã¯ãŠããããå«ã 2,870  2,303  転æåµå 3,616  3,616  ç·èš 12,721  13,942 Â
13. ãã¯ãµã¹ ã±ã©ãã£ãã¯ã¹ ã·ã£ã³ããŒïŒã³ã³ãã£ã·ã§ããŒã³ãããã¡ã³ãåã³ã³ã³ãã£ã³ãžã§ã³ã·ãŒ
ãã¯ãããžãŒã©ã€ã»ã³ã¹ããã³ãã®ä»ã®ã³ãããã¡ã³ã
ç§ãã¡ã¯ãç¹å®ã®æè¡ãæ
å ±ãç 究ããã»ã¹ããã³ãã®ä»ã®è£œåéçºã«äœ¿çšããæš©å©ã第äžè
ããã©ã€ã»ã³ã¹èªå¯ããŠããŸããé¢é£ããã©ã€ã»ã³ã¹ãŸãã¯æè¡å¥çŽã«åŸããã©ã€ã»ã³ãµãŸãã¯ãã®ä»£ç人ã«å¯ŸããŠãæ§ã
ãªå¥çŽæéäžã«äžå®ã®æ¯æããè¡ãããšã矩åä»ããããŠããŸãããããã®å¥çŽæéã®å€ãã¯ãåœç€Ÿãã©ã€ã»ã³ã¹èªå¯ããåºç€ãšãªãç¥ç財ç£ã®æ®å寿åœãšäžèŽããŠããŸãã2024幎6æ30æ¥çŸåšãæ¢åã®ã©ã€ã»ã³ã¹å¥çŽã«åºã¥ãåºå®æ¯æãããã³ãã£ã³ã»ã«å¯èœãªæ¯æããè¡ãããã®æ¬¡ã®5幎éã®åœç€Ÿã®ã³ãããã¡ã³ãã¯éèŠã§ã¯ãããŸããã
æ³çåé¡
ããžãã¹ã®éçšã§ã蚎èšã仲è£ãŸãã¯ãã®ä»ã®æ³çæç¶ãã®åœäºè
ã«ãªãããšããããŸãã以äžã«èª¬æããäºé
ãå«ããåœç€Ÿãé¢äžããå¯èœæ§ã®ããè«æ±ããã³èšŽèšæç¶ãã«ã¯ãåœç€Ÿã®è£œåãŸãã¯è£œååè£ã«é¢é£ããç¹èš±ã®ç¯å²ãæå¹æ§ããŸãã¯å·è¡å¯èœæ§ã«å¯Ÿããç°è°ç³ãç«ãŠãããã³åœç€Ÿãä»è
ãä¿æããç¹èš±ã®ç¯å²ãæå¹æ§ããŸãã¯å·è¡å¯èœæ§ã«å¯ŸããŠæèµ·ããç°è°ç³ãç«ãŠãå«ãŸããŸããããã«ã¯ã第äžè
ããåœç€Ÿããã®ç¹èš±ã䟵害ããŠãããšäž»åŒµãããããåœç€Ÿããã®ãããªç¬¬äžè
ãšã®ã©ã€ã»ã³ã¹å¥çŽãŸãã¯ä»ã®å¥çŽã«éåããããããšãããè«æ±ãå«ãŸããŸãããã®ãããªæ³çæç¶ãã®çµæã¯ããã®çç±ã«ãããããäžç¢ºå®ã§ãããå ããŠã蚎èšããã³é¢é£äºé
ã¯è²»çšãããããåœç€Ÿã®çµå¶é£ããã³ãã®ä»ã®ãªãœãŒã¹ãä»ã®æŽ»åã«åãçµãäºå®ã§ãã£ãå Žåããã®æ³šç®ããããããšããããŸãããã蚎èšæç¶ãã§å蚎ã§ããªãã£ãå Žåãåœç€Ÿã®ããžãã¹ãæ¥çžŸãæµåæ§ããã³è²¡åç¶æ³ã«äžå©ãªåœ±é¿ãçããããšããããŸããåœç€Ÿã®æ³çè²»çšã®è²»çšèªèæ¹éã¯ãçºçãããšèªèããããã®ãããªè²»çšãèªèããããšã§ãã
ç¹èš±äŸµå®³èšŽèš
2022幎3æãç§ãã¡ã¯ãïŒ1ïŒPfizer, Inc.ãšåäŒç€ŸPharmaciaïŒUpjohn Co. LLCïŒç·ç§°ã㊠Pfizer ãšåŒã¶ïŒåã³ïŒ2ïŒModerna, Inc.ãšãã®åäŒç€ŸModernaTX, Inc.ãããã³Moderna US, Inc. ïŒç·ç§°ã㊠Moderna ãšåŒã¶ïŒã«å¯Ÿããç±³åœç¹èš±ç¬¬11,246,933å·ïŒãâ933ç¹èš±ããšåŒã¶ïŒã«å¯Ÿãã䟵害ã®æå®³è³ åãæ±ãã蚎èšãããã©ãŠã§ã¢å°åºé£éŠè£å€æã«å¥ã
ã«èµ·ãããŸããããã®ç¹èš±ã¯ãmRNA COVID-19ã¯ã¯ãã³ã®è£œé ããã³è²©å£²ã«ãããŠãPfizerãšModernaã®äž¡ç€Ÿã䟵害ãããã®ã§ãããŸãããã®ç¹èš±ã¯ãmRNA COVID-19ã¯ã¯ãã³ã®æåã«åºç€ãæäŸãããåœç€Ÿã®çå解æ§ã«ããªã³æ§ãªããã察象ãšããŠããŸãã
ãã¡ã€ã¶ãŒãšã¢ãã«ããããããã933ç¹èš±ãã䟵害ããŠãããšã®å€æãšã䟵害ãè£åããããã«ååãªæå®³è³ åéãè«æ±ããŸãããã ãããã¡ã€ã¶ãŒãšã¢ãã«ããç¹èš±ä»ããªãããã䜿çšããããã®æªèš±å¯ã®äœ¿çšã«å¯Ÿããåççãªäœ¿çšæãäžåããªãé¡ãè£åããŸããå©æ¯ãè£å€æãåœããè²»çšãå«ããŠã蚎èšã®çµæã«åºã¥ããŠåŠçãããŸããæåºãããã¯ã¬ãŒã ã«æ瀺ãããŠããããã«ããããã®èšŽèšã«ãããŠå·®æ¢åœä»€ã¯æ±ããããŠããŸããã
2022幎5æ23æ¥ã«ãã¢ãã«ãã¯ã»ã¯ã·ã§ã³1498ïŒaïŒã«åºã¥ãç©æ¥µçãªãã£ãã§ã³ã¹ã䞻匵ããäžéšã®æ£åŽåè°ãæåºããŸãããç§ãã¡ã¯2022幎5æ27æ¥ã«ã圌ãã®åè°ã«å察ããŠãã¢ãã«ããæ¿åºä»¥å€ã®å£²äžã倧ããã£ãããšã䞻匵ããŸããã
ã¢ã«ãã©ã ãã¡ãŒãã·ã¥ãŒãã£ã«ã«ãºç€Ÿ
ã³ã³ãã³ã¹ãé£çµè²¡åè«žè¡šã«é¢ãã泚èš
ïŒæªç¢ºå®ïŒ
2022幎4æã«å¥çŽãçµäºããŸãããã¢ãã«ãã¯2022幎6æ13æ¥ã«åå¿ãã第1498æ¡ïŒaïŒã®äžã§ã®è²©å£²ã«é¢ãã䞻匵ã«ã€ããŠéšåçãªèšŽèšæ£åŽãèŠè«ããŸããã
2022幎5æ27æ¥ããã¡ã€ã¶ãŒã¯ç§ãã¡ã®æ蚎ã«å¯ŸããŠåçæžãæåºãã䞻匵ãåŠèªããç¡å¹æ§ãšé䟵害ã®æåŒã䞻匵ããŸãããããã«ããã¡ã€ã¶ãŒã¯ãã€ãªã³ããã¯ã蚎èšã«å ããç¹èš±ãç¡å¹ã§ãããšã®å€æ±ºãæ±ããå蚎ãè¿œå ããç¹èš±ã®äžæ£äœ¿çšã«ããç¹èš±ã®ç¡å¹ã䞻匵ããäºã€ç®ã®äž»åŒµãè¿œå ããŸãããç§ãã¡ã¯åœŒãã®æåŒãšå蚎ã«ã¯æ ¹æ ããªããšèããç§ãã¡ã®äž»åŒµã®åŠ¥åœæ§ãšåœŒãã®ç¹èš±ã®äžæ£äœ¿çšäž»åŒµã®æ ¹æ ã®ãªãã«é¢ããå
·äœçãªè«ç¹ã2022幎6æ10æ¥ã«åçããŸããã
2022幎7æ12æ¥ãç§ãã¡ã¯è¿œå ã®èšŽèšãæèµ·ããŸãããPfizerãšModernaããããã«å¯ŸããŠãç±³åœç¹èš±ç¬¬11,382,979å·ãŸãã¯ã'979ç¹èš±ãã®äŸµå®³ã«ã€ããŠãmRNA COVID-19ã¯ã¯ãã³ã®è£œé 販売ã«å¯Ÿããæå®³è³ åãæ±ããŸãããååœäºè
ã¯äž¡æ¹ã®ç¹èš±ãçµã¿åãããŠ1ã€ã®èšŽèšã«ããããšã«åæããŸããããŸããModernaãšPfizer / BioNTechããããã«å¯ŸããŠå¥ã
ã®èšŽèšãè¡ããŸããã two oneworldã¢ã©ã€ã¢ã³ã¹ã®ã¡ã³ããŒãšè¿œå ã®ã°ããŒãã«ããŒãããŒãšãšãã«ãã客æ§ã¯alaskaair.comã§30以äžã®èªç©ºäŒç€Ÿãšäžçäžã®1,000以äžã®ç®çå°ã§è³Œå
¥ãç²åŸããŸãã¯äº€æããéžæè¢ãä»ãŸã§ä»¥äžã«ãããŸãã
2023幎2æ8æ¥ãç±³åœç¹èš±åºããã第3ç¹èš±ã2023幎2æ28æ¥ã«U.S.ç¹èš±ç¬¬11,590,229å·ããŸãã¯ã229ç¹èš±ããšããŠçºè¡ãããããšãéç¥ãããŸãããããã¯ãåœç€Ÿãä¿¡ãããšããã«ããã°ããã¡ã€ã¶ãŒãšã¢ãã«ãã®COVID-19ã¯ã¯ãã³ã䟵害ãããšèããŠããŸãã2023幎2æ15æ¥ãåœç€Ÿã¯è£å€æã«å¯ŸããŠããã®ç¹èš±ããã¡ã€ã¶ãŒãšã¢ãã«ãã«å¯Ÿããæ¢åäºä»¶ã«è¿œå ããåè°ãæåºãã2023幎4æ26æ¥ã«ã¯ãè£å€æãéå»·ãã1498(a)ç¯ã«åºã¥ã販売ã«é¢ãã䞻匵ãæ£åŽããããã¢ãã«ããæåºããäžéšã®æ£åŽåè°ãåœç€ŸãæåºããïŒåœæã®èšŽèšã«ã229ç¹èš±ããè¿œå ããåè°ãåœç€Ÿã®èšŽèšã«å¯Ÿãããã¡ã€ã¶ãŒã®äžéšã®ç¡å¹äž»åŒµãã¢ãã«ãã以åã«æåºããç¡å¹äž»åŒµã«è£å®ããããã«æåºããåè°ïŒãåŽäžãããŸããã
2023幎5æ26æ¥ãç§ãã¡ã¯ãã©ãŠã§ã¢å·ã§PfizerãšModernaã«å¯ŸããŠã229ç¹èš±ãã®äŸµå®³ã«ããæå®³è³ åãæ±ããŠè¿œå ã®èšŽèšãèµ·ãããŸããããã®ç¹èš±ã«å ããç§ãã¡ã¯PfizerãšModernaã®äž¡æ¹ã«å¯ŸããŠç±³åœç¹èš±çªå·11,633,479å·ããã³11,633,480å·ãPfizerã®ã¿ã«å¯ŸããŠç±³åœç¹èš±çªå·11,612,657å·ã®äŸµå®³ã䞻匵ããŸããã
2023幎8æ9æ¥ãç±³åœãã©ãŠã§ã¢å°åºè£å€æã§ããŒã¯ãã³èŽèäŒãéå¬ããã'933ããã³'979ç¹èš±ã§äœ¿çšãããäºãããçšèªã®æå³ãæ€èšããŸããã2023幎8æ21æ¥ãè£å€æã¯çšèªã解éããåœä»€ãåºãã第3çšèªã®è£å®ã蚌æ 調æ»ãåŸ
ã£ãŠå»¶æãã2024幎1æ4æ¥ã«ã¯èšŒæ 調æ»ãè¡ããããã®åŸ2024幎7æ12æ¥ã«è¿œå 蚌æ 調æ»ã®çµæãåŸ
ã£ãŠæçµå€æ±ºãäžãããŸããã2023幎8æ21æ¥ã®åœä»€ã«ç¶ããç§ãã¡ã¯ã¢ãã«ã瀟ãšå
±ã«ç¹èš±äŸµå®³ã®æçµå€æ±ºã«ã€ããŠåæããè£å€æã¯2023幎8æ30æ¥ã«ãã®ãããªå€æ±ºãåºãã2023幎9æ7æ¥ã«ç§ãã¡ã¯ã¢ãã«ã瀟ã«å¯Ÿããåæ蚎èšã§ãè«æ±ã®æ§æã«é¢ããå€æ±ºãé£éŠæ§èšŽè£å€æã«äžèšŽããŸããã蚎èšã«ãããŠç¹èš±ã®æ®ãã®éšåã¯åããã2023幎5æ26æ¥ã«æèµ·ãããã¢ãã«ã瀟ã«å¯Ÿãã蚎èšã¯ãè£å€æã«ãã£ãŠèšå®ãããã¹ã±ãžã¥ãŒã«ã«åŸã£ãŠé²è¡äžã§ãã éå»1é±éã¯æ ªäž»ã«ãšã£ãŠå€§å€ãªæéã§ãã£ããããåºæ¬çãªãã¡ã³ãã¡ã³ã¿ã«åæãè¡ããäœãåŠã¶ããšãã§ãããã調ã¹ãŠã¿ãŸãããã '933ããã³'979ç¹èš±ã«ãããŠäºãããçšèªã®äœ¿çšã«é¢ããæå³ãèæ
®ããããã2023幎8æ9æ¥ã«ç±³åœãã©ãŠã§ã¢å°åºè£å€æã§ããŒã¯ãã³èŽèäŒãéå¬ãããŸããã2023幎8æ21æ¥ãè£å€æã¯ãã®çšèªã解éããåœä»€ãåºãã第3çšèªã«ã€ããŠã¯èšŒæ 調æ»ãåŸ
ã£ãŠè£æ±ºã延æããŸããã2024幎1æ4æ¥ã«ã¯ããã®ç¬¬3çšèªã®è£ãããã«èšŒæ 調æ»ãè¡ããããã®åŸ2024幎7æ12æ¥ã«ã¯è¿œå 蚌æ 調æ»ã®çµæãåŸ
ã£ãŠæçµå€æ±ºãäžãããŸããã two ãFalloutãéå»1é±éã¯æ ªäž»ã«ãšã£ãŠå€§å€ãªæéã§ãã£ããããåºæ¬çãªãã¡ã³ãã¡ã³ã¿ã«åæãè¡ããäœãåŠã¶ããšãã§ãããã調ã¹ãŠã¿ãŸãããã åœç€Ÿã®ç¹èš±ã®äŸµå®³ã«ã€ããŠã®é䟵害ã®æçµå€æ±ºãåãä»ããããã2023幎8æ21æ¥ã®åœä»€ã«ç¶ããç§ãã¡ã¯ã¢ãã«ã瀟ãšå
±ã«åæããŸãããè£å€æã¯ãã®ãããªå€æ±ºãåºãã2023幎8æ30æ¥ã«ãã®ãããªå€æ±ºãåºããŸããããããŠ2023幎9æ7æ¥ãç§ãã¡ã¯ã¢ãã«ã瀟ã«å¯Ÿããåæ蚎èšã§ãè«æ±ã®æ§æã«é¢ããå€æ±ºãé£éŠæ§èšŽè£å€æã«äžèšŽããŸããã two åœç€Ÿã®ç¹èš±ã®äŸµå®³ã«ã€ããŠã®é䟵害ã®æçµå€æ±ºãåãä»ããããã2023幎8æ21æ¥ã®åœä»€ã«ç¶ããç§ãã¡ã¯ã¢ãã«ã瀟ãšå
±ã«åæããŸãããè£å€æã¯ãã®ãããªå€æ±ºãåºãã2023幎8æ30æ¥ã«ãã®ãããªå€æ±ºãåºããŸããããããŠ2023幎9æ7æ¥ãç§ãã¡ã¯ã¢ãã«ã瀟ã«å¯Ÿããåæ蚎èšã§ãè«æ±ã®æ§æã«é¢ããå€æ±ºãé£éŠæ§èšŽè£å€æã«äžèšŽããŸããã oneworldã¢ã©ã€ã¢ã³ã¹ã®ã¡ã³ããŒãšè¿œå ã®ã°ããŒãã«ããŒãããŒãšãšãã«ãã客æ§ã¯alaskaair.comã§30以äžã®èªç©ºäŒç€Ÿãšäžçäžã®1,000以äžã®ç®çå°ã§è³Œå
¥ãç²åŸããŸãã¯äº€æããéžæè¢ãä»ãŸã§ä»¥äžã«ãããŸãã 蚎ããããã¢ãã«ã瀟ã«å¯Ÿããç¹èš±ã®äžéšãåããåœä»€ã§ãã2023幎8æ21æ¥ã®åœä»€ã¯ãç¹èš±ã®è«æ±ã«åœ±é¿ãäžããããã®èšŽèšã¯è£å€æã«ãã£ãŠèšå®ãããäºå®ã®ã¹ã±ãžã¥ãŒã«ã«åŸã£ãŠé²è¡äžã§ãã
The two 第3ã¯ã¬ãŒã çšèªã®å€æ±ºãåããŠããã¡ã€ã¶ãŒã«å¯Ÿããå¥ã
ã®èšŽèšãç¶ç¶äžã§ãã2023幎9æã«ãç§ãã¡ã¯ãã¡ã€ã¶ãŒãšåæããŠ2022幎ãš2023幎ã®èšŽèšã1ã€ã«ãŸãšããããšã«ãªããŸããããã®ããšã«ãããè£å€æ¥ã¯2024幎11æãã2025幎ååã«å€æŽãããæçµã¹ã±ãžã¥ãŒã«ã¯è£å€æã«ãã£ãŠæ±ºå®ãããŸãã oneworldã¢ã©ã€ã¢ã³ã¹ã®ã¡ã³ããŒãšè¿œå ã®ã°ããŒãã«ããŒãããŒãšãšãã«ãã客æ§ã¯alaskaair.comã§30以äžã®èªç©ºäŒç€Ÿãšäžçäžã®1,000以äžã®ç®çå°ã§è³Œå
¥ãç²åŸããŸãã¯äº€æããéžæè¢ãä»ãŸã§ä»¥äžã«ãããŸãã ããã«ãããè£å€æ¥ã¯2024幎11æãã2025幎äžåæã«ç§»åããå¿
èŠããããæçµã¹ã±ãžã¥ãŒã«ã¯è£å€æã«ãã£ãŠæ±ºå®ãããŸãã
2024幎7æ12æ¥ãAcuitas Therapeutics Inc.ïŒä»¥äžãAcuitasïŒãšç¹å®ã®åŸæ¥å¡ã¯ãç§ãã¡ã«å¯ŸããPfizer/BioNTechãModernaã«å¯ŸããŠèšŽèšãæèµ·ããç¹èš±ã«ãããŠç¹å®ã®AcuitasåŸæ¥å¡ãå
±åçºæè
ãšããŠè¿œå ããå€æ±ºãæ±ããç³ç«ãŠãç±³åœãã©ãŠã§ã¢å°æ¹è£å€æã«æåºããŸãããç§ãã¡ã¯ç³ãç«ãŠã«å¯ŸããŠé©åãªå¯Ÿå¿ãããäºå®ã§ãã
è£å
ç¥ç財ç£æš©ã«é¢ããã©ã€ã»ã³ã¹å¥çŽã«åºã¥ããæã
ã¯äŒæ¥ãšã®å¥çŽã«ãã£ãŠç¥ç財ç£æš©ãååŸããããšããããŸãããã®éã«ã¯ãã©ã€ã»ã³ã¹å¥çŽã«åºã¥ãç¥ç財ç£æš©ã«é¢é£ããæ害ã«ã€ããŠãäŒæ¥ãè£åããããšãæ±ããããå ŽåããããŸãããã®å Žåãåœç€Ÿã¯ãã©ã€ã»ã³ã¹å¥çŽãŸãã¯åœè©²ã©ã€ã»ã³ã¹ãããç¥ç財ç£æš©ã«é¢ãã蚎èšã«é¢é£ããè²»çšãã©ã€ã»ã³ã¹ãããç¥ç財ç£ã«é¢ãã蚎èšã«é¢ããè²»çšãå«ããåœè©²èšŽèšã«é¢é£ããè²»çšã®æ¯æã責任ããããŸãããŸããåœç€Ÿã¯ããžãã¹éå¶äžå¿
èŠãªæ°å€ãã®å¥çŽæžã«çœ²åããŠãããåœè©²å¥çŽæžã«ã¯å
žåçãªæ¡é
ãå«ãŸããŠãããåœè©²å¥çŽè
ãšåœŒããçºçããç¹å®ã®äºè±¡ã蚎èšãŸãã¯ãã®ä»ã®æ³çæç¶ãã«èµ·å ããæ害ãè£åããããšã矩åä»ããŠããŸããããã«ãåœç€Ÿã¯èªç€Ÿã®åœ¹å¡ããã³åç· åœ¹ã«å¯ŸããŠãè£å€ããã³å解éé¡ãå€æ±ºéé¡ã眰éãæ³äººçšããã³å解éæ¯æãã«å¿
èŠãªè²»çšã«ã€ããŠã圌ãã蚎èšãæ³çæç¶ãã«é¢äžããå Žåã«ãããå¶éã®äžã«è²¬ä»»ãè² ãããšãçŽæããŠããŸãããããã®è£åè²»çšã¯ã売äžé«ãäžè¬ç®¡çè²»çšã«è«æ±ãããŸãã
ãã®ãããªä¿èšŒæ¡é
ã«åºã¥ãå°æ¥ã®æ倧æœåšè²¬ä»»ã¯äžç¢ºå®ã§ããç§ãã¡ã¯ãå
šã»ã¯ã¿ãŒã®ä¿èšŒæ¡é
ã«åºã¥ã責任ã®èŠç©ãéèšã®å
¬æ£äŸ¡å€ã¯æå°éã§ãããšå€æãã2024幎6æ30æ¥æç¹ã§ããã®ãããªä¿èšŒæ¡é
ã«é¢é£ãã責任ãèšé²ããŠããŸããã
é
ç®2.財åç¶æ³åã³æ¥çžŸã«é¢ããçµå¶è
ã®è°è«ãšåæ
以äžã®è°è«ã«ã¯ãåœç€Ÿã®è²¡åç¶æ³ãæ¥çžŸã«ã€ããŠã®çµå¶é£ã®åæãå«ãŸããŠããããã®ç¬¬10-Qãã©ãŒã ã®å¥ã®å Žæã«å«ãŸããŠããåœç€Ÿã®æªç£æ»ã®é£çµè²¡åè«žè¡šããã³ãã®æ³šèšãšäžç·ã«èªãå¿
èŠããããŸãã
æŠèŠ
ç§ãã¡ã¯ããªãæ žé
žå¹²æžïŒRNAiïŒã«åºã¥ãæ°ããæ²»çæ³ãéçºããã°ããŒãã«ãªåæ¥åã¬ãã«ã®ãã€ãªå»è¬åäŒæ¥ã§ãã RNAiã¯ãéºäŒåçºçŸã®ã·ãŒã±ã³ã¹ç¹ç°çãªãµã€ã¬ã³ã·ã³ã°ãšèª¿ç¯ã®ããã«çŽ°èå
ã§èªç¶ã«èµ·ããçç©åŠççµè·¯ã§ãã RNAiçµè·¯ãå©çšããããšã§ãç§ãã¡ã¯RNAiæ²»çè¬ãšããŠç¥ãããé©æ°çãªæ°ããå»è¬åã®æ°ããã¯ã©ã¹ãéçºããŸããã RNAiæ²»çè¬ã¯ãçŸæ£ã®åå ãŸãã¯çµè·¯ã«é¢äžããã¿ã³ãã¯è³ªããšã³ã³ãŒãããã¡ãã»ã³ãžã£ãŒRNAïŒmRNAïŒã匷åã«ãµã€ã¬ã³ã·ã³ã°ããå°ããªå¹²æžRNAã§æ§æãããŠãããåŸæ¥ã®è¬å€ãããäžæµã§æ©èœããŸããããã«ããããããã®ã¿ã³ãã¯è³ªãäœãããªãããã«ããããšãã§ããŸããç§ãã¡ã¯ããããåžå°çŸæ£ããã³åºç¯ãªçŸæ£ã®æ£è
ã®æ²»çãå€é©ããå¯èœæ§ã®ããé©åœçãªã¢ãããŒãã§ãããšèããŠããŸãããããŸã§ã®ãšããããã®é©åœçãªã¢ãããŒããæšé²ããããã®ç§ãã¡ã®åãçµã¿ã¯ãAMVUTTRAïŒvutrisiranïŒãONPATTROïŒpatisiranïŒãGIVLAARIïŒlumasiranïŒããã³LeqvioïŒinclisiranïŒã®5ã€ã®ãã¡ãŒã¹ãã€ã³ã¯ã©ã¹RNAiããŒã¹ã®å»è¬åã®æ¿èªãåŒãåºããŸããã ® ïŒãŽããªã·ã©ã³ïŒãONPATTROïŒããã£ã·ã©ã³ïŒãGIVLAARIïŒã«ãã·ã©ã³ïŒããã³LeqvioïŒã€ã³ã¯ãªã·ã©ã³ïŒ ® ææ¥ã®å€©æ°ã¯ã©ãã§ããïŒ Â® ïŒgivosiranïŒãOXLUMO ® ïŒã«ãã·ã©ã³ïŒãšLeqvio ® ïŒã€ã³ã¯ãªã·ã©ã³ïŒ
ç§ãã¡ã®ç 究éçºã®æŠç¥ã¯ã人éã®çŸæ£ã®åå ãŸãã¯çµè·¯ã«é¢äžããéºäŒåãã¿ãŒã²ããã«ããããšã§ããN-ã¢ã»ãã«ã¬ã©ã¯ããµãã³ïŒGalNAcïŒå
±åœ¹ã¢ãããŒããŸãã¯è質ããç²åïŒLNPïŒãå©çšããŠãsiRNAã®èèæäžãå¯èœã«ããŠããŸããäžæ¢ç¥çµç³»ãç®ã®ïŒçŒå
æäžïŒã«é
éããããã«ãè溶æ§ãªã¬ã³ããšããŠãããµãã·ã«ïŒC16ïŒåºã«åºã¥ã代æ¿å
±åœ¹ã¢ãããŒãã䜿çšããŠããŸãããŸããsiRNAã®å¿èãéªšæ Œçãèèªçµç¹ãžã®é
éæ¹æ³ã«ã€ããŠãé²æ©ããŠããŸããç§ãã¡ã®çŠç¹ã¯ãé«ãæªè§£æ±ºã®ããŒãºãéºäŒçã«æ€èšŒãããã¿ãŒã²ãããèšåºç¬¬1çžè©Šéšã®èšåºæŽ»åè©äŸ¡ã®ããã®æ©æãã€ãªããŒã«ãŒãããã³è¬å€éçºãèŠå¶æ¿èªãæ£è
ã¢ã¯ã»ã¹ãåæ¥åã®å®çŸ©å¯èœãªéçãããèšåºæ瀺ã«ãããŸãã
2021幎åãç§ãã¡ã¯ç§ãã¡ã®æŠç¥ãéå§ããŸããã ãAlnylam P x25ãæŠç¥ã¯ãæç¶å¯èœãªé©æ°ãšåªãã財åæ¥çžŸãéããŠãçããç
æ°ããäžè¬çãªç
æ°ã«å€é©çãªè¬å€ãæäŸããããšã§ãã 5 ãAlnylam P x25ãæŠç¥ã¯ãæç¶å¯èœãªé©æ°ãšåªãã財åæ¥çžŸãéããŠãçããç
æ°ããäžè¬çãªç
æ°ã«å€é©çãªè¬å€ãæäŸããããšã§ãã 2025幎æ«ãŸã§ã«äžæµã®ãã€ãªãã¯ãããžãŒäŒæ¥ãžã®ç§»è¡ãèšç»ããæŠç¥ã«çŠç¹ãåœãŠãŠããŸããããã«ãããæç¶å¯èœãªã€ãããŒã·ã§ã³ãéããŠäžçäžã®æ£è
ã«é©æ°çãªåžå°çŸæ£ãå°éçŸæ£ãããã³éžæãããäžè¬çãªçŸæ£ã®è¬å€ãæäŸããåªãã財åããã©ãŒãã³ã¹ãå®çŸããããšãç®æããŠããŸãã ãAlnylam P x25ãæŠç¥ã¯ãæç¶å¯èœãªé©æ°ãšåªãã財åæ¥çžŸãéããŠãçããç
æ°ããäžè¬çãªç
æ°ã«å€é©çãªè¬å€ãæäŸããããšã§ãã 5 ãAlnylam P x25ãæŠç¥ã¯ãæç¶å¯èœãªé©æ°ãšåªãã財åæ¥çžŸãéããŠãçããç
æ°ããäžè¬çãªç
æ°ã«å€é©çãªè¬å€ãæäŸããããšã§ãã ãããã£ãŠãæç¶å¯èœãªã€ãããŒã·ã§ã³ãéããŠäžçäžã®æ£è
ã«é©æ°çãªåžå°çŸæ£ãå°éçŸæ£ãããã³éžæãããäžè¬çãªçŸæ£ã®è¬å€ãæäŸããããšãç®æããäŸå€çãªè²¡åæ¥çžŸãäžããããšãç®æããŠããŸãã
çŸåšãæã
ã¯5ã€ã®åžè²©è£œåãš10件以äžã®èšåºããã°ã©ã ãå±éããŠãããããã«ã¯æ°ä»¶ã®åŸæ段éã®éçºããã°ã©ã ãå«ãŸããŠããŸãããããã¯ãçãããå°éçãªãéžã°ããæ®å圢æ
ã«ãŸããã£ãŠããŸãã
AMVUTTRAã¯ãæ人ã®å€çºæ§ãã¥ãŒããããŒã䌎ãéºäŒæ§ãã©ã³ã¹ãµã€ã¬ãã³åã¢ããã€ããŒã·ã¹ïŒhATTRã¢ããã€ããŒã·ã¹ïŒã®ç±³åœã§ã®æ²»çæ¿èªã欧å·é£åïŒEUïŒããã³ã€ã®ãªã¹ïŒUKïŒã§ã¹ããŒãž1ãŸãã¯ã¹ããŒãž2ã®æ人æ£è
ã®æ²»ççšã®æ¿èªãpolyneuropathyã䌎ããã©ã³ã¹ãµã€ã¬ãã³ïŒTTRïŒã¿ã€ãã®å®¶ææ§ã¢ããã€ããŒã·ã¹ã®æ¥æ¬ã§ã®æ²»çæ¿èªãããã³ãã®ä»ã®å€ãã®åœã§ãæ¿èªãããŠããŸããèŠå¶åœå±ã®å¯©æ»ã¯ãä»ã®å°åã§ãç¶ç¶äžã§ãã2024幎6æãvutrisiranïŒAMVUTTRAã®éåæšåïŒã«é¢ããHELIOS-bè©Šéšã®éœæ§ãããã©ã€ã³çµæãå ±åããä»åŸãã«ã«ãã£ãªããªãããŒã䌎ãATTRã¢ããã€ããŒã·ã¹ã®æœåšçãªæ²»çæ³ãšããŠã®AMVUTTRAã®æ¿èªç³è«ããåªå
審æ»ããŒãã¹ã䜿çšããŠç±³åœé£åå»è¬åå±ïŒFDAïŒã«æ°è¬ç³è«ãè¿œå æåºããããšãèšç»ããŠããããšãçºè¡šããŸããã
ONPATTROã¯ãFDAã«ãã£ãŠæ¿èªãããæ人ã®hATTRã¢ããã€ããŒã·ã¹ã®å€çºæ§ç¥çµçã®æ²»çãšããŠããŸãEUã§ã¹ããŒãž1ãŸãã¯ã¹ããŒãž2ã®å€çºæ§ç¥çµç
ã䌎ãhATTRã¢ããã€ããŒã·ã¹ã®æ人æ£è
ã®æ²»çãšããŠãæ¥æ¬ã§ã¯TTRã¿ã€ãã®å®¶ææ§ã¢ããã€ããŒã·ã¹ã®å€çºæ§ç¥çµç
ã®æ²»çãšããŠãå€ãã®ãã®ä»ã®åœã
ã§ãæ¿èªãããŠããŸããããã£ã·ã©ã³ïŒONPATTROã®éåæšåïŒã¯ãã«ã«ãã£ãªããªãããŒã䌎ãATTRã¢ããã€ããŒã·ã¹ã®æ²»çã«ã€ããŠããã©ãžã«å¥åº·èŠå¶åœå±ïŒANVISAïŒã«ããèŠå¶å¯©æ»ã®å¯Ÿè±¡ãšãªã£ãŠããŸãã
GIVLAARIã¯ãæ¥æ§èæ§ãã«ãã£ãªã³çïŒAHPïŒãæã€æ人ã®æ²»çã®ããã«ãç±³åœã§æ¿èªãããŠãããEUã§ã¯12æ³ä»¥äžã®æ人ããã³é幎ã®AHPã®æ²»çã«æ¿èªãããŠããããã®ä»ã®ããã€ãã®åœã§ãæ¿èªãããŠããŸããã®ãã·ã©ã³ïŒGIVLAARIã®éåæšè¬ç©åïŒã®èŠå¶ç³è«ã¯2024幎以éã«ä¿çäžãŸãã¯èšç»ãããŠããŸãã
OXLUMOã¯ãå°å
ããã³æ人æ£è
ã«ãããŠå°¿äžããã³è¡æŒ¿äžã®ãªããµã¬ãŒãæ¿åºŠãäœäžããããããåçºæ§é«ãªããµã«é
žå°¿çã¿ã€ã1ïŒPH1ïŒã®æ²»çè¬ãšããŠãç±³åœã§æ¿èªãããEUããã³è±åœã§ã¯ãããã幎霢局ã®PH1ã®æ²»çè¬ãšããŠæ¿èªãããŠããŸããOXLUMOã¯ãä»ã®å€ãã®åœã
ã§ãæ¿èªãããè¿œå ã®å°åã«ã€ããŠã®èŠå¶ç³è«ã2024幎以éãäºå®ãããŠããŸãã
LeqvioïŒinclisiranïŒã¯ãåœç€Ÿã®å
±åéçºããŒãããŒã§ããããã«ãã£ã¹ç€ŸããŸãã¯ããã«ãã£ã¹ã«ãã£ãŠéçºããã³è²©å£²ããã欧å·å§å¡äŒã¯é«ã³ã¬ã¹ãããŒã«è¡çãŸãã¯æ··åç°åè質è¡çã®æ人ã®æ²»çãç±³åœFDAã¯ãããæ¥åå家ææ§é«ã³ã¬ã¹ãããŒã«è¡çããŸãã¯HeFHãèšåºçåè硬åæ§å¿è¡ç®¡çŸæ£ããŸãã¯ASCVDã§æ倧è容ã¹ã¿ãã³çæ³ã«è£å©çã«æäžãããæ²»çè¬ãšããŠæ¿èªãããäœå¯åºŠãªãèçœã³ã¬ã¹ãããŒã«ããŸãã¯LDL-Cãããã«äœäžãããå¿
èŠãããæ人ã«ãæ¿èªãããŠããŸãã 2023幎7æãFDAã¯Leqvioã®é©å¿æ¡å€§æ¿èªãçºè¡šããé«LDL-Cã§ãªã¹ã¯ãé«ãæ人ã®æ²»çãå«ã¿ãŸãã
å¿èç
ãLeqvioã¯äžåœãšæ¥æ¬ã§ãæ¿èªããã2024幎6ææ«ãŸã§ã«Leqvioã¯90ã«åœä»¥äžã§æ¿èªãããŠããŸãã
åžè²©è£œåã«å ããŠãåœç€Ÿã®äžéšãšã㊠ã¢ã«ããŒã©ã ã»P 5 x25 æŠç¥ãç§ãã¡ã¯ãæµè¡ããŠããç
æ°ãæ²»çããããã®é©æ°çãªå»è¬åã®éçºãªã©ãå°æ¥ã®æé·ãçœåŒããè€æ°ã®ãã©ã€ããŒãæã£ãŠããŸããã¬ã¯ããªã«å ããŠãã¢ã³ã®ãªãã³ã·ããŒã²ã³ïŒAgTïŒãæšçãšããæ²»éšäžã®ç®äžæäžåRNAiæ²»çè¬ã§ãããžã¬ãã·ã©ã³ãé«è¡å§æ²»çè¬ãšããŠéçºäžã§ãã2023幎ã«ãF. Hoffmann-La Roche Ltd.ããžã§ãã³ããã¯ç€ŸããŸãã¯ç·ç§°ããŠãã·ã¥ãšãã³ã©ãã¬ãŒã·ã§ã³ããã³ã©ã€ã»ã³ã¹å¥çŽããŸãã¯ãã·ã¥ã³ã©ãã¬ãŒã·ã§ã³ããã³ã©ã€ã»ã³ã¹å¥çŽãç· çµããŸãããããã«åºã¥ããŠãzilebesiranã®å
±åéçºãšåæ¥åã®ããã®äžçèŠæš¡ã®æŠç¥çã³ã©ãã¬ãŒã·ã§ã³ã確ç«ããŸããã2024幎3æãKARDIA-2èšåºè©Šéšã®è¯å®çãªçµæãå ±åãããŸããããã®è©Šéšã¯ãæšæºæ²»çã®éå§è¬ã§è¡å§ãé©åã«å¶åŸ¡ãããŠããªãæ£è
ã察象ã«ã䜵çšçæ³ãšããŠé幎æäžããããžã¬ãã·ã©ã³ã®å®å
šæ§ãšæå¹æ§ãè©äŸ¡ããããšãç®çãšããŠããŸãã2024幎4æãç§ãã¡ã¯KARDIA-3èšåºè©Šéšã®æåã®æ£è
ã«æäžããŸãããããã¯ãæšæºæ²»çè¬ã§ãã2ã4çš®é¡ã®æšæºæ²»çéå§è¬ã§æ²»çããã«ãããããããå¿è¡ç®¡ãªã¹ã¯ãé«ããé«è¡å§ãå¶åŸ¡ã§ããªãæ人æ£è
ã察象ã«ãè¿œå çæ³ãšããŠã®ãžã¬ãã·ã©ã³ã®æå¹æ§ãšå®å
šæ§ãè©äŸ¡ããããšãç®çãšããŠããŸãã
ç§ãã¡ã¯ãã¢ã«ããã€ããŒç
ãè³æ·æ§œæ§ç·ç¶ã¹ã¯ã¬ããŒã·ã¹ã®æ²»çã«åããŠãã¢ããã€ãåé§äœã¿ã³ãã¯è³ªãæšçãšããRNAiæ²»çå€ã§ããmivelsiran (æ§ALN-APP)ã®éçºãé²ããŠããŸãã2023幎ãç§ãã¡ã¯æ©æã¢ã«ããã€ããŒç
æ£è
ã察象ãšããmivelsiranã®ç¬¬1çžèšåºè©Šéšã®ååæäžéšåã«ãããéœæ§ãªéæçµæãå ±åããŸããããããã®çµæã¯ãCNSé
éã®ããã®ç§ãã¡ã®C16-siRNAã³ã³ãžã¥ã²ãŒããã©ãããã©ãŒã ã®åã®äººéãžã®é©çšãšRNAiæ²»çå€ã䜿çšãã人éã®è³å
éºäŒåãµã€ã¬ã³ã·ã³ã°ã®åã®èšåºçãã¢ã³ã¹ãã¬ãŒã·ã§ã³ãšãªããŸãã2024幎7æãç§ãã¡ã¯CAAæ£è
ã察象ãšããmivelsiranã®cAPPRicorn-1第2çžèšåºè©Šéšã®æäžãéå§ããŸããã
åœç€Ÿã¯ãåæ¥åã®å¯èœæ§ãããããã«é²ãã 調æ»ããã°ã©ã ãè¿œå ããŠããŸããããã«ã¯ãGenzyme Corporationããµããã£ã®åäŒç€Ÿã§ããåœç€Ÿã®ååè
ãé²ããè¡åç
æ²»çè¬fitusiranãããã³åœç€Ÿã®ååè
ã§ããRegeneron PharmaceuticalsãInc.ãŸãã¯Regeneronããéççç¡åçããã³å€éã®ãã©ãªãã·ãºãã«ãã¢ã°ããã³å°¿çã«ããããã§ãŒãº3èšåºè©Šéšã§pozelimabãšã®äœµçšã§é²ããŠããè£å®ä»åšæ§çŸæ£æ²»çè¬cemdisiranãå«ãŸããŸãã
ç§ãã¡ãããã«ãµããŒãã㊠ã¢ã«ããŒã©ã ã»P 5 x25 æŠç¥ãšãªã¹ã¯ãããã¡ã€ã«ã®é²åãèæ
®ããŠãç§ãã¡ã¯ãäž»èŠåžå Žã§ã®å·è¡ã«åããã°ããŒãã«æ§é ã®æé©åãåœç€Ÿã®äŸ¡å€èŠ³ã«æ²¿ã£ãæ¥çžŸã®åäžãæåã®ç¶ç¶çãªåŒ·åãªã©ã®äž»èŠãªç®æšãå«ããã°ããŒãã«ã€ã³ãã©ã¹ãã©ã¯ãã£ã®ç¶ç¶çãªé²åã«åŒãç¶ã泚åããŠããŸããç§ãã¡ã¯ããã®é²åãšåŒ·åãæšé²ããããã«ãã°ããŒãã«ãªã³ã³ãã©ã€ã¢ã³ã¹ããã°ã©ã ãæ§ç¯ãç¶ããŠããŸããåœç€Ÿã®ã³ã³ãã©ã€ã¢ã³ã¹ããã°ã©ã ã¯ãåœç€Ÿã®ã°ããŒãã«ãªããžãã¹è¡åèŠç¯ãšå«çèŠç¯ã«åºã¥ããŠæ§ç¯ãããŠãããåŸæ¥å¡ãååãã人ã
ããåœç€Ÿã®äŸ¡å€èŠ³ã«åŸããé©çšæ³ãèŠå¶ãéµå®ããŠåœç€Ÿã®æŠç¥ãå®è¡ã§ããããã«ãããªã¹ã¯ã軜æžããããšãç®çãšããŠããŸãããªã¹ã¯è©äŸ¡ãšç£èŠãããªã·ãŒãæé ãã¬ã€ãã³ã¹ããã¬ãŒãã³ã°ãšã³ãã¥ãã±ãŒã·ã§ã³ãå°éãªãœãŒã¹ã第äžè
ãšã®é¢ä¿ã調æ»ãæ¯æ£ãªã©ã®æŽ»åãæ¯æŽããã·ã¹ãã ãšããã»ã¹ãªã©ã®èŠçŽ ã§æ§æãããŠããŸããåœç€Ÿã®ããã°ã©ã ãšé¢é£çµ±å¶ã¯ãã°ããŒãã«äºæ¥å
šäœã«ãããããžãã¹ããã»ã¹ãæ§é ãçµ±å¶ã匷åããå«ççãªææ決å®ã匷åããããã«æ§ç¯ãããŠããŸãã
RNAiæ²»çè¬ã®å°éç¥èãšå¹
åºãç¥è²¡æš©ã掻ãããç§ãã¡ã¯RocheãRegeneronããµããã£ãNovartisïŒ2020幎ã«ç§ãã¡ã®å
±åç 究è
ã§ããThe Medicines CompanyããŸãã¯MDCOãè²·åããNovartisãå«ãïŒãªã©ã®äž»èŠãªå»è¬åäŒæ¥ãšååé¢ä¿ãç¯ããéçºã»åååã®åªåããµããŒãããŠããŸãã
2002幎ããäºæ¥ãéå§ããŠä»¥æ¥ãåœç€Ÿã¯å€§å¹
ãªæ倱ã被ã£ãŠããã2024幎6æ30æ¥çŸåšã环ç©èµ€åã¯70.9åãã«ã«éããŠããŸãããããŸã§ãåœç€Ÿã¯äž»ã«ç 究éçºæŽ»åãç¥ç財ç£æš©ã®ååŸãç³è«ãæ¡å€§ã販売ãäžè¬ç®¡çè²»ãé¢ããè²»çšããæ倱ãçºçãããŠããŸãããåœç€Ÿã®ç 究ãã©ãããã©ãŒã ãå»è¬åéçºããã°ã©ã ãèšåºè©Šéšããã³è£œé è²»çšãã°ããŒãã«ãªåæ¥æŽ»åãå«ãåŸæèšåºããã³åæ¥åèœåã®ç¢ºç«ãç¹èš±ããŒããã©ãªãªã®ç¶ç¶çãªç®¡çããã³æ¡å€§ãææºããã³äžè¬çãªäŒæ¥æŽ»åã®ããã®èšç»çãªè²»çšã«ãããè¿œå ã®éå¶æ倱ãçºçããèŠéãã§ããåœç€Ÿã¯ä»åŸã幎次éå¶æ倱ã被ãå¯èœæ§ããããRNAiæ²»çè¬ã®çºèŠãéçºãåååã®åãçµã¿ãæ¡å€§ãã2025幎æ«ãŸã§ã«è²¡åçãªèªå·±æç¶å¯èœæ§ãéæããããã«æ°å¹Žã«ãããè«å€§ãªè³æºãå¿
èŠãšãªããŸããåœç€Ÿã®æ¥çžŸã¯ä»åŸãäžå®å®ã§ããå¯èœæ§ããããããã«æé察æ¯ã¯ä»åŸã®æ¥çžŸã®äºæž¬ã«ã¯äŸæ ããªãã§ãã ããã
çŸåšãç§ãã¡ã¯å€ãã®æ²»çåéã«çŠç¹ãåœãŠãããã°ã©ã ãæã£ãŠããã2024幎6æ30æ¥çŸåšãäž»ã«ç±³åœãšãšãŒãããã§äž»ã«ONPATTROãAMVUTTRAãGIVLAARIãOXLUMOã®4ã€ã®åæ¥å補åããäžççãªè£œååçãçã¿åºããŠããŸãããã ããç§ãã¡ã®ç¶ç¶çãªéçºãšèŠå¶ã®åªåãæåããªãå¯èœæ§ãããããã®ä»ã®è£œåã®è²©å£²ãéå§ã§ããªããããŸãã¯æ¢åã®åæ¥å補åãŸãã¯å°æ¥çã«æ¿èªããããã®ä»ã®è£œåã®ã©ãã«ãæ¡å€§ããããåžå Žã«æµžéããããã売ã£ããããããšãã§ããªãå¯èœæ§ããããŸããè¿å¹Žãç§ãã¡ã®ç·åçã®æ矩ããéšåã¯ãRocheãRegeneronãNovartisãšã®åååçããåŸãããŠããŸããæ¿èªããã補åã®åæ¥è²©å£²ããã®åçããã³å°æ¥çãªè£œåã®è²©å£²ããã®åçã«å ããŠãç§ãã¡ã¯å°æ¥çã«è£œåã販売ããå¯èœæ§ããããŸãããã®ä»ã®åçæºã«ã¯ãäŸãã°ãææãªpipeline補åã®éçºãšåæ¥ããŒãããŒãšã®ææºã«ããåçãªã©ããããŸãã
ä»åŸæ°å¹Žéã®è³é調éã¯ãæ¢åããã³æ°èŠã®æŠç¥çææºã®äžéšã«ãã£ãŠç¶ç¶çã«æŽŸçããããšã«ãªããŸãã ãã®ãããªææºã«ã¯ãã©ã€ã»ã³ã¹æããã³ãã®ä»ã®æéãè³éæäŸãããç 究éçºããã€ã«ã¹ããŒã³æ¯æããç¹èš±è
ã«ãã補å販売ã«å¯Ÿãããã€ã€ãªãã£ïŒã³ã©ãã¬ãŒã¿ãŒã§ããããã«ãã£ã¹ã«ããLeqvioã®è²©å£²ãã€ã€ãªãã£ãå«ãïŒãããã³è³æ¬ãŸãã¯åµåã®å£²åŽçãå«ãŸããŸãã
ç 究éçº
åµæ¥ä»¥æ¥ãç§ãã¡ã¯äž»ã«è¬å€ã®çºèŠãéçºããã°ã©ã ã«éç¹ã眮ããŠããŸãããç 究éçºè²»çšã¯ç§ãã¡ã®å¶æ¥è²»çšã®å€§éšåãå ããŠãããç§ãã¡ã®åºç¯ãªèšåºéçºããã°ã©ã ã®ãã€ãã©ã€ã³ã«åæ ãããŠããŸãããã®ãã€ãã©ã€ã³ã«ã¯ãåŸæéçºæ®µéã«ããå€æ°ã®ããã°ã©ã ãå«ãŸããŠããŸãã
ç§ãã¡ã®è£œåãã€ãã©ã€ã³
ç§ãã¡ã®åºç¯ãªãã€ãã©ã€ã³ã«ã¯ã5ã€ã®æ¿èªè£œåãšå€æ°ã®åŸæããã³åæã®RNAiæ²»çæ³ãå«ãŸããå€æ°ã®çŸæ£é åã®æªæºããããããŒãºãã«ããŒããŠãããåžå°çŸæ£ãå°éçŸæ£ãéžæçã«å€çºæ§ã®çŸæ£ã®æ瀺ãå«ãã§ããŸãã以äžã§ç§ãã¡ã¯åæ¥åããã³èšåºæ®µéã®ãã€ãã©ã€ã³ã«ã€ããŠè©³ãã説æããŸãã以äžã«èª¬æãããŠããç 究ã®å¯Ÿè±¡ãšãªãæ²»çè¬ã¯ãããŸããŸãªèšåºéçºæ®µéã«ããããããã®æ²»çè¬ã«é¢ããç§åŠçæ
å ±ã¯äºåçã§èª¿æ»æ§ããããŸãããããã®æ²»çè¬ã®ããããFDAã欧å·å»è¬ååºãEMAããŸãã¯ãã®ä»ã®ä¿å¥åœå±ã«ãã£ãŠæ¿èªãããŠãããããããã®æ²»çè¬ã®å®å
šæ§ãŸãã¯æå¹æ§ã«ã€ããŠã®çµè«ãåŒãåºãããšã¯ã§ããŸããã
以äžã®è¡šã¯ã2024幎8æ1æ¥æç¹ã§ã®åçšè£œåããã³åŸæã»åæã®éçºããã°ã©ã ãè¡šããŠããŸãã
2024幎第2ååæããã³æè¿ã®æéã«ãããŠãåæ¥çã«æ¿èªããã補åããã³èšåºè©ŠéšåŸæ段éã®ããã°ã©ã ããã以äžã®ã¢ããããŒããå ±åããŸããã
åæ¥
åèšTTRïŒãªã³ããããšã¢ã ãããã©
⢠2024幎第2ååæãONPATTROããã³AMVUTTRAã®ã°ããŒãã«çŽè£œååçã¯ãããã77.2çŸäžãã«ã230.1çŸäžãã«ãéæããŸããã
ããŒã¿ã«ã¬ã¢ïŒGIVLAARIïŒOXLUMO
⢠2024幎第2ååæã®GIVLAARIãšOXLUMOã®ã°ããŒãã«çŽè£œå売äžé«ã¯ãããã6210äžãã«ãš4060äžãã«ã§ããã
åŸæ段éã®èšåºéçº
⢠ATTRã¢ããã€ããŒã·ã¹ãå䜵ããå¿ççæ£è
ã«ãããvutrisiranã®HELIOS-b第3çžç 究ã®éœæ§ãããã©ã€ã³çµæãå ±åããŸããã
⢠ç§ãã¡ã¯ãæšæºæ²»çè¬ã«è¿œå ãããå®éšçãªãžã¬ãã·ã©ã³ãäžååã«å¶åŸ¡ãããé«è¡å§æ£è
ã«ãããŠãKARDIA-2第2çžè©Šéšããéœæ§ã®çµæãå ±åããŸããã
⢠åœç€Ÿã®ååããŒãããŒã§ãããµããã£ã¯ãè¡åç
ã®æ€æ»è¬ããã£ãã¥ã·ã©ã³ã®èŠå¶ç³è«ãäžåœããã©ãžã«ãç±³åœã§è¡ããFDAã®å¯©æ»æéã¯2025幎3æ28æ¥ã§ãã
ããããè¬å€æ¢çŽ¢ãŸãã¯éçºããã°ã©ã ã売äžé«ãçã¿åºããªãå¯èœæ§ãããããã補ååè£ã®å®å
šæ§ãšæå¹æ§ãååã«èšŒæã§ããªãã£ãããæ¿èªãŸãã¯è£œååè£ã®ææã®ã©ãã«ãèŠå¶åœå±ããååŸã§ããªãã£ããããããšããããŸããããã«ãRNAiãå«ãããããæ°ããè¬å€æ¢çŽ¢åéã«ã¯äžç¢ºå®æ§ããããŸããONPATTROãAMVUTTRAãGIVLAARIãOXLUMOãªã©ãåŒç€Ÿãéçºãã補ååè£ã®æåã¯éåžžã«äžç¢ºå®ã§ããè¬å€ã®éçºã«é¢ããå€ãã®ãªã¹ã¯ããããããã©ã®ãããªæœåšçãªè£œååè£ãŸãã¯è¡šç€ºããŸãã¯æ¿èªããã補åãŸãã¯è¡šç€ºããç©è³ªçãªçŽçŸéæµå
¥ãéå§ãããæéãåççã«è©äŸ¡ããããšãã§ããŸãããä»»æã®æœåšç補åã®éçºãŸãã¯æ¡å€§ãããçšéã®æ¿èªããã補åã®éçºã®ã©ã®æ®µéãããŸããèªç€Ÿã®ååã®ãããããæåè£ã«ç«ã¡äžãã販売ããããã®ããããåªåã®æ§è³ªãææãèŠç©ããã³ã¹ããåççã«äºæž¬ããããšã¯ã§ããããã®å Žåãããããäºæ¥ã財åç¶æ³ãæµåæ§ã«é倧ãªåœ±é¿ãããå¯èœæ§ããããŸãããªãµãŒãã»ãããããã¡ã³ãããã°ã©ã ãèšç»ãããæéå
ãŸãã¯å
šãå®äºã§ããªãããšã«é¢é£ããããã€ãã®ãªã¹ã¯ãšäžç¢ºå®æ§ãããã³ãããè¡ããªãã£ãå Žåã®æœåšçãªåœ±é¿ã«ã€ããŠã¯ã以äžã®é
ç®II 1Aã®ããªã¹ã¯ãã¡ã¯ã¿ãŒããšããèŠåºãã®äžã§èª¬æãããŠããŸãã
æŠç¥çãªé£æº
ç§ãã¡ã®ããžãã¹ã®æŠç¥ã¯ãé©æ°çãªåžå°çŸæ£ãå°éçŸæ£ãããã³éžæçãªäžè¬ççŸæ£ã«åããåºç¯ãªRNAiæ²»ç補åã®ãã€ãã©ã€ã³ãéçºããåååããããšã§ãããã®æŠç¥ã®äžç°ãšããŠãç§ãã¡ã¯ãåœç€Ÿã®èª¿æ»äžã®RNAiæ²»çããã°ã©ã ãé²ããããã®ãªãœãŒã¹ãèœåãããã³è³éãåŸãæ段ãšããŠãè¿œå ã®ååããã³ã©ã€ã»ã³ã¹å¥çŽãç· çµããŠãããä»åŸãç· çµããå¯èœæ§ããããŸãã
以äžã¯ç§ãã¡ã®äž»ãªã³ã©ãã¬ãŒã·ã§ã³ã®ç°¡åãªèª¬æã§ãã
ãã·ã¥ 2023幎7æã«ãæã
ã¯ãã·ã¥ãšã®ã³ã©ãã¬ãŒã·ã§ã³ã»ã©ã€ã»ã³ã¹å¥çŽãç· çµãããžã¬ãã·ã©ã³ãå«ãå»è¬åã®å
±åéçºã®ããã®æŠç¥çãªäžçèŠæš¡ã®ææºãçµã³ãŸãããå¥çŽã«åºã¥ãããã·ã¥ã«ã¯(i) ãžã¬ãã·ã©ã³ã®äžççãªéçºããã³ç±³åœã§ã®åæ¥åã«å
±åç¬å æš©ã(ii) ç±³åœå€ã§ã®ãžã¬ãã·ã©ã³ã®åæ¥åç¬å æš©ãããã³(iii) ç±³åœå€ã§ã®ãžã¬ãã·ã©ã³ã®éçºã»åæ¥åã®ããã®ãžã¬ãã·ã©ã³ã®è£œé ã®éç¬å çæš©å©ãä»äžãããŸããããã·ã¥ã¯ã3.1åãã«ã®åæéãæ¯æããŸããã2024幎4æãKARDIA-3第IIçžèšåºè©Šéšã®æåã®æ£è
æäžã«é¢é£ããéçºãã€ã«ã¹ããŒã³ãéæãããã·ã¥ãã6.5åãã«ã®éçºãã€ã«ã¹ããŒã³æ¯æããåããæš©å©ãç²åŸããŸãããããã«ãç¹å®ã®éçºãèŠå¶ããã³å£²äžç®æšã®éæã«åºã¥ãæ¡ä»¶ä»ãæ¯æé¡ã§ãæ倧24.5åãã«ãåé ããæš©å©ããããŸãããžã¬ãã·ã©ã³ã®äžççãªèŠå¶æ¿èªãæ¯æŽããéçºæŽ»åã«ãããéçºè²»çšã®40ïŒ
ã¯åœç€Ÿããæ®ãã®60ïŒ
ã¯ãã·ã¥ãè² æ
ããŸããç±³åœã§ã®ãžã¬ãã·ã©ã³ã®èŠå¶æ¿èªã®æ¯æŽã®ããã«å®æœãããéçºæŽ»åã«ãããè²»çšã¯ãåœç€Ÿãšãã·ã¥ãå¹³çã«(50/50)è² æ
ããŸããèŠå¶æ¿èªåŸããã·ã¥ã¯ç±³åœå€ã§ã®ãžã¬ãã·ã©ã³ã®åæ¥åã«ãããè²»çšãåç¬ã§è² æ
ãããã€ã€ãªãã£æéäžããžã¬ãã·ã©ã³ã®çŽå£²äžé«ã«åºã¥ãäœäºæ¡å°ã®æ®µéçãªãã€ã€ãªãã£ãåœããšã«åœç€Ÿã«æ¯æããŸãããžã¬ãã·ã©ã³ã®ç±³åœå
ã§ã®å©çãšæ倱(åæ¥åè²»çšãå«ã)ã¯ãåœç€Ÿãšãã·ã¥ãå¹³ç(50/50)ã«åæ
ããŸãã
ã¬ãžã§ããã³ã 2019幎4æãåœç€Ÿã¯ã¬ãžã§ããã³ãšã°ããŒãã«ãªæŠç¥çææºãç· çµããçŒãšCNSã«çºçŸããæ²»çæšçã察象ãšããåºç¯ãªçŸæ£ã®RNAiæ²»çè¬ã®çºèŠãéçºãåæ¥åãè¡ãããšãšãªããŸããã
ç§ãã¡ãRegeneronã³ã©ãã¬ãŒã·ã§ã³ãšåŒã¶ãèèã§è¡šçŸãããç¹å®ã®ã¿ãŒã²ãããé€ããŠãRegeneronã³ã©ãã¬ãŒã·ã§ã³ã¯èŠå®ãããŠããŸããRegeneronã³ã©ãã¬ãŒã·ã§ã³ã¯ã2019幎5æã«çºå¹ããRegeneron Master AgreementãšåŒã°ãããã¹ã¿ãŒå¥çŽã«ãã£ãŠèŠå¶ãããŠããŸãã
ãªãžã§ããã³ã³ã©ãã¬ãŒã·ã§ã³ã®æ¡ä»¶ã«åŸããç§ãã¡ã¯åæç 究æéãšåŒã°ããæ倧7幎ã®æéãç®ãå«ãäžæ¢ç¥çµç³»çŸæ£ã®RNAiæ²»çè¬ãçºèŠããããããªãžã§ããã³ãšç¬å çã«ååããŠããŸãããªãžã§ããã³ã¯ã30,000äžãã«ã®ç 究æé延é·æãæ¯æãããšã§åæç 究æéãæ倧ã§5幎é延é·ããããšãã§ããŸãããªãžã§ããã³ã³ã©ãã¬ãŒã·ã§ã³ã¯ãèèã§çºçŸããéºäŒåãæšçãšããéžæçãªRNAiæ²»çè¬ããã°ã©ã ãã«ããŒããŠããŸããã³ã©ãã¬ãŒããè¡ã£ãŠããªããèèã«åããåºç¯å²ãªã°ããŒãã«ãªèšåºããã³èšåºåã®ãã€ãã©ã€ã³ããã°ã©ã ã®å
šãŠã®æš©å©ã¯ãç§ãã¡ãä¿æããŠããŸãã
å
šã»ã¯ã¿ãŒã®ã¢ã€çŸæ£æ²»çããªãŒãããã¬ãžã§ããã³ïŒäžéšã®äŸå€ãé€ãïŒã¯ãåœäºè
ã®åæã«åºã¥ãã©ã€ã»ã³ã¹å¥çŽã®æ¡ä»¶ã«åŸããããçš®ã®ãã€ã«ã¹ããŒã³ãšãã€ã€ã«ãã£æ¯æãã®å¯Ÿè±¡ãšãªãæš©å©ãæããŸããç§ãã¡ãšã¬ãžã§ããã³ã¯ãCNSãèèã®ããã°ã©ã ã§ã¯äº€äºã«ãªãŒããŒã·ããã亀代ãããªãŒãããŒãã£ãŒãã°ããŒãã«ãªéçºãšåæ¥è²¬ä»»ãä¿æããŠããŸãã
2019幎8æãã¬ãžã§ããã³ã»ãã¹ã¿ãŒå¥çŽã«é¢é£ããŠãç§ãã¡ãšã¬ãžã§ããã³ã¯(i)åœç€Ÿã®C5 siRNAã§ããcemdisiranãC5è£äœåªä»æ§çŸæ£ã®åå€çæ³ãšããŠéçºãç¶ããããã®å
±åéçºå¥çŽãC5å
±åéçºå¥çŽãåã³(ii)C5ãªã»ã³ã¹å¥çŽãRegeneronã®pozelimabãšcemdisiranã®æC5æäœ-siRNAçµã¿åããã®è©äŸ¡ãå«ãC5è£äœåªä»æ§çŸæ£çšã®ã©ã€ã»ã³ã¹å¥çŽãç· çµããŸããã2022幎11æãRegeneronã¯C5å
±åéçºå¥çŽã®äžã§ãcemdisiranã®åå€çæ³ãšããŠã®ãããªãéçºåã³åååããéããæš©å©ãè¡äœ¿ããåœæããcemdisiranã®åå€çæ³ã®éçºåã³åååã«ã€ããŠã¯ãç§ãã¡ãå®å
šè²¬ä»»ãè² ããRegeneronã¯åå€çæ³ããã°ã©ã ã®ãããªãè²»çšã«ãå
±æããªããªããŸãããRegeneronã¯ãcemdisiranã®åå€çæ³ã®çŽå£²äžé«ã«å¯Ÿãã段éçãªäºæ¡ã®ãã€ã€ã«ãã£ãåŒãç¶ãåãåãããšãã§ããŸãã
2024幎6æãç§ãã¡ã¯ä¿®æ£ããã³åç· çµãããC5ã©ã€ã»ã³ã¹å¥çŽããŸãã¯ä¿®æ£C5ã©ã€ã»ã³ã¹å¥çŽã«èª¿å°ããC5 Co-Co ã³ã©ãã¬ãŒã·ã§ã³å¥çŽã¯çµäºããRegeneronã¯æC5æäœãšã®äœµçšã«å ããŠãåå€ãšããŠã®cemdisiranã®äžççãªã©ã€ã»ã³ã¹ãåŸãŸãããä¿®æ£C5ã©ã€ã»ã³ã¹å¥çŽã«ãããRegeneronã¯ãåå€ãšããŠã®cemdisiranãããã³æC5æäœãšã®äœµçšã«ãããéçºã補é ãåæ¥åã«ã€ããŠåç¬ã§è²¬ä»»ãè² ãããšã«ãªããŸãããRegeneronã¯åæããšããŠ1,000äžãã«ãæ¯æããcemdisiranãåå€ãšããŠèŠå¶åœå±ã®æ¿èªãåããå Žåã«ã¯äžå®ã®ãã€ã«ã¹ããŒã³ãã€ã¡ã³ããåãåããããã売äžé«ã«å¯ŸããŠéå±€åŒã®äºæ¡ãã€ã€ãªãã£ãåãåããŸããä¿®æ£C5ã©ã€ã»ã³ã¹å¥çŽã«ãããcemdisiranã䜵åãå«ã補åã®äžéšãšããŠäœ¿çšãããå Žåã«ã¯ãå¯èœãªè£œå販売ã®äœäºæ¡ã®ãã€ã€ãªãã£ãš32,500äžãã«ãŸã§ã®åæ¥åãã€ã«ã¹ããŒã³ãåãåãæš©å©ãå€æŽãããŸããã§ããã
2024幎5æãRegeneronã¯ãmivelsiranã®æŽãªãå
±åéçºããè±éããããšãéç¥ããŸãããmivelsiranã¯ãéºäŒæ§CAAããã³åžžæè²äœåªæ§ã¢ã«ããã€ããŒç
ã®æ²»çã®ããã«éçºäžã®RNAiæ²»çè¬ã§ãåœç€Ÿãšã®å
±åéçºå¥çŽã«åºã¥ãå
±åå
±åéçºå¥çŽã«ãããŠãå
šæ瀺ã«å¯Ÿããmivelsiranã®ã°ããŒãã«éçºããã³åæ¥åæš©ãæããããã«ãªããŸãããRegeneronã®è±éã®çµæãçŸåšãåœç€Ÿã¯ãåœç€Ÿã®é²è¡äžã®ç¬¬1ãã§ãŒãºããã°ã©ã ãè¶
ããmivelsiranã®éçºããã³åæ¥åè²»çšãè² æ
ãã責任ãçããŸããRegeneronã¯ãmivelsiranã®å°æ¥ã®å£²äžããã®æœåšçãªå©çãããå
±æããªããªããŸãããåœç€Ÿã¯mivelsiranå
±åè²¢ç®å¥çŽã®äžã§Regeneronã«å¯Ÿããäžå®ã®è²¡åç矩åã«åŸãããšã«ãªããŸããåœç€Ÿã¯åŒãç¶ããRegeneronãšã®è€æ°ã®ä»ã®ããã°ã©ã ãé²ããŠããŸãã
ãµããã£ã 2014幎ã«ãç§ãã¡ã¯ãµããã£ãšåºç¯ãªæŠç¥çææºãçµã³ãŸããã 2018幎1æãç§ãã¡ã¯2014幎ã®ååé¢ä¿ãæ¹æ£ããæä»çTTRã©ã€ã»ã³ã¹ãšåŒã°ããæä»çã©ã€ã»ã³ã¹å¥çŽã«å
¥ããŸããããã®å¥çŽã«ãããONPATTROãAMVUTTRAãå«ãå
šTTR補åãããã³ããã¯ã¢ãã補åãäžççãªéçºããã³åæ¥åã®ããã«ç¬å çã«è¿œæ±ããæš©å©ããããŸãããŸããALN-AT3 Global License TermsãšåŒã°ããAT3ã©ã€ã»ã³ã¹èŠå®ã«åºã¥ãããµããã£ã¯ãã£ãã·ã©ã³ã®äžççãªéçºããã³åæ¥åãç¬å çã«è¿œæ±ããæš©å©ãæã£ãŠããŸããæä»çTTRã©ã€ã»ã³ã¹ã®äžããµããã£ã¯ã(i)ç±³åœãã«ãããããã³è¥¿ãšãŒããããé€ãå°åã§ã®ONPATTROã®å¹ŽéçŽå£²äžé«ã«åºã¥ãæéçµéã«äŒŽãäžæããæé«25ïŒ
ãŸã§ã®ãã€ã€ã«ãã£ãONPATTROã®å¹ŽéçŽå£²äžé«ã«å¯Ÿããæ¥æ¬ã§ã®ãã€ã€ã«ãã£ãæä»çTTRã©ã€ã»ã³ã¹ã®æå¹æ¥ãã25%ã§èšå®ããããšããŠæäŸããã(ii)ã°ããŒãã«å¹ŽéçŽå£²äžé«ã«åºã¥ã15ïŒ
ãã30ïŒ
ã®æ®µéçãªãã€ã€ã«ãã£ãåãåãæš©å©ããããŸãã2019幎4æãç§ãã¡ã¯ãµããã£ãšååé¢ä¿ãæ¹ããŠæ¹å®ããç 究ããã³ãªãã·ã§ã³ãã§ãŒãºãçµäºããAT3ã©ã€ã»ã³ã¹æ¡ä»¶ã®äžéšãä¿®æ£ããããšã決å®ããŸããããã£ãã·ã©ã³ã®éèŠãªååæ¡ä»¶ã¯å€æŽãããŠããŸãããä¿®æ£ããã³åç· çµãããAT3ã©ã€ã»ã³ã¹æ¡ä»¶ã®äžãç§ãã¡ã¯ããµããã£ããã®åäŒç€Ÿãããã³ãã®ãµãã©ã€ã»ã³ã·ãŒã«ãããã£ãã·ã©ã³ã®äžççãªå¹ŽéçŽå£²äžé«ã«åºã¥ã15ïŒ
ãã30ïŒ
ã®æ®µéçãªãã€ã€ã«ãã£ãåãåãæš©å©ããããŸãã
ããã«ãã£ã¹ã 2013幎2æãç§ãã¡ã¯MDCOïŒ2020幎1æã«ããã«ãã£ã¹AGã«è²·åãããŸããïŒãšã®æä»çãªäžççã©ã€ã»ã³ã¹å¥çŽãç· çµããMDCOã¯ããã¿ã³ããªã·ã³/ã±ãã·ã³ã¿ã€ã9ãæšçãšããRNAiæ²»çè¬ã®éçºã補é ãåæ¥åã®æš©å©ãåãåããŸãããé«ã³ã¬ã¹ãããŒã«è¡çããã³ä»ã®äººéã®çŸæ£ãLeqvioãå«ãã
ãŸããRNAiåéã«ãããç¥ç財ç£æš©ãååŸããããã®ã©ã€ã»ã³ã¹å¥çŽã«ãåå
¥ããŠããŸããããã«ãRNAiæ²»çæ³ã®é
ä¿¡ã¯ãåœç€Ÿã®ç 究掻åã«ãããŠéèŠãªç®æšã§ãã£ããããå
¥æããŠããŸãã
é
ä¿¡æè¡ãå«ãããŸããŸãªLNPé
ä¿¡æè¡ã«ã¢ã¯ã»ã¹ããããã«ãä»ã®äŒæ¥ãåŠè¡æ©é¢ãšã®ããŸããŸãªã³ã©ãã¬ãŒã·ã§ã³ããã³ã©ã€ã»ã³ã¹å¥çŽãç· çµããŠãããå°æ¥çã«ããã®ãããªå¥çŽãç· çµããå¯èœæ§ããããŸãã
éèŠãªäŒèšæ¹éããã³èŠç©ã
åœç€Ÿã®éèŠãªäŒèšæ¹éã«ã€ããŠã¯ã2023幎12æ31æ¥ã«çµäºããåœæã«é¢ããå¹Žæ¬¡å ±åæžïŒãã©ãŒã 10-kïŒã®ãçµå¶ã®è°è«ãšè²¡åç¶æ³ããã³æ¥çžŸã«é¢ããåæãã®ã»ã¯ã·ã§ã³ã«èšèŒãããŠããŸããåœç€Ÿã¯2024幎2æ15æ¥ã«SECã«æåºããŸãããåœç€Ÿã®éèŠãªäŒèšæ¹éã«ã¯ãåœæå以éã倧ããªå€æŽã¯ãããŸããã§ããã
æ¥çžŸ
次ã®ããŒã¿ã¯ãåœç€Ÿã®æ¥åã®çµæããŸãšãããã®ã§ãã
 6æ30æ¥ã«çµäºãã3ãæé 6æ30æ¥ã«çµäºãã6ãæé (ããŒã»ã³ããŒãžãé€ãååäœ) 2024 2023 $ å€æŽ % å€æŽ 2024 2023 $ å€æŽ % å€æŽ ç·åå
¥ $ 659,825 $ 318,754 $ 341,071 107 % $ 1,154,158 $ 638,044 $ 516,114 81 % éçšã³ã¹ããšçµè²»
$ 611,211ã§ã $ 548,585 $ 62,626 11 % $ 1,148,979 $ 1,017,682 $ 131,297 13 % äºæ¥ããã®åçïŒæå€±ïŒ $ 48,614 $ (229,831) $ 278,445 (121) % $ 5,179 $ (379,638) $ 384,817 (101) % çŽæ倱 $ (16,889) $ (276,024) $ 259,135 (94) % $ (82,824) $ (450,125) $ 367,301 (82) %
æ¥çžŸçµæã®è°è«
åç
ç·åçã¯äžèšã®éãã§ãïŒ
 6æ30æ¥ãŸã§ã®3ãæé 6æ30æ¥ãŸã§ã®6ãæé (ååäœã§ãããŒã»ã³ããŒãžãé€ã) 2024 2023 å€å % å€æŽ 2024 2023 å€å % å€æŽ 補åã®çŽåç $ 410,088ã $ 305,705ã $ 104,383ã 34 % $ 775,251ã $ 582,033ã $ 193,218ã 33 % ææºããã®çŽå£²äžé«
227,338ã 5,844ã 221,494ã * 345,886ã 42,306 303,580ã * ãã€ã€ãªãã£åå
¥ 22,399ã 7,205ã 15,194ã 211 % 33,021ã 13,705 19,316ã 141 % ç·èš $ 659,825ã $ 318,754ã $ 341,071ã 107 % $ 1,154,158ã $ 638,044ã $ 516,114ã 81 % *æéæ¯çã®å€åã500ïŒ
以äžã瀺ãããšã瀺ããŸãã
ããã補ååç
ããã補ååçã¯ã補åããã³å°åå¥ã«ä»¥äžã®ããã«æ§æãããŠããŸãïŒ
6æ30æ¥ã«çµäºãã3ãæé 6æ30æ¥ã«çµäºãã6ãæé (ããŒã»ã³ããŒãžãé€ãååäœ) 2024 2023 $ å€æŽ % å€æŽ 2024 2023 $ å€æŽ % å€æŽ ãªã³ããããŒ ç±³åœ $ 22,112 $ 25,560 $ (3,448) (13) % $ 38,651 $ 55,377ã§ã $ (16,726) (30) % ãšãŒããã 37,074 56,393 (19,319) (34) % 81,764 116,071 (34,307) (30) % ãã®ä»ã®å°å 18,058 9,505 8,553 90 % 26,046 22,503 3,543 16 % åèš 77,244 91,458 (14,214) (16) % 146,461 193,951 (47,490) (24) % ã¢ã ãããã© ç±³åœ 148,463 96,469 51,994ã§ã 54 % 278,701 175,482 103,219 59 % ãšãŒããã 56,760 14,405 42,355ã§ã 294 % 100,493 21,173 79,320 375 % ãã®ä»ã®å°å 24,886 21,262 3,624 17 % 46,156ã§ã 37,249 8,907 24 % åèš 230,109 132,136 97,973 74 % 425,350 233,904 191,446 82 % ã®ãã©ãªãã ç±³åœ 41,225ã§ã 35,196 6,029 17 % 79,956 65,487 14,469 22 % ãšãŒããã 16,314 14,051 2,263 16 % 31,629 28,522 3,107 11 % ãã®ä»ã®å°å 4,588 8,652 (4,064) (47) % 8,598 11,796 (3,198) (27) % åèš 62,127ã§ã 57,899 4,228 7 % 120,183 105,805 14,378 14 % ãªã¯ã¹ã«ã¢ãã ç±³åœ 15,744ã§ã 8,794 6,950 79 % 29,076 17,851 11,225 63 % ãšãŒããã 20,503 12,216 8,287 68 % 41,930 25,525 16,405 64 % ãã®ä»ã®å°å 4,361 3,202 1,159 36 % 12,251 4,997 7,254 145 % åèš 40,608 24,212 16,396ã§ã 68 % 83,257 48,373 34,884 72 % 補åã®ç·çŽåå
¥ $ 410,088 $ 305,705 $ 104,383 34 % $ 775,251 $ 582,033 $ 193,218 33 %
2024幎6æ30æ¥ãŸã§ã®3ã¶æããã³6ã¶æéã«ãããŠã2023幎ãšåãæéã«æ¯ã¹ãŠãæ£è
éèŠã®å¢å ã«ããAMVUTTRAããã®åŒ·åãªæé·ãããã³GIVLAARIãšOXLUMOæ²»çæ³ãžã®æ£è
æ°ã®å¢å ã«ãããçŽè£œååçãå¢å ããŸããã
ã³ã©ãã¬ãŒã·ã§ã³ããã®çŽå£²äžé«ããã³ãã€ã€ãªãã£åå
¥
ã³ã©ãã¬ãŒã·ã§ã³ããã®çŽå£²äžé«ãšãã€ã€ãªãã£å£²äžé«ã¯ã以äžã®ãšããã§ãïŒ
 6æ30æ¥ãŸã§ã®3ãæé 6æ30æ¥ãŸã§ã®6ãæé (ååäœã§ãããŒã»ã³ããŒãžãé€ã) 2024 2023 å€å % å€æŽ 2024 2023 å€å % å€æŽ ãã·ã¥
$ 16,506 $ â $ 16,506 該åœãªã $ 91,186 $ â $ 91,186 該åœãªã ãªãžã§ããã³ãã¡ãŒãã·ã¥ãŒãã£ã«ã«ãº 207,429 (2,837) 210,266 * 234,193 17,153 217,040 * ããã«ãã£ã¹ 2,304 8,627 (6,323) ïŒ73ïŒ % 16,820 23,560 (6,740) (29) % ä» 1,099 54 1,045 * 3,687 1,593 2,094 131 % ã³ã©ãã¬ãŒã·ã§ã³ããã®ç·çŽåç
$ 227,338 $ 5,844 $ 221,494 * $ 345,886 $ 42,306 $ 303,580 * ãã€ã€ãªãã£åå
¥
$ 22,399 $ 7,205 $ 15,194 211 % $ 33,021 $ 13,705 $ 19,316 141 % * æé察æ¯ã®å€åçã500ïŒ
ãè¶
ããããšã瀺ããŸãã
2024幎6æ30æ¥ãŸã§ã®3ãæããã³6ãæã®ååã«ããçŽå£²äžé«ã¯ã2023幎åæãšæ¯èŒããŠå¢å ããŸãããäž»ã«Regeneronãšã®ååã®äžã§èªèãããåçã«ãããã®ã§ããç§ãã¡ã¯2024幎6æã«Regeneronãšã®ååãä¿®æ£ããcemdisiranã®åç¬çæ³ãšããŠã®éçºã補é ãåæ¥åã®æä»çã©ã€ã»ã³ã¹ãRegeneronã«æäŸããŸããããã®ã©ã€ã»ã³ã¹ã«å²ãåœãŠãããå¥çŽäŸ¡æ Œ191.5çŸäžãã«ã¯ãRegeneronã«ã©ã€ã»ã³ã¹ã®ç§»è»¢ãè¡ãããæç¹ã§æºããããããããã«èªèãããŸãããã©ã€ã»ã³ã¹ã®ç®¡çæš©ã¯2024幎6æã«Regeneronã«ç§»è»¢ãããRegeneronã¯ã©ã€ã»ã³ã¹ã䜿çšããæ©æµãåããããšãã§ããŸããã
2024幎6æ30æ¥çµäºæç¹ã®3ãæéããã³6ãæéã«ããããã€ã€ã«ãã£å£²äžé«ã¯ã2023幎åãæéãšæ¯èŒããŠå¢å ããåœç€Ÿã®ååè
ã§ããããã«ãã£ã¹ã«ããLeqvioã®ã°ããŒãã«çŽå£²äžé«ããåŸããããã€ã€ã«ãã£ãå¢å ããããã圌ãã®ç¶ç¶çãªå±éåªåã«äž»ã«åž°å ããŸãã
åæ¥åã³ãã€ã€ãªãã£å£²äžé«ã®åç®çŽåçèªå®ã¯ãååè
ã«ããå ±é
¬ã®æ°Žæºãåæ¥å¥çŽã®ãã€ã«ã¹ããŒã³ã®éæãLeqvioã®è²©å£²ã«é¢é£ãããã€ã€ãªãã£ãªã©ãå€æ§ãªèŠå ã«äŸåããŠããŸãããã®ããã2024幎ã«ãããŠã¯ã2023幎ãšæ¯èŒããŠåæ¥åã³ãã€ã€ãªãã£å£²äžé«ã®çŽåçã«å€åãããå¯èœæ§ããããŸãã
å¶æ¥è²»çšåã³è²»çš
éå¶è²»çšåã³çµè²»ã¯ä»¥äžã®éãã§ã:
 6æ30æ¥ã«çµäºãã3ãæé 6æ30æ¥ã«çµäºãã6ãæé (ããŒã»ã³ããŒãžãé€ãååäœ) 2024 2023 $ å€æŽ % å€æŽ 2024 2023 $ å€æŽ % å€æŽ 売äžå䟡 $ 67,271 $ 75,336 $ (8,065) (11) % $ 121,884 $ 116,768 $ 5,116 4 % çŽè£œååçã«å¯Ÿãã売äžå䟡ã®å²å 16.4 % 24.6 % 15.7 % 20.1 % ã³ã©ãã¬ãŒã·ã§ã³ã®è²»çšãšãã€ã€ãªã㣠1,401 10,034 (8,633) (86) % 12,764 23,471 (10,707) (46) % ç 究éçº 294,142 248,526 45,616ã§ã 18 % 555,137 479,095 76,042 16 % 販売ãäžè¬ããã³ç®¡ç
248,397 214,689 33,708 16 % 459,194 398,348 60,846 15 % åèš $ 611,211ã§ã $ 548,585 $ 62,626 11 % $ 1,148,979 $ 1,017,682 $ 131,297 13 %
売äžå䟡ïŒcogsïŒ
2024幎6æ30æ¥çµäºã®3ãæããã³6ãæéã®çŽè£œååçã«å¯Ÿããå䟡売äžçã¯ã2023幎ãšåãæéãšæ¯èŒããŠäœäžããŸãããããã¯äž»ã«ãONPATTROã®è£œé æ¥åã®ãã£ã³ã»ã«ãåšåº«ã®ãã®ä»ã®èª¿æŽã«é¢é£ãã2023幎ã®é«ãã³ã¹ããã2024幎ã«ã¯çºçããªãã£ãããã§ãã
åœç€Ÿã¯2023幎ã«æ¯ã¹ãŠã2024幎ã«å£²äžé«ã®å¢å ãšå¢å ãããã€ã€ã«ãã£ã«ãããäž»ã«åºæ¥é«ãšAMVUTTRAã®çŽå£²äžé«ã«èª²ãããããã€ã€ã«ãã£çã®å¢å ã«ããã売äžå䟡ãå¢å ããããšãäºæ³ããŠããŸãã
ææºåã³ãã€ã€ã«ãã£ãŒè²»çš
2024幎6æ30æ¥çµäºæç¹åã³2023幎åæã«æ¯ã¹ãå
±åéçºè²»çšåã³ãã€ã€ãªãã£è²»çšãäœäžããäž»ãªçç±ã¯ãå
±åéçºè
ãç¬èªã«ææã調éããããã«ãªã£ãããšã«äŒŽããç¹å®ã®è£œé æ¥åã«ãããŠGalNAcææã®éèŠãæžå°ããããã§ãã
åœç€Ÿã®ååè
ãGalNAcãç¬èªã«çç£ããããã«ç§»è¡ããéçºäžè
ã®ç¥ç財ç£ã®ã©ã€ã»ã³ã¹ã倱å¹ããããšã«ãããååãšãã€ã€ãªãã£ã®è²»çšã¯2024幎ã«2023幎ã«æ¯ã¹ãŠåŒãç¶ãæžå°ããããšãäºæ³ãããŸãã
ç 究éçº Â
ç 究éçºè²»çšã¯æ¬¡ã®ãã®ã§æ§æãããŠããŸãïŒ
6æ30æ¥ã«çµäºãã3ãæé 6æ30æ¥ã«çµäºãã6ãæé (ããŒã»ã³ããŒãžãé€ãååäœ) 2024 2023 $ å€æŽ % å€æŽ 2024 2023 $ å€æŽ % å€æŽ èšåºç 究ãšå€éšãµãŒãã¹ $ 119,496 $ 109,698 $ 9,798 9 % $ 245,006 $ 221,295 $ 23,711ã§ã 11 % å ±é
¬ãšé¢é£ 86,762 64,707 22,055 34 % 163,971 129,427 34,544ã§ã 27 % å æçãšãã®ä»ãã¹ãŠã®è²»çš 39,769 41,320ã§ã (1,551) (4) % 78,830 79,340 (510) (1) % æ ªåŒããŒã¹ã®å ±é
¬ 48,115% 32,801 15,314 47 % 67,330% 49,033 18,297 37 % åèš $ 294,142 $ 248,526 $ 45,616ã§ã 18 % $ 555,137 $ 479,095 $ 76,042 16 %
2024幎6æ30æ¥çµäºã®3ãæããã³6ãæã«ãããã2023幎åæãšæ¯èŒããŠç 究éçºè²»ã®å¢å ã¯ãäž»ã«æ¬¡ã®çç±ã«ãããã®ã§ããã
⢠åœç€Ÿã¯ç 究éçºãã€ãã©ã€ã³ãæ¡å€§ãç¶ããäžã§ãåç©å®éšãªã©ã®åèšåºæŽ»åã«äŒŽãã³ã¹ããå¢å ããŠããŸãã
⢠KARDIA-3èšåºè©Šéšã«ãããzilebesiranãcAPPRicorn-1第2çžèšåºè©Šéšã«ãããmivelsiranã«é¢é£ããèšåºç 究費çšã®å¢å ã¯ãããããã®èµ·å掻åãå¢å ããããã§ãã
⢠2024幎6æã®ãããã©ã€ã³ããŒã¿çºè¡šã«åããŠã®è²»çšãšææ°æã®å¢å ã«äŒŽããHELIOS-bèšåºè©Šéšã«é¢é£ããè²»çšãå¢å ããŸããã
⢠ç 究éçºãã€ãã©ã€ã³ãšéçºè²»çšãæ¯æŽããããã«ãåŸæ¥å¡ã®å ±é
¬ãšé¢é£è²»çšãå¢ãããŸããã
⢠ç¹å®ã®ããã©ãŒãã³ã¹ããŒã¹ã®è³ã«å¯ŸããäŒèšåŠçã«ããæ ªåŒå ±é
¬è²»çšã®å¢å ã
ãªãã»ãã
⢠ãã®ä»ã®èšåºããã°ã©ã ãç¹ã«ããã·ã©ã³ã®APOLLO-b第3çžèšåºè©Šéšã«ãããŠããªãŒãã³ã©ãã«å»¶é·æéäžã®èšåºæŽ»åã®çž®å°ã«ããçµè²»åæžïŒ
⢠ã¬ãžã¹ã¿ã³ã¹ãšèšåºããã°ã©ã ããµããŒãããããã®è£œé 掻åã®ã¿ã€ãã³ã°ã«é¢é£ããçµè²»ã®æžå°ã
2024幎6æ30æ¥ããã³2023幎6æ30æ¥ã«çµäºãã3ãæããã³6ãæã«ããããå
±ååååå®ã«åºã¥ã掻åãæšé²ãããããèšåºè£œåã®è£œé ãå«ãå€éšéçºããã³èšåºãµãŒãã¹ã«äž»ã«é¢é£ããç 究éçºè²»ãè² æ
ããŸããã
次ã®è¡šã¯ãåœç€Ÿã®ååé¢ä¿ã«çŽæ¥é¢äžããç 究éçºè²»çšãçŽå£²äžé«ãèªèãããã®ããŸãšãããã®ã§ãã
6æ30æ¥ã«çµäºãã3ãæé 6æ30æ¥ã«çµäºãã6ãæé (ååäœ) 2024 2023 2024 2023 ããã·ã¥
$ 26,236 $ â $ 44,317% $ â ãªãžã§ããã³ãã¡ãŒãã·ã¥ãŒãã£ã«ã«ãº 14,284 20,196 32,987 39,315% ãã®ä» 1,816 548 4,629 1,346 åèš $ 42,336 $ 20,744 $ 81,933 $ 40,661
販売ã»äžè¬ç®¡çè²»çš
売äžé«ç·è²»çšã¯æ¬¡ã®ããã«æ§æãããŠããŸãïŒ
6æ30æ¥ã«çµäºãã3ãæé 6æ30æ¥ã«çµäºãã6ãæé (ããŒã»ã³ããŒãžãé€ãååäœ) 2024 2023 $ å€æŽ % å€æŽ 2024 2023 $ å€æŽ % å€æŽ å ±é
¬ãšé¢é£ $ 96,538 $ 75,507 $ 21,031 28 % $ 187,747 $ 149,833 $ 37,914 25 % ã³ã³ãµã«ãã£ã³ã°ãšå°éãµãŒãã¹ 66,731 57,848 8,883 15 % 123,490 108,536 14,954 14 % å æçãšãã®ä»ãã¹ãŠã®è²»çš 43,955 38,333 5,622 15 % 80,652 73,263 7,389 10 % æ ªåŒããŒã¹ã®å ±é
¬ 41,173% 43,001ã§ã (1,828) (4) % 67,305 66,716 589 1 % åèš $ 248,397 $ 214,689 $ 33,708 16 % $ 459,194 $ 398,348 $ 60,846 15 %
2024幎6æ30æ¥ãŸã§ã®3ãæéã«ããã売äžç·å©çã«æ¯ã¹ãŠã2023幎ã®åæéãšæ¯èŒããŠè²©å£²ãäžè¬ç®¡çè²»çšã®å¢å ã¯ãTTRæ²»çè¬ã®ããã¢ãŒã·ã§ã³ã«é¢ããããŒã±ãã£ã³ã°æè³ã®å¢å ããã³åŸæ¥å¡ã®å ±é
¬è²»çšã®å¢å ã«äž»ã«ãããã®ã§ãã
2024幎ã«ã¯ãã°ããŒãã«ãªåååããã³ã³ã³ãã©ã€ã¢ã³ã¹ã®ã€ã³ãã©æŽåãæ°ããåžå Žãžã®ååã®æå
¥ãå
±åç 究ããã°ã©ã ãå«ãã補ååè£è
ã®åŸæéçºããã©ãããã©ãŒã ããã³åç©å®éšã®ãã€ãã©ã€ã³ã®é²å±ãããã³èŠå¶ç³è«ã®æºåãé²å±ãããšäºæ³ãããç 究éçºè²»ãšè²©å£²ãäžè¬ç®¡çè²»ãåãããè²»çšã2023幎ã«æ¯ã¹ãŠå¢å ãç¶ãããšäºæ³ãããŸããã補é ãããã®ã¿ã€ãã³ã°ãèšåºè©Šéšã®åå è
ã調æ»ã®çµæã補ååè£è
ããã³ããã°ã©ã ã®èŠå¶å¯©æ»ãããã³æ ªåŒããŒã¹ã®å ±é
¬è²»çšãšãã£ãäžéšã®è²»çšã¯ãææã«åºã¥ãè³ã®ãã¹ãã®å¯èœæ§ã«é¢ããæã
ã®æ±ºå®ã«ãããå¯å€çã§ãããšäºæ³ãããŸãã
ãã®ä»(è²»çš)åç
ãã®ä»ïŒè²»çšïŒåå
¥ã¯æ¬¡ã®éãã§ãïŒ
 6æ30æ¥ã«çµäºãã3ãæé 6æ30æ¥ã«çµäºãã6ãæé (ããŒã»ã³ããŒãžãé€ãååäœ) 2024 2023 $ å€æŽ % å€æŽ 2024 2023 $ å€æŽ % å€æŽ æ¯æå©æ¯ $ (33,258) $ (30,035) $ (3,223) 11 % $ (68,511) $ (58,990) $ (9,521) 16 % å©æ¯åå
¥ 29,182 21,075% 8,107 38 % 58,827 39,730 19,097 48 % ãã®ä»ã®è²»çšãçŽé¡ åžå Žæ§ã®ããæ ªåŒã®å®çŸæ倱ãšæªå®çŸæ倱 (1,367) 1,400ã§ã (2,767) (198) % (1,289) (867) (422) 49 % éçºããªããã£ãè² åµã®å
¬æ£äŸ¡å€ã®å€å (55,642) (30,215) (25,427) 84 % (64,228) (36,686) (27,542) 75 % ãã®ä» 1,304ã§ã (6,603) 7,907 (120) % (4,732) (10,120) 5,388 (53) % åèš $ (59,781) $ (44,378) $ (15,403) 35 % $ (79,933) $ (66,933) $ (13,000) 19 %
2024幎6æ30æ¥ãçµäºãã3ãæãš6ãæã®éã«ãHELIOS-bèšåºè©Šéšã®éœæ§ãããã©ã€ã³çµæãåããŠçºçããéçºæŽŸçåµåã®å
¬æ£äŸ¡å€ã®å€åã«äŒŽãçµè²»å¢å ãããã³åžå Žåµåžã®éå©ã®äžæã«ããå©ååå
¥å¢å ãéšåçã«çžæ®ºãããããã2023幎ãšåãæéã«æ¯ã¹ãŠããã®ä»ã®ç·çµè²»ãå¢å ããŸããã
æåŸçšè²»çš
2024幎6æ30æ¥çµäºã®3ã¶æããã³6ã¶æéã«ãããŠãæã
ã¯$5.7çŸäžãã«ããã³$8.1çŸäžãã«ã®æåŸçšåŒåœéãèšäžãããããã¯äž»ã«å©çãäžããŠããå€åœåäŒç€Ÿã®çšéãšå·çšã代衚ããŠããŸãã
ç§ãã¡ã¯ãå
éãããã課çšè³ç£ã®å®çŸå¯èœæ§ã«é¢é£ãããã©ã¹ãšãã€ãã¹ã®ãšããã³ã¹ãè©äŸ¡ããŸããã2024幎6æ30æ¥çŸåšãç§ãã¡ã¯ãç±³åœãããã¥ãŒãåã³ã¹ã€ã¹ã®å
éã課çšè³ç£ã«å¯ŸããŠåŒãç¶ãå®å
šãªè©äŸ¡åŒåœéãç¶æããŠããŸããå
éã課çšè³ç£ãå®çŸãããå¯èœæ§ãããããªããã£ãŠããããšããçµè«ãæ¯æããååãªããžãã£ããªãšããã³ã¹ãããå Žåãç§ãã¡ã¯è©äŸ¡åŒåœéã解é€ããŸããã¹ã€ã¹ã«åž°å±ããè©äŸ¡åŒåœéã®äžéšãäžèŠã«ãªããšçµè«ä»ããååãªããžãã£ããªãšããã³ã¹ã次ã®12ã¶æ以å
ã«å
¥æã§ããå¯èœæ§ããããŸããè©äŸ¡åŒåœéã®å
šé¢çãŸãã¯äžéšã®è§£é€ã¯ãäžå®ã®å
éã課çšè³ç£ã®èªèãããããã解é€ãèšé²ãããæéã®æåŸçšè²»çšã®å®è³ªçãªæžå°ãåŒãèµ·ããå¯èœæ§ããããŸãã
æµåæ§ãšè³æ¬ãªãœãŒã¹
2024幎2æ29æ¥ãŸã§ã®3ãæéã®éå¶æŽ»åã«ãããŠãã¢ã¡ãªã«ããã³ã«ãã蚌åžå§å¡äŒã«é¢é£ãããããã§ãã·ã§ãã«æéãšã幎次èŠå¶ç³è«æžãããã³ã蚌åžååŒæããã³NYSE AmericanååŒæãžã®å¹ŽäŒè²»ãããã³äŒæ¥ã®äººä»¶è²»ã«å¯ŸããŠãåèš60äžãã«ãæ¯åºããŸããã
以äžã®è¡šã¯åœç€Ÿã®ãã£ãã·ã¥ãããŒæŽ»åããŸãšãããã®ã§ã:
6æ30æ¥ã«çµäºãã6ãæé (ååäœ) 2024 2023 æäŸããçŽçŸéïŒäœ¿çšéïŒ:
å¶æ¥æŽ»å $ 42,643 $ (225,461) æè³æŽ»å $ (33,680) $ (84,930) è³é調é掻å $ 160,407 $ 99,765
å¶æ¥æŽ»å
2024幎6æ30æ¥ãŸã§ã®6ã¶æéã«ãããå¶æ¥æŽ»åããã®çŽçŸéæµå
¥ã¯ã2023幎åæéãšæ¯èŒããŠå¢å ããŸãããäž»ã«ãåå販売ã®å¢å ã«äŒŽãçŸéååé«ã®å¢å ãšãé転è³æ¬æ¯æãã«é¢ããçŸéæ¯åºã®æžå°ã圱é¿ããŠããŸãã
æè³æŽ»å
2024幎6æ30æ¥ãŸã§ã®6ãæéã«ãããæè³æŽ»åã«ä¿ãç·ååŒé«ã®é¡ã¯ã2023幎ã®åãæéãšæ¯èŒããŠæžå°ããŸãããããã¯ãåžå Žã«ãããåµåžã»åµå蚌åžãžã®çŸéã®çŽæè³ã®ã¿ã€ãã³ã°ã«äž»ã«èµ·å ããŠããŸãã
財å掻å
2024幎6æ30æ¥çµäºæç¹ã®6ãæéã«ããã財å掻åã«ããçŽçŸéã¯ã2023幎ã®åãæéãšæ¯èŒããŠå¢å ããŸãããããã¯äž»ã«ãæ ªåŒãªãã·ã§ã³è¡äœ¿ã«äŒŽãæ®éæ ªåŒã®çºè¡ã«ããçŽååé«ã®å¢å ã«èµ·å ããŸãã
è¿œå ã®è³æ¬èŠå¶èŠä»¶
çŸåšãå€ãã®æ²»çåéã«çŠç¹ãåœãŠãããã°ã©ã ãæã¡ã2024幎6æ30æ¥ã«ã¯4ã€ã®è£œåãèŠå¶åœå±ããæ¿èªãååŸããåæ¥çã«å±éããŠããŸããããããªãããä»åŸãåœç€Ÿã®éçºåªåãå®ãçµã°ãªãå Žåãããããã®ä»ã®è£œåã販売ã§ããªãå¯èœæ§ããããŸãããŸããAMVUTTRAãå«ãæ¿èªè£œåã®é©å¿çã®æ¡å€§ã«ãæåããªãå¯èœæ§ããããŸããããã«ãåœç€Ÿã¯ãåœç€Ÿã®ç 究ãã©ãããã©ãŒã ãåœç€Ÿã®èšåºè©Šéšã補é ã³ã¹ããå«ãè¬å€éçºããã°ã©ã ãåŸæèšåºã補é ãåæ¥ãã³ã³ãã©ã€ã¢ã³ã¹æ©èœã®ç¢ºç«ãã°ããŒãã«ãªæ ç¹ã®ç¶ç¶çãªç®¡çãšæ¡å€§ãç¹èš±ããŒããã©ãªãªã®ç®¡çãšæé·ãååé¢ä¿ããã³äžè¬çãªäŒæ¥æŽ»åã®èšç»çãªæ¯åºã®çµæãåŒãç¶ãæ倱ãèšäžããèŠèŸŒã¿ã§ãã
ç§ãã¡ã®äºæ³ãããçš®é¡ã®äœæ¥ãšä»ã®è³æ¬èŠä»¶ã¯ã2023 幎㮠10-k ãã©ãŒã ã®ãããŒã IIãã¢ã€ãã 7. 財åç¶æ³ããã³äºæ¥ã®çµæã«é¢ããçµå¶é£ã®èª¬æãšåæãã«èšèŒãããŠããŸãã2024 幎 6 æ 30 æ¥æç¹ã§ã¯ããã³ã³ãã³ã¹åãããé£çµè²¡åè«žè¡šã®æ³šéãããã³æ¬ååæå ±åæžã®ãæµåæ§ããã³è³æ¬ãªãœãŒã¹ãã»ã¯ã·ã§ã³ã§é瀺ãããå€æŽä»¥å€ã«ãåœç€Ÿã®äºæ³ãããäœæ¥ãšä»ã®è³æ¬èŠä»¶ã«ã¯ã2023 幎㮠10-k ãã©ãŒã ã§èª¬æããããã®ä»ã®éèŠãªå€æŽã¯ãããŸããã
çŸåšã®éçšèšç»ã«åºã¥ããšããã®ååæå ±åæžïŒãã©ãŒã 10-QïŒæåºæ¥ããå°ãªããšã次ã®12ãæéã®çæçãªè³æ¬ãšéå¶ã®å¿
èŠæ§ãæºããããã«ã2024幎6æ30æ¥æç¹ã®çŸéãçŸéåçç©ãæµå蚌åžãšã補å販売ãšçŸåšã®ææºã«ãã£ãŠæåŸ
ãããçŸéãå«ããã¹ãŠæä¿¡ã¯ååã§ãããšèããŠããŸãããã ãããã®ååæå ±åæžïŒãã©ãŒã 10-QïŒã®PartIIãItem1Aããªã¹ã¯ãã¡ã¯ã¿ãŒãã®ãã£ãã·ã§ã³ã®äžã§ããã«è©³çŽ°ã«èª¬æãããŠããå€æ°ã®èŠå ã«ãããèªå¯ããã補åãåæ¥åããè¿œå ã®åè£è¬ãéçºãèšåºè©Šéšãå®æœãã補é ããèªå¯ãããå Žåã¯è²©å£²ããããã«ãçŸåšäºæ³ããŠãããããæ©ããéèŠãªè¿œå è³éãå¿
èŠã«ãªãå ŽåããããŸãã
é
ç®3.åžå Žãªã¹ã¯ã«é¢ããéçã»è³ªçæ
å ±ã®é瀺
å©åã«é¢é£ããéèåžå Žã®ãªã¹ã¯ã¯ã2023幎12æ31æ¥çµäºã®åœ¢åŒ10-Kã®å¹Žæ¬¡å ±åæžã§èª¬æãããŠããŸãã2024幎6æ30æ¥çŸåšã2023幎12æ31æ¥ã«èª¬æãããéèåžå Žãªã¹ã¯ã«é倧ãªå€æŽã¯ãããŸããã§ãããç§ãã¡ã¯ãéèåžå Žãªã¹ã¯ã«é¢ããç§ãã¡ã®æ§è³ªããšã¯ã¹ããŒãžã£ãŒãããã³ãã®ãšã¯ã¹ããŒãžã£ãŒã管çããããã®çµå¶ç®çããã³æŠç¥ã«ã€ããŠã®ä»ã®è¿æã®å€æŽãçŸåšäºæ³ããŠããŸããã
é
ç® 4. çµ±å¶ããã³æé
é瀺ã®ç®¡çãæé ãããã³ããã»ã¹
åœç€Ÿã¯ãåœç€Ÿã®æé«çµå¶è²¬ä»»è
ïŒäž»èŠçµå¶è²¬ä»»è
ïŒããã³ãšã°ãŒã¯ãã£ããã€ã¹ãã¬ãžãã³ããæé«è²¡å責任è
ïŒäž»èŠè²¡å責任è
ïŒã®åå ã«ããã2024幎6æ30æ¥çŸåšã®åœç€Ÿã®é瀺管çããã³æé ã®å¹æãè©äŸ¡ããŸããããé瀺管çããã³æé ããšã¯ãååŒææ³13a-15ïŒeïŒããã³15d-15ïŒeïŒã®èŠå®ã«ããå®çŸ©ããããäŒæ¥ãååŒææ³ã«åºã¥ãå ±åæžã«èšèŒãŸãã¯æåºããå¿
èŠã®ããæ
å ±ããSECã®èŠåããã³æžåŒã§æå®ãããæéå
ã«èšé²ãåŠçãèŠçŽãããã³å ±åãããããšã確ä¿ããããã«èšèšãããäŒæ¥ã®ã³ã³ãããŒã«ããã³æé ãæå³ããŸããé瀺管çããã³æé ã«ã¯ãäŸãã°ãäŒæ¥ãååŒææ³ã«åºã¥ãå ±åæžã«èšèŒããå¿
èŠã®ããæ
å ±ãèç©ããã³é©åã«å ±åãããå¿
èŠã«å¿ããŠå瀟ã®æé«çµå¶è²¬ä»»è
ããã³æé«è²¡å責任è
ãå«ãå瀟ã®ç®¡çé£ã«äŒéãããå¿
èŠãªé瀺ã«é¢ããè¿
éãªå€æã容æã«ããããã«èšèšãããã³ã³ãããŒã«ããã³æé ãå«ãŸããŸããåœç€Ÿã®ç®¡çé£ã¯ãã©ã®ããã«ããèšèšãããéçšããããšããŠããå¯èœãªã³ã³ãããŒã«ããã³æé ã®ã³ã¹ããšå©çã®é¢ä¿ãè©äŸ¡ããããã«ãå€æãè¡ãå¿
èŠãããããšãèªèããŠããŸãã2024幎6æ30æ¥çŸåšã®åœç€Ÿã®é瀺管çããã³æé ã®è©äŸ¡ã«åºã¥ããåœç€Ÿã®æé«çµå¶è²¬ä»»è
ããã³ãšã°ãŒã¯ãã£ããã€ã¹ãã¬ãžãã³ããæé«è²¡å責任è
ã¯ãåœè©²æ¥æç¹ã§ãåœç€Ÿã®é瀺管çããã³æé ãåççã«ä¿èšŒã¬ãã«ãæºããããšçµè«ã¥ããŸããã
å
éšçµ±å¶ã®å€æŽ
2024幎6æ30æ¥æ«æ¥ãŸã§ã®ååæã«ãããŠã財åå ±åã«é¢ããå
éšçµ±å¶ã«é¢ããŠé倧ãªåœ±é¿ãåãŒãæ§ãªå€æŽã¯ãããŸããã§ããã
第IIéš ãã®ä»ã®æ
å ±
ITEM 1. æ³çæç¶ã«é¢ããèšèŒ
åœç€Ÿã®ãã®ååæå ±åæžã®ç¬¬ I éšé第 I é
ã財åè«žè¡šïŒæªç£æ»ïŒãã«å«ãŸããããŒã 13ãã³ãããã¡ã³ãããã³äžç¢ºå®äºé
ããåç
§ããŠãæªè§£æ±ºã®æ³çæç¶ãã«é¢ããäºé
ã«ã€ããŠè°è«ããŠãã ãããåœããŒãã¯åç
§ãšããŠæ¬é
ç®ã«çµã¿èŸŒãŸããŠããŸãã
é
ç®1A. ãªã¹ã¯ãã¡ã¯ã¿ãŒ
ç§ãã¡ã®èšŒåžã«æè³ããããšã¯ãé«åºŠãªãªã¹ã¯ã䌎ããŸããåœç€Ÿããã³ããžãã¹ãè©äŸ¡ããéã«ãåœåã®10-Qãã©ãŒã ã«èšèŒãŸãã¯åç
§ãããåœç€Ÿã®é£çµè²¡åè«žè¡šãé¢é£æ³šèšã財åç¶æ³ããã³æ¥çžŸã«é¢ãã管çè
ã®èšè«æžãå«ãã以äžã®ãªã¹ã¯èŠå ãæ
éã«æ€èšããå¿
èŠããããŸãã以äžã®ãªã¹ã¯ããŸãã¯çŸåšåœç€Ÿãç¥ããªãè¿œå ãªã¹ã¯ããŸãã¯çŸåšç§ãã¡ãéèŠã§ãªããšå€æããŠããè¿œå ãªã¹ã¯ã®ãããããå®éã«çºçããå Žåãç§ãã¡ã®æ¥çžŸãèŠéããçµå¶æ瞟ããŸãã¯è²¡åç¶æ³ã«é倧ãªäžå©ãªåœ±é¿ãäžããå¯èœæ§ããããŸãããã®å Žåãæ®éæ ªåŒã®ååŒäŸ¡æ Œãäžèœããå¯èœæ§ããããæè³é¡å
šäœãŸãã¯äžéšã倱ãå¯èœæ§ããããŸãã
ç§ãã¡ã®ããžãã¹ã«é¢é£ããç©è³ªçãªã¹ã¯ã®æŠèŠ
åŒç€Ÿã®ããžãã¹ã¯ã以äžã®ã»ã¯ã·ã§ã³ã§è©³ãã説æãããŠããå€æ°ã®ãªã¹ã¯ãšäžç¢ºå®èŠå ã«ãããããŠããŸãããããã®ãªã¹ã¯ã«ã¯ã以äžã®äž»èŠãªãªã¹ã¯ãå«ãŸããŸã:
ããžãã¹ã«é¢é£ãããªã¹ã¯ - ç§ãã¡ã®è²¡åçµæã«é¢é£ãããªã¹ã¯
⢠åœç€Ÿã®æ¿èªããã補åãŸãã¯å°æ¥ã®è£œåã®ããŒã±ãã£ã³ã°ããã³è²©å£²ãäºæ³ãããããŸãããããAMVUTTRAã®æ¿èªãããé©å¿çãæ¡å€§ã§ããªãå ŽåããããŸãã
⢠ç§ãã¡ã¯æ倱ã®æŽå²ããããå©çãåŸãããšãç¶æããããšãã§ããªããããããŸããã
⢠ç§ãã¡ã¯ãç 究ãéçºãååå掻åãç¶ããããã«çžåœãªè³éãå¿
èŠã§ãããã¹ãŠæä¿¡ã
⢠ã¬ãããªã«é¢é£ããã©ããªãã€ãã¹ãªå±éããããã«ãã£ã¹ããæªæ¥ã®ãã€ã€ãªãã£ãŒåååã³ãã€ã«ã¹ããŒã³æ¯æãã«å¯Ÿãã圱é¿ãåãŒãããšããããŸãã
第äžè
ãžã®äŸåã«é¢é£ãããªã¹ã¯
⢠åœç€Ÿã®äžéšã®è£œååè£ã®éçºããã³åååã®ããã®ããžãã¹ããã³ç§åŠçèœåããã³è³éãæäŸã§ããä»ã®äŒæ¥ãšã®æ¢åã®ååé¢ä¿ã®ç¶æãŸãã¯æ°ããååé¢ä¿ãçµã¶ããšãã§ããªãå¯èœæ§ããããŸãããã¹ãŠæä¿¡
⢠ããå
±åéçºè
ãç§ãã¡ãšã®å¥çŽãå®è³ªçã«ä¿®æ£ãçµäºãã¯ãããã«çŸ©åãå±¥è¡ããªãå Žåãåœç€Ÿã®ãã補ååè£ã®éçºãšåæ¥åãé
ãããæã¡åãããå¯èœæ§ããããŸãã
⢠補é æ¥ã®èœåãšè³æºã®çºå±ã補é æ¥ã®å°éç¥èã®ç²åŸã«èªç€Ÿã§å€å€§ãªã³ã¹ããããç¶ããããšãäºæ³ããŠããããã®éã補åã®è£œé ã«ã€ããŠã¯ç¬¬äžè
ã«äŸåããä»åŸãäŸåããããšãäºæ³ããŠããŸãã
⢠ç§ãã¡ã¯èšåºè©Šéšãè¡ãããã«ç¬¬äžè
ã«é Œã£ãŠããŸããããã®ãããªç¬¬äžè
ã矩åãæãããªãå Žåãç§ãã¡ã®éçºèšç»ã«äžå©ãªåœ±é¿ãäžããå¯èœæ§ããããŸãã
äºæ¥éçšã«é¢é£ãããªã¹ã¯
⢠ãããç§ãã¡ãé©æ ŒãªããŒãããžã¡ã³ããç§åŠè
ãéçºãå»çé¢é£ãåæ¥ã¹ã¿ãããã³ã³ãµã«ã¿ã³ããã¢ããã€ã¶ãåŒãä»ãç¶æããããšãã§ããªãå Žåã¯ãããžãã¹èšç»ãå®è¡ããèœåã«æªåœ±é¿ãåãŒãå¯èœæ§ããããŸãã
⢠米åœãšãšãŒããããæ ç¹ãšããŠããäŒç€Ÿãããã¢ãžã¢ãã©ãã³ã¢ã¡ãªã«ãäžæ±ãå«ãè€æ°ã®å°åã§è€æ°ã®è¬å€ãéçºããåååããã°ããŒãã«äŒæ¥ãžã®å±éãç¶ããäžã§ãåœç€Ÿã®äºæ¥æ¡å€§ãæåããããšã«å°é£ããããããããŸããã 以åã¯çºèŠãèšåºåæ€æ»ãããã³èšåºéçºã«äž»ã«é¢äžããŠããŸããã
ç§ãã¡ã®è£œååè£ã®éçºãèšåºè©ŠéšãèŠå¶æ¿èªåã³æ¿èªæžè£œåã®åæ¥åã«é¢é£ãããªã¹ã¯ã«ã€ããŠã®æ¥çš®ãªã¹ã¯
⢠ç§ãã¡ãååäŒæ¥ãéçºãã補ååè£ã¯ãéçºã«å€±æãããããã®è£œååè£ãåæ¥çã«å®çŸäžå¯èœã«ãªããŸã§é
延ããå¯èœæ§ããããŸãã
⢠ç§ãã¡ãŸãã¯ç§ãã¡ã®ååè
ã¯ãç±³åœãŸãã¯å€åœã®èŠå¶æ¿èªãååŸã§ããªãå Žåãããããã®çµæãç§ãã¡ãŸãã¯ç§ãã¡ã®ååè
ã¯ãã®ãããªè£œååè£ãåæ¥åã§ããªãå¯èœæ§ããããŸãã
⢠ããšãç§ãã¡ãŸãã¯ç§ãã¡ã®ååè
ãèŠå¶åœå±ã®æ¿èªãååŸãããšããŠããç§ãã¡ã®è£œåã¯ç¶ç¶çãªèŠå¶ç£èŠã®å¯Ÿè±¡ãšãªããŸãã
⢠æªæ¿èªã®è£œååè£ã«ã€ããŠåæ¥æŽ»åãè¡ã£ãŠãããšããããã¯é©çšæ³èŠã«éåããããã«åæ¥çã«æ¿èªããã補åã宣äŒããå Žåã«ãå·è¡åœå±ã䞻匵ããããå€æããå Žåãåœç€Ÿã¯é倧ãªè²¬ä»»ãè² ãå¯èœæ§ããããŸãã
⢠補ååè£ãèŠå¶åœå±ããæ¿èªãããŠããåæ¥åãããéã«åžå Žãåãå
¥ããªãå¯èœæ§ããããå©çãåŸãããšãã§ããªããªãæãããããŸãã
⢠åœç€Ÿã¯å€æ§ãªè£œåãæäŸããåæ¥äŒç€Ÿã§ãããåŒãç¶ãããŒã±ãã£ã³ã°ãå¶æ¥ãåžå Žã¢ã¯ã»ã¹ãæµéèœåãæ§ç¯ããã°ããŒãã«ãªã€ã³ãã©é¢é£ãæŽã«ç¢ºç«ããããã®è«å€§ãªè²¡æ¿çåã³ç®¡ççè³æºã®æè³ãããããšãæåŸ
ããŠãããæã
ã®åãçµã¿ãæåãããšã¯éããªãå¯èœæ§ããããŸãã
⢠çŸåšãŸãã¯å°æ¥éçºããå¯èœæ§ã®ãã補åã¯ãäžå©ãªäŸ¡æ ŒèŠå¶ã第äžè
ã®æãæ»ãæ¹æ³ãå»çæ¹é©ã€ãã·ã¢ããã«ãããæã
ã®ããžãã¹ã«æ害ãäžããå¯èœæ§ããããŸãã
ç¹èš±ãã©ã€ã»ã³ã¹ãååŒç§å¯ã«é¢é£ãããªã¹ã¯
⢠ç§ãã¡ã®çºèŠã«ç¹èš±ä¿è·ãåŸãããã匷å¶ã§ããªãå Žåã補ååè£ã®éçºãšåååèœåãæãªãããå¯èœæ§ããããŸãã
⢠åœç€Ÿã¯ã第äžè
ææè
ããç¹èš±æš©ãã©ã€ã»ã³ã¹ããå ŽåããããŸãããã®ãããªææè
ããããã®ã©ã€ã»ã³ã¹ã®æ ¹åºã«ããç¹èš±ãæ£ãããŸãã¯å¹æçã«ååŸãç¶æãŸãã¯åŒ·å¶å·è¡ããããšãã§ããªãå Žåãåœç€Ÿã®ç«¶äºåãæãªãããå¯èœæ§ããããŸãã
⢠ãã®ä»ã®äŒæ¥ãå£äœããç¹èš±æš©ãäºãã補åã®éçºãåååã劚ããå¯èœæ§ããããŸãã
⢠ç¹èš±äŸµå®³èšŽèšçã®ç¥ç財ç£èšŽèšãŸãã¯é¢é£ãã蚎èšã«å·»ã蟌ãŸããå Žåããã¡ã€ã¶ãŒç€ŸããŸãã¯ãã¡ã€ã¶ãŒç€Ÿãããã³ã¢ãã«ã瀟ããŸãã¯ã¢ãã«ã瀟ã«å¯Ÿããç§ãã¡ã®ç¹èš±äŸµå®³èšŽèšãå«ããè«žè²»çšããã³çµè²»ãçºçãããŸããç§ãã¡ã«å¯Ÿããåœè©²èšŽèšãŸãã¯æç¶ããããå Žåã«ã¯ãè«å€§ãªæå®³è³ å責任ãè² ãããšããŸãã¯è£œåéçºããã³åååã®åãçµã¿ãåæ¢ããå¿
èŠããããŸãã
⢠ã©ã€ã»ã³ã¹ãŸãã¯é¢é£å¥çŽã®çŸ©åã«éåããå Žåããã¡ãŒãžãæ¯æããªããã°ãªããªãå Žåãããããªãæ žé
žå¹²æžïŒRNAiïŒãã¯ãããžãŒã®éçºãåæ¥åãããã³ä¿è·ã«å¿
èŠãªã©ã€ã»ã³ã¹ãŸãã¯ãã®ä»ã®æš©å©ã倱ãå¯èœæ§ããããŸãã
競äºã«é¢é£ãããªã¹ã¯
⢠å»è¬ååžå Žã¯æ¿ãã競äºçã§ããæã
ãŸãã¯å
±åç 究è
ãæ¢åã®è¬å€ãæ°ããæ²»çæ³ãæ°ããæè¡ã«åå競äºã§ããªãå Žåãéçºããããããè¬å€ãåæ¥åããããšãã§ããŸããã
⢠ç§ãã¡ãååè
ã¯ãåæ§ã®ãã¯ãããžãŒã䜿çšããŠæ°è¬ããã¯ãããžãŒãã©ãããã©ãŒã ãéçºããããšããŠããä»ã®äŒæ¥ãããã³æ°èæè¡ãå©çšããäŒæ¥ãã競åããŠããŸãã
åœç€Ÿã®æ®éæ ªåŒã«é¢ãããªã¹ã¯
⢠åœç€Ÿã®æ ªäŸ¡ã¯éå»ã«äžå®å®ã§ãããä»åŸãäžå®å®ãšãªãå¯èœæ§ããããŸããåœç€Ÿã®æ®éæ ªåŒãžã®æè³ã¯äŸ¡å€ã®äžèœã被ãå¯èœæ§ããããŸãã
⢠ç§ãã¡ã¯ãç§ãã¡èªèº«ãå
±åç 究è
ã®èšåºéçºæŽ»åã競åä»ç€Ÿã®èšåºéçºæŽ»åãããå®æçã«çµæãçºè¡šãããç§ãã¡ã®æ®éæ ªåŒã®äŸ¡æ Œã«å€§ããªå€åãããããå¯èœæ§ãããããšãäºæ³ããŠããŸãã
ç§ãã¡ã®è»¢æ瀟åµã«é¢é£ãããªã¹ã¯
⢠ç§ãã¡ã®ããžãã¹ããã®ååãªãã£ãã·ã¥ãããŒããªããããããªããããç§ãã¡ã¯åµåãæ¯æãããšãã§ããªããããããŸããã
⢠ãã¹ãŠæä¿¡ã«å¿
èŠãªè³éã調éããèœåããªãå ŽåããããŸããããã¯ã2027幎ã«æºæãè¿ããå²å1ïŒ
ã®åªå
åµ/ã·ãã¢åµã®çŸéæç®ãŸãã¯çŸéã§ã®åµåžã®è²·ãæ»ãããŸãã¯åºæ¬çå€æŽæã®åµåžã®çŸéåã«å¿
èŠãªãã®ã§ãã
⢠ããŒãã®æ¡ä»¶ä»æç®æ©èœãããªã¬ãŒããããšãæµåæ§ã«æªåœ±é¿ãäžããå¯èœæ§ããããŸãã
åœç€Ÿã®ããžãã¹ã«é¢é£ãããªã¹ã¯
ç§ãã¡ã®è²¡åçµæã«é¢ãããªã¹ã¯
åœç€Ÿã®æ¿èªããã補åãŸãã¯å°æ¥ã®è£œåã®ããŒã±ãã£ã³ã°ãšè²©å£²ãäºæ³ããã倱æãããããŸãã¯æåããªãå ŽåããããAMVUTTRAãå«ãåæ¥çšè£œåã®äžéšã®æ¿èªãããé©çšç¯å²ãæ¡å€§ããããšãã§ããªãå ŽåããããŸãã
åæ¥çã«4補åãçºå£²ããŠããããæ¿èªããã補åãåžå Žã§è²©å£²ãããŸãç¹å®ã®åæ¥è£œåã®èš±å¯ãããé©å¿çãæ¡å€§ããããšãã§ãããã©ãããäºæž¬ããããšã¯ã§ããŸãããããšãã°ã2022幎8æãš9æã«ã¯ãå¿èççã䌎ãATTRã¢ããã€ããŒã·ã¹æ£è
ã®æ©èœçèœåãšç掻ã®è³ªã«å¯Ÿããããã·ã©ã³ã®å¹æãè©äŸ¡ããããã«èšèšãããäžã€ãã¯ãŒã調æŽããã¢ããããŒçžIIIèšåºè©Šéšã«ãããŠãå®å
šæ§ãšæå¹æ§ã®æ£ã®çµæãå ±åããŸãããããããåœç€Ÿã®ã¢ããããŒèšåºè©Šéšããã®å®å
šæ§ãšæå¹æ§ã®æ£ã®çµæã«ããããããã2023幎10æããã¡ã€ã¶ãŒã¯ATRã¢ããã€ããŒã·ã¹æ£è
ã®å¿çççšããã·ã©ã³ã®sNDAã«å¯ŸããŠå®å
šåçæžãŸãã¯CRLãçºè¡ããããã·ã©ã³ã®æ²»çå¹æã®èšåºçææ矩æ§ã確ç«ãããŠããªããããsNDAã¯æåºããã圢åŒã§æ¿èªãããããšã¯ã§ããŸããã§ããã
2025幎ãŸã§ã«åçæ§ã®é«ãããããã£ã¢ã®ãã€ãªããã¯äŒæ¥ãæ§ç¯ããæŠç¥åã³é¢é£ææšãéæãããããæ¿èªããã補åã®è²©å£²ãšå±éãæåãããå¿
èŠããããŸãã ãAlnylam P x25ãæŠç¥ã¯ãæç¶å¯èœãªé©æ°ãšåªãã財åæ¥çžŸãéããŠãçããç
æ°ããäžè¬çãªç
æ°ã«å€é©çãªè¬å€ãæäŸããããšã§ãã 5 ãAlnylam P x25ãæŠç¥ã¯ãæç¶å¯èœãªé©æ°ãšåªãã財åæ¥çžŸãéããŠãçããç
æ°ããäžè¬çãªç
æ°ã«å€é©çãªè¬å€ãæäŸããããšã§ãã ããã«ãæ¿èªããã補åã®æ¿èªææšãåžå Žè²©å£²ããæ¡å€§ããããã«æ¬¡ã®ããšãæåãããå¿
èŠããããŸãã
⢠RNAiã«é¢ããæ°ããæè¡ããèèãäžæ¢ç¥çµç³»ãç®ãèºãèèªãçèãªã©ã®é¢é£ããçµç¹ã现èã«siRNAãé
éããããã®è£œåéçºæŽ»åãå®è¡ãç¶ããæ°ããæè¡ã掻çšããŠãã ããã
⢠匷åãªç¥ç財ç£ããŒããã©ãªãªãæ§ç¯ããç¶æããããšïŒ
⢠åœç€Ÿã®è£œååè£ã®éçºããã³åååã®èŠå¶æ¿èªãåŸãŠãæ¿èªããã補åãããã³ãã®ä»ã®ååãããŸãããŒã±ãã£ã³ã°ããããšã§ãããã®ä»è£œåã販売ããå Žåãåæ§ã§ãã
⢠ç§ãã¡ã®è£œåãåŒãä»ãã顧客ãç¶æããããšã§ãã
⢠æåããååé¢ä¿ãç¯ããç¶æããããšã§ãã
⢠èšåºè©ŠéšãèŠå¶æ¿èªãåååã«äŒŽã£ãŠãã³ã¹ããšçµè²»ãå¢å ãããããæ¯åºã管çããå¿
èŠããããŸãã
äžèšã®ç®æšãéæã§ããªãå Žåã補ååè£ãéçºã§ãããæ¿èªããã補åãå°æ¥ã®è£œåãæåè£ã«åååã§ããªãå¯èœæ§ããããå¿
èŠã«å¿ããŠè³é調éãã§ãããè² åµãè¿æžã§ããã財åçãªèªå·±æç¶æ§ãå®çŸã§ããªãã£ãããäºæ¥ãç¶ç¶ã§ããªããªãå¯èœæ§ããããŸãã
ç§ãã¡ã¯æ倱ã®æŽå²ããããå©çãåŸãããšãç¶æããããšãã§ããªããããããŸããã
åµæ¥ä»¥æ¥ãç§ãã¡ã¯å€§ããªå¶æ¥æ倱ãçµéšããŠããŸãã2024幎6æ30æ¥æç¹ã§ã环ç©èµ€åã¯7.09åãã«ã«éããŸãããçŸåšãŸã§ã«ãç±³åœãEUãããã³äžçååœã§4ã€ã®è£œåãçºå£²ããŠããã2024幎以éãåæ¥çã«æ¿èªããã補åãããã«å€ãã®åœã«çºå£²ããããšãæåŸ
ããŠããŸãããå©çãäºæ¥ç¶ç¶çãªçŸéåçæ§ãéæããããšãã§ããªãå¯èœæ§ããããŸãã2024幎6æ30æ¥ãŸã§ã®3ã«æéãš6ã«æéã«ãONPATTROãAMVUTTRAãGIVLAARIãããã³OXLUMOã®è£œå売äžé«ããããããã4,101çŸäžãã«ãš7,753çŸäžãã«ã®çŽè£œå売äžé«ãèšäžããŸãããåœç€Ÿã¯åŒãç¶ã幎次å¶æ¥æ倱ã被ãå¯èœæ§ããããRNAiæ²»çè¬ã®éçºãšåæ¥åã®åãçµã¿ãæ¡å€§ããã«ããããä»åŸæ°å¹Žéã«ããã£ãŠå€§éã®è³æºãå¿
èŠãšããèŠéãã§ãããŸãã2025幎æ«ãŸã§ã«è²¡åçã«èªå·±æç¶å¯èœãªãããã£ãŒã«ãéæããããšãç®æããŠããŸããçŸåšã®çŸéãçŸéåçç©ãæµååžå Žæ§ã®ããæ ªåŒããã³åµåžã»åµå蚌åžãããã³æ¢åã®ã³ã©ãã¬ãŒã·ã§ã³ã«ãã補å販売ããã³ãã€ã«ã¹ããŒã³ããã³Leqvioã®ãã€ã€ã«ãã£åå
¥ãå«ããèŠèŸŒãŸããåçã¯ãå°æ¥ã®æ ªåŒéèéèŠã®å¿
èŠæ§ãåé¿ããªããèªå·±æç¶å¯èœãªãããã£ãŒã«ãéæããããšãå¯èœã«ããã¯ãã§ããããã®ç®æšãéæããããã«ã¯ã補åãã³ã©ãã¬ãŒã·ã§ã³ãããã³ãã€ã€ã«ãã£åå
¥ãçæããèœåã«äŸåããå¿
èŠããããŸããåæ¥çã«æ¿èªãããçŸåšåã³å°æ¥è£œåã®å£²äžé«ã ãã§ãªããä»åŸæ°å¹Žéã«ããã£ãŠç§ãã¡ãçæããåçã®äžéšã¯ãRocheãRegeneronããµããã£ãããã³Novartisãå«ã補è¬ããã³ãã€ãªãã¯ãããžãŒäŒæ¥ãšã®ã³ã©ãã¬ãŒã·ã§ã³ããåŒãç¶ãåŸãããããšãäºæ³ãããŠããŸããç§ãã¡ã¯ãæ¢åã®ã³ã©ãã¬ãŒã·ã§ã³ãç¶æã§ããããæ°ããã³ã©ãã¬ãŒã·ã§ã³ãç· çµãç¶æã§ããããã³ã©ãã¬ãŒã·ã§ã³å¥çŽã®çŸ©åãå±¥è¡ã§ãããããŸãã¯æ¢åã®ãããã¯æ°ããã³ã©ãã¬ãŒã·ã§ã³ã®äžã§æ¯æããåããããã«å±¥è¡ãŸãã¯éæããå¿
èŠããããã€ã«ã¹ããŒã³ãéæã§ãããã©ãããä¿èšŒããããšã¯ã§ããŸãããããã«ãNovartisãå«ãåœç€Ÿã®ããŒãããŒããåœç€Ÿãšã®ã³ã©ãã¬ãŒã·ã§ã³å¥çŽã®äžã§ãã®çŸ©åãéè¡ããåœç€Ÿã®ããã«ã³ã©ãã¬ãŒã·ã§ã³ããã³ãã€ã€ã«ãã£åå
¥ãçæãç¶ããä¿èšŒã¯ã§ããŸããã
å©çãäžãç¶ããããã«ã¯ãææãªåžå Žã®å¯èœæ§ãæã€æ°ãã補ååè£ãçºèŠããéçºããåååããããšã«æåããå¿
èŠããããŸãããã®ããã«ã¯ãç¶ç¶çãªãã©ãããã©ãŒã ã®é©æ°ãèšåºåè©Šéšãèšåºè©Šéšæ®µéãæ°ãã補ååè£ã®èŠå¶æ¿èªããã³æãæ»ãã®ç²åŸããããŠè£œé ãããŒã±ãã£ã³ã°ããã³è²©å£²ãå«ãŸããäžé£ã®ãã£ã¬ã³ãžã«æåããå¿
èŠããããŸããæã
ãå©çãäžããããšãã§ããªãã£ãå ŽåããŸããå©çãéæãããšããŠããååæãŸãã¯å¹Žæ¬¡åºç€ã§å©çãæç¶ãŸãã¯å¢å ãããããšãã§ããªãå ŽåããããŸãã
æ®éæ ªåŒã®åžå ŽäŸ¡æ Œãäžè²«ããŠåçæ§ãé«ããªãå Žåãäžèœããå¯èœæ§ããããŸãããŸããè³æ¬ã調éã§ãããããžãã¹ãæ¡å€§ããããè¿œå ã®è£œååè£ãéçºãããããªãã¬ãŒã·ã§ã³ãç¶ç¶ããããšãã§ããªãå¯èœæ§ããããŸãã
ç§ãã¡ã¯ãç 究éçºããã³åæ¥å掻åãç¶ç¶ããããã«ãããªãã®æè³è³éãå¿
èŠã§ããäºæ³ãããå€ãã®è³éãå¿
èŠã«ãªã£ãå Žåãç¹å®ã®æŽ»åãå³ããå¶éãããã倧å¹
ã«çž®å°ããããäžæ¢ãããããªããã°ãªããªããããããŸããããã¹ãŠæä¿¡ãšããŠããŸãã
åœç€Ÿã¯RNAiæè¡ãéçºããããã«å€é¡ã®è³éãæããåååè£ã®èšåºåè©Šéšããã³èšåºè©Šéšãããã³åã€ã®æ¿èªè£œåãšãã®ä»ã®åæ¥è²©å£²ãæ¿èªããã補åã®è£œé ã販売ã«å¿
èŠãªå€é¡ã®è³éãå¿
èŠã§ããåååè£ã®éçºã«æåããããã«å¿
èŠãªæéãŸãã¯æŽ»åç¯å²ãäºæ³ããã倧ããå Žåã補ååè£ãéçºããåååããããã«å®éã«å¿
èŠãªè³éãèŠç©ããããšãã§ããŸããã
åœç€Ÿã®çŸéãçŸéåçç©ãæµåæ§ã®ããæ ªåŒãšåµå蚌åžãããã³è£œåã®è²©å£²ããäºæ³ããã売äžé«ãããã³NovartisããLeqvioã®è²©å£²ã«é¢ããŠäºæ³ããããã€ã«ã¹ããŒã³ããã³ãã€ã€ã«ãã£ãå«ããçŸåšã®ã³ã©ãã¬ãŒã·ã§ã³ã®äžã§æåŸ
ããã売äžé«ã«ãã£ãŠãå°æ¥ã®è³æ¬èª¿éã®å¿
èŠæ§ãªãã«ãèªå·±æç¶å¯èœãªè²¡åãããã¡ã€ã«ãéæã§ãããšä¿¡ããŠããŸãããã ããå°æ¥ã®è³æ¬éèŠããã³çŸåšã®è³æºããªãã¬ãŒã·ã§ã³ããµããŒãããæéã¯ãçŸåšã®äºæž¬ãšç°ãªãå¯èœæ§ããããŸããå€ãã¯äºæž¬ãé£ãããŸãã¯ç§ãã¡ã®ã³ã³ãããŒã«ãè¶
ããèŠå ã«åºã¥ããŠãç§ãã¡ã¯äºæ³ãç«ãŠãŠããŸãããäºæ³ãšç°ãªãçµæã«ãªãå¯èœæ§ããããŸãã
⢠ç§ãã¡ã®ç 究éçºããã°ã©ã ã®é²å±ãåžå°çŸæ£ãšäžè¬çãªçŸæ£ã®äž¡æ¹ã®ããã°ã©ã ãããã³ãããã®ããã°ã©ã ãæšé²ããããã«èŠå¶åœå±ãå¿
èŠãšããããšã
⢠çŸåšããã³å°æ¥ã®å
±åéçºè
ããã®ãã€ã«ã¹ããŒã³ããã€ã€ã«ãã£ããã®ä»ã®æ¯æãã®ã¿ã€ãã³ã°ãåé éé¡ããŸãã¯ãã€ã«ã¹ããŒã³ããã³ãã€ã€ã«ãã£ã»æ¯æãïŒRocheããã®Zilebesiranã®éçºãšåååã«é¢ãããã®ãããã³Novartisããã®Leqvioã®åååã«é¢ãããã®ãå«ãïŒã«é¢ããæ
å ±ïŒ
⢠远å ã®ã³ã©ãã¬ãŒã·ã§ã³ãæ°ããããžãã¹ã€ãã·ã¢ãããç¶æããã³ç¢ºç«ããèœå
⢠æ°ããæè¡ãšéèèçµç¹ã«ãããé
ä¿¡ã®åãçµã¿ãæåãããèœåããæ¹åããã補åãããã¡ã€ã«ãçããå¯èœæ§ãããïŒ
⢠åœç€Ÿã®åèšåºç 究ãèšåºè©Šéšãæåè£ã«éå§ãå®äºãããèŠå¶åœå±ã®æ¿èªãååŸãã補ååè£ãã°ããŒãã«ã«åæ¥åããããã«å¿
èŠãªãªãœãŒã¹ãæéãã³ã¹ããããã³ç¬¬äžè
ã®ç¥ç財ç£ã®ã©ã€ã»ã³ã¹ãååŸããã³ç¶æããããã«å¿
èŠãªè²»çšã§ãã
⢠èªç€Ÿã®è£œé æœèšãè¿
éãã€è²»çšå¯Ÿå¹æãé«ãç¶æã»éå¶ããèœåã
⢠èšåºè©Šéšã®ããã®è£œååè£ããã³åçšè²©å£²çšè£œåã®è£œé ããŸãã¯ç¬¬äžè
ãšã®å¥çŽã«ãã補é èœåã
⢠å°æ¥ã®ãã³ãããã¯ãŸãã¯å
¬è¡è¡çäžã®ç·æ¥äºæ
ããŸãäžæ±ãšãŠã¯ã©ã€ãã«ãããç¶ç¶çãªçŽäºããåèšåºç 究ãèšåºè©Šéšã®éå§ãå®äºãããã³è£œåã補ååè£ã®äŸçµŠã«ã©ã®ãããªåœ±é¿ãäžãããã
⢠ç¹èš±è«æ±ã®æºåãæåºã審æ»ãç¶æã匷å¶ã«å¿
èŠãªãªãœãŒã¹ãæéãè²»çšïŒ
⢠ããžãã¹æŽ»åã®éçšã§çãã蚎èšãæ¿åºèª¿æ»ã«é¢é£ããè²»çšãšããã®ãããªæ³ççŽäºã調æ»ã«å蚎ãŸãã¯æºè¶³ã®ããçµæã«å°éããèœåïŒ
⢠åœç€Ÿã®æ¿èªããã補åããã³æœåšçãªè£œåãæ¿èªãããå Žåã®ã»ãŒã«ã¹ãã€ã«ã¹ããŒã³ããã³ãã€ã€ãªãã£ã®ã¿ã€ãã³ã°ãåé æ¥ãããã³éé¡ã
⢠èŠå¶å¯©æ»ããã»ã¹ã®çµæããã³ç§ãã¡ã®è£œåãAMVUTTRAãããã³ãã€ã€ã«ãã£ãåãåãæš©å©ãæã€è£œåãLeqvioã®åæ¥çæåã®çµæã
ãããã®èŠå ã«é¢ããç§ãã¡ã®èŠç©ãããäºæž¬ã財åã¬ã€ãã³ã¹ã誀ã£ãŠããå Žåãç§ãã¡ã¯åœç€Ÿã®éå¶èšç»ãå€æŽããå¿
èŠãããå¯èœæ§ããããä»åŸè¿œå ã®è³é調éãè¡ãå¿
èŠãããå ŽåããããŸããç§ãã¡ã¯ãååçãªåã決ããå
¬çãŸãã¯æ°éã®æ ªåŒå
¬éãåµå調éããã€ã€ãªãã£ãŸãã¯ãã®ä»ã®åçåååŒããŸãã¯ãããã®è³é調éæºã®1ã€ä»¥äžã®çµã¿åãããéããŠè¡ãããšãã§ããŸããè¿œå ã®è³é調éã¯ãæ¡ä»¶ãåããªãå Žåãå
šãå©çšã§ããªãå ŽåããããŸããå
šã»ã¯ã¿ãŒã®æä¿¡ã«æ³šæããŠããããŠãpeã䜿çšããŠãã ããã
ä»åŸè¡ãããå¿
èŠãããå Žåã®èè³æ¡ä»¶ã¯æ ªäž»ã®ä¿æãŸãã¯æš©å©ãæãªãå¯èœæ§ããããŸããè¿œå ã®è³é調éã«ããæ ªåŒã®çºè¡ã«ãããæ¢åæ ªäž»ã®åžéãçããå¯èœæ§ããããŸãããŸããè¿œå è³éæäŸã®æ¡ä»¶ãšããŠãå°æ¥ã®æè³å®¶ã¯æ¢åæ ªäž»ããåªå
çãªæš©å©ãèŠæ±ãããããèªããããå ŽåããããŸãã
è¿œå è³éãå¿
èŠã§ããå Žåãé©æã«ãã®ãããªè³éãååŸã§ããªãå Žåãåœç€Ÿã®ç 究éçºããã°ã©ã ã®1ã€ä»¥äžã倧å¹
ã«é
延ãŸãã¯åæžããå¿
èŠãããããããªãéçºãé
ãããããåæžããå¿
èŠãããå ŽåããããŸãã
ç§ãã¡ã®ã°ããŒãã«åçšã€ã³ãã©é¢é£ããã³é·æçãªæŠç¥ç®æšã®éæèœåãé
ãããäœäžããå¯èœæ§ããããŸãããŸããç¬èªã§è¿œæ±ããäºå®ã®æè¡ã補ååè£ã補åã®äžéšã®æš©å©ãæŸæ£ããããšãå¿
èŠã«ãªããå
±åç 究è
ããã®ä»ã®é¢ä¿è
ãšã®åã決ããéããŠè³éãå¿
èŠãšããããšããããŸãããã¹ãŠæä¿¡ã§è³éã調éããå¿
èŠãããå ŽåããããŸãã
ããã«ãã£ã¹ã«ããLeqvioã®ã°ããŒãã«ã»ãŒã«ã¹ããã®äžéšã®ãã€ã€ã«ãã£ã¹ããªãŒã ããã³åæ¥çãªãã€ã«ã¹ããŒã³ã売åŽããŸããããæ®ãã®å°æ¥ã®ãã€ã€ã«ãã£ããã³åæ¥çãªãã€ã«ã¹ããŒã³æ¯æãã®éšåãä¿æããæš©å©ãæããŠãããLeqvioã«é¢é£ããã©ããªè² ã®å±éãããããã®æ¯æããåãåãããšã«é倧ãªæªåœ±é¿ãäžããå¯èœæ§ããããŸãã
2020幎4æãç§ãã¡ã¯Novartisããã®é¢é£äŒç€ŸãŸãã¯ãµãã©ã€ã»ã³ã·ãŒãæ¯æããã€ã€ã«ãã£ã®ãã¡ãååã«çžåœããéšåãšãMDCOã©ã€ã»ã³ã¹å¥çŽã«åºã¥ãåæ¥çãªãã€ã«ã¹ããŒã³æ¯æãã®ãã¡ã75%ã«çžåœããéšåããThe Blackstone Group Inc.ã®é¢é£äŒç€Ÿã§ããBX Bodyguard Royalties L.P.ïŒä»¥äžããBlackstone RoyaltiesããšããïŒã«å£²åŽããŸãããããBlackstoneããLeqvioã®ã°ããŒãã«ã»ãŒã«ã¹ã«é¢ãããã€ã€ã«ãã£æ¯æãã2029幎12æ31æ¥ãŸã§ã«å°ãªããšã10åãã«åãåããªãå ŽåãBlackstone RoyaltiesãLeqvioã®ãã€ã€ãªãã£ã«å¯Ÿããæš©çã55%ã«åŒãäžãïŒç§ãã¡ã®æš©çã¯45%ã«æžå°ïŒã2023幎1æ1æ¥ããæå¹ã«ãªããŸãããã®ãããLeqvioã®ã»ãŒã«ã¹ã«æªåœ±é¿ãäžããèŠå ã¯ããã®æéå
ã«10åãã«ã®è¿æžåºæºãæºããèœåã«åœ±é¿ãäžããç§ãã¡ãä¿æããLeqvioãã€ã€ãªãã£ã¹ããªãŒã ã®å²åã«æªåœ±é¿ãäžããå¯èœæ§ããããŸãã BX Bodyguard Royalties L.PïŒThe Blackstone Group Inc.ã®é¢é£äŒç€ŸïŒã«å£²åŽããŸãã ãã©ãã¯ã¹ããŒã³ã»ã°ã«ãŒãã»ã€ã³ã³ãŒãã¬ãŒãããã®åäŒç€Ÿã§ããBX Bodyguard Royalties L.P.ããŸãã¯Blackstone Royaltiesã«ããLeqvioãïŒããã«ãã£ã¹ããã®é¢é£äŒç€ŸãŸãã¯ãµãã©ã€ã»ã³ã·ãŒã«ãããããã»ãŒã«ã¹ã«å¯Ÿããç§ãã¡ã®æ¯æãå¯èœãªãã€ã€ã«ãã£ã®50ïŒ
ããã³MDCOã©ã€ã»ã³ã¹å¥çŽã«åºã¥ãåæ¥çãªãã€ã«ã¹ããŒã³æ¯æãã®75ïŒ
ïŒã®ãã€ã€ãªãã£ã®50ïŒ
ã売åŽããŸããã ãLeqvioãã®ã°ããŒãã«ã»ãŒã«ã¹ã«é¢ãããã€ã€ã«ãã£æ¯æãã«å¯Ÿããç§ãã¡ã®æ¯æãå¯èœãªãã€ã€ã«ãã£ã®50ïŒ
ãšããMDCO License Agreementãã«åºã¥ãåæ¥çãªãã€ã«ã¹ããŒã³æ¯æãã®75ïŒ
Leqvio ãLeqvioãã®ã°ããŒãã«ã»ãŒã«ã¹ã«é¢ãããã€ã€ã«ãã£æ¯æãããå°ãªããšã10åãã«ã«çžåœãããã®ã§ãªãå Žå Leqvio 10åãã« 10åãã« 2029幎12æ31æ¥ãŸã§ã«ãLeqvioã®ã°ããŒãã«è²©å£²ã«é¢ãããã€ã€ã«ãã£æ¯æããå°ãªããšã10åãã«ã«éããªãå ŽåãBlackstone Royaltiesã®Leqvioãã€ã€ãªãã£ã«å¯Ÿããæš©çã¯2023幎1æ1æ¥ãã55ïŒ
ã«å¢å ããç§ãã¡ã®æš©çã¯åé¡æžå°ããŸãããã®ãããLeqvioã®è²©å£²ã«æªåœ±é¿ãäžããèŠå ã¯ããã®æéæ å
ã«10åãã«ã®è¿æžåºæºãæºããèœåã«åœ±é¿ãäžããç§ãã¡ãä¿æããLeqvioãã€ã€ãªãã£ã¹ããªãŒã ã®å²åã«æªåœ±é¿ãäžããå¯èœæ§ããããŸãã Leqvioã®ã»ãŒã«ã¹ã«äžå©ãªèŠå ã¯ãLeqvioãã€ã€ãªãã£ã¹ããªãŒã ã®ç§ãã¡ãä¿æããå²åã«æªåœ±é¿ãäžããå¯èœæ§ããããŸãã
Leqvioã®è²©å£²ã«æªåœ±é¿ãäžããå¯èœæ§ãããèŠå ã¯æ¬¡ã®ãšããã§ãïŒ
⢠競åä»ç€ŸããHeFHããã³ASCVDã®æ°ããæ²»çæ³ãŸãã¯ä»£æ¿è£œå€ãéçºããå¯èœæ§ããããŸãã
⢠Leqvioã®æ£è
ãå»çã³ãã¥ããã£ã第äžè
æ¯æãè
ããã®åãå
¥ãã®äžè¶³ïŒ
⢠Leqvioã«é¢ããã©ããªæªãé²å±ããå®å
šæ§ãæå¹æ§ãè«æ±åé¡ãªã©ïŒ
⢠ç¹èš±ãç¬å æš©ã«é¢ããçŽäºããŸãã¯ã©ã€ã»ã³ã¹ãååå¥çŽã®äžã§ã®çŽäºïŒ
⢠å€åœçºæ¿ååŒã¬ãŒãã®å€å;ããã³
⢠Leqvioã®è²©å£²ãå¶éãŸãã¯çŠæ¢ããéè¡æ§èŠå¶ãŸãã¯ç«æ³ã®çºå±ãLeqvioã®äœ¿çšã«é¢ããå¶éãããã³å®å
šã«é¢ããã©ãã«ã®å€æŽãããã«ã¯ãªã¹ã¯ç®¡çããã°ã©ã ã®åŒ·åãå«ãŸããŸãã
Leqvioã®å£²äžãäºæ³ããäœãå ŽåãçŸåšäºæ³ããŠããåæ¥ãã€ã«ã¹ããŒã³æ¯æãããã³/ãŸãã¯ãã€ã€ã«ãã£ãåãåããªããªãå¯èœæ§ããããåœç€Ÿã®ããžãã¹ãèŠéããéå¶æ瞟ã財åç¶æ³ãé倧ãã€äžå©ã«åœ±é¿ãåããå¯èœæ§ããããŸãã
åœç€Ÿã®è²¡åè«žè¡šãäºæž¬ã«é¢ããèŠç©ãããåææ¡ä»¶ãäžæ£ç¢ºã ã£ãå Žåãå®éã®çµæã¯äºæ³ãç©ç®ãšã¯ç°ãªãå¯èœæ§ããããŸãã
åœç€Ÿã®ç°¡æé£çµè²¡åè«žè¡šã¯ãç±³åœã«ãããäžè¬çã«åãå
¥ããããŠããäŒèšååïŒGAAPïŒã«åŸã£ãŠäœæãããŠããŸãããããã®ç°¡æé£çµè²¡åè«žè¡šã®äœæã«ã¯ãåœç€Ÿèªèº«ãæããè³ç£ãè² åµãåçãè²»çšãããã³åœç€Ÿãè«æ±ããæéã®éé¡ãããã³é¢é£ããæªæ±ºæžè³ç£ãšè² åµã«é¢ããé瀺ã®éé¡ã«åœ±é¿ãäžããèŠç©ãããšå€æãè¡ãããšãå¿
èŠã§ããåœç€Ÿã¯ããããã®èŠç©ããããéå»ã®çµéšãšæ§ã
ãªä»ã®ä»®å®ã«åºã¥ããŠè¡ã£ãŠãããåœç€Ÿããã®ç¶æ³äžã§åççã§ãããšä¿¡ãããã®ã§ããããããªãããåœç€Ÿã®èŠç©ããããŸãã¯ãããã«åºã¥ãä»®å®ãæ£ç¢ºã§ããããšãä¿èšŒããããšã¯ã§ããŸããã
ãã®ä»ãåœç€Ÿã¯ææãåœç€Ÿã®è£œå販売ãåæ¥ã»ãã€ã€ãªãã£åçãGAAPããã³éGAAPã®ç·åçãªç 究éçºè²»çšããã³è²©å£²ã»äžè¬ç®¡çè²»çšã«é¢ããäºæ³ã«åºã¥ã財åã¬ã€ãã³ã¹ãçºè¡šããŠããŸãããã®ã¬ã€ãã³ã¹ã¯ãåœç€Ÿã®çµå¶é£ã®å€æãšèŠç©ã«åºã¥ããŠããŸããäœããã®çç±ã§åœç€Ÿã®è£œå販売ãåçãããã³/ãŸãã¯è²»çšã財åã¬ã€ãã³ã¹ãšå€§ããç°ãªãå Žåãåœç€Ÿã¯å
¬è¡šãã財åã¬ã€ãã³ã¹ã調æŽããå¿
èŠããããŸããåœç€Ÿãå
¬è¡šãã財åã¬ã€ãã³ã¹ãŸãã¯åœç€Ÿã®äºæ¥ã«é¢ãããã®ä»ã®æåŸ
ã®ãããããæºãããªãå ŽåããŸãã¯å€æŽãŸãã¯æŽæ°ããå¿
èŠãããå Žåãåœç€Ÿã®æ ªäŸ¡ã¯äžèœããå¯èœæ§ããããŸãã
åœç€Ÿã®çŸéãçŸéåçç©åã³åžå Žã§å£²è²·å¯èœãªèšŒåžæè³ã¯æ倱ãåŒãèµ·ããããããã®æè³ã®æµåæ§ã«åœ±é¿ãäžããå¯èœæ§ããããŸãã
2024幎6æ30æ¥çŸåšãçŸéãçŸéåçç©åã³æµå蚌åžã§26.2åãã«ãä¿æããŠããŸããç§ãã¡ã¯ãããã®éé¡ãé«ççŽäŒæ¥ããŒããã³ããŒã·ã£ã«ããŒããŒãã¢ã¡ãªã«æ¿åºãçºè¡ãŸãã¯ã¹ãã³ãµãŒããç§ãã¡ã®è³æ¬ä¿åã«çŠç¹ãåãããæè³æ¹éã®åºæºãæºãã蚌åžãé é蚌æžããããŠæè³åºéã«æè³ããŠããŸããäŒæ¥ããŒãã«ã¯ç±³ãã«å»ºãŠã®å€åœåµåžãå«ãŸããŸãããããã®æè³ã¯äžè¬çãªä¿¡çšãæµåæ§ãåžå Žãéå©ãªã¹ã¯ã«åœ±é¿ãåããå¯èœæ§ããããŸãããããã®æè³ã®å
¬æ£äŸ¡å€ã«æ倱ãçºçããããå®å
šã«å€±ãããšãããã°ãåœç€Ÿã®è²¡åç¶æ³ã«åŠå®çãªåœ±é¿ãäžããå¯èœæ§ããããŸããããã«ãæè³ãæ¯æãããªããªã£ãããæã
ã«æ¯æãããå©æ¯é¡ãæžå°ããå Žåãåœç€Ÿã®å©æ¯åå
¥ã¯æžå°ããã§ããããæè³ããŒããã©ãªãªã«é¢é£ããåžå Žãªã¹ã¯ã¯ãåœç€Ÿã®æ¥çžŸãæµåæ§ã財åç¶æ³ã«è² ã®åœ±é¿ãäžããå¯èœæ§ããããŸãã
çºæ¿ã¬ãŒãã®å€åã¯ãåœç€Ÿã®æ¥çžŸã«é倧ãªæªåœ±é¿ãåãŒãå¯èœæ§ããããŸãã
ç§ãã¡ã®æµ·å€ããã®å£²äžé«ã¯ãç§ãã¡ãŸãã¯ç§ãã¡ã®å
±åéçºè
ã«ãã£ãŠåæ¥åããã補åããã®ç®¡èœåºåã§ã®ããŒã±ãã£ã³ã°æ¿èªãååŸããã«ã€ããŠå¢å ãããšäºæ³ãããŸããç§ãã¡ã®äž»èŠãªå€åœçºæ¿ãªã¹ã¯ã¯ãæ¥æ¬åããŠãŒããããã³è±åœãã³ãã®åãã«é¢ä¿ããŠããŸããç±³ãã«ãç¹å®ã®å€åœçºæ¿ã«å¯ŸããŠåŒ±ããªããšãåœæçŽå©çã«è¯ã圱é¿ãäžããããšãšãªãã売äžé«ãå¢å ããŸãããå
šäœçãªçµè²»ãå¢å ããŸããéã«ãç±³ãã«ãç¹å®ã®å€åœçºæ¿ã«å¯ŸããŠåŒ·åããããšãåœæçŽå©çã«æªåœ±é¿ãäžãã売äžé«ãæžå°ããå
šäœçãªçµè²»ãæžå°ããŸããå°æ¥ã®å€åœçºæ¿ã¬ãŒãã®å€åã«ã€ããŠã¯ãç§ãã¡ã®æ¥çžŸããã³è²¡åç¶æ³ã«åœ±é¿ãäžããå¯èœæ§ããããŸãã
çšæ³ã®å€æŽã¯ãããžãã¹ãèŠéããæ¥çžŸã財åç¶æ³ã«æªåœ±é¿ãäžããå¯èœæ§ããããŸãã
ç§ãã¡ã®ããžãã¹ã¯ãçšå¶æ¹é©ãçšæ³æ¹æ£ãæ°ããçšæ³ããŸãã¯æ¹èšãããçšæ³ã®è§£éãªã©ãå€æ°ã®åœéãé£éŠãå·ãããã³ãã®ä»ã®æ¿åºã®æ³åŸãèŠåãããã³èŠå¶ã®å¯Ÿè±¡ãšãªããŸãããããã®èŠå¶ã¯ãåç¬ã§ãããŸãã¯çµã¿åãããŠæå¹çšçãå¢å ãããå¯èœæ§ããããåœç€Ÿã®æ¥çžŸã«æªåœ±é¿ãåãŒãå¯èœæ§ããããŸããã¢ã¡ãªã«åè¡åœã§ã¯ãé£éŠãå·ãããã³å°æ¹æåŸçšã«é¢ããèŠåã¯ãç«æ³ããã»ã¹ã«é¢äžãã人ã
ãå
åœæ³å
¥åºããã³ã¢ã¡ãªã«åè¡åœè²¡åçã«ãã£ãŠåžžã«èŠçŽãããŠããŸããçšæ³ã®å€æŽïŒãããã®å€æŽã¯ãè¿œã£ãŠé©çšãããå¯èœæ§ããããŸãïŒããç§ãã¡ãç§ãã¡ã®æ®éæ ªåŒã®ä¿æè
ã«äžå©ãªåœ±é¿ãäžããå¯èœæ§ããããŸããéå»æ°å¹Žéã«å€ãã®çšå¶æ¹æ£ãè¡ãããä»åŸãæ¹æ£ãç¶ãå¯èœæ§ããããŸããçšæ³ã®å°æ¥çãªå€æŽããç§ãã¡ã®ããžãã¹ãèŠéããæ¥çžŸãããã³è²¡åç¶æ³ã«é倧ãªæªåœ±é¿ãäžããå¯èœæ§ããããŸãã
è¿å¹Žãçµæžååéçºæ©æ§ïŒOECDïŒã欧å·å§å¡äŒïŒECïŒãããã³ç§ãã¡ãšé¢ä¿ã®ããããžãã¹ãè¡ã£ãŠããåå¥ã®èª²çšç®¡èœåºåã¯ãå€åœç±äŒæ¥ã®èª²çšã«é¢é£ããåé¡ã«çŠç¹ãåœãŠãŠããŸããOECDã§ã¯ãããŒã¹ã»ãšããŒãžã§ã³ãšãããã£ããã»ã·ããã£ã³ã°ãé²ãããã®åœéçãªã«ãŒã«ã®åæ圢æã«åããå
æ¬çãªèšç»ãçºè¡šãããŠããŸããããã«ãOECDãECãããã³åã
ã®åœã
ã¯ãããžã¿ã«çµæžãèæ
®ããåœã
éã§ã®èª²çšæš©ã®é
åã«é¢ããå€æŽãæ€èšããŠããŸãããã®çµæãç§ãã¡ãã¢ãã£ãªãšã€ãäŒæ¥ãããžãã¹ãè¡ã£ãŠããç±³åœããã®ä»ã®åœã
ã®çšæ³ã¯å°æ¥çãŸãã¯æ¢åã®åºç€ãå€æŽããå¯èœæ§ãããããã®ãããªå€æŽã¯ç§ãã¡ã®ããžãã¹ãèŠéããéå¶çµæãããã³è²¡åç¶æ³ã«é倧ãªåœ±é¿ãäžããå¯èœæ§ããããŸãã
ç§ãã¡ã¯äºæ¥ã«é¢é£ããè¿œå ã®çšéè² æ
ãè² ãå¯èœæ§ããããŸãã
ç§ãã¡ã¯ãç±³åœããã³ç§ãã¡ãäºæ¥ãè¡ãå€åœã®ç®¡èœåºåã§æåŸçšã®å¯Ÿè±¡ãšãªã£ãŠããŸããç§ãã¡ã®äžççãªçšåµåã決å®ããã«ã¯å€§ããªå€æãèŠæ±ãããç§ãã¡ã®æå¹çšçã¯ã課çšç®¡èœåºåããšã®é¢é£åçããã³é©çšãããæ³å®çšçããå°åºãããŸããç§ãã¡ã¯ãæ³ã®é©çšã«é¢ããéèŠãªãããžã¡ã³ãã®å€æãå¿
èŠãšãããäžç¢ºå®ãªçšåããžã·ã§ã³ã®ããã®è² åµãèšé²ããŠããŸããåœå
ãŸãã¯å€åœã®èª²çšåœå±ã¯ãç§ãã¡ããã³ç§ãã¡ã®åäŒç€Ÿã®äºæ¥ã«é©çšãããçšæ³ã«å¯Ÿããç§ãã¡ã®è§£éãŸãã¯ç¹å®ã®çšååé¡ã«é¢ããç§ãã¡ã®åãç«å Žã«ç°è°ãå±ããå¯èœæ§ããããŸãããã®ãããç§ãã¡ã®è²¡åè«žè¡šã®æºåã«ããã£ãŠèŠç©ãã£ãèç©é¡ãè¶
ããçšåè©äŸ¡ãŸãã¯å€æããç§ãã¡ã®å ±åãããæå¹çšçãŸãã¯çŸéæµã«å¯ŸããŠé倧ãã€äžå©ãªåœ±é¿ãäžããå¯èœæ§ããããŸããããã«ãç§ãã¡ã®æå¹çšçã«æªåœ±é¿ãäžãããã®ä»ã®èŠå ããããŸããããã«ã¯ãåœã«ããåçæ§ã®ããã¯ã¹ã®å€åãæ ªåŒå ±é
¬ã®çšç圱é¿ïŒç§ãã¡ã®æ ªäŸ¡ã«äžå®ã®äŸåæ§ãããããããã£ãŠç§ãã¡ã®ã³ã³ãããŒã«ãè¶
ããŠããŸãïŒãçšæ³ãŸãã¯èŠå¶ã®å€æŽãªã©ãå«ãŸããŸããããšãã°ãOECDã®ã°ããŒãã«åæ¡æ£ã¢ãã«ã¯ãæäœçšã®å°å
¥ãå«ãç§ãã¡ãäºæ¥ãè¡ãåœã
ã®çšæ³ã«åœ±é¿ãäžããŠããŸããããããŸãã¯ãã®ä»ã®æ³åŸããã³èŠå¶ããããã¯ãããã®è§£éã®å€æŽã¯ãç§ãã¡ã®æå¹çšçãŸãã¯çŸéæµã«é倧ãã€äžå©ãªåœ±é¿ãäžããå¯èœæ§ããããŸãã
ä»åŸã®ãã³ãããã¯ãŸãã¯å
¬è¡è¡çäžã®ç·æ¥äºæ
ã¯ãç§ãã¡ã®ããžãã¹ãæ¥çžŸããã³è²¡åç¶æ³ã«çŽæ¥ãŸãã¯éæ¥çã«æªåœ±é¿ãäžããå¯èœæ§ããããŸãã
å°æ¥çã«ã¯ããã³ãããã¯ãå
¬è¡è¡çäžã®ç·æ¥äºæ
ããäºæ¥ãæ¥åã«åœ±é¿ãåããå¯èœæ§ããããããæ¿èªããã補åãåæ¥åããããšãã§ããªãå¯èœæ§ãããããšããåæ¥è²©å£²ã®æåŸ
ã«æ·»ããªãããšããããããããŸãããããã«ããã³ãããã¯ãå
¬è¡è¡çäžã®ç·æ¥äºæ
ã®åœ±é¿ã§ãæ£è
ãæ²»çãé
ãããããšã«ãªãã°ãæ¿èªããã補åã«å¯Ÿããæ£è
ã®éèŠãæžå°ããå¯èœæ§ããããŸãããã³ãããã¯ãå
¬è¡è¡çäžã®ç·æ¥äºæ
ã«ããæ¥åã®äžæã«ãããã¢ã¡ãªã«ããã³æµ·å€ã«ãããŠåœç€ŸãŸãã¯å
±åç 究è
ãåœç€Ÿã®æ¿èªè£œåãååã«è£œé ãã補ååè£ãååãªæ°éã§çç£ããããã«é Œããšãã第äžè
ããã¹ã¿ããäžè¶³ãåææããã®ä»ã®ãµãã©ã€ãã§ãŒã³äžè¶³ãçç£æžéãé
éã·ã¹ãã ã®æ··ä¹±ãªã©ã«åœ±é¿ãåããããšããããåœç€Ÿã®åæ¥åã®åãçµã¿ããã®ä»ã®ç 究éçºæŽ»åãããã³åœç€Ÿã®è£œååè£ã®åæ¥åã«æªåœ±é¿ãäžããå¯èœæ§ããããŸãã
ãŸããèšåºå掻åã®é©æãªå®äºãšèšç»ãããèšåºè©Šéšã®éå§ã«ã¯ãäŸãã°èšåºåããã³èšåºè©Šéšæœèšãç 究è
ã調æ»è
ãåéããã³ç»é²å¯èœãªæ£è
ãŸãã¯å¥åº·ãªãã©ã³ãã£ã¢è¢«éšè
ãªã©ã®å©çšå¯èœæ§ã«äŸåããããšããããã°ããŒãã«ãªå¥åº·åé¡ã®åœ±é¿ãåããå¯èœæ§ããããŸããã°ããŒãã«ã«ãããå¥åº·èŠå¶åœå±ãããã³ãããã¯ãå°æ¥ã®å
¬è¡è¡çäžã®ç·æ¥äºæ
ãªã©ãå¥åº·åé¡ã«ããäºæ¥ã«æ¯éããããå¯èœæ§ãããã審æ»ãæ»å¯ãæ¿èªã®ã¿ã€ã ã©ã€ã³ã«åœ±é¿ãäžããå¯èœæ§ããããŸãã
ãã³ãããã¯ãå
¬è¡è¡çäžã®ç·æ¥äºæ
ã®æçµçãªåœ±é¿ã¯äžç¢ºå®ã§ããããã®ãããªãã³ãããã¯ãå
¬è¡è¡çäžã®ç·æ¥äºæ
ã®ãã¬ãã£ããªåœ±é¿ã¯ä»ã®ãªã¹ã¯èŠå ãæªåãããå¯èœæ§ããããŸãã
ããã«ããã³ãããã¯ãå
¬è¡è¡çäžã®ç·æ¥äºæ
ããã©ã®çšåºŠç§ãã¡ã®æ¥åã財åããã©ãŒãã³ã¹ãæ ªäŸ¡ã«æªåœ±é¿ãåãŒããã¯ãäºæž¬äžèœã§é«åºŠã«äžç¢ºå®ãªå°æ¥ã®å±éã«ãããã®ã§ãã
第äžè
ãžã®äŸåã«é¢é£ãããªã¹ã¯
ãã§ã«æã£ãŠããå
±åç 究ãç¶æã§ããªãå ŽåããŸãã¯ããžãã¹ããã³ç§åŠçèœåããã³è£œååè£ã®éçºããã³åæ¥åã®è³éãæäŸã§ããä»ã®äŒæ¥ãšæ°ããå
±åç 究ãéå§ã§ããªãå Žåãåœç€Ÿã®ããžãã¹ãèŠéããæ¥çžŸã財åç¶æ
ã«åŠå®çãªåœ±é¿ãäžããå¯èœæ§ããããŸãã
ç§ãã¡ã¯ãæé·ããRNAiæ²»çè¬ã®ãã€ãã©ã€ã³ããçãããã¹ãŠã®æ©äŒãé²ããããã«ååãªèœåãèœåãæã£ãŠããªãããã第äžè
ã®å
±åäœæ¥è
ãšã®ååé¢ä¿ã«å
¥ã£ãŠãç¹å®ã®å°åã補ååè£ã®ããã«ãã®ãããªèœåãèœåãæäŸã§ãããšèããŠããŸãããããŠãå°æ¥çã«ã¯ããã«ãã®ãããªææºé¢ä¿ã«åå
¥ããäºå®ã§ããå
·äœçã«ã¯ãç§ãã¡ã¯çŸåšããã€ãã©ã€ã³ã®ããŸããŸãªè£œåãšè£œååè£ãæ±ã£ãŠããããã·ã¥ãã¬ãžã§ããã³ããµããã£ãããã«ãã£ã¹ãå«ãä»ç€Ÿãšã®æŽ»çºãªååé¢ä¿ãæã£ãŠããŸãã
ãã®ãããªååé¢ä¿ã§ã¯ãç§ãã¡ã¯çŸåšã®ããã³å°æ¥ã®ããŒãããŒã«ãèšåºéçºãèŠå¶é¢é£äºé
ãããã³/ãŸãã¯ããŒã±ãã£ã³ã°ã販売ãé
åžã«é¢ããå®çžŸãæäŸããŠãããããšãæåŸ
ããŠããŸããç§ãã¡ã®äžéšã®ååé¢ä¿ã®äžã§ã¯ãç¹å®ã®å°åãŸãã¯äžçèŠæš¡ã§ãããŒãããŒã«ç§ãã¡ã®è£œååè£ã®äžéšéçºã販売ãããã³/ãŸãã¯ããŒã±ãã£ã³ã°ãæåŸ
ãããããã®ããŒãããŒã®éçºã販売ãããŒã±ãã£ã³ã°ãããã³é
åžæŽ»åãå¶éãŸãã¯å¶åŸ¡ã§ããªãå¯èœæ§ãããããããã®ç¬¬äžè
ã®åªåã®æåã«ãã£ãŠå°æ¥çãªåçã¯å€§ããå·Šå³ãããå¯èœæ§ããããŸããäŸãã°ãç§ãã¡ã¯ïŒiïŒãã¹ãŠã®çŒçŸæ£ã察象ãšããããã°ã©ã ã®éçºããã³åååã«ã€ããŠïŒéãããäŸå€ãé€ãïŒãããã³æœåšçã«ä»ã®CNSããã³èèããã°ã©ã ã«ã€ããŠãå®å
šã«Regeneronã«äŸåããããšã«ãªããŸãã ïŒiiïŒLeqvioã®äžçèŠæš¡ã§ã®éçºããã³åååã«ã€ããŠã¯Novartisã«äŸåããïŒiiiïŒfitusiranã®äžçèŠæš¡ã§ã®éçºããã³åååã«ã€ããŠã¯Sanofiã«äŸåããïŒivïŒzilebesiranã®ç±³åœå€ã§ã®åååã«ã€ããŠã¯Rocheã«äŸåããããšã«ãªããŸãã ïŒiïŒ-ïŒivïŒã«èšåãããååæ¥å¥çŽã®å Žåãåœç€Ÿã¯é¢é£ãã補åã®è²©å£²ãããã€ã€ã«ãã£ãšãäžéšã®å Žåã¯åæ¥çãªãã€ã«ã¹ããŒã³ãã€ã¡ã³ããåããæš©å©ããããŸããããŒãããŒãéçºãåååã®åªåã§æåããªãå Žåããã®é¢é£è£œåãŸãã¯è£œååè£ããã®å°æ¥ã®åçã¯äžå©ã«åœ±é¿ãåããå¯èœæ§ããããŸããäŸãã°ã2020幎12æã«Novartisã¯ã第äžè
補é æœèšã§æªè§£æ±ºã®æ€æ»é¢é£ã®æ¡ä»¶ããããããPDUFAã¢ã¯ã·ã§ã³æ¥ãŸã§ã«NDAãæ¿èªã§ããªããšããFDAããã®CRLãåãåããŸãããLeqvioã¯ãæçµçã«2021幎12æã«FDAã«ãã£ãŠæ¿èªãããŸããããCRLã®è§£æ±ºã«ããæ¿èªãã€ã«ã¹ããŒã³ããã³æœåšçãªç±³åœã®ãã€ã€ã«ãã£ã®æ¯æããé
ããŸãããäžèšã®ããã«ãBlackstone Royaltiesãšã®å¥çŽã®äžã§ã2029幎æ«ãŸã§ã«Blackstone RoyaltiesãLeqvioã®å£²äžããåãåããã€ã€ã«ãã£ã«ãã£ãŠçæãããåçãäžå®æ°Žæºã«éããªãå ŽåãBlackstone Royaltiesã¯2030幎ããããé«ããã€ã€ã«ãã£çã«æš©å©ãæããããã«ãªãã2030幎以éãåœç€Ÿã®ãã€ã€ã«ãã£åçã«äžå©ãªåœ±é¿ãäžããå¯èœæ§ããããŸãã
ç§ãã¡ã¯ãæ°ãããã¯ãããžãŒãç¹ã«IKARIAãã©ãããã©ãŒã ãå«ãç§ãã¡ã®æè¡ã«ããæ¹åããã補åãããã¡ã€ã«ã蚌æããããšãã§ããèœåããããã¯ç¹å®ã®çµç¹ãŸãã¯çŸæ£é åã®äººéã«ãããæè¡ã®æŠå¿µå®èšŒã®æåãç¹å®ã®è£œååè£ã®å®å
šæ§ãšæå¹æ§ã蚌æããèœåãRNAiæ²»çè¬ã補é ãããŸãã¯ãµãŒãããŒãã£ãŒã«è£œé ããèœåãç§ãã¡ã®ç¥ç財ç£ããŒããã©ãªãªã®åŒ·ããããã³/ãŸãã¯ç§ãã¡ã®ç¥ç財ç£ããŒããã©ãªãªã«å¯Ÿãã課é¡ãŸãã¯æœåšç課é¡ãžã®æžå¿µãªã©ãããŸããŸãªèŠå ã«ãããå°æ¥ã®åæ¥ã«æå©ãªæ¡ä»¶ã§åå ããããšã«æåããªããããããŸããã ãããã®æ°ããååé¢ä¿ã確ä¿ã§ããå Žåã§ãã補ååè£ã®éçºãŸãã¯æ¿èªãé
ãããšããç¥ç財ç£ã®æå¹æ§ãŸãã¯ç¯å²ã«ã€ããŠçåãåãããå Žåããã€ã€ãŒããååãªå¥çŽéã確ä¿ã§ããªãå Žåãæ¿èªãããè¬å€ã®è²©å£²ãæåŸ
ããã»ã©é«ããªãå ŽåããŸãã¯å
±åéçºè
ãæŠç¥ççŠç¹ãå€æŽããå Žåããããã®é¢ä¿ãç¶æã§ããªãå ŽåããããŸãã
ããã«ãæ°ããååå¥çŽãç· çµããããšã®é
ãããã£ãå Žåãç¹å®ã®è£œååè£ã®éçºããã³åæ¥åã劚ãããé
ããããããå¯èœæ§ããããããæçµçã«åžå Žã«å°éããå Žåããã®ãããªè£œååè£ã®ç«¶äºåãäœäžãããå¯èœæ§ããããããã«ãã£ãŠããžãã¹ãèŠéããéå¶ææåã³è²¡åç¶æ
ã«åœ±é¿ãåãŒãå¯èœæ§ããããŸãã
ç¹å®ã®è£œååè£ã«ã€ããŠãRocheãRegeneronããµããã£ãNovartisãšã®ååé¢ä¿ã圢æããŠãæ°è¬ã®éçºããã³åååã®äžéšãŸãã¯å
šéšã®è²»çšãè³ãããã«ããã¹ãŠã®æä¿¡ãæäŸããŠããŸãããã ããäžéšã®ä»ã®ããã°ã©ã ã«ã€ããŠã¯ãããã«ååé¢ä¿ãç¯ãããšãã§ããªãå Žåãããã確ä¿ããååé¢ä¿å¥çŽã®æ¡ä»¶ãæå©ã§ãªãå ŽåããããŸããç§ãã¡ã®è£œååè£ã®1ã€ä»¥äžã«é¢ããŠå°æ¥çãªååé¢ä¿ãç¯ãããã®åªåãæåããªãå Žåããããã®è£œååè£ãŸãã¯ãã®ä»ã®è£œååè£ãå
éšçã«éçºããããã®ååãªè³éããã®ä»ã®ãªãœãŒã¹ãæãããåžå Žã«ç»å Žãããããšãã§ããŸããããã®ãããªç¶æ³ã§ã¯ããããã®è£œååè£ããåçãäžããããšã¯ã§ãããããã¯ç§ãã¡ã®ããžãã¹ãèŠéããæ¥çžŸãããã³è²¡åç¶æ³ã«é倧ãªæªåœ±é¿ãäžããŸãã
ããååè
ãæã
ãšã®å¥çŽãå®è³ªçã«ä¿®æ£ã解é€ããŸãã¯å±¥è¡ããªãã£ãå Žåãåœç€Ÿã®è£œååè£ã®éçºãšåååãé
ãããäžæ¢ãããå¯èœæ§ããããŸãã
ååè
ã«äŸåããŠèœåãšè³éãåŸãŠãããããååè
ãåŒç€Ÿãšã®ååå¥çŽãéèŠãªç¹ã§ä¿®æ£ãŸãã¯çµäºãããããã®å¥çŽã®çŸ©åãæãããªãã£ãå Žåãããžãã¹ãžã®åœ±é¿ãçããå¯èœæ§ããããŸããçŸåšãŸãã¯å°æ¥ã®ååå¥çŽãç§åŠçã»åæ¥çã«æåãããšã¯éããŸãããååè
ãšéçºããæè¡ã補åã®æææš©ã«é¢ããŠãå°æ¥çã«çŽäºãçºçããå¯èœæ§ããããŸãã
åœç€Ÿã®éçºå¯Ÿè±¡ã®è£œåã«åœ±é¿ãäžããå¯èœæ§ããããŸããçŸåšãåœç€Ÿã®ååé¢ä¿ã¯ãã©ã¡ããã®åœäºè
ãé倧ãªéåãè¡ã£ãå Žåã«è§£é€ããããšãã§ããŸããããã«ãç¹å®ã®ããã°ã©ã ãååå
šäœã«é¢ããŠãåœç€Ÿã®ååçžæã¯ãéœåã«ããçµäºããæš©å©ãæããå ŽåããããŸããããšãã°ãåœç€Ÿãšããã«ãã£ã¹ã®éã®inclisiranã®éçºããã³åæ¥åã«é¢ããå¥çŽã¯ãããã«ãã£ã¹ã4ã¶æåã«æžé¢ã§éç¥ããããšã«ããããã€ã§ã解é€ããããšãã§ããŸãããã ããããã«ãã£ã¹ãéœåã«ããå¥çŽã解é€ããå Žåãããã«ãã£ã¹ã¯ãå¥çŽã®éçšã§éçºãããäžå®ã®æè¡ã«åºã¥ããŠåœç€Ÿã«ç¹å®ã®ã©ã€ã»ã³ã¹ãäžããå¿
èŠããããåœäºè
éã§åè°ããããã€ã€ã«ãã£ã«åŸãå¿
èŠããããŸããããã«ãããã«ãã£ã¹ã«ããMDCOã©ã€ã»ã³ã¹å¥çŽã«é¢ããä»»æã®äžå©ãªè¡åãMDCOã©ã€ã»ã³ã¹å¥çŽã«é¢ããçŽäºã¯ãåœç€ŸãBlackstone Royaltiesãšã®å¥çŽã®çŸ©åãå±¥è¡ããèœåã«æªåœ±é¿ãäžããå¯èœæ§ããããŸããåæ¥åã®ååé¢ä¿ãéåããå Žåãåœç€Ÿã¯æ°ããååè
ãåŒãä»ããå¿
èŠããããŸãããã®å Žåãããäžå©ãªæ¡ä»¶ã§ååããããšã«ãªãå¯èœæ§ããããããåœç€Ÿã¯å
éšçã«è²©å£²ãé
åžãããã³ããŒã±ãã£ã³ã°èœåãæ¡å€§ããå¿
èŠããããå€å€§ãªè²¡åããã³ç®¡çãªãœãŒã¹ãæè³ããå¿
èŠããããŸãã
ããã«ããã¯ãããžãŒãŸãã¯ãã®ä»ã®æææš©ã«é¢ããŠå
±åç 究è
ãšçŽäºãçããå Žåããããã¯å
±åç 究è
ãéåãŸãã¯ãã®ä»ã®äºç±ã«ããå
±åç 究ãçµäºããããå圱é¿è£œåãŸãã¯åè£è£œåã®ç 究ãéçºãããã³/ãŸãã¯åååãè¿œæ±ããªãããšãããå Žåãåè£è£œåã®éçºãé
ãããè¿œå ã®äŒæ¥ãªãœãŒã¹ãæå
¥ããŠåè£è£œåãéçºããå¿
èŠãããå¯èœæ§ããããããè¿
éãªã¿ã€ã ã©ã€ã³ã§æ¡å€§ããã販売ããã³ããŒã±ãã£ã³ã°èœåãéçºããããã®æéãšãªãœãŒã¹ãè²»ããå¿
èŠããããæ°ããå
±åç 究è
ãåŒãä»ããããšãããå°é£ã«ãªãå¯èœæ§ããããããžãã¹ããã³è²¡åã³ãã¥ããã£ããã©ã®ããã«èªèããããã«æªåœ±é¿ãåãŒãå¯èœæ§ããããŸãã
ãŸããå
±åç 究è
ããããã¯å
±åç 究è
ã®æ¯é
æš©ãå€æŽãããå Žåããå
±åç 究å¥çŽã第äžè
ã«è²æž¡ãããå ŽåãMDCOãšNovartisã®å Žåãšåæ§ã«ãåŸç¶äŒç€ŸãŸãã¯è²å人ãèªèº«ã®å©çã«ãã£ãå€æãè¡ãå¯èœæ§ãããã
⢠ç§ãã¡ãšååããŠãã補åãšç«¶åããå¯èœæ§ã®ãã代æ¿æè¡ãŸãã¯ä»£æ¿è£œåããç¬èªã§éçºãããããŸãã¯ä»ç€Ÿãšå
±åéçºããããšããããŸããããã¯ã圌ããç§ãã¡ãšã®ååé¢ä¿ã«åœ±é¿ãäžããå¯èœæ§ããããŸãã
⢠åªå
床ã®é«ãããã°ã©ã ãè¿œæ±ããããéçºããã°ã©ã ã®çŠç¹ãå€æŽããããšããããããã¯å
±åäœæ¥è
ã®ç§ãã¡ã«å¯Ÿããã³ãããã¡ã³ãã«åœ±é¿ãäžããå¯èœæ§ããããŸãã
⢠ããããŒã±ãã£ã³ã°æš©å©ãããå Žåã¯ãæ¿èªããã補ååè£ã«å¯ŸããŠãæã
以å€ã®éçºããã補ååè£ãããå°ãªããªãœãŒã¹ãããŒã±ãã£ã³ã°ã«å²ãåœãŠãããšãéžæããŠãã ããã
ãããããã®ãããããèµ·ãã£ãå ŽåãåŒç€Ÿãéçºããã³åååãç¬èªã§ç¶ããããã«ååãªè²¡æ¿çãªãœãŒã¹ãŸãã¯èœåãæããŠããªãå¯èœæ§ãããããã1ã€ä»¥äžã®è£œåãŸãã¯è£œååè£ã®éçºããã³åæ¥åãé
ããåæžãŸãã¯äžæ¢ãããå¯èœæ§ããããŸãã
補é æ¥ã®èœåãšè³æºã®æ¡å€§ã補é ã®å°éç¥èã®éçºã«äŒŽããçžåœãªè²»çšãããããšäºæ³ããŠããŸãããã®äžæ¹ã§ãåœç€Ÿã®è£œåã®è£œé ã«ã€ããŠã¯ç¬¬äžè
ã«äŸåããŠãããä»åŸãäŸåãç¶ããäºå®ã§ãããã®ãããªç¬¬äžè
äŸçµŠè
ã®åªå€±ãŸãã¯ä»åŸã®åé¡ãååãªäŸçµŠãæäŸã§ããªãå Žåãåœç€Ÿã®ããžãã¹ã«æªåœ±é¿ãäžããå¯èœæ§ããããŸãã
æã
ã¯è£œé æ¥èœåã®æ¡å€§ãé²ããŠãããæ¿èªããã補åãåååãç¶ããçŸåšã®åè£è£œåãéçºãç¶ããèŠå¶åœå±ã®æ¿èªãç³è«ããæ¿èªãããã°å°æ¥ã®è£œåãåååããããã«ãèªç€Ÿå
補é èœåã®éçºãç¶ããå¿
èŠããããŸããèªç€Ÿå
補é èœåã¯ããã€ãŠã¯ vitro è©Šéšã vivo è©Šéšã§äœ¿çšããããã®ç©è³ªã®å°èŠæš¡çç£ã«éããããã®ãããªç©è³ªã¯çŸåšã®è¯å¥œè£œé èŠç¯ïŒcGMPïŒã«åºã¥ããŠè£œé ããå¿
èŠã¯ãããŸããã§ããããããã2012 幎ã«ã¯ãé
æèšåºè©Šéšã§äœ¿çšãããããã·ã©ã³ã®è£œé ã«ããã cGMP èœåãšããã»ã¹ãéçºããŸããããŸãã2020 幎ã«ãããµãã¥ãŒã»ããå·ããŒãã³ã« cGMP 補é æœèšã建èšããæ©æèšåºéçºçšã®è¬ç©ç©è³ªã補é ããå°æ¥çã«ã¯é
æèšåºéçºããã³åæ¥çšã®è¬ç©ç©è³ªã補é ããå¯èœæ§ãæã£ãŠããŸãã
çŸåšã®ãšãããç§ãã¡ã¯èšåºè©Šéšçšå»è¬åç©è³ªã®éãããéã®è£œé ã«ãã察å¿ã§ããããã®ä»ã®å»è¬åç©è³ªã«ã€ããŠã¯ã第äžè
ã®CMOã«é Œã£ãŠãèšåºããã³åæ¥çšãã©ãã°è£œåã®ãã¹ãŠã®èŠä»¶ã«ã€ããŠãã第äžè
ã®CMOã«é Œã£ãŠããŸããç§ãã¡ã®siRNAæ²»ç補åã補é ãããšãã¹ããŒããéãããŠãããçŸåšãç§ãã¡ã¯åç±³ããšãŒããããã¢ãžã¢ã®éãããæ°ã®CMOã«é Œã£ãŠããŸããå»è¬å補é ã«ã¯ãªã¹ã¯ã䌎ããç§ãã¡ã®CMOãé
éæéèŠä»¶ãæºãããããç§ãã¡ã®ããŒãºã«å¿ããé©åãªéã®ç©è³ªãæäŸããèœåã«åœ±é¿ãåãŒãå¯èœæ§ããããŸããCMOããããã®ããšãéæã§ããªãå Žåãç§ãã¡ã®èšåºè©Šéšãé
延ããåæ¥çãªäŸçµŠãå±éºã«ããããããŸããç§ãã¡ã«è¿œå è²»çšããããå¯èœæ§ããããŸããå°æ¥çãªèŠä»¶ãæºããããã«ãç§ãã¡ã¯ããããä»ã®CMOãšå¥çŽããå¿
èŠããããŸããããã®ãããªä»£æ¿ãµãã©ã€ã€ãŒã¯éãããŠããå Žåãããã容æã«å©çšã§ããªãå ŽåããããŸãããŸããåççãªæ¡ä»¶ã§ã¿ã€ã ãªãŒã«å¥çŽãç· çµããããšãã§ããªãå¯èœæ§ããããŸãã
人工åæsiRNAã®è£œé ã«å ããŠãåœç€Ÿã¯ãLNPsãã³ã³ãžã¥ã²ãŒãããã®ä»ã®å»è¬åããªããªãŒæè¡ãªã©ãé©åãªçŽ°èãçµç¹ã¿ã€ãã«siRNAãé
ä¿¡ããããã«å¿
èŠãªæè¡ã«é¢é£ããè¿œå ã®è£œé èŠä»¶ãæã€å ŽåããããŸããããããé
ä¿¡æè¡ãå©çšããå Žåãæã«ã¯é«åºŠã«ç¹æ®åãŸãã¯ç¬èªã®ç©ã§ãããæè¡çããã³/ãŸãã¯æ³çãªçç±ã«ããããã®ãããªé
ä¿¡æè¡ã®æœåšçãªè£œé æ¥è
ã1瀟ãŸãã¯éå®ãããæ°ããååšããªãå ŽåããããŸããããã«ãç§ãã¡ã®é
ä¿¡æè¡ã®æ¡å€§ã«ã¯éåžžã«å°é£ãã€æéããããå ŽåããããŸããç§ãã¡ã¯ãŸããããããæ¡å€§ããã³è£œé ã«éå®ããã第äžè
æ¥è
ã«äŸåãããããããããã¿ã€ã ãªãŒãªæ¹æ³ã§ããŸãã¯å
šãæäŸã§ããªãå ŽåããããŸãã補é æ¥è
ãåœç€Ÿã®é
ä¿¡æè¡ãé©åã«è£œé ãããŸãã¯é
ä¿¡çšã«åœç€Ÿã®siRNAã調æŽã§ããªãå Žåã䜿çšã§ããªã補åãäŸçµŠã®é
ãããã³å»è¬åäžè¶³ã®åå ãšãªãå¯èœæ§ããããŸããããã«ã補é æ¥è
ã®ä»ç€Ÿããã®äŸçµŠç«¶äºã圌ãã®å¥çŽçŸ©åéåããŸãã¯è£œé æ¥è
ãšã®è«äºã¯ãåœç€Ÿã®çºèŠããã³éçºæŽ»åã«é
延ããããããåœç€Ÿã«è²»çšã®å¢å ãããããå¯èœæ§ããããŸãã
èªç€Ÿè£œé æœèšã®å»ºèšã«ãã補é èœåã®éçºã«ãããŠãçžåœãªæ¯åºãè² æ
ããŠãããä»åŸãéèŠãªè¿œå åºè²»ãèŠèŸŒãŸããŸãããŸããåœç€Ÿæœèšãã¹ã¿ãããããããé©æ ŒãªåŸæ¥å¡ãæ¡çšã»éçšããèšç·Žããå¿
èŠããããŸããææã®ååãªæ°éã補é ã§ããªãå Žåããå°æ¥æœèšã§åé¡ãçºçããå Žåã¯ã代æ¿äŸçµŠæ¥è
ã確ä¿ããå¿
èŠãããããã®ä»£æ¿äŸçµŠæ¥è
ãå©çšã§ãããåççãªæ¡ä»¶ã§ããã³é©æã«å¥çŽãç· çµããããšãã§ããªãå¯èœæ§ããããŸããéå®ãããæ°ã®CMOããåæ¥è£œåããã³èšåºåè£ã®è£çµŠãåããäŸå床ãé«ããåœç€ŸæœèšãåŒãç¶ãå©çšããããšãèæ
®ãããšã補å補é ã«ãããŠé
延ãé害ãçºçããå Žåãèšåºããã³åæ¥è£çµŠã«æ¯éãåŒãèµ·ãããåœç€Ÿã®ããžãã¹ãèŠéããæ¥çžŸã財åç¶æ³ã«é倧ãªåœ±é¿ãåãŒãå¯èœæ§ããããŸããããã«ãåœç€ŸãŸãã¯åœç€Ÿã®å
±åéçºè
ã補ååè£ãäŸçµŠããããã«CMOã«äŸåããå ŽåãäŸçµŠã®é
延ãæ··ä¹±ãç 究éçºæŽ»åããã³åœç€ŸãŸãã¯åœç€Ÿã®å
±åéçºè
ã®è£œååè£ã®æœåšçåæ¥åã«é倧ãªæªåœ±é¿ãäžããå¯èœæ§ããããŸãã
ç§ãã¡ã®è£œåããã³éçºããããã®ä»ã®ãããªã補ååè£ã®è£œé ããã»ã¹ã¯FDAããã³å€åœã®èŠå¶åœå±ã®æ¿èªããã»ã¹ã®å¯Ÿè±¡ãšãªããç¶ç¶çã«ãã¹ãŠã®é©çšå¯èœãªFDAããã³å€åœã®èŠå¶åœå±ã®èŠä»¶ãæºããããã®ãããªèŠä»¶ãæºããããšãã§ããCMOãšå¥çŽããå¿
èŠããããŸããã©ã®CMOãå¿
èŠãªèŠå¶åœå±ã®èŠä»¶ãæºãããªãå ŽåãèŠå¶ç³è«ã®é
延ããŸãã¯ç§ãã¡ãŸãã¯çŸåšãŸãã¯å°æ¥ã®ææºå
ã®ããããã®è£œååè£ã®èŠå¶æ¿èªã®é
延ãçºçããå¯èœæ§ããããŸããããšãã°ã2022幎4æã«ã¯ããµãŒãããŒãã£ãŒã®äºæ¬¡å
è£
ããã³ã©ããªã³ã°æœèšã§ä¿çäžã®æ€æ»åé¡ã«å¯ŸåŠããããã«ãvutrisiranã®NDAæåºæžã®æ¹èšã«ããFDAã¯å¯©æ»æéã延é·ããŸããã ãŸãã補ååè£ã«å¿
èŠãªèŠå¶åœå±ã®æ¿èªãåããå Žåãåæ¥çãªå
±åç 究è
ãå«ãã第äžè
ã«é Œãããšãäºæ³ããŠããŸããåæ¥äŸçµŠã«å¿
èŠãªææã®çç£ãè¡ãããã«ã ç§ãã¡ã®vutrisiran NDAæåºæžã®æ¹èšã«ããããµãŒãããŒãã£ãŒã®äºæ¬¡å
è£
ããã³ã©ããªã³ã°æœèšã«ãããä¿çäžã®æ€æ»åé¡ã«å¯ŸåŠãããããFDAã審æ»æéã延é·ããã ããã«ã補åã®åæ¥çäŸçµŠã«å¿
èŠãªææãçç£ããããã«ãåæ¥çå
±åç 究è
ãå«ãã第äžè
ã«é Œãå¿
èŠããããŸãã
ãŸãã2024幎1æã«ç±³äžé¢ã¯BIOSECUREæ³æ¡ïŒH.R. 7085ïŒãæåºãã5æ15æ¥ã«ä¿®æ£ãããããã®åŸãäžé¢ã¯æ¬è³ªçã«åãæ³æ¡ïŒS.3558ïŒãæåºããäž¡æ¹ãšããæžå¿µããããã€ãªãã¯ãããžãŒäŒæ¥ãã®ãã€ãªãã¯ãããžãŒæ©åšããµãŒãã¹ãå¥çŽã®å±¥è¡ã«äœ¿çšãããå Žåãç±³é£éŠè¡æ¿æ©é¢ããã®äŒæ¥ãšå¥çŽããããšãçŠæ¢ãããã®ã ãäžè¬çã«ããæžå¿µããããã€ãªãã¯ãããžãŒäŒæ¥ããšã¯ãç±³åœã®åœå®¶å®å
šä¿éã«ãªã¹ã¯ãããããå€åœã®æµå¯Ÿæ¿åºã®ç®¡èœãææ®ãæ¯é
ããŸãã¯ãã®ããã«éå¶ãããã€ãªãã¯ãããžãŒäŒæ¥ãæãããããã®æ³æ¡ãŸãã¯èŠå®ãæ³åŸã«ãªãããã®æçµçãªæèšãé²è·¯ãããã³ã¿ã€ãã³ã°ã¯äžç¢ºå®ã§ããããããããããã®æ³æ¡ãæ³åŸã«ãªãã°ããããã¯åæ§ã®æ³åŸãå¶å®ãããã°ãäžåœã®ç¹å®ã®ãæžå¿µããããã€ãªãã¯ãããžãŒäŒæ¥ããããµãŒãã¹ã補åã賌å
¥ããããååãããããèœåãé倧ã«å¶éãããå¯èœæ§ãããããã ããç±³æ¿åºããå¥çŽãåããããè£åãåãããããããšãã§ããªããªãããšãªãããã®ä»ã®äžåœäŒæ¥ãšããžãã¹ãè¡ã£ãŠãããããäžèšã®æ³åŸãå¥çŽã®çžæå
ã«åœ±é¿ãäžããå¯èœæ§ãããã代æ¿æ¡ãå¿
èŠã«ãªãå¯èœæ§ãããã
ãããã®ãµãŒãããŒãã£ãŒã®äŸçµŠè
ããããã¯éèšåºè©Šéšããã³èšåºè©ŠéšãŸãã¯åæ¥çãªäŸçµŠã®ããã«åååè£ãŸãã¯è£œåã補é ããããã«æã
ãéçšãããµãŒãããŒãã£ãŒãäœããã®çç±ã§ãããè¡ããªããªã£ãå Žåãç§ãã¡ã¯è£å
ã®ãµãã©ã€ã€ãŒã補é æ¥è
ãç¹å®ããèªèšŒããªããã°ãªããããã®ãã補åã®éèšåºè©Šéšããã³èšåºè©Šéšã®é²æç¶æ³ãé
ããå¯èœæ§ããããåæ¥çãªäŸçµŠã®äžæãçµéšããããšããããããããŸããããŸããé©æ Œãªä»£æ¿åã®ä»å
¥ããã§ããããã®ããæãŸããæ¡ä»¶ã§è£å
ãã§ããªãããŸãã¯å
šãäŸçµŠãåããããšãã§ããªããããããŸãããæã
ã補ååè£ãŸãã¯è£œåãäŸçµŠããããã®ååãªäŸçµŠéã確ä¿ã§ããªãå Žåãåœç€Ÿã®ããžãã¹ãå°æ¥ã®èŠéããæ¥çžŸããŸãã¯è²¡æ¿ç¶æ³ã«é倧ãªåœ±é¿ãåãŒãå¯èœæ§ããããŸãã
ä»åŸã第äžè
ãšã®è£œé å¥çŽãçŸåããå ŽåãŸãã¯å°æ¥ã®å¥çŽãç· çµããå Žåãåœè©²ç¬¬äžè
ãå¥çŽäžããã³èŠå¶äžã®èŠä»¶ãå質管çããã³å質ä¿èšŒãå«ãã矩åãé©æäžã€é©åã«å±¥è¡ããããšãå¿
èŠã§ãããåŒç€Ÿã¯åœè©²ç¬¬äžè
ã«äŸåããããšã«ãªããä»åŸãäŸåãç¶ããããšãšãªããŸããCROãå¥çŽéãã®çŸ©åå±¥è¡ãããªãã£ãå Žåããããã¯åŒç€Ÿã補ååè£ã®ãã¹ãŠãŸãã¯äžéšãèªç€Ÿè£œé ããå Žåã補é äžã®èŠä»¶ã«å¯Ÿããå±¥è¡äžå
šããã£ãå ŽåãåŒç€Ÿã®ããžãã¹ã«å€ãã®åé¡ãããããå¯èœæ§ããããŸããäžèšãå«ãäžå©ãªåœ±é¿ãçããæãããããŸãïŒ
⢠åœç€ŸãŸãã¯çŸåšããã³å°æ¥ã®ååè
ããéçºäžã®è£œååè£ã®èšåºè©Šéšãéå§ãŸãã¯ç¶ç¶ã§ããªãå¯èœæ§ããããŸãã
⢠åœç€ŸãŸãã¯åœç€Ÿã®çŸåšã®ãŸãã¯å°æ¥ã®ææºå
ãã補ååè£ã®èŠå¶ç³è«ã®æåºãèŠå¶åœå±ããã®æ¿èªã®åé ã«é
ããå¯èœæ§ããããŸãã
⢠ç§ãã¡ã¯ååè
ãã¡ãšã®ååé¢ä¿ã倱ãå¯èœæ§ããããŸãã
⢠åœç€Ÿã®æœèšããã³åèšè£œé æ¥è
ïŒCMOïŒã®æœèšãããã³åœç€Ÿã®è£œåã¯ãèŠå¶åœå±ã«ããæ€æ»ã®å¯Ÿè±¡ãšãªãå¯èœæ§ãããããã®çµæãäŸçµŠã®é
ããçããå¯èœæ§ããããŸãã
⢠å
šã»ã¯ã¿ãŒã®è£œåã®é
åžãåãæ¢ããããååããããã«è¡åããããèšåºè©ŠéšçŸå Žããèšåºè©Šéšææãååããå¿
èŠãããå¯èœæ§ããããŸãã
⢠æçµçã«ã¯ã補ååè£ããã³è£œåã®èšåºçããã³åæ¥çãªèŠæ±ãæºããããšãã§ããªããããããŸããã
ç§ãã¡ã¯èšåºè©Šéšãè¡ãããã«ç¬¬äžè
ã«é Œã£ãŠããŸããããã®ãããªç¬¬äžè
ã矩åãæãããªãå Žåãç§ãã¡ã®éçºèšç»ã«äžå©ãªåœ±é¿ãäžããå¯èœæ§ããããŸãã
ç§ãã¡ã¯ç¬ç«ããèšåºèª¿æ»è
ãCROããã®ä»ã®ç¬¬äžè
ãµãŒãã¹ãããã€ããŒã«é Œã£ãŠãèšåºè©Šéšãå®æœããäžã§ã®ç®¡çãç£èŠããã®ä»ã®æ¯æŽãè¡ã£ãŠããã£ãŠããŸããç¹å®ã®ãµãŒãã¹ãæäŸããããã«ããµã€ãéžå®ãç»é²ãç£èŠãç£æ»ãããŒã¿ç®¡çãªã©ã®ãµãŒãã¹ãå®æœããããã«ãç¹å®ã®ç¬¬äžè
ãšå¥çŽããŠãããä»åŸãå¥çŽããäºå®ã§ãããããã®èª¿æ»è
ãCROã¯ç§ãã¡ã®åŸæ¥å¡ã§ã¯ãªãã圌ããç§ãã¡ã®ããã°ã©ã ã«åããæéãšãªãœãŒã¹ã«ã¯éãããããŸãããããã®ç¬¬äžè
ãä»ã®ç«¶åäŒæ¥ãªã©ãšå¥çŽé¢ä¿ãæã£ãŠããå Žåãããããããç§ãã¡ã®ããã°ã©ã ããæéããªãœãŒã¹ãåŒãé¢ãããšããããŸãããããã®ããŒãããŒã«å€§ããäŸåããäžæ¹ãç§ãã¡ã¯åœŒãã®æŽ»åã®äžéšã«ããå¶åŸ¡ãæã£ãŠããããèŠå¶ããã³ãã®ä»ã®æ³çèŠä»¶ãå
éšæ¹éã»æç¶ãã«æºæ ããŠåœŒãã®å¥çŽçŸ©åã®å
šãŠãååã«å®è¡ããããšãä¿èšŒã§ããŸãããããã«ãããããããç§ãã¡ã¯åã¹ã¿ãã£ãé©çšå¯èœãªãããã³ã«ãæ³çãèŠå¶ããã³ç§åŠçåºæºã«åã£ãŠå®æœãããããšãä¿èšŒãã責任ãæã£ãŠããã第äžè
ã«é Œãããšã¯ç§ãã¡ã®èŠå¶äžã®è²¬ä»»ãå
é€ãããã®ã§ã¯ãããŸãããç§ãã¡ãšç§ãã¡ã®CROã¯ãéçºäžã®è£œååè£ã«å¯ŸããŠFDAãåæ§ã®å€åœã®èŠå¶åœå±ã匷å¶ããèŠå¶ããã³æéã§ããè¯ãèšåºå®è·µããŸãã¯GCPã®èŠä»¶ã«åŸãå¿
èŠããããéé©åããã£ãå Žåã«ã¯é©æã®æ¯æ£æªçœ®ãå®æœããªããã°ãªããŸãããèŠå¶åœå±ã¯ãããŒã±ãã£ã³ã°ç³è«ã®å¯©æ»ãšé¢é£ããŠãè©Šéšã¹ãã³ãµãŒã䞻任調æ»å¡ãè©Šéšãµã€ããå®æçã«æ€æ»ããããšã«ããããããã®GCPèŠä»¶ã匷å¶ããŸããç§ãã¡ãŸãã¯ç§ãã¡ã®CROã®ãããããé©çšå¯èœãªGCPã®èŠä»¶ã«éåãããããã®ãããªæ¯æ£æªçœ®ãåããªãå Žåãèšåºè©Šéšã§çæãããèšåºããŒã¿ã¯ä¿¡é Œæ§ããªããšãããFDAãEMAãPMDAããŸãã¯ä»ã®å€åœã®èŠå¶åœå±ã¯ãç§ãã¡ã®ããŒã±ãã£ã³ã°ç³è«ãæ¿èªããåã«ãè¿œå ã®æªçœ®ãèšåºè©Šéšãå®æœããããšãæ±ããå¯èœæ§ããããŸããå°æ¥çã«èŠå¶åœå±ã«ããæ€æ»ãè¡ãããå Žåããã®èŠå¶åœå±ãç§ãã¡ã®ããããã®èšåºè©ŠéšãGCPã®èŠå¶ã«æºæ ããŠãããšå€æãããã©ãããä¿èšŒããããšã¯ã§ããŸããã
ããããããããã®ç¬¬äžè
ãµãŒãã¹æäŸè
ãäœããã®çç±ã§ååãã€è¿
éã«çŸ©åãæãããªãã£ãå ŽåããŸãã¯ãã®ãããªç¬¬äžè
ãµãŒãã¹æäŸè
ãããããã®ãããã³ã«ãèŠå¶èŠä»¶ã«åŸãããèšåºè©ŠéšããŒã¿ã®å質ãæ£ç¢ºããæãªãããå ŽåããŸãã¯ãã®ãããªç¬¬äžè
ãµãŒãã¹æäŸè
ãææ¥ã«éã«åããªãã£ãå Žåãããããã®éçºèšç»ãŸãã¯ããŒã±ãã£ã³ã°æ¿èªã®èŠå¶å¯©æ»ãé
ããäžæ¢ãããå¯èœæ§ããããŸãããã®çµæãããããã®ããžãã¹ãèŠéããæ¥çžŸã財åç¶æ³ãæãªãããæ ªäŸ¡ã«ãè² ã®åœ±é¿ãäžããå¯èœæ§ããããŸãã
INDç³è«ããã®ä»ç®¡èœäžã®é¡äŒŒç³è«ã®ãµããŒããšããŠãç§ãã¡ã®è£œååè£ã®å®å
šæ§ãšæå¹æ§ã人éã§ç€ºãèšåºè©Šéšãå®æœããåã«ãåç©å®éšãå«ãåèšåºè©Šéšãå®äºããå¿
èŠããããŸãããŸããåèšåºè©Šéšã®äžéšã«å¿
èŠãªææãå
¥æããããã«ç¬¬äžè
ãµãŒãã¹ãããã€ããŒã«äŸåããŠããŸããåèšåºè©Šéšãå®äºããããã®ç§ãã¡ã®èœåã¯ãä»ã®èŠå ã«å ããŠããã®ãããªç 究ã®å®æœã«å¿
èŠãªåç©ããã®ä»ã®å¿
éåãå
¥æã§ãããã©ããã«ããã£ãŠããŸãããã®ãããªå¿
éåãå
¥æã§ããªãå Žåãé©æãŸãã¯å
šãåèšåºè©Šéšãå®äºã§ããªãå¯èœæ§ããããŸãã
äºæ¥éçšã«é¢é£ãããªã¹ã¯
ãããç§ãã¡ãé©æ ŒãªããŒãããžã¡ã³ããç§åŠè
ãéçºãå»çé¢é£ãåæ¥ã¹ã¿ãããã³ã³ãµã«ã¿ã³ããã¢ããã€ã¶ãåŒãä»ãç¶æããããšãã§ããªãå Žåã¯ãããžãã¹èšç»ãå®è¡ããèœåã«æªåœ±é¿ãåãŒãå¯èœæ§ããããŸãã
ç§ãã¡ã¯ãç§ãã¡ã®ã·ãã¢ãããžã¡ã³ããç§åŠãèšåºãå¶æ¥ãå»çã¹ã¿ããã«éåžžã«äŸåããŠããŸããã·ãã¢ãããžã¡ã³ãã®ãããªãã¡ã³ããŒã®ãµãŒãã¹ã®å€±å€±ãã補åéçºãåååããã®ä»ã®ããžãã¹ç®æšã®éæãé
ããããé»æ¢ãããããæ ªäŸ¡ã«æªåœ±é¿ãäžããå¯èœæ§ããããŸããäž»èŠãªäººæãšã®éçšå¥çŽã¯ãéç¥ãªãã«çµäºã§ããŸããç§ãã¡ã¯ãåŸæ¥å¡ã®ãããªã人ã«ãäž»èŠäººç©çåœä¿éºãå å
¥ããŠããŸããã
éå»æ°å¹Žéãããããã¯åŸæ¥å¡æ°ã倧å¹
ã«å¢ãããå°æ¥çã«ãåŸæ¥å¡æ°ã®å¢å ãèŠèŸŒãŸããŠããŸããããããªãããæ°å€ãã®å»è¬åã»ãã€ãªãã¯ãããžãŒäŒæ¥ã倧åŠãæ¿åºæ©é¢ãä»ã®ç 究æ©é¢ãããåªç§ãªäººæã確ä¿ããããã«ç«¶åããç¶æ³ã«ãããæã
ãããã¯ããã«å€ãã®è³æºãæã€è
ããããŸãããŸããæ¿èªããã補åãåžå Žã«æå
¥ããããšã«æåããªãå Žåãé«åºŠãªã»ãŒã«ã¹ãããŒã±ãã£ã³ã°ã®ãããã§ãã·ã§ãã«ã確ä¿ããç¶æããããšãã§ããªãå¯èœæ§ããããè³æ Œã®ããã»ãŒã«ã¹ãããŒã±ãã£ã³ã°ã®ãããã§ãã·ã§ãã«ã確ä¿ã§ãããæ¿èªããã補åãå°æ¥ã®è£œåãåžå Žã«æå
¥ããèœåã«æªåœ±é¿ãåãŒãå¯èœæ§ããããŸãããããã£ãŠãããããã®æé·ãæ¯æŽããããã«é©æ Œãªäººæã確ä¿ããç¶æããããšãã§ããªãå ŽåããããããããŸããã
ç§ãã¡ã®ããžãã¹èšç»ãå®è¡ããèœåã«æªåœ±é¿ãäžããå¯èœæ§ããããããç 究éçºåã³ã°ããŒãã«ãªåååã®åãçµã¿ãè¡ããªãå Žåãå°æ¥ã®ããžãã¹èšç»ãå®æœããèœåã«æªåœ±é¿ãäžããå¯èœæ§ããããŸãã
米欧ãäžå¿ã«çºèŠãèšåºåè©Šéšãèšåºéçºã«äž»ã«é¢äžããäŒæ¥ãããè€æ°ã®è£œåãéçºã»åååããã°ããŒãã«äŒæ¥ãžã®é²åãç¶ããã«ã€ããæ¥åæ¡å€§ã«æåããããšãå°é£ã«ãªãå¯èœæ§ããããŸãã
åœç€Ÿãæ¿èªããã補åã®åæ¥çºå£²ãç¶ç¶ããéçºäžã®è£œååè£ã®æ°ãå¢ããã«ã€ããŠãç±³åœã«ãããåœç€Ÿã®äºæ¥ãæ¡å€§ããEUãã¢ãžã¢ãã©ãã³ã¢ã¡ãªã«ãªã©ã®ãã®ä»ã®å°åã§äºæ¥ãæŽã«å±éããå¿
èŠããããŸããçŸåšãŸã§ã«ã4ã€ã®è£œåã®èŠå¶æ¿èªãåãããããã®è£œåãã°ããŒãã«ãªå€å°åã§çºå£²ããŠãããè¿œå ã®èŠå¶ç³è«ãçºå£²ãè¡ããªããããããã®è£œåã®ç¯å²ãåºãç¶ããŠããŸãã
ç§ãã¡ã¯éå»æ°å¹Žéã§åŸæ¥å¡ã倧å¹
ã«å¢ãããŸãããæ¿èªããã補åã®åååãšéæã«æ³šåããã«ã€ããŠãå°æ¥çã«ã¯äžçäžã§ããã«åŸæ¥å¡ãå¢ãããšäºæ³ããŠããŸã ã¢ã«ããŒã©ã ã»P 5 25å æŠç¥ããã®æé·ã¯ãåœç€Ÿã®ç®¡çããã³éå¶ã€ã³ãã©ã«è² æ
ããããŠããŸãããã®çµæãåœç€Ÿã®æé·ãæ¯ããç±³åœãEUãæ¥æ¬ãäžåç±³ããã®ä»ã®å°åã§ã°ããŒãã«äºæ¥ãè¡ãããã®è¿œå ã®ã¹ããŒã¹ã確ä¿ããããã«ãè¿œå ããã³/ãŸãã¯æ°ããã€ã³ãã©ã¹ãã©ã¯ãã£ãšæ©èœãåŒãç¶ãéçºããå¿
èŠããããŸãããã®ãããªè¿œå ã€ã³ãã©ãéçºããããæé·ã«å¯Ÿå¿ããããã®ååãªã¹ããŒã¹ãã¿ã€ã ãªãŒã«ãåæ¥çã«åççãªæ¡ä»¶ã§ç¢ºä¿ã§ããªãã£ãããããšãåœç€Ÿã®äºæ¥ã«æªåœ±é¿ãåã¶å¯èœæ§ããããŸããæ¿èªããã補åã®åååãç¶ããéçºãã補ååè£ãèšåºè©Šéšã«å
¥ã£ãŠé²æ©ããã«ã€ããŠãã°ããŒãã«ãªéçºãèŠå¶ã補é ãå質ãã³ã³ãã©ã€ã¢ã³ã¹ãããŒã±ãã£ã³ã°ããã³è²©å£²èœåãæ¡å€§ãç¶ããããä»ã®çµç¹ãšå¥çŽããŠãããã®æ©èœãæäŸããå¿
èŠããããŸããããã«ãäºæ¥ãæ¡å€§ãç¶ããã«ã€ããŠãããŸããŸãªååè
ããµãã©ã€ã€ãŒãæµéæ¥è
ããã®ä»ã®çµç¹ãšã®ãããªãé¢ä¿ãããŸã管çããå¿
èŠããããŸããäºæ¥ã管çããèœåãšå°æ¥ã®æé·ã«ãããéå¶ã財åã管çã®çµ±å¶ãšã·ã¹ãã ãå ±åã·ã¹ãã ãšã€ã³ãã©ã¹ãã©ã¯ãã£ãå«çãšã³ã³ãã©ã€ã¢ã³ã¹æ©èœãããªã·ãŒãšæé ãåŒãç¶ã匷åããå¿
èŠããããŸãã管çæ
å ±ãçµ±å¶ã·ã¹ãã ã®åŒ·åãå¹ççãã€ã¿ã€ã ãªãŒã«å®æœã§ããªãå Žåããæ¢åã®ã·ã¹ãã ãçµ±å¶ã«æ¬ é¥ãããããšã«æ°ä»ãå ŽåããããŸãã
ãœãŒã·ã£ã«ã¡ãã£ã¢ã®å©çšã«ã¯ãªã¹ã¯ã課é¡ãååšããŸãã
åœç€Ÿã¯ãæ¿èªããã補åã®åæ¥åã«é¢é£ããŠãæ²»éšRNAiæ²»çæ³ã®éçºããã°ã©ã ããã³å¯Ÿè±¡çŸæ£ã«ã€ããŠã³ãã¥ãã±ãŒã·ã§ã³ãè¡ãããã«ãœãŒã·ã£ã«ã¡ãã£ã¢ã䜿çšããŠããŸããåœç€Ÿã®å°æ¥ã®è£œåã«ã€ããŠããæ¿èªãããå Žåã¯åæ§ã«è¡ãäºå®ã§ããçŸè¡ã®èŠå¶æå°ã«åŸã£ãŠãåœç€Ÿã®ãœãŒã·ã£ã«ã¡ãã£ã¢å©çšã¯é©åã§ãããšèããŠããŸããããã€ãªå»è¬åæ¥çã®ãœãŒã·ã£ã«ã¡ãã£ã¢ã®æ
£è¡ã¯åžžã«é²åãããã®å©çšã«é¢ããèŠå¶ããã³èŠå¶æå°ã¯é²åããåžžã«æ確ã§ã¯ãããŸããããã®é²åã«ãããåœç€Ÿã®äºæ¥ã«é©çšãããèŠå¶ã«éåãããªã¹ã¯ãããªãã©ãã«ããŒã±ãã£ã³ã°ããã®ä»çŠæ¢ããã掻åã«é¢é£ãã蚎èšã®å¯èœæ§ãçããåœç€Ÿã«å¯ŸããèŠå¶è¡åã®ãªã¹ã¯ãçããŸããããšãã°ãåœç€Ÿã®èšåºæ®µéã®åè£ç©ã«ã€ããŠãæ£è
ã¯é²è¡äžã®èšåºè©Šéšã§ã®èªåã®çµéšã«ã€ããŠãœãŒã·ã£ã«ã¡ãã£ã¢ã®ãã£ã³ãã«ã§ã³ã¡ã³ããããã䞻匵ãããæ害äºè±¡ãå ±åãããããããšãã§ããŸãããã®ãããªé瀺ãããå Žåãè©Šéšãžã®åå ã«æªåœ±é¿ãåã¶ãªã¹ã¯ã該åœããæ害äºè±¡ã®å ±å矩åãç£èŠããéµå®ã§ããªããªã¹ã¯ããŸãã¯ç 究段éã®å»è¬åã«é¢ããçºèšã«ã€ããŠå¶éãããããããœãŒã·ã£ã«ã¡ãã£ã¢ã«ãã£ãŠçããæ¿æ²»çããã³åžå Žå§åã«ç«ã¡åããããšãã§ããªããªã¹ã¯ããããŸãããŸããã€ã³ã¿ãŒãããäžã®ããã°ããŠã§ããµã€ãã®æçš¿ãå«ãããªã³ã©ã€ã³ãã©ãããã©ãŒã ã§ã®åœç€Ÿã«é¢ããæ©å¯æ
å ±ãŸãã¯åŠå®çãŸãã¯äžæ£ç¢ºãªæçš¿ãã³ã¡ã³ãã®äžé©åãªé瀺ã®ãªã¹ã¯ããããè¿
éã«é
ä¿¡ãããåœç€Ÿã®è©å€ã«åŠå®çãªåœ±é¿ãäžããå¯èœæ§ããããŸãããããã®ããããã®ã€ãã³ããçºçããå ŽåããŸãã¯é©çšãããèŠå¶ã«éåããå Žåãåœç€Ÿã¯è²¬ä»»ãè² æ
ããããšã«ãªããèŠå¶è¡åãåããããããžãã¹ãžã®ãã®ä»ã®æ害ã被ã£ããããå¯èœæ§ããããŸãã
ã·ã¹ãã ã®æ
éãã·ã¹ãã ãžã®äžæ£ã¢ã¯ã»ã¹ãŸãã¯äžé©åãªå©çšããã£ãå Žåãç§ãã¡ã®ããžãã¹ããã³éçšã«åœ±é¿ãäžããå¯èœæ§ããããŸãã
ç§ãã¡ã®ããžãã¹ã«ã¯æ
å ±æè¡ã·ã¹ãã ãšã€ã³ãã©ããŸããŸãäŸåããŠããŸããç§ãã¡ã¯ãç¥ç財ç£ããããã©ã€ãšã¿ãªããžãã¹æ
å ±ïŒé«åºŠã«æ©å¯æ§ã®é«ãèšåºè©ŠéšããŒã¿ãå«ãïŒãããã³ããžãã¹æŽ»åã«é¢é£ããå人æ
å ±ãå«ãæ©å¯æ
å ±ãåéãä¿ç®¡ãããã³éä¿¡ããŠããŸãããã®æ
å ±ãå®å
šã«ä¿ç®¡ããããšã¯ãç§ãã¡ã®ãªãã¬ãŒã·ã§ã³ãšããžãã¹æŠç¥ã«ãšã£ãŠéèŠã§ãããããã®æ
å ±ã®äžéšã¯ãçµç¹ç¯çœªã°ã«ãŒããããã¯ãã£ãã¹ãããæ£è
ã°ã«ãŒããäžé©åãªçŸåšãŸãã¯å
åŸæ¥å¡ãªã©ãå¹
åºãåæ©ãšå°éç¥èãæã€ç¬¬äžè
ã«ãã£ãŠç¯çœªæ»æãŸãã¯äžæ£ã¢ã¯ã»ã¹ããã³äœ¿çšã®å¯Ÿè±¡ã«ãªãå¯èœæ§ããããŸãããŸãããµã€ããŒæ»æã¯ãŸããŸãé«åºŠåããŠãããã»ãã¥ãªãã£å¯Ÿçããã£ãŠããæ
å ±æè¡ããã³ã€ã³ãã©ãæ»æããããã瀟å¡ã®èª€ããŸãã¯äžæ£è¡çºã«ããå Žåãªã©ã䟵害ãããå¯èœæ§ããããŸãã
ã»ãã¥ãªãã£ã€ã³ã·ãã³ãã®æ®åãšãµã€ããŒç¯çœªãªã¹ã¯ã¯è€éã§é²åãç¶ããŠããŸããç§ãã¡ã¯æ
å ±ã·ã¹ãã ã®ã»ãã¥ãªãã£ãšå®å
šæ§ãç¶æããããã«éèŠãªåªåãããŠãããã»ãã¥ãªãã£äŸµå®³ãæ··ä¹±ã®ãªã¹ã¯ã管çããããã®ããŸããŸãªå¯Ÿçãæ€èšããŠããŸãããã»ãã¥ãªãã£ã®åªåã察çãå¹æçã§ããä¿èšŒã¯ãããŸããããã»ãã¥ãªãã£äŸµå®³ãæ··ä¹±ãæåããããæ害ãäžããå¯èœæ§ããªãããã§ã¯ãããŸãããã»ãã¥ãªãã£å¯Ÿçãå®æœããŠããèªç€Ÿãè«è² æ¥è
ãã³ã³ãµã«ã¿ã³ããå
±åäœæ¥è
ã®å
éšã³ã³ãã¥ãŒã¿ãŒã·ã¹ãã ã¯ãã³ã³ãã¥ãŒã¿ãŒãŠã€ã«ã¹ãäžæ£ãŸãã¯äžé©åãªã¢ã¯ã»ã¹ãèªç¶çœå®³ãªã©ã«ããæå·ãäžæã®è匱æ§ããããŸãã
ãã³ãããã¯ãå
¬è¡è¡çäžã®ç·æ¥äºæ
ããããæŠäºïŒãŠã¯ã©ã€ããäžæ±ã®çŽäºãå«ãïŒãéä¿¡ã»é»åé害ãªã©ã®ä»ã®åºæ¥äºããæã
ã®æ¥åã®äžæãåŒãèµ·ããå¯èœæ§ããããŸããããšãã°ãç§ãã¡ã®è£œååè£ã®ãã¬èšåºè©ŠéšããŒã¿ãŸãã¯æ¢ã«è¡ãããŠããèšåºè©ŠéšããŒã¿ã倱ãããå ŽåãèŠå¶ç³è«ãéçºæŽ»åã®é
延ã補åã®åååã®é
ãããããŠã³ã¹ãã®å¢å€§ãçºçããããšããããŸãããããã©ã㪠disruptionsãã»ãã¥ãªãã£äŸµå®³ãèš±å¯ãããŠããªããŸãã¯äžé©åãªã·ã¹ãã ãžã®ã¢ã¯ã»ã¹ãç§ãã¡ã®ããŒã¿ã®æ倱ãæ害ãæ©å¯æ
å ±ã®äžé©åãªé瀺ïŒæ£è
ãåŸæ¥å¡ããã³ããŒæ
å ±ãå«ãïŒã«ã€ãªããå Žåã圱é¿ãåããå人ãæ¿åºæ©é¢ã«å¯Ÿããéç¥çŸ©åãæ£è
ãå
±åç 究è
ã瀟å¡ãæ ªäž»ãŸãã¯ãã®ä»ç¬¬äžè
ããã®æœåšçãªèšŽèšãå人æ
å ±ã®ãã©ã€ãã·ãŒãšã»ãã¥ãªãã£ãä¿è·ããåœå
å€ã®æ³åŸã«åºã¥ãæ³ç責任ãçºçãã補ååè£ã®éçºãšå¯èœãªåååãé
ããå¯èœæ§ããããŸãã
ãŸããã¯ã©ãŠããã¯ãããžãŒã®å©çšå¢å ã«ããããããã®ãµãŒãããŒãã£ãŒããã³ãã®ä»ã®æ¥åãªã¹ã¯ãé«ãŸããŸãããŸããã¯ã©ãŠããŸãã¯ãã®ä»ã®æè¡ãµãŒãã¹ãããã€ããŒãã·ã¹ãã ã®é©åãªä¿è·ãšãµã€ããŒæ»æã®é²æ¢ãé©åã«è¡ããªãå Žåãåœç€Ÿã®æ¥åãæ··ä¹±ããæ©å¯æ
å ±ãŸãã¯æææš©æ
å ±ãäžæ£ãªæµåºãæ¹ç«ããŸãã¯æ倱ãçºçããããšããããŸãã瀟å¡ãé éã§åãããšã«ããããµã€ããŒæ»æã®ãªã¹ã¯ãé«ãŸããŸãããªã¢ãŒãã¯ãŒã¯ã¯ããã£ãã·ã³ã°æ»æããã®ä»ã®ã»ãã¥ãªãã£è
åšãªã©ã®ãµã€ããŒã»ãã¥ãªãã£ã«é¢ããã€ãã³ãã«å¯ŸããŠè匱ã§ããå¯èœæ§ããããŸãã
ç§ãã¡ã®æ¥çã«é¢é£ãããªã¹ã¯
補ååè£ã®éçºãèšåºè©ŠéšãèŠå¶æ¿èªãæ¿èªæžè£œåã®åæ¥åã«é¢é£ãããªã¹ã¯
ç§ãã¡ãååäŒæ¥ãéçºãã補ååè£ã¯ãéçºã«å€±æãããããã®è£œååè£ãåæ¥çã«å®çŸäžå¯èœã«ãªããŸã§é
延ããå¯èœæ§ããããŸãã
åœç€Ÿã®è£œååè£ãåæ¥çã«é
åžããããã«èŠå¶åœå±ã®æ¿èªãååŸããåã«ã人éã®å®å
šæ§ãš/ãŸãã¯æå¹æ§ã瀺ãããã«ãèªå·±è² æ
ã§åºç¯ãªéèšåºè©Šéšãšèšåºè©Šéšãå®æœããå¿
èŠããããŸããéèšåºè©Šéšããã³èšåºè©Šéšã¯è²»çšãé«ããèšèšããã³å®æœãå°é£ã§ãããå®äºãŸã§ã«å€ãã®å¹Žæ°ãèŠããçµæãäžç¢ºå®ã§ããã補ååè£ã®å€±æçãé«ãããšãäºæ³ãããŸããçŸåšãèªç€Ÿéçºãšååéçºã®è€æ°ã®ããã°ã©ã ã第3çžéçºããã³ããã€ãã®æ©æèšåºããã°ã©ã ã«ãããŸãããåœç€Ÿã®ãããã®è£œååè£ãèšåºè©ŠéšãšèŠå¶åœå±ã®æ¿èªãéããŠããã«é²å±ãããããšãã§ããªãå¯èœæ§ããããŸãã
ã¯ãªãã«ã«è©Šéšã«é²ããšã補ååè£ã®éèšåºè©Šéšãæ©æãŸãã¯åŸæã®èšåºè©Šéšã®çµæãã補ååè£ãŸãã¯ãã®ä»ã®è£œååè£ã®åŸç¶ã®è¢«éšè
ãŸãã¯åŸç¶ã®äººéèšåºè©Šéšã§åŸãããçµæãäºæž¬ããªãå ŽåããããŸããããšãã°ãç§ãã¡ã¯æè¿ãATTRã¢ããã€ããŒã·ã¹ãæã€å¿ççã®æ£è
ã®æ²»çã®ããã®vutrisiranã®HELIOS-b第3çžèšåºè©Šéšã®éœæ§ãããã©ã€ã³çµæãå ±åããŸãããvutrisiranã¯èšåºè©Šéšã§éœæ§ã®ãããã©ã€ã³çµæã瀺ããŸããããHELIOS-bã®çµæãvutrisiranãATTRã¢ããã€ããŒã·ã¹ãæã€å¿ççæ£è
ã®æ²»çã®æ¿èªãæ¯æãããã©ããã¯ç¢ºå®çã§ã¯ãããŸãããèšåºè©ŠéšãçµãŠé²ãè¬å€ã®å€±æçã¯é«ãã§ããå»è¬åã»ãã€ãªãã¯ãããžãŒæ¥çã®å€æ°ã®äŒæ¥ã¯ã以åã®ç 究ã§ææãªçµæãåŸãåŸã§ããèšåºéçºã§é倧ãªæ«æãçµéšããŠãããvutrisiranã«é¢ããèšåºéçºã«ãããŠãããã®ãããªæ«æãäºæ¥ãå±æãæ¥çžŸãããã³è²¡åç¶æ³ã«é倧ãªæªåœ±é¿ãäžããå¯èœæ§ããããŸããããã«ãç§ãã¡ã®æ¿èªããã補åãšçŸåšã®è£œååè£ã¯ãInclisiranãé€ããŠã人éèšåºè©Šéšã§åºç¯ã«è©äŸ¡ãããå®å
šãã€å¹æçã§ããããšã蚌æãããŠããŸããã
ããã«ãèšç»ãããèšåºè©Šéšããã³é²è¡äžã®å€ãã®èšåºè©Šéšã§ã¯ãããªãŒãã³ã©ãã«ãè©Šéšãã¶ã€ã³ã䜿çšãããŠããŸããããªãŒãã³ã©ãã«ïŒé瀺ã©ãã«ïŒãèšåºè©Šéšãšã¯ãæ£è
ãšèª¿æ»è
ã®äž¡æ¹ããæ£è
ãå®éšç補ååè£ãæ¢åã®æ¿èªãããè¬å€ããŸãã¯ãã©ã»ããåãåã£ãŠãããã©ãããç¥ã£ãŠããè©Šéšã§ããå€ãã®å ŽåããªãŒãã³ã©ãã«èšåºè©Šéšã§ã¯ãå®éšç補ååè£ã ããæ€èšããå Žåã«ãã£ãŠã¯ç°ãªãæäžéã¬ãã«ã§è¡ãããšããããŸãããªãŒãã³ã©ãã«èšåºè©Šéšã¯ãæ£è
ãæ²»çãåããŠããããšãç¥èŠããŠãããããããã€ãã®å¶éããããæ²»çå¹æãèªåŒµããå¯èœæ§ããããŸãããã®ããããªãŒãã³ã©ãã«èšåºè©Šéšã¯ããæ£è
ãã€ã¢ã¹ãã«é¢ããŠæ
éã§ããå¿
èŠããããŸããæ£è
ãå®éšçæ²»çãåããŠããããšãèªèããã ãã§ãèªåã®çç¶ãæ¹åãããšèªèããããšããããŸããããã«ããªãŒãã³ã©ãã«èšåºè©Šéšã¯ãã調æ»è
ãã€ã¢ã¹ããšãããã€ã¢ã¹ããããããããŸãããèšåºè©Šéšã®ççåŠççµæãè©äŸ¡ããã³ã¬ãã¥ãŒãã人ã
ã¯ãæ²»çãåããæ£è
ã誰ã§ããããç¥ã£ãŠããããã®ç¥èã«åºã¥ããŠæ²»ç矀ã®æ
å ±ã奜æçã«è§£éããå¯èœæ§ããããŸãããªãŒãã³ã©ãã«è©Šéšããã®çµæã¯ããã©ã»ããŸãã¯æå¹æåã䜿çšããç²æ€ã§ã¯ãªãç°å¢ã§ç 究ãããå Žåãå°æ¥ã®è£œååè£ã®èšåºè©Šéšã®çµæãäºæž¬ããããšãã§ããªãå ŽåããããŸãã
ãŸããåœç€ŸãFDAãã®ä»è©²åœããèŠå¶åœå±ããããã¯IRBãã€ãŸãã¯åŠäŒå«ç審æ»å§å¡äŒããããã¯åçã®å€åœã®å¯©æ»å§å¡äŒçããå€æ§ãªçç±ã«åºã¥ããŠè£œååè£ã®èšåºè©Šéšãéå§ããã®ãé
ãããããäžæ¢ãããå ŽåããããŸãããã®çç±ã«çãŸããã補ååè£ãé¢é£è£œåãå¥åº·ãªãã©ã³ãã£ã¢ã«åãŒãæ害ãªå¯äœçšãèšåºè©Šéšã«åå ããŠããæ£è
ã«çããå Žåãåœç€ŸãFDAãŸãã¯å€åœã®èŠå¶åœå±ã«ãããŠã該åœãã補ååè£ã®äžéšãå
šãŠã®é©å¿çããŸãã¯ãã®å
šãŠãæ¿èªããªã決å®ããªãããèšåºè©Šéšãäžæ¢ãããããšããããŸãã
æ°è¬åè£ã®èšåºè©Šéšã§ã¯ãæ²»ç察象çŸæ£ãæ£ã£ãŠããæ£è
ãããã³ãã®ä»ã®é©æ Œåºæºãæºããæ£è
ã®ååãªæ°ã®ç»é²ãå¿
èŠã§ããæ£è
ç»é²çã¯ãæ£è
人å£ã®å€§ãããæ£è
ã®å¹Žéœ¢ãšç¶æ
ãçŸæ£ã®æ®µéãšéç床ãåãçŸæ£ãŸãã¯ç¶æ
ã«å¯Ÿããä»ã®èª¿æ»è¬ã«ããèšåºè©Šéšã®å©çšå¯èœæ§ããããã³ã«ã®æ§è³ªãæ£è
ã®èšåºçŸå Žãžã®è·é¢ãé¢é£çŸæ£ã®å¹æçãªæ²»çã®å©çšå¯èœæ§ãããã³èšåºè©Šéšã®é©æ Œåºæºãªã©å€ãã®èŠå ã«åœ±é¿ãåããŸããæ¢åã®æ¿èªæ²»çæ³ã®å©çšå¯èœæ§ããéçºäžã®ãã®ä»ã®èª¿æ»è¬ã®ååšã«ãããç§ãã¡ãŸãã¯ç§ãã¡ã®å
±åç 究è
ã¯ãèšåºè©Šéšã®ç»é²ã«èŠåŽãããããããŸãããäŸãã°ã2018幎11æã«ãcemdisiranãçšããéå
žåç溶è¡æ§å°¿æ¯çå矀ã®ãã§ãŒãº2èšåºè©Šéšãåéã®é£ããããäžæ¢ããcemdisiranèšåºéçºã®åªåãå¥ã®é©å¿çã«çŠç¹ãåœãŠãããšãçºè¡šããŸãããæ£è
ç»é²ã®é
延ãå°é£ãèšåºè©Šéšåå è
ã®ä¿æã®å°é£ãæ¢åã®æ¿èªæ²»çæ³ããã®ä»ã®èª¿æ»è¬ã®å©çšå¯èœæ§ããŸãã¯å®å
šæ§äžã®æžå¿µããã³ãããã¯ãŸãã¯ãã®ä»ã®å
¬è¡è¡çäžã®ç·æ¥äºæ
ã®åœ±é¿ã«ãããèšåºè©Šéšã®ã³ã¹ãå¢å ãéçºæéã®å»¶é·ããŸãã¯äžæ¢ã«ã€ãªããå¯èœæ§ããããŸãã
æã
ã®RNAiæ²»çè¬ã¯ããããŸã§ã®èšåºè©Šéšã«ãããŠäžè¬çã«è¯å¥œãªè容æ§ã瀺ããŠããŸãããæ°ããå®å
šæ§ã®åé¡ãçºçããå¯èœæ§ããããŸããé節ãªæ害äºè±¡ïŒSAEsïŒãŸãã¯æ害äºè±¡ïŒAEsïŒã®çºçã«ãããç§ãã¡ãç§ãã¡ã®å
±åç 究è
ãFDAãŸãã¯å€åœã®èŠå¶åœå±ã補ååè£ã®èšåºè©Šéšãäžæ¢ãŸãã¯äžæ¢ããããšãããã圱é¿ãåãã補ååè£ã®èšåºçããã³/ãŸãã¯èŠå¶ã®ã¿ã€ã ã©ã€ã³ã«æªåœ±é¿ãäžããå¯èœæ§ããããŸããäŸãã°ã2016幎10æã«ã¯revusiranããã°ã©ã ãäžæ¢ãã2017幎9æã«ã¯ããã£ãã·ã©ã³ãæäžããŠããæ£è
ãPhase 2 OLEèšåºè©Šéšã§èŽæ»çãªè¡æ æ§SAEãçµéšããããããã£ãã·ã©ã³ã®ãã¹ãŠã®é²è¡äžã®è©Šéšã®æäžãäžæçã«äžæ¢ããããšãçºè¡šããŸããã
ãŸããSAEãAEã®çºçã¯ãç¹å®ã®è£œååè£ãFDAãå€åœã®èŠå¶åœå±ãã©ã®äœ¿çšç®çã«å¯ŸããŠãæ¿èªããªããããŸãã¯æ¿èªããã補åã®ã©ãã«ã«å¶éãå ããå¯èœæ§ããããŸãã
èšåºè©Šéšã«ã¯ãç¶ç¶çã«èšåºèª¿æ»ã審æ»ãã被éšè
ã®æš©å©ãšçŠç¥ãä¿è·ããIRBããŸãã¯ç±³åœä»¥å€ã®ç¬ç«ããå«çå§å¡äŒã®å¯©æ»ãç£ç£ãæ¿èªãå¿
èŠã§ããIRBãŸãã¯å«çå§å¡äŒã®æ¿èªãåŸãããªãå ŽåãŸãã¯æ¿èªãåŸãã®ã«é
ããçããå Žåãèšåºè©Šéšã®éå§ãå®äºã劚ããããããšããããç¹ã«åæããã³ç¶ç¶çãªIRBæ¿èªãŸãã¯å«çå§å¡äŒå¯©æ»ã®å¯Ÿè±¡ã«ãªããªãèšåºè©Šéšã§åŸããããã¹ãŠã®ããŒã¿ãæ
å ±ãåžè²©ç³è«ã®ãµããŒããšããŠFDAãåœå€ã®èŠå¶åœå±ãæ€èšããããšã決å®ããªãããšããããŸãã
åœç€Ÿã®è£œååè£ããèšåºè©Šéšäžã«åé¡ãèµ·ããç§ãã¡ãIRbãå«çå§å¡äŒãŸãã¯èŠå¶åœå±ããããã®èšåºè©Šéšãé
延ãäžæ¢ããŸãã¯äžæ¢ãããåå ãšãªãå ŽåããŸãã¯ãããã®èšåºè©Šéšããã®ããŒã¿åæãé
ããããæ··ä¹±ããããããå ŽåããããŸããåœç€Ÿã®è£œååè£ããã®ãããªåé¡ã«çŽé¢ããå Žåã圱é¿ãåãã補ååè£ãŸãã¯ãã®ä»ã®è£œååè£ã®éçºãç¶ç¶ããããã«å¿
èŠãªè²¡åãªãœãŒã¹ãæã£ãŠããªãå ŽåããããŸãããŸãã圱é¿ãåãã補ååè£ãŸãã¯ãã®ä»ã®è£œååè£ã«å¯ŸããŠãååé¢ä¿ãç¯ããããç¯ããªãã£ããããå ŽåããããŸãã
ç§ãã¡ã®1ã€ä»¥äžã®èšåºè©Šéšã®å€±æã¯ããã¹ãã®ã©ã®æ®µéã§ãçºçããå¯èœæ§ããããŸãã éèšåºè©Šéšãèšåºè©Šéšããã»ã¹äžã«å€æ°ã®äºæãã¬äºè±¡ãçºçããåœç€Ÿã®è£œååè£ã®èšåºéçºã®æéã延é·ããèŠå¶æ¿èªã®é
ããé»æ¢ã補åã®åååã®èœåã«åœ±é¿ãäžããå¯èœæ§ããããŸããããã«ã¯ã次ã®ãã®ãå«ãŸããŸã:
⢠åœç€Ÿã®éèšåºè©ŠéšãŸãã¯èšåºè©Šéšã¯åŠå®çãŸãã¯äžç¢ºå®ãªçµæãåºãå¯èœæ§ããããåœç€Ÿãè¿œå ã®éèšåºè©ŠéšãŸãã¯èšåºè©Šéšãå®æœããããšã決å®ããããèŠå¶åœå±ããã®ããã«èŠæ±ããããšããããŸãããŸããææãªå¯èœæ§ããããããžã§ã¯ããæŸæ£ããããšããããŸãã
⢠èŠèŸŒã¿è©Šéšå Žæã§èšåºè©Šéšãéå§ããããã«èŠå¶åœå±ãŸãã¯IRB / å«çå§å¡äŒããå¿
èŠãªæ¿èªãåŸãããšã«é
ããããå ŽåããŸãã¯åçã®å€åœç³è«ãŸãã¯é
ãããããèšåºè©Šéšãéå§ããå Žåã®ãŸãã¯ãã®äžæ¢ãŸãã¯äžæ¢;
⢠ç§ãã¡ã®èšåºè©Šéšã®ç¯å²ãèšèšã«é¢ããIRBãå«çå§å¡äŒãFDAããŸãã¯åæ§ã®å€åœã®èŠå¶åœå±ããã®èª²ããããæ¡ä»¶ïŒ
⢠èšåºè©Šéšã®ç£ç£ãè¡ãIRBãå«çå§å¡äŒãåå ããããšã«åé¡ããããããŸãã¯èšåºè©Šéšã®IRBãå«çå§å¡äŒã®æ¿èªãååŸãŸãã¯ç¶æããããšã«åé¡ãããå ŽåïŒ
⢠COVID-19ãã³ãããã¯ãå°æ¥ã®ãã³ãããã¯ãŸãã¯å
¬è¡è¡çäžã®ç·æ¥äºæ
ããŠã¯ã©ã€ãã®çŽäºã®ç¶ç¶ã«ãããèšåºè©Šéšãžã®æ£è
ããã³ãã©ã³ãã£ã¢ã®ç»é²ã®é
延ãããã³å©çšå¯èœãªæ£è
ããã³ãã©ã³ãã£ã¢ã®æ°ãçš®é¡ã®å€åã«ããèšåºè©Šéšã®å®æœïŒ
⢠人çºçãŸãã¯èªç¶çœå®³ããã³ãããã¯ãæµè¡ç
ãå
¬è¡è¡çäžã®ç·æ¥äºæ
ããã®ä»ã®ããžãã¹ã®äžæã«ããæ··ä¹±ïŒ
⢠èšåºè©Šéšã«ãããæ£è
ããã©ã³ãã£ã¢ã®é«ãäžéçïŒ
⢠åœç€Ÿã®è£œååè£ãšåæ§ã®è£œåã®èšåºè©ŠéšãŸãã¯ä»ç€Ÿã®èšåºè©ŠéšããåŠå®çãªãŸãã¯äžç¢ºå®ãªçµæïŒ
⢠å°æ¥çãªãã³ãããã¯ãå
¬è¡è¡çäžã®ç·æ¥äºæ
ã«ããèšåºè©Šéšã®å®æœã«å¿
èŠãªè£œååè£ç©è³ªããã®ä»ã®å¿
èŠãªè³æã®äžååãªäŸçµŠãŸãã¯å質ããŸãã¯èšåºäŸçµŠã®é
ããäžæ
⢠äºæ³ãäžåãèšåºè©Šéšè²»çšïŒ
⢠åœç€Ÿæ¿èªè£œåãåœç€Ÿã®èšåºè©Šéšã«åå ããæ£è
ãåœç€Ÿã®è£œåã補ååè£ã«é¡äŒŒããè¬å€ã䜿çšããå人ãçµéšãããæ·±å»ã§äºæããªãã£ãè¬å€é¢é£ã®å¯äœçšïŒ
⢠èšåºè©Šéšäžã«åœç€Ÿåè£è¬ã®å¹æãäœããŸãã¯å€±æããããã®ã§ããããšïŒ
⢠FDAãŸãã¯ä»ã®èŠå¶åœå±ã«ããèšåºè©ŠéšçŸå ŽãŸãã¯èšåºã»éèšåºç 究ã®èšé²ã®äžå©ãªæ€æ»ãšã¬ãã¥ãŒïŒ
⢠第äžè
ã®è«è² æ¥è
ãŸãã¯èª¿æ»è
ããGCPããã³cGMPãå«ãèŠå¶èŠä»¶ã«éµå®ãããå¥çŽäžã®çŸ©åãé©æããã³å®å
šã«æãããªãå ŽåããŸãã¯æãããªãå Žåããã
⢠æã
ã®ãã¯ãããžãŒã«é¢ããŠãäžè¬çã«èšåºè©Šéšã«ãããè¿œå ã®èŠå¶ç£ç£ã®å°å
¥ãå«ããŠãèŠå¶é
延ããã³èŠå¶èŠä»¶ãæ¿çãã¬ã€ãã©ã€ã³ã®å€æŽã«ãã圱é¿;ãŸãã¯ãããã®åœ±é¿
⢠FDAãåæ§ã®å€åœã®èŠå¶æ©é¢ã«ããããŒã¿ã®è§£èª¬ã³ã¡ã³ããç§ãã¡ãšç°ãªãå ŽåããããŸãã
補ååè£ã®èšåºè©Šéšã«æåããå Žåã§ãã察象ãšãªãçŸæ£ã®å®å
šãã€å¹æçãªæ²»çæ³ãšãªããªãå ŽåããããŸãã
ç§ãã¡ãŸãã¯ç§ãã¡ã®ååè
ããç±³åœãŸãã¯å€åœã®èŠå¶åœå±ããã®æ¿èªãååŸã§ããªãå ŽåããããŸãããã®çµæãç§ãã¡ãŸãã¯ç§ãã¡ã®ååè
ã¯ãã®ãããªè£œååè£ãåžå Žæå
¥ã§ããªããªãå¯èœæ§ããããŸãã
ç§ãã¡ãšååããŠéçºããŠãã補ååè£ã¯ãç 究ãè©Šéšãéçºã補é ãå®å
šæ§ãæå¹æ§ãæ¿èªãèšé²ã®åãæ±ããå ±åãã©ãã«ä»ããä¿ç®¡ãäŸ¡æ Œèšå®ã販売ä¿é²åã³å»è¬åã®é
åžã«é¢ããåºç¯å²ãã€å³æ Œãªæ¿åºèŠå¶ã®å¯Ÿè±¡ãšãªããŸããæ°è¬ã®è²©å£²ãéå§ããåã«ãå³æ Œãªéèšåºè©Šéšãèšåºè©Šéšåã³åºç¯ãªèŠå¶æ¿èªããã»ã¹ãç±³åœãå€ãã®å€åœç®¡èœåºåã§æ£åžžã«å®äºããå¿
èŠããããŸãããããããã³ãã®ä»ã®èŠå¶èŠä»¶ãæºããããšã¯ãã³ã¹ããããããæéãããããäžç¢ºå®ã§äºæãã¬é
延ã®å¯Ÿè±¡ãšãªããŸããç§ãã¡ãç§ãã¡ã®å
±åéçºè
ãéçºããŠãã補ååè£ãã販売ãéå§ããããã«å¿
èŠãªèŠå¶æ¿èªãååŸã§ããªãå ŽåããããããããŸããããŸããvutrisiranã®å ŽåãçŸåšã®æ¿èªãããŠããå¹èœä»¥å€ã®åºç¯ãªé©å¿çã®ããã«è²©å£²ããããã®èŠå¶æ¿èªãåŸãããšãã§ããªãå¯èœæ§ããããŸãããŸããFDAããã®ä»ã®èŠå¶åœå±ã¯ã補ååè£ã®èšåºè©Šéšã§çæãããããŒã¿ããèŠå¶æ¿èªç³è«ã®æ¿èªãæ¯æããã«ã¯ååã§ãªããšå€æããå ŽåããããŸããããšãã°ãç§ãã¡ã¯ãATTRå¿ççãæã€æ£è
ã察象ã«ããpatisiranã®APOLLO-bãã§ãŒãº3èšåºè©Šéšã§éœæ§ã®çµæãå ±åããFDAã®CRDACããATTRå¿ççã®æ²»çã«ãããŠpatisiranã®å©çããªã¹ã¯ãäžåããšãã9:3ã®æ祚ãåããŸãããã2023幎10æãFDAã¯ãpatisiranã®sNDAã«å¯ŸããCRLãçºè¡ããçŸè¡ã®åœ¢åŒã§ã¯sNDAãæ¿èªã§ããªããšããŸããã
FDAããã³ä»ã®èŠå¶åœå±ã®æ¿èªãååŸããããã«å¿
èŠãªæéã¯äºæž¬ã§ããŸãããã補ååè£ã®ã¿ã€ããè€éããæ°èŠæ§ã«å¿ããŠãéåžžã¯èšåºè©Šéšã®éå§ããæ°å¹ŽããããŸããFDAããã³æµ·å€ã®èŠå¶åœå±ãèŠå¶ã«äœ¿çšããåºæºã¯ãåžžã«äºæž¬å¯èœãŸãã¯åäžã«é©çšãããããã§ã¯ãªããæéã®çµéãšãšãã«å€åããå¯èœæ§ããããŸããéèšåºããã³èšåºæŽ»åããã®ããŒã¿ã®è§£æã«ã€ããŠè¡ã解éã¯ãèŠå¶åœå±ã«ãã£ãŠç¢ºèªããã解éãããªããã°ãªãããèŠå¶åœå±ã®æ¿èªã®é
ããå¶éããŸãã¯é»æ¢ãåŒãèµ·ããããå¯èœæ§ããããŸãããŸããæã
ãŸãã¯ç§ãã¡ã®å
±åç 究è
ã¯ã補åéçºãèšåºè©ŠéšãFDAèŠå¶å¯©æ»æéäžã®æ°ããæ¿åºèŠå¶ãäŸãã°å°æ¥ã®ç«æ³ãè¡æ¿æªçœ®ãããFDAããªã·ãŒã®å€æŽãããäºæããªãé
延ãŸãã¯å¢å ããã³ã¹ãã«çŽé¢ããå¯èœæ§ããããŸããç«æ³ã®å€æŽãæç«ãããã©ãããFDAãŸãã¯å€åœã®èŠå¶ãã¬ã€ãã³ã¹ããããã¯è§£éãå€æŽããããã©ãããå€æŽã®åœ±é¿ãããå Žåããããã©ãããäºæž¬ããããšã¯äžå¯èœã§ãã
åååè£ãç§ãã¡ãŸãã¯ç§ãã¡ã®ååè
ãéçºããŠããããšã¯æ°ããè¬ã®åéã代衚ãããããFDAããã³ãã®æµ·å€ã®çžåœæ©é¢ã¯ããããã®è¬ã«é¢ããæ確ãªæ¹éãæ
£è¡ããŸãã¯ã¬ã€ãã©ã€ã³ã確ç«ããŠããŸãããæ¹éãæ
£è¡ãŸãã¯ã¬ã€ãã©ã€ã³ããªããããFDAã«ããç§ãã¡ãŸãã¯ç§ãã¡ã®ååè
ãæåºããèŠå¶ç³è«ã®å¯©æ»ã劚ãããé
ããããããããšããããŸããããã«ãFDAã¯ãããã®æåºã«å¯ŸããŠãç§ãã¡ãŸãã¯ç§ãã¡ã®ååè
ãäºæããŠããªãã£ãèŠä»¶ãå®çŸ©ããããšããããŸãããã®ãããªå¿çã¯ãç§ãã¡ãŸãã¯ç§ãã¡ã®ååè
ãéçºãã補ååè£ã®éçºã«ãããŠãé倧ãªé
延ãå¢å ããã³ã¹ãã«ã€ãªããå¯èœæ§ããããŸããããã«ãç§ãã¡ãŸãã¯ç§ãã¡ã®ååè
ãæ¿èªãæ±ããå¯èœæ§ã®ããçŸæ£ã®ããã€ãã«ã¯æ¢ã«æ¿èªãããæ²»çæ³ãããå¯èœæ§ãããããïŒã«ã«ãžãªããªãããŒã䌎ãATTRã¢ããã€ããŒã·ã¹ã®æ²»çã«ãããvutrisiranãå«ãïŒããŸãã¯ç§ãã¡ãŸãã¯ç§ãã¡ã®ååè
ãæ¿èªç³è«ãæåºããããã«æ¿èªãããæ²»çæ³ãéçºäžã§ããå¯èœæ§ããããããèŠå¶åœå±ã®æ¿èªãåããããã«ã¯ãç§ãã¡ãéçºãã補ååè£ãå®å
šãã€å¹æçã§ããããšã ãã§ãªããæ¢åã®æ¿èªããã補åãããå®å
šã§/ãŸãã¯å¹æçã§ããããšãèšåºè©ŠéšãéããŠèšŒæããå¿
èŠããããŸããFDAãEMAãããã³åçã®å€åœã®èŠå¶åœå±ã®éå¶ã®äžæãŸãã¯é
延ã¯ãç§ãã¡ãŸãã¯ç§ãã¡ã®ååè
ãéçºããåååè£ã®å¯©æ»ãæ€æ»ãããã³æ¿èªã®ã¿ã€ã ã©ã€ã³ã«åœ±é¿ããå¯èœæ§ããããŸããCOVID-19ã®å
¬è¡è¡çç·æ¥äºæ
äžãFDAã¯ããŠãŒã¶ãŒæéããã©ãŒãã³ã¹ç®æšã«æ²¿ã£ãå»ç補åã®ç³è«ã®ã¿ã€ã ãªãŒãªå¯©æ»ã確ä¿ããããã«åããŸããããŸããFDAå質åºæºã«æºæ ããŠè£œé æœèšã審æ»ããããã«ã䜿åœäžéèŠãªåœå
å€ã®æ€æ»ãå®æœããŸããã
ãŸããCOVID-19å
¬è¡è¡çäžã®ç·æ¥äºæ
æéäžãå€ãã®äŒæ¥ããFDAãå¿
èŠãšãã審æ»ãå®äºã§ããªãã£ããããå®å
šåçæžã¬ã¿ãŒãåé ããããšãçºè¡šããŸããã2020幎12æãFDAã¯ãUnresolved facility inspection-related conditionsã®ãããNovartisã®Inclisiran NDAã«é¢ããŠCRLãçºè¡ããPDUFA action dateãŸã§ã«NDAãæ¿èªã§ããªãããšãè¿°ã¹ãŸããã2021幎7æãNovartisã¯ãå®å
šåçæžã¬ã¿ãŒã«å¯ŸåŠããããã®Inclisiran NDAã®åæåºãFDAã«ç³è«ããFDAã¯2021幎12æã«LeqvioïŒInclisiranãU.S.åžå Žã§è²©å£²ããéã®åæšåïŒãæ¿èªããŸãããLeqvioã®æ¿èªã®é
延ã¯ãç§ãã¡ãžã®ãã€ã«ã¹ããŒã³ããã³ãã€ã€ã«ãã£å£²äžé«ã®é
延ãåŒãèµ·ãããŸãããFDAãEMAããŸãã¯é¡äŒŒããå€åœã®èŠå¶åœå±ã«ããåæ§ã®äžæãŸãã¯é
延ãããåŸãŸãããã®å Žåãç§ãã¡ãŸãã¯ç§ãã¡ã®å
±åç 究è
ããç§ãã¡ã®è£œååè£ã®èŠå¶æ¿èªãååŸããããã®åªåã«æ·±å»ãªæªåœ±é¿ãäžããç§ãã¡ã®ããžãã¹ãèŠéããæ¥çžŸããŸãã¯è²¡åç¶æ³ã«é倧ãªæªåœ±é¿ãäžããå¯èœæ§ããããŸããããšãã°ãFDAã¯ãç§ãã¡ãŸãã¯ç§ãã¡ã®å
±åç 究è
ã®è£œååè£ã®èŠå¶å¯©æ»ã«é¢é£ããŠãè¿œå ã®èšåºããŒã¿ãŸãã¯ãã®ä»ã®ããŒã¿ãŸãã¯æ
å ±ãèŠæ±ããå ŽåããããŸããããã«ã¯ãç§ãã¡ãŸãã¯ç§ãã¡ã®å
±åç 究è
ãè¿œå ã®èšåºããŒã¿ãŸãã¯ãã®ä»ã®ããŒã¿ãæåºããå¿
èŠãããå®å
šåçæžãçºè¡ããå ŽåããããŸããæœèšã®æ€æ»ãå¿
èŠãªå ŽåããããŸãããã®ãããªããŒã¿ãæ
å ±ãæåºããããšããŠãããŸãã¯ãã®ãããªæ€æ»ãå®äºãããšããŠããFDAã¯æçµçã«NDAãæ¿èªã®åºæºãæºãããŠããªããšå€æããå¯èœæ§ããããŸãã
åœç€Ÿã®è£œååè£ãŸãã¯å
±åéçºè£œååè£ã®æ¿èªãååŸããéã®é
延ãŸãã¯å€±æã¯ãå°æ¥ãåœç€ŸãŸãã¯åœç€Ÿã®å
±åéçºè
ãæ¿èªãæ±ããå¯èœæ§ã®ãããããã補ååè£ããåçãçã¿åºãèœåã«å¯ŸããŠãé倧ãªæªåœ±é¿ãããããå¯èœæ§ããããŸããããšãã°ãATTRã«ã«ãã£ãªããªãããŒã®æ²»çè¬ãšããŠã®ããã£ã·ã©ã³ã®sNDAã«å¯ŸããFDAããã®CRLã®çµæãããã£ã·ã©ã³ã®è£œååçãçã¿åºãèœåãåŠå®çã«åœ±é¿ãåããŸããããã«ãã©ããªè£œåã®è²©å£²æ¿èªããåœç€ŸãŸãã¯åœç€Ÿã®å
±åéçºè
ã補åã販売ããããã®æ¿èªããã䜿çšæ³ã«å¶éã課ããããæšèšãŸãã¯ãã®ä»ã®å¶éãããå Žåããããããã«ãããåœè©²è£œåã®åžå Žæ©äŒãå¶éããåœç€Ÿã®æ¥åãèŠéããæ¥çžŸã財åç¶æ³ãããã³æ ªäŸ¡ã«åŠå®çãªåœ±é¿ãäžããå¯èœæ§ããããŸããããã«ãFDAã«ã¯ãNDAã®å¯©æ»ã®äžç°ããŸãã¯æ¿èªåŸããªã¹ã¯è©äŸ¡ããã³è»œæžæŠç¥ïŒREMSïŒèšç»ãèŠæ±ããæš©éããããŸãããããã«ãããèš±å¯ãããè¬åã®é
åžãŸãã¯äœ¿çšã«é¢ããè¿œå ã®èŠä»¶ãŸãã¯å¶éã課ããããå ŽåããããŸãããã®èšç»ã«ã¯ãç¹å®ã®å»åž«ãå°éçãªãã¬ãŒãã³ã°ãåããå»çã»ã³ã¿ãŒã«åŠæ¹ãå¶éããå®å
šã«äœ¿çšã§ããç¹å®ã®åºæºãæºããæ£è
ã«æ²»çãå¶éãããæ²»çãåããæ£è
ãç»é²ãããªã©ã®èŠæ±ãå«ãŸããå ŽåããããŸããEUã§ã¯ãåœç€ŸãŸãã¯åœç€Ÿã®å
±åéçºè
ã¯ããªã¹ã¯ç®¡çèšç»ãšããŠç¥ãããé¡äŒŒã®èšç»ãæ¡çšããå¿
èŠããããåœç€Ÿã®è£œåã¯ãåŠæ¹ããã³äŸçµŠã®å¶éãããŒã±ãã£ã³ã°åŸã®å®å
šæ§ãŸãã¯æå¹æ§ã®èª¿æ»ãæ£è
ããã³/ãŸãã¯åŠæ¹å»æè²è³æã®é
åžãªã©ã®ç¹å¥ãªãªã¹ã¯æå°åçã«å¯Ÿè±¡ãšãªãå¯èœæ§ããããŸããã©ã¡ãã®å Žåã«ãããŠãããããã®å¶éãšå¶çŽã¯ãåœç€Ÿã®è£œåã®åžå ŽèŠæš¡ãå¶éãã第äžè
æ¯æãè
ã«ããæãæ»ãã«åœ±é¿ãäžããå¯èœæ§ããããŸãã
ãã®ä»ãèšåºè©Šéšã補é ã販売èªå¯ãäŸ¡æ Œèšå®ããµãŒãããŒãã£ãŒã«ããæãæ»ãã«é¢ããå€æ°ã®å€åœèŠå¶èŠä»¶ã®å¯Ÿè±¡ãšãªãããšããããŸããå€åœã®èŠå¶æ¿èªããã»ã¹ã¯åœããšã«ç°ãªããç±³åœFDAã®æ¿èªã«é¢é£ãããã¹ãŠã®ãªã¹ã¯ã®ä»ã«ãå€åœç®¡èœåºåã§ã®å°å
ã®èŠå¶éµå®ã«é¢é£ãããªã¹ã¯ããããŸããFDAã«ããæ¿èªã¯ãç±³åœå€ã®èŠå¶åœå±ã«ããæ¿èªãä¿èšŒãããã®ã§ã¯ãªãããã®éããŸãåæ§ã§ãã
ç§ãã¡ãŸãã¯ååè
ãèŠå¶åœå±ããæ¿èªãåŸããšããŠããåæ¥åããã補åã¯ç¶ç¶çãªèŠå¶äžã®ç£èŠãåããŸããç§ãã¡ãŸãã¯ååè
ãç±³åœããã³å€åœã®èŠä»¶ã«éåããå Žåãæ¿èªãå¶éããããåãæ¶ããããããå¯èœæ§ãããããã®å Žåã«ã¯çœ°éãç§ããããå¯èœæ§ãããããã®å Žåã¯ããžãã¹ã«é倧ãªåœ±é¿ãçããå¯èœæ§ããããŸãã
åœç€ŸãŸãã¯ååå
ãéçºãã補åã«é¢ããåæã®èŠå¶æ¿èªã®åŸãåœç€Ÿã®ïŒã€ã®æ¿èªè£œåãå«ãã補åãåæ¥çã«å©çšå¯èœã«ãªã£ãåŸã«å ±åãããæ害è¬å€äœéšãèšåºçµæã®ã¬ãã¥ãŒãå«ããç¶ç¶çãªèŠå¶ç£ç£ã®å¯Ÿè±¡ãšãªããŸããããã«ã¯ãæ¿èªã®æ¡ä»¶ãŸãã¯åœç€Ÿãåæãããã®ä»ã®è£œåã®å®å
šæ§ããã³æå¹æ§ãç£èŠããããã®ãã¹ãããŒã±ãã£ã³ã°ãã¹ããç£èŠã®çµæãå«ãŸããŸããåŒç€ŸãONPATTROãAMVUTTRAãGIVLAARIãOXLUMOã®ããã«åãåã£ãèŠå¶æ¿èªãããã³è£œååè£ã®ããããã®ããã«åãåãèŠå¶æ¿èªããAMVUTTRAã®æ¡åŒµãããã©ãã«ãå«ãã補åãããŒã±ãã£ã³ã°ããããã«æ¿èªããã䜿çšæ¹æ³ã«å¶éã課ããããå ŽåããããŸããå®å
šæ§ããã³ãã®ä»ã®ãã¹ãããŒã±ãã£ã³ã°æ
å ±ããã³ã¬ããŒãã®æåºãç»é²ããã³ãªã¹ãã¢ãããcGMPèŠä»¶ãæ¿èªåŸã«è¡ããã¹ãŠã®èšåºè©Šéšã®ããã®GCPèŠä»¶ãå«ããé©åãªå質ã¬ã€ãã©ã€ã³ããã³èŠå¶ã«å¯Ÿããéµå®ã®ç¶ç¶ãããã®ä»ã®èŠå¶èŠä»¶ã®äžéšã§ãããŸããå ããŠãåœç€Ÿã¯è£œååè£ã«é¢ããŠèšåºè©Šéšãè¡ããç±³åœå€ã®ç®¡èœåºåã§åœç€Ÿã®è£œååè£ãåžå ŽæäŸããããã®æ¿èªãæ±ããäºå®ã§ããããã®ãããããã®ç®¡èœåºåã§ã®èŠå¶èŠä»¶ã«åŸãå¿
èŠããããŸãã
ç±³åœFDAã¯ãååãåžå Žæå
¥ããåŸã«ãéèŠãªèŠå¶æš©éãæã¡ãŸããæ°ããªå®å
šæ
å ±ã«åºã¥ãã©ãã«å€æŽãã補å䜿çšã«é¢ããæ·±å»ãªå®å
šäžã®ãªã¹ã¯ãè©äŸ¡ããããã®åžå Žæå
¥åŸã®ç 究ãèšåºè©Šéšã®å®æœã補åã®åžå Žããã®æ€åãèŠæ±ããæš©éããããŸããFDAã¯ãŸããæ¿èªåŸã«REMSèšç»ãèŠæ±ããæš©éããããããã«ããæ¿èªããã補åã®æµéã䜿çšã«ããã«èŠä»¶ãå¶éã課ãããšãã§ããŸããæ¿èªããã補åãåæ¥çã«äœ¿çšãããã«ã€ããŠãç§ãã¡ãä»ã®äººã
ã以åã«ç¥ãããŠããªãã£ãå¯äœçšãç¹å®ããããšããããŸãããŸããèšåºè©Šéšãå
è¡ããåžå Žæå
¥æéããããæ¢ç¥ã®å¯äœçšãé »ç¹ã«çºçãããããŸãã¯éçã§ããããšã芳å¯ãããå¯èœæ§ããããŸãããã®å Žå:
⢠æ¿èªããã補åã®å£²äžé«ã¯ãåœåã®äºæ³ããäœããªãå¯èœæ§ããããŸãã
⢠åœç€Ÿã®æ¿èªããã補åã«é¢ããèŠå¶åœå±ã®æ¿èªã¯å¶éãããå ŽåãããããŸãã¯åãæ¶ãããå¯èœæ§ããããŸãã
⢠ç§ãã¡ã¯ãå»åž«ãè¬å€åž«ãç
é¢ã«è£œåã®èŠåææžãçŸå Žã¢ã©ãŒããéãããšã決å®ããããšããããŸãããŸãã¯èŠæ±ãããå¯èœæ§ããããŸãã
⢠远å ã®éèšåºç 究ãèšåºè©Šéšãã©ããªã³ã°ã®å€æŽãREMSèšç»ã®æ¡çšã補é ããã»ã¹ãä»æ§ããã³/ãŸãã¯æœèšã®å€æŽãå¿
èŠã«ãªãå ŽåããããŸãã; ãããŠ/ãŸãã¯
⢠æ¿åºã®èª¿æ»ã蚎èšãéå£èšŽèšãªã©ãç§ãã¡ã«å¯ŸããŠèµ·ããããå¯èœæ§ããããŸãã
äžèšã®ãããªãäºè±¡ããæ¿èªããã補åã®è²©å£²ãæžå°ããããäžæ¢ããå¯èœæ§ããããŸããããã«ãããè²»çšãå¢å ãããããã®è£œåã®æåè£ã«åååããèœåãæãªãããå¯èœæ§ããããŸãã
åœç€Ÿãæ¿èªããã補åããã³äžéšã®çŸè¡è£œååè£ã補é ããããã«äœ¿çšããCMOããã³è£œé æœèšãå
æ¬çã«ã¯ãåœç€Ÿã®ã±ã³ããªããžæœèšãããŒãã³æœèšããŸãAgilentããã³ãã®ä»ã®CMOã«é¢ããŠã¯ãFDAããã³ãã®ä»ã®èŠå¶åœå±ã«ããå®æçãªå¯©æ»ããã³æ€æ»ã®å¯Ÿè±¡ãšãªããŸããããšãã°ãAgilentããã³åœç€Ÿã®ã±ã³ããªããžæ ç¹ã®æœèšã¯ãONPATTROããã³GIVLAARIã®èŠå¶æ¿èªã®ç³è«ã®å¯©æ»ã«é¢é£ããŠFDAããã³EMAã«ããèŠå¶æ€æ»ã®å¯Ÿè±¡ãšãªããä»ã®å°åã§åœç€Ÿã®1ã€ä»¥äžã®è£œåã®èŠå¶æ¿èªã®ããã®åŸç¶ã®ç³è«ã«é¢é£ããŠåæ§ã®æ€æ»ã®å¯Ÿè±¡ãšãªãå¯èœæ§ããããŸããåœç€ŸãŸãã¯åœç€Ÿã®CMOã®è£œé ããã»ã¹ãŸãã¯æœèšã«æ°ããåé¡ãŸãã¯ä»¥åã«æªç¥ã®åé¡ãçºèŠãããå Žåããã®æœèšãŸãã¯æœèšã§è£œé ããã補åã«å¶éã課ãããã補åãåžå Žããã®æ€éãŸãã¯æ¿èªã®é
延ãªã©ãçºçããå¯èœæ§ããããŸããããšãã°ãæ人ã®hATTRã¢ããã€ããŒã·ã¹ã®æ²»ççšãããªã·ã©ã³ã®èŠå¶æ¿èªã®ããã®åœç€Ÿã®èŠå¶çãªæåºã®ä¿®æ£ãäœåãªãããããããCMOæœèšã®å®æçãªFDAã®æ€æ»ã«ããä¿çäžã®æ€æ»åé¡ãšãªã£ããããåœç€Ÿã®PDUFAç®æšæ¥ããã³AMVUTTRAã®FDAæ¿èªãé
ããŸãããåœç€Ÿã¯ãåæ¥çšããã£ã·ã©ã³ãã©ãŒã 補å€ã®cGMPèœåããã³ããã»ã¹ãéçºããèšåºããã³å°æ¥çã«åæ¥çšã®è¬å€ç©è³ªã®ããã«ãããµãã¥ãŒã»ããå·ã®ããŒãã³ã«cGMP補é æœèšã建èšããããšãã§ããŸããããå°æ¥çã«åºç¯ãªåæ¥çãªèŠæš¡ã§ç©è³ªã補é ããèœåãŸãã¯å®¹éãæã£ãŠããªãå¯èœæ§ããããŸãããŸããåœç€Ÿãèšåºè©Šéšææã補é ããå ŽåããŸãã¯ç¬¬äžè
ã«ãã®ææã®è£œé ãå§èšããå ŽåããããŸããCMOãžã®äŸåã¯ãèªç€Ÿã§è£œåã補é ããå Žåã«ã¯é¢äžããªããªã¹ã¯ã䌎ããŸããèŠå¶é å®ã«å¯Ÿãã該åœããCMOãžã®äŸåãå«ãŸããŸãã
ãããç§ãã¡ãå
±åç 究è
ãCMOãŸãã¯ãµãŒãã¹ãããã€ããŒããç±³åœãŸãã¯ååãåžå Žã«åºãå€åœã®ç®¡èœåºåã§ãé©çšãããç¶ç¶çãªèŠå¶èŠä»¶ã«æºæ ããªãå Žåãç§ãã¡ãŸãã¯åœŒãã¯ã眰éãèŠåæžãèšåºè©Šéšã®äžæ¢ãFDAãŸãã¯å€åœã®èŠå¶åœå±ã«ããä¿çãæ¿èªç³è«æžãŸãã¯æ¿èªæžã¿ç³è«æžã®è£è¶³æžé¡ã®æ¿èªæåŠãèŠå¶æ¿èªã®äžæåæ¢ãŸãã¯åãæ¶ãã補åãªã³ãŒã«ãæŒåã補åã®èŒžå
¥ãŸãã¯èŒžåºãèš±å¯ããªãããšãæ¥åå¶éãå·®ãæ¢ããæ°äºçœ°éãåäºèšŽè¿œãªã©ããã®ä»ã®æªçœ®ã«å¯Ÿãã被ååŠåãåããå¯èœæ§ãããããŸãã
æªæ¿èªã®è£œååè£ã«ã€ããŠåæ¥æŽ»åãè¡ã£ãŠãããšããããã¯é©çšæ³èŠã«éåããããã«åæ¥çã«æ¿èªããã補åã宣äŒããå Žåã«ãå·è¡åœå±ã䞻匵ããããå€æããå Žåãåœç€Ÿã¯é倧ãªè²¬ä»»ãè² ãå¯èœæ§ããããŸãã
å»çé¢é£ã®ããããåéã«ãããŠãå»åž«ã¯è£éã®äœå°ãããã補åã©ãã«ã«èšèŒãããŠããªã䜿çšæ¹æ³ããFDAãŸãã¯ãã®ä»ã®é©çšèŠå¶æ©é¢ãæ¿èªãããã®ãšç°ãªã䜿çšæ¹æ³ã«ã€ããŠãæ¿èªãããè¬å€è£œåãåŠæ¹ããããšãã§ããŸãããªãã©ãã«äœ¿çšã¯å»çåéå
šè¬ã§äžè¬çã§ããè¬å€è£œåãæ¿èªããFDAããã®ä»ã®èŠå¶åœå±ã¯ãå»åž«ã®å»çã®å®è·µãæ²»çéžæãèŠå¶ããŸãããã補é æ¥è
ã®ãªãã©ãã«äœ¿çšã«é¢ããéä¿¡ããªãã©ãã«ããã¢ãŒã·ã§ã³ãåœããŸãã¯èª€ã£ãã©ãã«ãããã¢ãŒã·ã§ã³è³æã®æ¡æ£ã代ç人ã«ãããããã®è¡çºãèŠå¶ããŠããŸãã補é æ¥è
ããã®ä»£ç人ã¯ãæ¿èªã©ãã«ã«åèŽããªããªãã©ãã«äœ¿çšã®è¬å€ãæ¹åããããšã¯ã§ããããŸããã®ãããªè£œåã«é¢ããæ¿èªã©ãã«ãšççŸããæ
å ±ã補åã®ããã¢ãŒã·ã§ã³ã§æäŸããããšã¯ã§ããŸãããããšãã°ãã¢ã¡ãªã«ã§ã¯ONPATTROãŸãã¯AMVUTTRAããæ人ã«ãããããªãã¥ãŒããããŒã®hATTRã¢ããã€ããŒã·ã¹ã®æ²»ç以å€ã®é©å¿çã«ã€ããŠçŸåšããã¢ãŒã·ã§ã³ããããšã¯ã§ããŸãããFDAããã®ä»ã®èŠå¶åœå±ã¯ããªãã©ãã«äœ¿çšã®ããã¢ãŒã·ã§ã³ãããŒã±ãã£ã³ã°æ¿èªãåããŠããªã補åã®ããã¢ãŒã·ã§ã³ãçŠæ¢ããæ³åŸãèŠå¶ãç©æ¥µçã«æœè¡ããŠãããå°æ¥çã«åŒç€Ÿãåæ¥è£œåã®äžé©åãªããŒã±ãã£ã³ã°ãããã¢ãŒã·ã§ã³ãè¡ã£ãå Žåãå¹
åºãæ°äºãè¡æ¿ãåäºçœ°éãå¶è£ãå«ãå·®ãæ¢ãæªçœ®ãå«ãã補åã®ããã¢ãŒã·ã§ã³æŽ»åã«é¢ããäžå©ãªæ±ºå®ãçµè«ã䞻匵ãå·è¡æš©ãŸãã¯èŠå¶æš©éãããã°ãåŒç€Ÿã®ããžãã¹ãå±æãæ¥çžŸã財åç¶æ
ã«å®³ãåãŒãããšããããŸããä»ã®å
éšãŸãã¯æ¿åºã®èª¿æ»ãæ³çãŸãã¯èŠå¶äžã®æç¶ããå人çãªèšŽèšã«ãã蚎èšãè¿œéããå¯èœæ§ããããŸãã
補åã®ããã¢ãŒã·ã§ã³ã«é¢ããèŠå¶ã«ããããããFDAããã³ãã®ä»ã®èŠå¶åœå±ã¯ãçå®ã§ããã誀解ãæããªãç§åŠçãªæ
å ±äº€æãéããŠã補åã«é¢ããæ
å ±ãæäŸããããšãäŒæ¥ã«èš±å¯ããŠããŸããæã
ã¯ãé¢é£æ³åŸããã³èŠå¶ã¬ã€ãã³ã¹ã«æºæ ããŠãå»çæè²æŽ»åã«åŸäºããå»çåŸäºè
ãšã³ãã¥ãã±ãŒã·ã§ã³ããšãããšãæå³ããŠããŸããããããFDAããã®ä»ã®èŠå¶åœå±ã競åä»ç€Ÿããã®ä»ã®ç¬¬äžè
ãæã
ããã®ãããªèŠå¶ã«éåããŠãããšããç«å Žãåãå¯èœæ§ããããããããéåã蚌æãããã°ãæã
ã®è©å€ãæãªãããšããã³ã¢ããžãã¹ããè³éã管çãªãœãŒã¹ãéžããããšã«ã€ãªãããé倧ãªæªåœ±é¿ãåãŒãå¯èœæ§ããããŸãã
ç§ãã¡ã®ããžãã¹ãèŠéããéå¶çµæããŸãã¯è²¡åç¶æ³ã«é¢ããäžç¢ºå®æ§ãããå ŽåããããŸããããã«ã第äžè
ã«ããè
åšãŸãã¯å®éã®è¡æ¿å·è¡æªçœ®ããŸãã¯èšŽèšã¯ãæªåœ±é¿ãããããå¯èœæ§ããããŸãããã®ãããªåœ±é¿ã¯ãåœç€Ÿè£œåãžã®éèŠã®äœäžãæããããžãã¹ã®ãã®ä»ã®åŽé¢ã«ãããŠçç£çã«äœ¿çšã§ããå€å€§ãªãªãœãŒã¹ãå¿
èŠãšããããšã«ãªããããåŸãªãããšããããŸãã
åœç€Ÿã®å»çæè²æŽ»åã«å ããŠãåæ¥çã«æ¿èªããã補åãçšããæ²»çãåããæ£è
ãæ¯æŽããæ£è
æ¯æŽãµãŒãã¹ãæäŸããŠããŸãã補é æ¥è
ã¯ããããããµãŒãã¹ãéããŠå»åž«ãæ£è
ã«éæ³ãªèªå ãæäŸããã¡ãã£ã±ã¢ãã¡ãã£ã±ã€ãããã®ä»ã®æ¿åºããã°ã©ã ãéããŠæ¿åºã®è³æºã®äžé©åãªå©çšã«ã€ãªãããšããåçºãåããæ¿åºã®èª¿æ»å¯Ÿè±¡ãšãªã£ãŠããŸããé£éŠåããã¯ããã¯æ³ãé£éŠåœèšè«æ±æ³ãFCAãªã©ã®æ³åŸã«éåããäŒæ¥ã¯ãæ°äºããã³è¡æ¿çœ°éãåäºåŠçœ°ãããã³æ¿åºããã°ã©ã ãžã®åå çŠæ¢ãªã©ãé倧ãªè²¬ä»»ãè² ãããšã«ãªããŸãã
以äžã«èª¬æããããã«ãç§ãã¡ã¯é©çšæ³ã«åŸã£ãŠãããã®ããã°ã©ã ã掻åãå®è¡ããããã®ã°ããŒãã«ã³ã³ãã©ã€ã¢ã³ã¹ããã°ã©ã ã«æ³šåããŠããŸãããããã®ããã°ã©ã ã掻åããµããŒããããããã«èšèšãããŠããŸãã
ç§ãã¡ãŸãã¯ååè
ã補ååè£ãåžå Žã«æå
¥ããããã®èŠå¶æ¿èªãåãããšããŠããåžå Žã補ååè£ãåãå
¥ããªãå Žåããããããã¯ç§ãã¡ã®ããžãã¹ãå°æ¥æ§ãæ¥çžŸã財åç¶æ³ã«æªåœ±é¿ãäžããå¯èœæ§ããããŸãã
æã
ãéçºããŠãã補ååè£ã¯æ¯èŒçæ°ããæè¡ãæ²»çã¢ãããŒãã«åºã¥ããŠãããæåã®è£œåã§ããONPATTROã¯2018幎8æã«åæ¥è²©å£²æ¿èªãåããŸãããå»åž«ãªã©ã®å»è¬ååžå Žã®äž»èŠãªé¢ä¿è
ã第äžè
å¥åº·ä¿éºäŒç€Ÿãæ¶è²»è
ãRNAiãã¯ãããžãŒã«åºã¥ãæ²»çæ瞟ã®æ¹åãç®çãšãã補åãåãå
¥ããªãå ŽåããããŸãããã®ãããç§ãã¡ã®è£œåãåãå
¥ãã䜿çšããããã«å»çã³ãã¥ããã£ã第äžè
å¥åº·ä¿éºäŒç€Ÿã説åŸããããšããŸãã¯å¥œæçãªæãæ»ããæäŸããããšãããå°é£ã§ããå¯èœæ§ããããŸãã
åœç€Ÿã®è£œåã®åžå Žåãå
¥ãã«éèŠãªåœ±é¿ãäžãããšèããããä»ã®èŠå ã«ã¯ã以äžãå«ãŸããŸãïŒ
⢠ããŒã±ãã£ã³ã°æ¿èªã®åé ã¿ã€ãã³ã°ãæ¿èªæ¡ä»¶ãæ¿èªãååŸãããåœã
ã
⢠èšåºè©Šéšã«ãããæã
ã®è£œååè£ã®å®å
šæ§ãšæå¹æ§ãããã³ä»£æ¿åŠçœ®ãšã®æ¯èŒã«ãããŠããã®æå¹æ§ã瀺ããŸãã
⢠åœç€Ÿã®è£œååè£ã®çžå¯Ÿçãªå©äŸ¿æ§ãæäžã¹ã±ãžã¥ãŒã«ãããã³æäžã®å®¹æã;
⢠æ£è
ãæ°ããæäžçµè·¯ãæ°ããæ²»çã¢ãããŒããäœçšã¡ã«ããºã ãåãå
¥ããæ欲
⢠ç§ãã¡ã®å»åž«æè²ããã°ã©ã ã®æåïŒ
⢠ååãªæ¿åºããã³ç¬¬äžè
æ¯æãè
ã®æãæ»ãã®å¯çšæ§;
⢠ç§ãã¡ã®è£œåã®äŸ¡æ Œã¯ã代æ¿æ²»çãšæ¯èŒããŠç¹ã«éèŠã§ãããåžå Žããã®äŸ¡æ Œãšå°æ¥çãªäŸ¡æ Œäžæã«å¯Ÿããèªèãæã£ãŠããŸãã
⢠åœç€Ÿã®éçºãã補ååè£ãæ²»çããçŸæ£ã«å¯Ÿãã代æ¿æå¹æ²»çæ³ã®å
¥æå¯èœæ§ãããã³ãããã®æ²»çæ³ã®çžå¯Ÿçãªãªã¹ã¯ãå©çãããã³è²»çšã
äŸãã°ãONPATTROã¯ãç°ãªãéžæè¢ãšæ¯èŒããŠãå»åž«ãæ£è
ãç°¡åã«æ¡çšããªãéè
çµè·¯ãçšããéèå
æäžæ³ã䜿çšããŠããã倧人ã®hATTRã¢ããã€ããŒã·ã¹ã®ç¥çµçç¶ã䌎ãæ²»çã«ãããŠã¯ãã¢ã¹ãã©ãŒãã«ãšã¢ã€ãªãã¹ã販売ããç®äžæ³šå°ã®WAINUAïŒãšããã³ãã«ã»ã³ïŒãŸãã¯ãã¡ã€ã¶ãŒãè€æ°ã®åœã§è²©å£²ããé å€ã®tafamidisãšç«¶åããããšãã§ããªãå¯èœæ§ããããŸããããã«ãfitusiranã¯è¡åç
ã®æ²»çã«å¯Ÿããæ°ããã¢ãããŒããè¡šããããå»åž«ãæ£è
ãä»è·è
ã«ãã£ãŠããã«åãå
¥ããããªãå¯èœæ§ããããŸããVutrisiranãATTRã¢ããã€ããŒã·ã¹ã®å¿ççã®æ²»çã«æ¿èªãããå Žåãåæ§ã®åžå Žåãå
¥ãã«å¯Ÿãã課é¡ã«çŽé¢ããå¯èœæ§ããããŸãã
ç§ãã¡ã¯ãã«ããããã¯ãã®åæ¥äŒç€Ÿã§ãããåŒãç¶ãããŒã±ãã£ã³ã°ãã»ãŒã«ã¹ãåžå Žã¢ã¯ã»ã¹ãæµéèœåãæ§ç¯ããããã«è«å€§ãªè²¡åããã³ãããžã¡ã³ãã»ãªãœãŒã¹ã®æè³ãç¶ããããšãäºå®ããŠãããããã«ã°ããŒãã«ãªã€ã³ãã©é¢é£ã®ç¢ºç«ãé²ããŸãããããã®èœåãéçºããã¹ã±ãŒã«ããããšãã§ããªããã°ãçŸåšã®è£œåããã³å°æ¥ã®è£œåãåæ¥åããããšãã§ããªãå¯èœæ§ããããŸãã
2018幎8æã«æåã®è£œåæ¿èªãåããéå»æ°å¹Žéã«ãããããŒã±ãã£ã³ã°ã販売ãåžå Žã¢ã¯ã»ã¹ããã³æµéã®èœåã確ç«ããŸãããæ¿èªãããå Žåãäžéšã®å°åã®è£œååè£ã®çºå£²ãããŒã±ãã£ã³ã°ã«ã¯ã第äžè
ã«äŸåããããšãäºæ³ãããŠããŸãããã ããONPATTROãAMVUTTRAãGIVLAARIããã³OXLUMOãå®éã«åååããæ¿èªãããããäž»èŠåžå Žã§èªç€Ÿã§ä»ã®è£œååè£ã®åååãã°ããŒãã«ã«å®æœããããšãæå³ããŠããŸãããã®ãããç§ãã¡ã¯ãæåã¯ç±³åœããšãŒããããæ¥æ¬ãå«ãäž»èŠåžå Žã§ã®äž»å補åæŠç¥ã®äžç°ãšããŠãå
éšã§ã®ããŒã±ãã£ã³ã°ã販売ãåžå Žã¢ã¯ã»ã¹ããã³æµéåãéçºããŸãããã°ããŒãã«ã§ã®æ¡å€§ãç¶ããŠããŸããã倧ããªè²¡åããã³ç®¡çãªãœãŒã¹ãå¿
èŠãšããŠããŸããONPATTROãAMVUTTRAãGIVLAARIãOXLUMOãå«ããç§ãã¡ãããŒã±ãã£ã³ã°ã販売ãåžå Žã¢ã¯ã»ã¹ãæµéæ©èœãèªç€Ÿã§å®æœãã補åã«ã€ããŠã¯ã
ãããŠãå°æ¥ã®è£œåã«ã€ããŠãéçºãšåæ¥åã®æš©å©ãç¶æããããšãæåããå Žåã以äžã®è¿œå çãªãªã¹ã¯ã«çŽé¢ããå¯èœæ§ããããŸãïŒ
⢠ã°ããŒãã«ãªå¶æ¥ãããŒã±ãã£ã³ã°ãããã³ç®¡çã€ã³ãã©ã¹ãã©ã¯ãã£ãŒãšèœåã®æ¡å€§ããã³ç¶æ;
⢠äžçäžã®äººå¡ã®æ¡çšãç ä¿®ã管çãç£ç£;
⢠ç¹å®ã®è£œåããã³/ãŸãã¯ç¹å®ã®å°åã§çæãããåçã«æ¯ã¹ãŠæ£åœåãããªãå Žåãããã確ç«ãããããŒã±ãã£ã³ã°ãŸãã¯å¶æ¥åãããã«éçºãŸãã¯å©çšããããã®ã³ã¹ã; ãããŠ
⢠ç§ãã¡ã®çŽæ¥è²©å£²ãšããŒã±ãã£ã³ã°ã®åªåãããŸããããªããããããŸããã
çŸåšããã³å°æ¥ã®è£œåã®ããŒã±ãã£ã³ã°ãã»ãŒã«ã¹ãåžå Žã¢ã¯ã»ã¹ãé
åžæ©èœãã°ããŒãã«ã«éçºã»æ¡å€§ã§ããªãå ŽåããµãŒãããŒãã£ãŒã«äŸåããã«è£œåãåæ¥åããããšãã§ããŸããã
hATTRã¢ããã€ããŒã·ã¹ãAHPãPH1ã®å€çºæ§ãã¥ãŒããããŒãæ£ã£ãŠããæ£è
éå£ã¯å°ãããæ£ç¢ºã«ç¢ºç«ãããŠããŸããããããã®çŸæ£ãæ£ã£ãŠããå®éã®æ£è
æ°ãç§ãã¡ãæšå®ãããããå°ãªãå ŽåããŸãã¯ãããã®çŸæ£ã®èªç¥ãæ¹åãããã«èšºæãæ¹åãããªãå Žåãç§ãã¡ã®ããžãã¹ãèŠéããæ¥çžŸã財åç¶æ
ã«äžå©ãªåœ±é¿ãäžããå¯èœæ§ããããŸãã
ç§ãã¡ãåæ¥åãéå§ããæç¹ã§ã®ONPATTROãAMVUTTRAãGIVLAARIãOXLUMOããŸãã¯å°æ¥ã®è£œåã«é¢ããæœåšçãªåžå ŽèŠæš¡ã«é¢ããç§ãã¡ã®èŠç©ããã¯ãèŠå¶åœå±ãæ¿èªããæ瀺ã®çµæãå«ããå®éã®åžå ŽèŠæš¡ãšå€§ããç°ãªãå Žåããããããã¯ç§ãã¡ã®äºæ¥èšç»ã«é倧ãªå€æŽãããããããšããããç§ãã¡ã®äºæ¥ãèŠéããæ¥çžŸããã³è²¡åç¶æ³ã«é倧ãªæªåœ±é¿ãåãŒãå¯èœæ§ããããŸããå€ç«ããç
æ°ã®å Žåããããã®ç
æ°ã«é¢ããèªç¥åºŠãé«ãã蚺æãæ¹åããããšãã§ããªããã°ãç§ãã¡ã®äºæ¥ãèŠéããæ¥çžŸãŸãã¯è²¡åç¶æ³ã«é倧ãªæªåœ±é¿ãäžããå¯èœæ§ããããåçæ§ãå®çŸããããšã¯ããå°é£ãŸãã¯äžå¯èœã«ãªãå¯èœæ§ããããŸãã
çŸåšåžå Žã§è²©å£²ããŠãããŸãã¯å°æ¥éçºããå¯èœæ§ã®ãããã¹ãŠã®è£œåããäžå©ãªäŸ¡æ ŒèŠå¶ã第äžè
ã®æãæ»ããã©ã¯ãã£ã¹ããŸãã¯å»çæ¹é©ã€ãã·ã¢ããã®å¯Ÿè±¡ãšãªãå¯èœæ§ããããããã«ãããç§ãã¡ã®ããžãã¹ãèŠéããæ¥çžŸãããã³è²¡åç¶æ³ã«æªåœ±é¿ãäžããå ŽåããããŸãã
æ°ããå»è¬åã®è²©å£²æ¿èªãã«ãã¬ããžãäŸ¡æ Œèšå®ãããã³æãæ»ãã«é¢ããèŠå¶ã¯ãåœã«ãã£ãŠéåžžã«ç°ãªããå€æŽãããå¯èœæ§ããããŸããäžéšã®åœã§ã¯ãè¬å€ã®è²©å£²äŸ¡æ Œã®æ¿èªãå¿
èŠã§ããå€ãã®åœã§ã¯ãäŸ¡æ ŒèŠçŽãæéã¯ãããŒã±ãã£ã³ã°æ¿èªãŸãã¯è£œåã©ã€ã»ã³ã¹æ¿èªåŸã«å§ãŸããŸããäžéšã®æµ·å€åžå Žã§ã¯ãåææ¿èªåŸãåŠæ¹è¬ã®äŸ¡æ Œèšå®ã¯ç¶ç¶çã«æ¿åºã®çµ±å¶äžã«ããå ŽåããããŸããæ¿èªããã補åã販売ããŠããæäžã«ãæ¿èªãåŸããã補ååè£ãåŸæéçºæ®µéãé²ããã«ã€ãããããã®èŠå¶ãç©æ¥µçã«ç£èŠããŠããŸãããã ããåœç€Ÿã®è£œååè£ã®å€ãã¯çŸåšæ©æéçºæ®µéã«ããããã®ãããªèŠå¶ã®åœ±é¿ããã®éçºããã°ã©ã ã«å¯Ÿããå€æŽã®åœ±é¿ãæ°å¹Žéè©äŸ¡ã§ããªãå ŽåããããŸãããŸããç¹å®ã®åœã§è£œåãåœç€Ÿã®æ¿èªè£œåã®1ã€ä»¥äžãå«ã補åã®èŠå¶äžã®æ¿èªãåŸãããšããããŸãããååã®åæ¥çãªçºå£²ã«é
ããçããäŸ¡æ ŒèŠå¶ãŸãã¯äŸ¡æ Œçµ±å¶ã®åœ±é¿ãåãããã®åœãä»ã®åœã§ã®åå販売ããã®åçã«æªåœ±é¿ãäžããå¯èœæ§ããããŸãã
æ¿åºã第äžè
æ¯æè
ã«ããå»çè²»ã®æå¶ãåæžã«é¢ããåãçµã¿ãå»çã®å©çšæ¡å€§ã«é¢ããç«æ³ã»èŠå¶ææ¡ããå»è¬åã»ãã€ãªå»è¬åäŒæ¥ã®ããžãã¹ããã³è²¡åç¶æ³ã«åœ±é¿ãäžãç¶ãããšèããŠããŸããã¢ã¡ãªã«ã§ã¯ã補è¬åã®äŸ¡æ Œèšå®ã¯æ¿åºããã³äžè¬ã®ç£èŠã®äžã«ãããæ¹é©ãæ±ãã声ãé«ãŸã£ãŠãããã¢ã¡ãªã«æ¿åºã¯ã³ã¹ã管çãç®çãšããç«æ³ã»èŠå¶å€æŽã«æ³šåãç¶ããŠããŸããå
·äœçã«ã¯ãåŠæ¹è¬ã«é¢ããU.S.äžé¢è°äŒã®èª¿æ»ãæ°ä»¶è¡ãããŠãããé£éŠããã³å·ã®ææ¡ã»æç«æ³åŸã»èŠå¶ã«ãããå»è¬åã®è²©å£²äŸ¡æ Œã®éææ§åäžãã¡ãã£ã±ã¢ã«ãããåŠæ¹è¬è²»çšã®åæžã補é æ¥è
æ£è
ããã°ã©ã ãšè²©å£²äŸ¡æ Œã®é¢ä¿ã®èŠçŽããè¬å€ã®æ¿åºããã°ã©ã ã«ãããå ±é
¬æ¹æ³ã®æ¹é©çãç®çãšããŠããŸãããããã®ååã¯ãæ¿èªãããå Žåã«ãONPATTROãAMVUTTRAãGIVLAARIãOXLUMOãããã³ä»åŸã®è£œåãæå©ãªäŸ¡æ Œã§è²©å£²ããå¯èœæ§ã«çŽæ¥çãŸãã¯éæ¥çã«åœ±é¿ãäžããããšããããŸãã
ããšãã°ãé£éŠã¬ãã«ã§ã¯ãã€ã³ãã¬æå¶æ³ïŒIRAïŒã«ã¯ãåœç€Ÿã®ããžãã¹ã«æ§ã
ãªåœ±é¿ãäžããããã€ãã®èŠå®ãå«ãŸããŠããŸããããšãã°ãIRAã«ãããã¡ãã£ã±ã¢ããŒãBãŸãã¯Part Dè¬ã®è²»çšãã€ã³ãã¬çãããéãå¢å ããå ŽåããªããŒããæ¯æãå¿
èŠããããããããŸãããããã«ãæ¿èªããã補åããIRAå®æœåã®Part Dã®çŠå©åçãã¶ã€ã³ã«æ¯ã¹ãŠæ°ãããã¶ã€ã³ã«åºã¥ãå Žåãã¡ãã£ã±ã¢Part Dã§ã«ããŒããä»»æã®æ¿èªããã補åã«å¯Ÿããè²»çšè² æ
ãããªã倧ãããªãå¯èœæ§ããããŸããIRAã®äŸ¡æ Œäº€æžããã°ã©ã ã«ãããæ網èçã®æ²»çã«å¯Ÿããvutrisiranã®FDAæ¿èªã«ãããåœç€Ÿã¯Medicareã®äŸ¡æ Œäº€æžããã®AMVUTTRAã®å€å
é€å€æš©ã倱ãããšã«ãªããŸãããã®çµæã2022幎10æãæ網èçã®æ²»çã«å¯Ÿããvutrisiranã®ç¬¬3çžèšåºè©Šéšãè¡ããªãããšãçºè¡šããŸãããIRAã«éåãã補é æ¥è
ã¯ãæ°äºçœ°éãŸãã¯æœåšçãªæ¶è²»çšãå«ãæ§ã
ãªå¶è£ã®å¯Ÿè±¡ãšãªãå¯èœæ§ããããŸããIRAã®åœç€Ÿã®ããžãã¹ããã³å»çç£æ¥å
šè¬ãžã®åœ±é¿ã¯åŒãç¶ãé²å±ããåœç€ŸãŸãã¯æ¥çš®å
šäœã«ããã«äžå©ãªåœ±é¿ãåãŒãå¯èœæ§ããããŸããIRAã¯ããã®åé¡ã«ãããŠå€§ããªåœ±é¿ãäžããããšãäºæ³ãããŸãã
å»è¬åæ¥çš®ã«ãããŠããã®ä»ã®åœ±é¿ã®äžã«ãç§ãã¡ã補åã販売ããéã«è«æ±ã§ããäŸ¡æ Œãè£åãåãåãããšãã§ããéé¡ãæžå°ããå¯èœæ§ããããŸãã
ããã«ããã€ãã³æ¿æš©ã¯åŠæ¹è¬ã®äŸ¡æ ŒåŒãäžããåªå
äºé
ãšããŠç€ºããŠããŸãããå»çä¿éºå¶åºŠæ¹é©ã»ã³ã¿ãŒã¯ãFDAïŒç±³åœé£åå»è¬åå±ïŒã®æ¿èªããã»ã¹ãççž®ããããã«æ¿èªãããè¬åã®æ°ããæ¯æãæ¹æ³ã®èšèšãæé¡2ãã«ã§äžéãèšå®ããããžã§ããªãã¯è¬åã®ãªã¹ãã®äœæã现èããã³éºäŒåçæ³ã®ã¢ãŠãã«ã ããŒã¹ã®å¥çŽã®å®æœã«åããŠæ°ããã¢ãããŒãã確ç«ãããªã©ãã¡ãã£ã±ã¢ããã³ã¡ãã£ã±ã€ãã®è¬å€ã³ã¹ãåæžãç®çãšããæ°ããã¢ãã«ãéçºããŠããŸãããã€ãã³æ¿æš©ãåŠæ¹ç®ã®å€äžããè©Šã¿ãããã«ããã«ã©ã®ãããªæé ãåããããŸããã®ãããªæé ã®åœ±é¿ã¯äžæã§ãããããã®ææ¡ãããæªçœ®ã®å€ãã¯ãæå¹ã«ãªãããã«è¿œå ã®æ³æ¡ã®æ¿èªãå¿
èŠãšãªãå ŽåããããçŸåšã®ç±³åœå€§çµ±é æ¿æš©ããããã®æªçœ®ãå転ãããããå€æŽããããããå¯èœæ§ããããŸãããçŸåšã®ç±³åœå€§çµ±é æ¿æš©ããã³è°äŒã¯ãè¬å€ã³ã¹ããæå¶ããããã®æ°ããæªçœ®ãç¶ç¶çã«æ¢æ±ããæåã瀺ããŠããŸãã
å·ã¬ãã«ã§ã¯ã補è¬åã®äŸ¡æ Œãã³ã³ãããŒã«ããããã«ç«æ³ãèŠå¶ãå®æœããããã«ãæ¿åºããŸããŸãæ»æçã«ãªã£ãŠããŸãããããã®å¯Ÿçã®äžéšã«ã¯ãäŸ¡æ Œãæãæ»ããå²åŒãååã¢ã¯ã»ã¹ãããŒã±ãã£ã³ã°ã®å¶éãè¬åäŸ¡æ Œãè²»çšãããŒã±ãã£ã³ã°ã®æ瀺ãéææ§ã®èŠä»¶ã課ãããšãä»ã®åœããã®èŒžå
¥ãèš±å¯ããããšã倧é賌å
¥ã奚å±ããããšãå«ãŸããŸããããšãã°ã2024幎1æ5æ¥ã«ãç±³åœé£åå»è¬åå±ã¯ãããªãå·ä¿éºå±ã®è¬ç©èŒžå
¥ææ¡ãæ¿èªããã«ããããç¹å®ã®åŠæ¹ç®è¬ç©ã®èŒžå
¥ããããªããä¿é²ããããã®æåã®æ®µéãèžã¿åºããŸãããã«ãããææµåœïŒMFNïŒã¢ãã«ããã®è¬å€ã®èŒžå
¥ã¯ãåæ¥çšè£œåã®äŸ¡æ Œã«å¯ŸããŠé倧ãã€äžå©ãªåœ±é¿ãäžããå¯èœæ§ããããŸãããŸããå°åã®å»çåœå±ãåã
ã®ç
é¢ã¯ãå
¥ææé ã䜿çšããŠãåŠæ¹è¬ããã³ãã®ä»ã®å»çããã°ã©ã ã«å«ãã補è¬åããã³äŸçµŠæ¥è
ã決å®ããããšãå¢ããŠããŸãããããã®å¯Ÿçã«ãããæ¿èªåŸã«åœç€Ÿã®è£œåã®æçµçãªéèŠãæžããå¯èœæ§ããããã補åäŸ¡æ Œã«å§åããããããšãã§ããŸããç±³åœãŸãã¯ä»ã®å€åœã®åœã§å°æ¥æ¡çšãããå»çæ¹é©ã€ãã·ã¢ããã¯äºæž¬ã§ããŸãããããã«ãé£éŠãå·ãããã³å€åœã®ç«æ³ããã³èŠå¶çãªé²å±ã¯ãä»åŸãç¶ãããšãäºæ³ãããç±³åœå
ã®åãçµã¿ã¯è¬äŸ¡ã«å¯Ÿããå§åãå¢å€§ãããããšãæåŸ
ãããŠããŸãããã®ãããªæ¹é©ã¯ãåœç€Ÿãæ¿èªããã補åãŸãã¯åœç€Ÿãæåè£ã«éçºããèŠå¶åœå±ã®æ¿èªãåŸãå¯èœæ§ããããããžãã¹ãèŠéããéå¶æ瞟ã財åç¶æ
ãããã³è¬å€åè£ãéçºããèœåã«åœ±é¿ãäžããå¯èœæ§ããããŸãã
æ¿èªããã補åãä»åŸã®è£œåãåæ¥åããèœåã¯ãæ¿åºå¥åº·è¡æ¿åœå±ãæ°éå»çä¿éºè
ããã®ä»ã®çµç¹ãªã©ã®ç¬¬äžè
æ¯æè
ããããããã®è£œåãé¢é£æ²»çã®ã«ãã¬ããžããã³ææ»ããã©ã®çšåºŠå©çšå¯èœãã«ãéšåçã«äŸåããŸããç§ãã¡ãæ¿èªããã補åã®1ã€ä»¥äžããã³è£œåéçºã«å¯Ÿããåœç€Ÿã®æè³ã§é©åãªãªã¿ãŒã³ãå®çŸããããã«ã競äºåã®ããåºç€ã§ãã®è£œå(ãŸãã¯ä»åŸã®è£œå)ã販売ããããšãã§ãããã©ãããããã³æãæ»ããäžååã§ããå¯èœæ§ããã補åãå»çäžå¿
èŠãŸãã¯è²»çšå¯Ÿå¹æã«åªããªããšèããããªãå ŽåããããŸããæ°è¬ã®ã«ãã¬ããžãååŸããããã®å€§å¹
ãªé
延ãããå Žåããããã«ãã¬ããžã¯FDAãŸãã¯å€åœã®èŠå¶åœå±ã«ãã£ãŠæ¿èªãããç®çãããå¶éãããå ŽåããããŸããããã«ãã«ãã¬ããžã®å¯Ÿè±¡ãšãªãããšã¯ãå
šãŠã®å Žåã«è¬å€ãæãæ»ãããããšãæå³ãããã®ã§ã¯ãããŸããããŸããç¹å®ã®æäŸè
ã補åãååŸããããã®ã³ã¹ããã«ããŒããããã«æãããã¬ãŒããšãç 究éçºè£œé 販売æµéãå«ããç§ãã¡ã®ã³ã¹ããã«ããŒããæãæ»ãã¯ãäžèŽãããšã¯éããªãå ŽåããããŸããæ°è¬ã«å¯Ÿããäžéæããé©çšãããå Žåããããç§ãã¡ã®ã³ã¹ããã«ããŒããã«ã¯ååã§ã¯ãªãå Žåããããæ°žç¶çã«ãªããªãå ŽåããããŸããæãæ»ãã¯ãæ¢ã«åžå Žã«åºåã£ãŠããäœã³ã¹ãã®è¬å€ã«åºã¥ãå Žåããããæ¢åã®ä»ã®ãµãŒãã¹ã®æ¯æãã«çµã¿èŸŒãŸããå Žåããããäºç®çå¶çŽãŸãã¯ããŒã¿ã®äžå®å
šãªæ§è³ªã«åºã¥ãå ŽåããããŸããè¬å€ã®çŽäŸ¡æ Œã¯ãæ¿åºã®å»çä¿å¥ããã°ã©ã ãæ°éæ¯æè
ãèŠæ±ãã矩åçãªå²åŒããªããŒãããŸãçŸåšãã¢ã¡ãªã«ãããäœäŸ¡æ Œã§è²©å£²ãããŠããåœããã®è¬å€ã®èŒžå
¥ãå¶éããŠããæ³åŸã®ç·©åã«ãã£ãŠåŒãäžããããå ŽåããããŸããç¹ã«ãEUãè±åœãæ¥æ¬ãäžåœãªã©ã®ç¹å®ã®åžå Žã®æ¿åºãå»çãæäŸããŠããäœ(ãŸãã¯ãŒã)ã®çŽæ¥è²»çšãæ¶è²»è
ã«æäŸããŠããããã倧ããªäžæ¬æ¯æè
ãšããŠäŸ¡æ ŒãèŠå¶ãããããã®ä»ã®ã³ã¹ãå¶åŸ¡æ©æ§ã課ãããšãã§ããŸãããŸããç±³åœã«ããããããŒãžãã±ã¢ãžã®éç¹ã¯å¢ãç¶ããŠããã補è¬äŸ¡æ Œã«å¯ŸããŠäžæ¹å§åããããããšãäºæ³ãããŸããã«ãã¬ããžããªã·ãŒã第äžè
æãæ»ãçãããã³è£œè¬äŸ¡æ ŒèŠå¶ã¯ããã€ã§ãå€æŽãããå¯èœæ§ããããŸããèŠå¶åœå±ããæ¿èªãåãã1ã€ä»¥äžã®è£œåã«å¯ŸããŠæå©ãªã«ãã¬ããžããã³æãæ»ãã®ã¹ããŒã¿ã¹ãéæããããšããŠããå°æ¥çã«ã¯äžå©ãªã«ãã¬ããžæ¿çãæãæ»ãçãå°å
¥ãããå¯èœæ§ããããŸãã
æè¿ãæ¿åºãæ°éä¿éºãªã©ãæ£è
ãå»çæäŸè
ã«ä»£éãè¿éãã第äžè
ã®æ¯æè
ã¯ãè¬å€äŒç€Ÿã«ååã®ãªã¹ãäŸ¡æ Œãã決ããããå²åŒãæäŸããããæ±ããŠãããè¬å€è£œåã®å€æ®µãäžããããè¿éãããéé¡ãæžãããŠããŸããç§ãã¡ã¯ãã¢ã¡ãªã«ã§ã¯40以äžã®ããªã¥ãŒããŒã¹ãã¢ã°ãªãŒã¡ã³ã(VBA)ã«åå ããåæ¥ä¿éºäŒç€Ÿãšè¿œå ã®VBAã亀æžããŠããŸãããããã®åå®ã®ç®çã¯ãåæ¥çã«æ¿èªããã補åãèšåºè©Šéšã§ç€ºãããçµæãšåæ§ã®çŸå®ã®äžçã§ã®çµæã瀺ãããšã«åºã¥ããŠæ¯æããåããããšã確ä¿ããããšã§ããããããã®åå®ã¯æ¿èªããã補åã®çŸå®ã®äœ¿çšã§ã®ããã©ãŒãã³ã¹ã財åæ¡ä»¶ã«ãªã³ã¯ãããããæ§æãããŠããŸãããããã®åå®ã«ããæ¯æããåãåãããšããŸãã¯ãã®ãããªè£œåã«æäŸãããè¿éããç§ãã¡ã®éèŠãªææã«äžé©åã§ããå Žåãæ¯æããåããããš
ãã®ä»ã®è²»çšãæãæ»ããæåŠãããå Žåãç§ãã¡ã®æè³åççãæªåœ±é¿ãåããå¯èœæ§ããããŸããå ããŠãç§ãã¡ã¯ç§åŠçãªé©æ°ãç¶ããããšã§æé·ããããšãå
¬èšããŠãããæ£æçãªäŸ¡æ Œäžæã§ã¯ãªããç¹ã«ãéœåžæ¶è²»è
ç©äŸ¡ææ°ïŒçŸåšçŽ3.5ïŒ
ïŒã«ãã£ãŠæ±ºå®ãããã€ã³ãã¬çãè¶
ããŠåžå Žèªå¯ãåãã補åã®äŸ¡æ ŒãåŒãäžããããšã¯ãããŸãããéèŠãªäŸ¡å€ãã©ã€ããŒããªãéããå°æ¥çã«è²©å£²ãã1ã€ä»¥äžã®è£œåããåŸãããåçã«ãæªåœ±é¿ãäžããå¯èœæ§ããããŸããç§ãã¡ã®æ£è
ã¢ã¯ã»ã¹å²åŠãå°æ¥ã®è£œå販売ããåŸãããåçã«æªåœ±é¿ãåãŒãããšããããŸãã
ä¿éºäŒç€Ÿã¯ãæ£è
ãå»è¬åã«ã¢ã¯ã»ã¹ããããšãå¶éããã¢ãŠãã»ãªãã»ãã±ããã³ã¹ããå¢ããããã°ã©ã ãæ¿çãæ¡çšããããšããŸããŸãå¢ããŠããŸããç±³åœã§ã¯ãæ¿èªããã補åã«ã¢ã¯ã»ã¹ããããããæ¯æãå¯èœã«ããããã«ãæ£è
æ¯æŽããã°ã©ã ãã察象è
ã®ããã®åææžã¯ãŒãã³ããã°ã©ã ãå«ãããã°ã©ã ãå©çšããããšããããŸããåææžã¯ãŒãã³ïŒã¯ãŒãã³ã¢ãã¥ã ã¬ãŒã¿ãšããã·ãã€ã¶ãŒããã°ã©ã ãªã©ïŒãæ£è
æ¯æŽããã°ã©ã ïŒä»£æ¿è³éããã°ã©ã ãªã©ïŒã«é¢ããä¿éºäŒç€Ÿã®ããªã·ãŒã®å€æŽãæ°ããæ³åŸãèŠå¶æªçœ®ã®å°å
¥ãããã³æœè¡ã¯ããããã®åææžã¯ãŒãã³ããã°ã©ã ãæ£è
æ¯æŽããã°ã©ã ã®å¶éãŸãã¯ãã以å€ã«æªåœ±é¿ãåãŒãå¯èœæ§ãããã圱é¿ãåãã補åã䜿çšããæ£è
ãå°ãªããªãããã®çµæãåœç€Ÿã®å£²äžãããžãã¹ãããã³è²¡åç¶æ³ã«é倧ãªæªåœ±é¿ãåãŒãå¯èœæ§ããããŸãã
ç§ãã¡ã¯ç±³åœããã³ç¹å®ã®å€åœã®èŒžåºå
¥å¶éãå¶è£ã茞åºçŠæ¢ãåæ±è·æ³ãåãããŒãã³ããªã³ã°æ³ããã³èŠå¶ã®å¯Ÿè±¡ãšãªã£ãŠããŸãããããã®æ³çåºæºã«éåãããšãåœå
å€ã®åžå Žã§ã®ç«¶äºåã«æªåœ±é¿ãåãŒãå¯èœæ§ããããŸããéåãããšåäºè²¬ä»»ãä»ã®é倧ãªçµæã«çŽé¢ããããšããããããžãã¹ã«æ害ãäžããããšããããŸãã
æã
ã¯ãç±³åœã®èŒžåºç®¡çèŠå¶ãç±³åœã®çšé¢èŠå¶ãç±³åœè²¡åçå€åœè³ç£ç®¡çå±ãé©çšããåçš®çµæžå¶è£èŠå¶ãç±³åœã®æ¹æ£å€åœå
¬åå¡èŽåè³è¡çºïŒFCPAïŒã18 USC § 201ã«å«ãŸããç±³åœã®åœå
èŽåè³çœªãç±³åœã®æ
è¡æ³ãUSA PATRIOTæ³ã2010幎è±åœèŽåè³æ³ãªã©ãåæ±è·æ³ãããã³åãããŒãã³ããªã³ã°æ³ãå«ã茞åºç®¡çã茞å
¥èŠå¶çã®æ³åŸãèŠå¶ã®å¯Ÿè±¡ã§ããåæ±è·æ³ã¯åºã解éãããå
Œ
±ã»ã¯ã¿ãŒããã©ã€ããŒãã»ã¯ã¿ãŒã®åè³è
ã®è¡çºã決å®ã«äžé©åã«åœ±é¿ãäžããããžãã¹ãååŸãŸãã¯ç¶æããããã«å©çäŸäžãŸãã¯ãã®ä»ã®äŸ¡å€ãçŽæ¥ãŸãã¯éæ¥çã«èš±å¯ãçŽæãæäŸãå§èªãåé ããããšããäŒæ¥ã圹å¡ãåç· åœ¹ãåŸæ¥å¡ã代ç人ãå¥çŽæ¥è
ãããã³ãã®ä»ã®ç¬¬äžè
代衚ãçŠæ¢ãããŠããŸããææãç§ãã¡ã¯ç±³åœå€ã§èšåºè©Šéšãè¡ãããã補åãæµ·å€ã«è²©å£²ãããããããã³å¿
èŠãªèš±å¯ãã©ã€ã»ã³ã¹ãç¹èš±ç»é²ããã®ä»ã®èŠå¶æ¿èªãååŸããããã«ç¬¬äžè
ãšäº€æžããããšããããŸããæ¿åºæ©é¢ãæ¿åºé¢é£ç
é¢ã倧åŠããã®ä»ã®çµç¹ã®åœ¹å¡ãè·å¡ãšçŽæ¥çãŸãã¯éæ¥çãªãããšãããããŸããç§ãã¡ã¯ã代ç人ãæ¥è
ãããã³ç¬¬äžè
代衚ãç§ãã¡ã®ããã«è¡ãæ±è·è¡çºããã®ä»ã®éæ³è¡çºã«ã€ããŠãæ瀺çã«èªå¯ãŸãã¯å®éã®ç¥èãæã£ãŠããªããŠãã責任ãè² ãããšããããŸããäžèšã®æ³åŸãèŠå¶ã«éåããå Žåãå€é¡ã®çœ°éãå¶è£ãè©å€ã®æ害ããã®ä»ã®äžå©çãæãããå¯èœæ§ããããŸãã
ç§ãã¡ã¯ãããã®æ³åŸãšèŠå¶äžã§ã®æŽ»åã«çŠç¹ãåããã以äžã«è©³è¿°ããããã«ãã°ããŒãã«ã³ã³ãã©ã€ã¢ã³ã¹ããã°ã©ã ãç¶æããå¿
èŠãªèŠä»¶ã«æºæ ããããžãã¹éå¶ãå¯èœã«ããããã«èšèšãããŠããŸãã
ç±³åœå€ã®æ¿åºã¯å³æ ŒãªäŸ¡æ Œçµ±å¶ã課ãå¯èœæ§ããããããã¯åœç€Ÿã®åå
¥ã«æªåœ±é¿ãäžããå¯èœæ§ããããŸãã
åŠæ¹ç®å»è¬åã®äŸ¡æ Œã¯ãç±³åœå€ã§ãæ¿åºã®ç®¡çã®å¯Ÿè±¡ã§ãããããã®åœã§ã¯ã補åã®èŠå¶æ¿èªãåããåŸãæ¿åºåœå±ãšã®äŸ¡æ Œäº€æžã«ã¯ããªãã®æéããããããšããããŸããäžéšã®åœã§ã¯ã補ååè£ã®è²»çšå¯Ÿå¹æãä»ã®æ²»çæ³ãšæ¯èŒããèšåºè©Šéšãå®æœããå¿
èŠããããæéãšè²»çšããããå ŽåããããŸãã補åã®æãæ»ããå©çšã§ããªãããç¯å²ãéé¡ãå¶éãããŠããå ŽåããŸãã¯äŸ¡æ Œãäžååãªæ°Žæºã§èšå®ãããŠããå Žåãåçãçã¿åºããå©çãåŸãèœåãäœäžããå¯èœæ§ããããŸãã
EUå çåœããã³æ¥æ¬ãå«ãããã€ãã®åœã§ã¯ãåŠæ¹è¬ã®äŸ¡æ Œèšå®ãæ¿åºã®ç®¡çäžã«ããå ŽåããããŸãããã®ä»ã®åœã§ããåŠæ¹è¬ã®äŸ¡æ Œèšå®ã«åæ§ã®ã¢ãããŒããæ¡çšããå ŽåããããŸãããã®ãããªåœã§ã¯ãèŠå¶æ¿èªåŸã«æ¿åºåœå±ãšã®äŸ¡æ Œäº€æžã«ã¯çžåœãªæéããããå ŽåããããŸãããŸããæ¿åºããã®ä»ã®é¢ä¿è
ã¯ãã³ã¹ãåæžæªçœ®ã®äžç°ãšããŠãäŸ¡æ Œãæãæ»ãã¬ãã«ã«çžåœãªå§åããããããšãã§ããŸããããã«ãæ¿æ²»ãçµæžãããã³èŠå¶äžã®ååãäŸ¡æ Œäº€æžãããã«è€éã«ããå ŽåããããŸããã«ãã¬ããžãšæãæ»ããèªããããåŸã§ããäŸ¡æ Œäº€æžãç¶è¡ãããå ŽåããããŸããååœã§äœ¿çšãããåç
§äŸ¡æ ŒããŸãã¯äœäŸ¡æ Œãšé«äŸ¡æ Œã®åœã®éã®äžŠå茞å
¥ããŸãã¯å¥çŽé¢ä¿ã«ãããäŸ¡æ Œãããã«äœäžããå ŽåããããŸãããã®ãããªäŸ¡æ Œãšææ»ããç§ãã¡ãŸãã¯å
±åäœæ¥è
ã«ãšã£ãŠèš±å®¹å¯èœãã©ããã¯ããããŸããã第äžè
ã®æ¯æè
ãåœå±ã«ããå²åŒã®å
¬è¡šã¯ãå
¬è¡šåœããã³ä»ã®åœã§ã®äŸ¡æ ŒãŸãã¯æãæ»ãã¬ãã«ã«ããã«å§åããããå¯èœæ§ããããŸããäŸ¡æ Œãäžååãªã¬ãã«ã«èšå®ãããå ŽåããŸãã¯ç§ãã¡ã®è£œåã®ææ»ããå©çšã§ããªãå Žåãç¯å²ãŸãã¯é¡ãéå®ãããŠããå Žåãç§ãã¡ãŸãã¯å
±åäœæ¥è
ã«ãã販売ããã®åçããã³ãããã®åœã§ã®æ¿èªè£œåãŸãã¯å°æ¥ã®è£œåã®æœåšçãªåçæ§ãåŠå®çã«åœ±é¿ãåããå¯èœæ§ããããŸããç¹èš±ãŸãã¯ãã®ä»ã®æä»çæš©å©ã®æéãåããåŸãããå®äŸ¡ãªãžã§ããªãã¯è£œåãŸãã¯ãã€ãªã·ãã©ãŒãããã¯ãããã®ãã倧ããªç«¶äºã«ããäŸ¡æ Œç®¡çãå³æ Œåããå Žåã«ã圱é¿ãåããå¯èœæ§ããããŸããäžéšã®æ¿åºã¯ãã³ã¹ãåæžã®ããã«åŠæ¹ããã補åããžã§ããªãã¯ããŒãžã§ã³ã«åãæ¿ããæ¿çãæ¡çšããŠããŸãã
ç§ãã¡ãŸãã¯å
±åäœæ¥è
ãCMOããµãŒãã¹ãããã€ããå»çæ³ä»€ããã©ã€ãã·ãŒãããŒã¿ä¿è·ãæ
å ±ã»ãã¥ãªãã£ã«é¢ããæ³ç矩åã«éåããå Žåãç§ãã¡ãŸãã¯åœŒãã¯å·è¡æªçœ®ã®å¯Ÿè±¡ãšãªãã補åã®éçºãåžå Žåã販売ã«æªåœ±é¿ãäžããè©å€ãæãªãå¯èœæ§ããããŸãã
å»çåŸäºè
ãå»åž«ããããŠç¬¬äžè
ã®æ¯æè
ããç§ãã¡ãããŒã±ãã£ã³ã°æ¿èªãåŸã補åã®æšå¥šããã³åŠæ¹ã®äž»èŠãªåœ¹å²ãæãããŸããç§ãã¡ã第äžè
ã®æ¯æè
ã顧客ãšã®æ¢åããã³å°æ¥ã®åå®ã«ã¯ãåºãé©çšãããè©æ¬ºããã³èåŸ
è¡çºãªã©ã®å»çæ³åŸã«é¢ããæ³åŸããã³èŠå¶ãå«ãŸããå Žåããããããããç§ãã¡ã補åãããŒã±ãã£ã³ã°ã販売ãããã³é
åžããããã®äºæ¥ãŸãã¯è²¡åååŒããã³é¢ä¿ãå¶éããå¯èœæ§ããããŸããé©çšãããé£éŠããã³å·ã®å»çæ³ä»€ã«ããå¶éã«ã¯ã以äžãå«ãŸããŸãïŒ
⢠米åœé£éŠåããã¯ããã¯æ³ã¯ãç¥ããªãããæå³çã«ä»»æã®å ±é
¬ïŒããã¯ããã¯ãèŽè³ããªããŒããå«ãïŒãçŽæ¥ãŸãã¯éæ¥ã«ãå
¬ç¶ãŸãã¯å
å¯ã«ãçŸéãŸãã¯ãã®ä»ã®åœ¢ã§ãæ¯æã£ããåãåã£ããããããèªå ãšããŠããŸãã¯å¯ŸäŸ¡ãšããŠãç±³åœã®å»çä¿å¥ããã°ã©ã ïŒã¡ãã£ã±ã¢ããã³ã¡ãã£ã±ã€ãããã°ã©ã ãªã©ïŒã®äžã§å
šé¡ãŸãã¯äžéšæ¯æãããå¯èœæ§ã®ããååãæœèšãã¢ã€ãã ããŸãã¯ãµãŒãã¹ã®è³Œå
¥ããªãŒã¹ããªãŒããŒãé
眮ããŸãã¯æšå¥šãèªçºããããšãçŠæ¢ãããŠããŸãããŸããç±³åœåããã¯ããã¯æ³ãŸãã¯ç¹å®ã®éæ³æå³ãç¥ããªããŠãéåãç¯ãããšãã§ããŸããéåã¯æ°äºããã³åäºçœ°éãšçœ°åãæçãããã³æ¿åºä¿å¥å»çããã°ã©ã ããã®é€å€ã®å¯Ÿè±¡ãšãªããŸãããããŠãæ¿åºã¯ãç±³åœåããã¯ããã¯æ³ã«éåããŠåŸãããã¢ã€ãã ãŸãã¯ãµãŒãã¹ãå«ãè«æ±ããç±³åœFCæ³ãŸãã¯é£éŠæ°äºè³ åéã®ç®çã§èåœãŸãã¯äžæ£ãªè«æ±ã§ãããšäž»åŒµããããšãã§ããŸãã
⢠米åœã®é£éŠåœèšŒé²æ¢æ³ã«ã¯ãFCAãå«ããã®ããããŸãããããã®æ³åŸã«ãããã¡ãã£ã±ã¢ãã¡ãã£ã±ã€ããªã©æ¿åºã®è³éæŽå©ããã°ã©ã ã«å¯ŸããŠèåœãŸãã¯è©æ¬ºçãªè«æ±ãæå³ããŠæåºããããšãçŠæ¢ãããŠãããé£éŠæ¿åºã«èåœãŸãã¯è©æ¬ºçãªè«æ±ãåŒãèµ·ããããèåœãŸãã¯è©æ¬ºçãªè«æ±ã«é¢é£ããèåœèšé²ãŸãã¯å£°æãäœæããããšãçŠæ¢ãããŠããŸãããŸããã¡ãŒã«ãŒã¯ãçŽæ¥æ¿åºã®æ¯æãè
ã«è«æ±ãæåºããªããŠããèåœãŸãã¯è©æ¬ºçãªè«æ±ã®æåºããåŒãèµ·ãããããšå€æãããå Žåã«ãFCAã«ãã£ãŠè²¬ä»»ãè² ãããšããããŸããFCAã¯ããå
éšåçºè
ããšããŠè¡åããç§äººãFCAã«éåããç³ãç«ãŠãé£éŠæ¿åºã®ä»£ç人ãšããŠæèµ·ããééçãªå埩ãå
±æããããšãèš±å¯ããŠããã眰éã¯è³ªåãããè«æ±é¡ã®3å以äžã®éé¡ãå«ãŸããŸãã
⢠é£éŠæ°äºçœ°åæ³ã«ã¯ãã¡ãã£ã±ã¢ãŸãã¯ã¡ãã£ã±ã€ãã®åçè
ã«å ±é
¬ãæäŸãŸãã¯è»¢éããããšãå«ãŸããŠããããã®äººãåçè
ã®ç¹å®ã®æäŸè
ãéæ¥å»ããŸãã¯ã¡ãã£ã±ã¢ãŸãã¯ã¡ãã£ã±ã€ãã«ãã£ãŠè£åå¯èœãªãµãŒãã¹ã®æäŸè
ãéžæããããšã«åœ±é¿ãåãŒãå¯èœæ§ãããããšãç¥ã£ãŠãããããŸãã¯ãã®ãããªç¥èãå¿
èŠã§ããå ŽåãäŸå€ãé©çšãããŠããªãéããæ°äºçœ°éã課ããããŸãã
⢠1996幎ã«å¶å®ãããé£éŠå¥åº·ä¿éºæºåž¯æ§åã³èª¬æ責任æ³ïŒHIPAAïŒã¯ããã®ä»ã®æ¡é
ãåµèšããå»çä¿å¥ã®å©çããã°ã©ã ãè©æ¬ºãããã®æå³çãªè¡çºãåœããè©æ¬ºçãªèšèŸããŸãã¯çŽæãéããŠãä»»æã®å»çä¿å¥ããã°ã©ã ãææãã財ç£ãŸãã¯ç®¡èœäžã«ãã財ç£ãå
¥æããããšãçŠæ¢ããé£éŠåäºæ³èŠãå«ãã§ããŸããå©çæ¯æè
ïŒäŸïŒå
¬çãŸãã¯æ°éïŒã«é¢ä¿ãªããå¥åº·ä¿å¥ããã°ã©ã ãå«ãå
šãŠã®åé¡ã«é¢ããŠãå»çä¿å¥ã®å©çãã¢ã€ãã ããŸãã¯ãµãŒãã¹ã®æäŸãŸãã¯æ¯æãã«é¢é£ããŠãç¥ãããéãããŸãã¯äœããã®ããªãã¯ãŸãã¯è£
眮ã«ãã£ãŠææäºå®ãåœããé ããããã«ããŒãããããããšãçŠæ¢ãããŠããŸããé£éŠã¢ã³ãã»ããã¯ããã¯æ³ãšåæ§ã«ãHIPAAéåã®çœªã§æ眪å€æ±ºãåããå Žåãç¹å®æå³ãæ¡äŸã®å®éã®ç¥èããªããŠã人ãŸãã¯ãšã³ãã£ãã£ã責任ãè² ãããšããããŸãã
⢠å人æ
å ±ãç¹å®ã§ããå¥åº·æ
å ±ã®ãã©ã€ãã·ãŒãã»ãã¥ãªãã£ãå€éæ©ã«é¢é£ããèŠä»¶ã課ããé¢é£ããå人ãšèŠå¶åœå±ã«ç¹å®ã®å人æ
å ±ã®ã»ãã¥ãªãã£éåã®éç¥ãèŠæ±ããããã«ã¹ã»ã€ã³ãã©ã¡ãŒã·ã§ã³ã»ãã¯ãããžãŒæ³ã«ãã£ãŠæ¹æ£ãããHIPAAåã³ãã®æœè¡èŠåãå«ããã®ã
⢠å»çé¢é£ã®è£œè¬ãå»çæ©åšããã€ãªå»è¬åãå»ççšåã¡ãŒã«ãŒããã¡ãã£ã±ã¢ãã¡ãã£ã±ã€ããåäŸå¥åº·ä¿éºããã°ã©ã ã®æ¯æãå¯èœæïŒäžå®ã®äŸå€ãé€ãïŒã«ãOpen Payments Programã®äžã§ä¿å¥çŠç¥çã«å¹Žæ¬¡å ±åãã矩åãããé£éŠâäžçŽéœå
âèŠä»¶ãšããŠãå»åž«ïŒå»åž«ãæ¯ç§å»åž«ãçŒç§å»åž«ã足ç
å»åž«ãã«ã€ããã©ã¯ã¿ãŒãå«ãïŒãå»åž«è£å©è
ãçè·åž«ãã©ã¯ãã£ã·ã§ããŒãªã©ã®äžéšã®éå»åž«ãããã€ããŒãæè²ç
é¢ãå»åž«ããã³ãã®çŽç³»ã®å®¶æãä¿æããæš©å©ããã³æè³é¢å¿ã«é¢ããæ
å ±ãå«ããå»åž«ããã®çŽå±ã®å®¶æã®ææããã³æè³é¢å¿ã«å ãã決å®ã䟡å€ã®â転éâã«é¢ããæ¯æããŸãã¯ãã®ä»ã®å ±åã«å¯ŸããŠãé
延ãäžæ£ç¢ºããã³å®å
šã§ã¯ãªãæ
å ±ã®æåºã¯ãæ°äºééå¶è£ã«ã€ãªããå¯èœæ§ãããã
⢠é£éŠäŸ¡æ Œå ±åæ³ã¯ã補é æ¥è
ãè€éãªäŸ¡æ Œææšãèšç®ããŠæ¿åºããã°ã©ã ã«å ±åããããšãèŠæ±ããå ±åãããäŸ¡æ Œãæ¿èªããã補åã®æãæ»ããå²åŒã®èšç®ã«äœ¿çšãããå ŽåããããŸãã
⢠é£éŠæ¿åºæ©é¢ãžã®è£œåã®äŸ¡æ Œèšå®ãšè²©å£²ã«é©çšãããé£éŠæ³åŸããã³èŠå¶èŠä»¶ã
⢠æ¶è²»é¢é£ãšå
¬æ£ç«¶äºã«é¢ããé£éŠæ³ã¯ãåžå ŽæŽ»åãæ¶è²»è
ã«æœåšçãªè¢«å®³ãäžãã掻åãå¹
åºãèŠå¶ããŠããŸãã
⢠äžèšé£éŠæ³ãšåæ§ã®å·ããã³å€åœã®æ³åŸïŒEUã®èŠå¶ã§ãæã
ã®è£œåã®åŠæ¹ãèªå ãšããŠå»çåŸäºè
ã«å¯ŸããŠèŽãç©ãéåãäžããããšãçŠæ¢ããæ³åŸãå»çåŸäºè
ããã³æ©é¢ãžã®æ¯æãã®å
¬éã矩åä»ããåœæ°ã®éææ§æ³ãããŒã¿ãã©ã€ãã·ãŒæ³ïŒã ãŸããåæ¥ä¿éºäŒç€Ÿããã³ãã®ä»ã®éé£éŠã®æ¯æãè
ã«é©çšãããããã¯ããã¯çŠæ¢æ³ããã³èåœè«æ±æ³ã瀟å
ã³ã³ãã©ã€ã¢ã³ã¹ããã°ã©ã ã®çŸ©ååãªã©ã®çŸ©åãæ¿åºè£åããã°ã©ã ã«é¢ããæ³åŸãæ£è
ããŒã¿ã®ãã©ã€ãã·ãŒãšã»ãã¥ãªãã£ã«é¢ããæ³åŸãªã©ãå«ãŸããŸãã
⢠EUäžè¬ããŒã¿ä¿è·èŠåïŒGDPRïŒãšè±åœã®GDPRã®ãããªã2016/679å·èŠåãšããŠç¥ããã欧å·ãã©ã€ãã·ãŒæ³ãåã³ããããåãå
¥ããe-ãã©ã€ãã·ãŒæ什ïŒ2002/58/ECïŒãããã³ããããå®æœããååœã®æ³åŸãããã³è±åœã®å
Œ
±ããã³é»åéä¿¡èŠå¶2003幎ãšæ¥æ¬ããã©ãžã«ãªã©ã®å°åã®ãã©ã€ãã·ãŒæ³ãå«ããGDPRãšé¢é£ãããã¹ãŠã®æ³åŸã
⢠2018幎ã«æ¹æ£ãããã«ãªãã©ã«ãã¢æ¶è²»é¢é£ãã©ã€ãã·ãŒæ³ïŒCCPAïŒããŸãã¯2020幎ã«æ¹æ£ãããã«ãªãã©ã«ãã¢ãã©ã€ãã·ãŒæš©å©æ³ïŒCPRAïŒã¯ããã®ä»ã®æ¡é
ã®äžã§ãã«ãªãã©ã«ãã¢å·ã®å±
äœè
ã«ãå人æ
å ±ã®ã¢ã¯ã»ã¹ãèšæ£ãããŒã¿ããªãã£ãåé€ã®æš©å©ããããã€ãã®éžæè¢ãäžããŸãã CCPAã¯ããã©ã€ãã·ãŒéç¥ã®ç¶æãåççãªã»ãã¥ãªãã£æé ã®å®è£
ãããŒã¿ããã»ããµãšã®å¥çŽã«ç¹å®ã®æ¡ä»¶ãå«ãããªã©ãèŠå¶å¯Ÿè±¡æ¥çã«ããŸããŸãªçŸ©åã課ããŸãã CCPAã¯ãæ³åŸã®æœè¡ïŒèŠåäœæã«ãã£ãŠãå«ãŸããïŒãšæœè¡æš©éãäžããããæ°ããåœå®¶æ©é¢ãèšç«ããŸããã CCPAã¯éåã«å¯Ÿããæ°äºçœ°åãå®ããŠãããããŒã¿æŒããã«å¯Ÿããéå®çãªãã©ã€ããŒãæš©å©èšŽèšãæäŸããŠããŸãã
⢠ãã®ä»ã®10以äžã®å·ã§CCPAã«äŒŒãå
æ¬çãªãã©ã€ãã·ãŒæ³ãå¶å®ãããããã€ãã®å·ã§ã¯ææ¡ãããŠããŸããããã«ã3ã€ã®å·ã§ã¯ãæ¶è²»è
ã®å¥åº·ããŒã¿ãèŠå¶ããæ³åŸãå¶å®ãããŠããããããã¯ç¶ç¶çãªãã©ã€ãã·ãŒæ³ã«å ããŠãç¹å®ã®å¥åº·ããŒã¿ã®åéãå
±æã®ããã«ç¬èªã®åæãåŸãããæ¶è²»è
ã®å¥åº·ããŒã¿ã売ãããã«èªå¯ãåŸãããæ¶è²»è
ã®å¥åº·ããŒã¿ãã©ã€ãã·ãŒããªã·ãŒãç¶æããããã®è¿œå ã®çŸ©åã課ããã®ã§ããã¯ã·ã³ãã³å·ã®æ¶è²»è
å¥åº·ããŒã¿ãèŠå¶ããæ³åŸã«ã¯ãæ°äºèšŽèšã®æš©å©ããããŸããCCPAããã³ä»ã®å·ã®ãã©ã€ãã·ãŒæ³ã®åœ±é¿ã¯ãæœåšçã«é倧ã§ãããããŒã¿åéãŸãã¯åŠçãã©ã¯ãã£ã¹ããã³ããªã·ãŒãå€æŽããå¿
èŠãããå Žåããããããã«å¯Ÿå¿ããŠåççãªã³ã¹ããè²»çšãè² æ
ããå¿
èŠãããå ŽåããããèŠå¶å·è¡ããã³/ãŸãã¯èšŽèšã«å¯Ÿããæœåšçãªãªã¹ã¯ãå¢å€§ãããå¯èœæ§ããããŸãã
äžéšã®å·æ³ã¯ãå»è¬åã¡ãŒã«ãŒããå»è¬åæ¥çãä»»æçã«éµå®ããã¬ã€ãã©ã€ã³ããã³é£éŠæ¿åºã«ãã£ãŠçºåžããã該åœããã³ã³ãã©ã€ã¢ã³ã¹ã¬ã€ãã³ã¹ã«æºæ ããããšãæ±ããã ãã§ãªããå»åž«ããã®ä»ã®å»çåŸäºè
ãžã®æ¯æããããŒã±ãã£ã³ã°è²»çšããã³äŸ¡æ Œæ
å ±ã«é¢ããæ
å ±ãå ±åããããšãæ±ããå ŽåããããŸããå·æ³ãå€åœæ³ã¯ãå¥åº·æ
å ±ã®ãã©ã€ãã·ãŒãã»ãã¥ãªãã£ãèŠå¶ããå€ãã¯HIPAAã«ãã£ãŠå
äŸãèŠãããããšã¯ãªããäºãã«éèŠãªç¹ã§ç°ãªããããæã
ã®ã³ã³ãã©ã€ã¢ã³ã¹ã®åªåãè€éã«ããŠããŸãã
ããåœç€Ÿã®æäœãåè¿°ã®èŠä»¶ã®ããããã«éåããŠããå Žåãåœç€Ÿã¯æ°äºãŸãã¯åäºçœ° (å人ã®æçŠãå«ã)ãåäºåžæ³æç¶ããééçæ害ãåœç€Ÿã®äºæ¥ã®åæžãŸãã¯åç·šæããããã¯æ¿åºå¥çŽãå»çè²»ã®éä»éãŸãã¯ã¡ãã£ã±ã¢ããã³ã¡ãã£ã±ã€ããå«ãããã®ä»ã®æ¿åºããã°ã©ã ããã®é€å€ããŸãã¯ä¿å¥çŠç¥ç(OIG)ã®è·å¡ç£æ»å®ãšã®æ³äººèª å®æ§åææžã®èª²ããããããšããããŸãããããã¯ããããäºæ¥ãå°æ¥èŠéããæ¥çžŸãŸãã¯è²¡åç¶æ³ãå®è³ªçãã€é倧ã«æªåœ±é¿ãåãŒãå¯èœæ§ããããŸããåœç€Ÿã¯ãç±³åœã欧å·é£åãããã³è€æ°ã®ä»ã®å°åã§éå»4幎éã«ããã4ã€ã®ååãåæ¥çã«ç«ã¡äžããåŸãã°ããŒãã«ãªã³ã³ãã©ã€ã¢ã³ã¹ã€ã³ãã©ã匷åããããšã«æ³šåããŠãããèŠå¶åœå±ã®æ¿èªãåæã«ãè¿œå ã®åœã§ã®è£œåã®ç«ã¡äžãã«åããŠããŸããæå¹ãªã³ã³ãã©ã€ã¢ã³ã¹ããã°ã©ã ã¯ãããã®æ³åŸã®éåãé²æ¢ã§ããŸããããããã®ãªã¹ã¯ã¯å®å
šã«æé€ã§ããªãå ŽåããããŸãããæªæ¿èªã®è£œååè£ã«é¢ããåæ¥æŽ»åã«åŸäºããããšããŸãã¯é©çšå¯èœãªèŠå¶ã«éåããŠåæ¥çã«æ¿èªããã補åãæšé²ããããšãããå Žåãåœç€Ÿã¯é倧ãªè²¬ä»»ãè² ãå¯èœæ§ããããŸãã詳现ã«ã€ããŠã¯ãããªã¹ã¯èŠå ãã®èŠåºããåç
§ããŠãã ãããåœç€Ÿã«å¯Ÿãããããªãè¡åã«å¯ŸããŠããçãããéåã«å¯ŸããŠã®èª¿æ»ã起蚎ã®ãªã¹ã¯ã軜æžããããšãã§ããå¹æçãªã³ã³ãã©ã€ã¢ã³ã¹ããã°ã©ã ããã£ãŠããåŒè·ãæåãããšããŠããåœç€Ÿã«å€§ããªæ³çè²»çšãè² ãããåœç€Ÿã®çµå¶å±€ã®æ³šæãåœç€Ÿã®æ¥åéå¶ãããããããå¯èœæ§ããããŸããããã«ãé©çšãããæ³åŸããã³èŠå¶ã«å¯Ÿããã³ã³ãã©ã€ã¢ã³ã¹ã®éæãšç¶æã¯ãåœç€Ÿã«ãšã£ãŠééçã«ãæéçã«ãããã³äººçè³æºçã«ã³ã¹ãããããå¯èœæ§ããããŸãã
ããç§ãã¡ããããã¯ç§ãã¡ã®å
±åäœæ¥è
ãCMOããŸãã¯ãµãŒãã¹ãããã€ããŒããé£éŠãå·ããŸãã¯å€åœã®é©çšæ³ä»€ã«éåããå Žåãç§ãã¡ã¯å·è¡è¡çºã®å¯Ÿè±¡ãšãªããæ¿èªããã補åããŸãã¯ä»åŸã®è£œåãéçºã販売ããèœåã«åœ±é¿ãäžããç§ãã¡ã®è©å€ãæãªãå¯èœæ§ããããåžå Žã«ãã補åã®åãå
¥ããæžå°ããå¯èœæ§ããããŸãããããã®å·è¡è¡çºã«ã¯ãæ°äºããã³åäºçœ°éãå»çè²»åéããã°ã©ã ããã®é€å€ãããã³ååæãžã®å
¥çã䌎ãåäºèšŽè¿œãå«ãŸããŸãã
ãŸããæ¿åºãå·ãããã³å€åœã®æ³åŸãŸãã¯èŠå¶ã¯å€æŽãããå¯èœæ§ããããŸããçŸåšãç§ãã¡ãååè
ãCMOãããã³/ãŸãã¯ãµãŒãã¹æäŸè
ã¯ã³ã³ãã©ã€ã¢ã³ã¹ãç¶æããŠãããããããŸãããã解éã®å€æŽãæ¯é
çãªæ¥çš®åºæºãæ³åŸæ§é ã®å€æŽã«ãããã³ã³ãã©ã€ã¢ã³ã¹ããå€ããããšããããŸãã
äŒæ¥ããã®çµæžçæ¯æŽãåãã第äžè
æ£è
æ¯æŽããã°ã©ã ã¯ãæ¿åºããã³èŠå¶åœå±ã®åŒ·åãããç£æ»ã®å¯Ÿè±¡ãšãªã£ãŠããŸãã OIGã¯ãå»è¬å補é æ¥è
ãMedicareæ£è
ã«å
±åæ¯æãæŽå©ãæäŸããæ
åå£äœã«å¯ä»ããããšãåæ³ã§ããããšã瀺åããã¬ã€ãã©ã€ã³ãèšå®ããŠããããã®ãããªæ©é¢ãæ
åå£äœã§ãããã¡ãŒã«ãŒã«å®å
šã«ç¬ç«ããŠãããè£å©éãç³è«è
ã«äžå®ã®è²¡æ¿åºæºã«åŸã£ãŠå
çé ã«æäŸãããããŒã®è£œåã®äœ¿çšãšã¯é¢é£ããŠæŽå©ãæäŸããŠããªãå Žåãåæ³ã§ãããšãããŠããŸããããããæ£è
æ¯æŽããã°ã©ã ãžã®å¯ä»ã¯ããã¬ãã£ããªå®£äŒãåããä»ã®ããäœã³ã¹ããªä»£æ¿åããããã©ã³ãè¬å€ã®ä¿é²ã«äœ¿çšããããšããçæã«é¢é£ããŠãè€æ°ã®æ¿åºã®å·è¡è¡åã®å¯Ÿè±¡ãšãªã£ãŠããŸããå
·äœçã«ã¯ãããæ°å¹Žã§ãé£éŠããã³å·æ³ã®ããŸããŸãªçš®é¡ã«åºã¥ãæ£è
æ¯æŽããã°ã©ã ã®åæ³æ§ã«å¯Ÿããæ¿åºã®äž»åŒµã«ããå€æ°ã®å解ãæç«ããŠããŸããç§ãã¡ã¯ãçµæžçã«å°çª®ããæ£è
ããã¬ãã¢ã ãå
±åæ¯æããããã³å
±åä¿éºã®çŸ©åããå©ããç¬ç«ããæ
ååºéã«å¯ŸããŠå©æéã亀ä»ããŠãããä»åŸãç¶ç¶ããå¯èœæ§ããããŸãããã®å Žåãç§ãã¡ãŸãã¯å¯ä»å
ãé¢é£ããæ³åŸãèŠå¶ããŸãã¯é²åããæ¿åºã®æéã«éåããŠãããšèŠãªãããå Žåãæå®³è³ åã眰éãåäºãæ°äºããŸãã¯è¡æ¿çãªå¶è£ãŸãã¯å·è¡æªçœ®ã®å¯Ÿè±¡ãšãªãå¯èœæ§ããããŸãã
ãã©ã€ãã·ãŒãããŒã¿ä¿è·ãæ
å ±ã»ãã¥ãªãã£ã«é¢é£ããæ¿åºèŠå¶ããã³ãã®ä»ã®æ³ç矩åã®å¯Ÿè±¡ã§ãããç§ãã¡ã¯ããŒã±ãã£ã³ã°ãã©ã¯ãã£ã¹ãèŠå¶ããäžæ£è¡çºãŸãã¯äžå
¬æ£è¡çºãçŠæ¢ããæ¶è²»è
ä¿è·æ³ã®å¯Ÿè±¡ã§ãããããã®çŸ©åã«éåããå®éã®ãŸãã¯ç¥ãããäºå®ã¯ãç§ãã¡ã®ããžãã¹ã«å®³ãäžããå¯èœæ§ããããŸãã
GDPRã¯ãEEAããã³è±åœã«ããããŒã¿äž»äœã®å¥åº·ãçäœæ
å ±ãéºäŒæ
å ±ãªã©ã®ãç¹å¥ã«ããŽãªã®ããŒã¿ããå«ãå人ããŒã¿ã®ç®¡çè
ããã³ããã»ããµãŒã«å³æ ŒãªèŠä»¶ã課ããŸããããã«ãGDPRã¯ãå¥åº·ãéºäŒããã³çäœããŒã¿ã®åŠçã«é¢ããæ³åŸãªã©åœå
æ³ãå¶å®ããEEAå çåœã«å¹
åºãæš©å©ãäžãããã®ãããªããŒã¿ã®äœ¿çšãšå
±æãå¶éããå¯èœæ§ããããã³ã¹ãå¢å ã«ã€ãªãããäºæ¥ããã³è²¡åç¶æ³ã«æªåœ±é¿ãäžããããšããããŸãã
GDPRãšEEAå çåœã®é¢é£ããåœå
ããŒã¿ä¿è·æ³ã«é©åããªãå Žåãããã«UK GDPRãšè¥å¹²ç°ãªãå¯èœæ§ããããããæ倧ã°ããŒãã«å¹Žé売äžé«ã®4ïŒ
ãŸãã¯â¬2,000äžïŒè±åœGDPRäžã§ã¯Â£17.5mnïŒã®çœ°éã課ããããå ŽåããããŸãããã®ä»ã«ãããã®ãããªçœ°éã«å ããŠã蚎èšãäžå©ãªå®£äŒã®å¯Ÿè±¡ãšãªãå¯èœæ§ããããããããåœç€Ÿã®è©å€ããã³ããžãã¹ã«å¯ŸããŠé倧ãªæªåœ±é¿ãäžããå¯èœæ§ããããŸãã GDPRã®å®æœçµæãåœç€Ÿã¯ããŒã¿ä¿è·èŠå¶ã«é©åããããã«äžå®ã®æªçœ®ãè¬ããå¿
èŠããããŸãã GDPRã¯ãïŒiïŒããŒã¿äž»äœã«å人ããŒã¿ã®åŠçæ¹æ³ãšåœŒããã©ã®ããã«ããŠèªåãã¡ã®æš©å©ãè¡äœ¿ã§ããããç¥ãããå¿
èŠãããããšãïŒiiïŒå人ããŒã¿ãåŠçããããã®æå¹ãªæ³çæ ¹æ ãããããšã確èªããå¿
èŠãããããšïŒãããåæã®å ŽåãåæãåŸãããã®èŠä»¶ãããé«ãèŠä»¶ãæã£ãŠããããšïŒãïŒiiiïŒå€§èŠæš¡ã«å人ããŒã¿ïŒã€ãŸããå¥åº·ããŒã¿ïŒãåŠçããå ŽåãããŒã¿ä¿è·è²¬ä»»è
ãä»»åœããå¿
èŠãããããšãïŒivïŒEEAããã³UKå
šåã§åŒ·å¶çãªããŒã¿äŸµå®³éç¥èŠä»¶ãå°å
¥ããããšãïŒvïŒé«ããªã¹ã¯åŠçãããå Žåã«ã¯åŠç掻åã®èšé²ãç¶æããããŒã¿ä¿è·åœ±é¿è©äŸ¡ãææžåããå¿
èŠãããããšãïŒviïŒãµãŒãã¹ãããã€ããŒãšå¥çŽããå Žåã«è¿œå ã®çŸ©åã課ãããšãïŒviiïŒå人ããŒã¿ãä¿è·ããããã«é©åãªæè¡çã»çµç¹çæªçœ®ãè¬ããããšãããã³ïŒviiiïŒé©åãªãã©ã€ãã·ãŒã¬ããã³ã¹ãæ¡çšããããªã·ãŒãæé ããã¬ãŒãã³ã°ãããã³ããŒã¿ç£æ»ãææžåããå¿
èŠããããŸãã
GDPRã¯ãEEAããã³è±åœããç±³åœãŸãã¯ãé©åãªããã©ã€ãã·ãŒä¿è·ãæäŸããŠããªãä»ã®å°åãžã®å人ããŒã¿ã®è»¢éã«å³æ Œãªã«ãŒã«ã課ããŠããŸããéå»ã«ãç±³åœã®äŒæ¥ã¯ãEU-USãUK-USãããã³Swiss-USãã©ã€ãã·ãŒçŸæ çµã¿ãåºç€ã«ããŠãEUããã³è±åœããå人ããŒã¿ãç±³åœã«åæ³çã«è»¢éããããšãã§ããŸããã2020幎7æã欧å·é£ååžæ³è£å€æïŒCJEUïŒã¯ãC-311/18ïŒããŒã¿ä¿è·å§å¡äŒå¯ŸFacebook Irelandããã³Maximillian SchremsããŸãã¯Schrems IIäºä»¶ïŒã§ã欧å·é£å-ç±³åœãã©ã€ãã·ãŒçŸãEUã®å人ããŒã¿ã®ç±³åœãžã®è»¢éã«é©åãªä¿è·ãæäŸããŠããªããšã®çç±ã§ç¡å¹ãšå€æããŸãããCJEUã¯ãåäžã®æ±ºå®ã§ã欧å·å§å¡äŒã«ãã£ãŠå
¬è¡šãããæšæºå¥çŽæ¡é
ïŒSCCïŒãæå¹ã§ãããšå€æããŸããããã ããCJEUã¯ãSCCã«ãã£ãŠè¡ããã転éãåä¿¡åœã®æ³åŸãEUãšåæ§ã«è»¢éãããå人ããŒã¿ãä¿è·ããã®ã«ãæ¬è³ªçã«åçã®ãä¿è·ãæäŸããŠããããšããäºäŸã«åºã¥ããŠè©äŸ¡ããå¿
èŠãããããã®åºæºãæºãããŠããªãå Žåã¯ãäºæ¥è
ãè£è¶³çãªæªçœ®ãæ¡çšããå¿
èŠããããšå€æããŸããã以éã欧å·ããŒã¿ä¿è·å§å¡äŒïŒEDPbïŒã2021幎6æã«å
¬è¡šããæéã§ã¯ããã®ãããªè£è¶³çãªæªçœ®ãå¿
èŠã§ãããè£è¶³çãªæªçœ®ãæäŸãããªãå Žåã¯ãå人ããŒã¿ã®è»¢éãé¿ããããåæ¢ããå¿
èŠããããšè¿°ã¹ãŠããŸãã2021幎6æ4æ¥ã欧å·å§å¡äŒã¯ãCJEUã®Schrems IIå€æ±ºã§æããã«ãªã£ãåé¡ã«å¯ŸåŠããæ°ããSCCã®å®æœæã«åœäºè
ãå®æœãã転éè©äŸ¡ã«é¢ãã詳现ãæäŸããæ°ããããŒãžã§ã³ã®SCCãå
¬è¡šããŸããããã ããSCCããã³ãã®ä»ã®ã¡ã«ããºã ãããã«åé¡ã«çŽé¢ããå¯èœæ§ãããããšã«é¢ããæžå¿µãç¶ããŠããŸããåæ§ã«ã2020幎9æãã¹ã€ã¹ã®ããŒã¿ä¿è·åœå±ã¯ãã¹ã€ã¹-ç±³åœãã©ã€ãã·ãŒçŸæ çµã¿ãã¹ã€ã¹-ç±³åœããŒã¿è»¢éã®æå¹ãªã¡ã«ããºã ã§ã¯ãªããSCCãã¹ã€ã¹ããå人ããŒã¿ã転éããããã®ã¡ã«ããºã ãšããŠã®æå¹æ§ã«ã€ããŠçåãæããããŸãããSCCã¯EU-USããŒã¿ãããŒã®ãã©ã€ãã·ãŒã·ãŒã«ãèªèšŒã®ä»£æ¿çãæäŸããŸããããã®æ±ºå®ïŒããã³ãã®åŸçºè¡ãããäžéšã®èŠå¶äžã®æéïŒã¯ãäžè¬ã«EU-USããŒã¿ãããŒã®åæ³æ§ã«ã€ããŠçåãæããããããŠããŸãã転éã®é害ãè² æ
ãçããå ŽåããŸãã¯åçã®ä¿è·ãæäŸãããªãå Žåãå人ããŒã¿ã®è»¢éãé¿ããå¿
èŠããããŸãã
é©çšãããããŒã¿ä¿è·æ³ã«æºæ ããŠãEUããç±³åœãžã®å人ããŒã¿ã®ç§»è»¢èœåãæã€ããšã¯ãèšåºè©Šéšãå®æœããèœåã«åæ»ãçããå¯èœæ§ããããããžãã¹ãèŠéããæ¥çžŸã財æ¿ç¶æ³ã«æªåœ±é¿ãäžããå¯èœæ§ããããŸããè±åœã¯ECã®æ°ããSCCã®å¯Ÿè±¡ã§ã¯ãããŸããããèªèº«ã®ç§»è»¢ã¡ã«ããºã ã§ããåœéããŒã¿è»¢éå¥çŽãŸãã¯åœéããŒã¿è»¢éè¿œå èŠå®ãå
¬è¡šããŠãããè±åœãã転éãå¯èœã§ãã2022幎3æ25æ¥ãECãšç±³åœã¯ãç¡å¹ãšãªã£ããã©ã€ãã·ãŒã·ãŒã«ãã代æ¿ããæ°ããã暪æçããŒã¿ãã©ã€ãã·ãŒãã¬ãŒã ã¯ãŒã¯ãã«é¢ããæ¿æ²»äžã®åæãçºè¡šããŸããããã¬ãŒã ã¯ãŒã¯ã¯ãSchrems IIã§æ瀺ãããæžå¿µã«å¯ŸåŠããããã®æ°ããææçãªä¿éæªçœ®ãå°å
¥ããŸããã2023幎7æ10æ¥ãECã¯ãEU-USããŒã¿ãã©ã€ãã·ãŒãã¬ãŒã ã¯ãŒã¯ãšåŒã°ãããã®ããŒã¿ãã©ã€ãã·ãŒãã¬ãŒã ã¯ãŒã¯ã«ã€ããŠãé©æ§æ±ºå®ãæ¡æããããšãçºè¡šããŸãããé©æ§æ±ºå®ã¯ãæ°ãããã¬ãŒã ã¯ãŒã¯ã®äžã§EUããç±³åœã®äŒæ¥ã«è»¢éãããå人ããŒã¿ã«å¯Ÿããååãªä¿è·ã¬ãã«ãç±³åœã確ä¿ããŠãããšçµè«ä»ããECã¯ããã®çµæããã¬ãŒã ã¯ãŒã¯ã«åå ããç±³åœäŒæ¥ã«å¯ŸããŠãè¿œå ã®ããŒã¿ä¿è·ä¿éãèšããããšãªããEUããå人ããŒã¿ãå®å
šã«æµåãããããšãã§ãããšè¿°ã¹ãŸãããEU-USããŒã¿ãã©ã€ãã·ãŒãã¬ãŒã ã¯ãŒã¯ã¯ãECãä»ã®æ¬§å·ã®ããŒã¿ä¿è·åœå±ãç±³åœåœå±ãšå
±åã§å®æçã«èŠçŽãããé©æ§æ±ºå®ã®æ¡æåŸ1幎以å
ã«æåã®èŠçŽããè¡ãããŸããEU-USããŒã¿ãã©ã€ãã·ãŒãã¬ãŒã ã¯ãŒã¯ã®æå¹æ§ãäºãäºä»¶ãEUè£å€æã«æ蚎ãããçŸåšãæªæ±ºçã§ãã
EEAå çåœã¯ãGDPRãå®è£
ããããã®å®æœæ³ãæ¡æããŠããŸããããã¯GDPRããéšåçã«éžè±ããŠããå¯èœæ§ããããEEAå çåœã®åœå±ã¯åœã«ãã£ãŠGDPRã®çŸ©åãããç°ãªãæ¹æ³ã§è§£éããããšãã§ãããããEUå
ã«åäžãªæ³çç°å¢ãå®çŸãããããšã¯æåŸ
ãããŠããŸãããããã«ãè±åœæ¿åºã¯çŸåšãããŒã¿ä¿è·ãšããžã¿ã«æ
å ±æ³æ¡ããŸãã¯è±åœæ³æ¡ãè±åœã®ç«æ³ããã»ã¹ã«å°å
¥ããŠããŸããè±åœæ³æ¡ã®ç®çã¯ãBrexitã«ç¶ãè±åœã®ããŒã¿ä¿è·äœå¶ãæ¹é©ããããšã§ããæç«ããã°ãè±åœæ³æ¡ã®æçµçã¯ãè±åœãšEEAã®ããŒã¿ä¿è·äœå¶ã®é¡äŒŒæ§ãããã«å€ããå¹æãæã€å¯èœæ§ããããŸãã2024幎ã®è±åœç·éžæãäºæ³ãããŠãããè±åœæ³æ¡ã®å¯æ±ºãé
ãããå¯èœæ§ããããŸãã
ç§ãã¡ã¯ãEEAãŸãã¯UKã®å人ã®è¡åãç£èŠããïŒã€ãŸããèšåºè©Šéšãå®æœããïŒå°åã§ãçŸå°ã®ããŒã¿ä¿è·åœå±ã®ç£ç£ãåããŠããŸããç§ãã¡ã¯ããµãŒãã¹ã®æäŸã«é¢ããŠç¬¬äžè
ã«äŸåããŠããããã®ãã¡ã®ããã€ãã¯ãEUããã³/ãŸãã¯UKã®å人ã®å人ããŒã¿ãç§ãã¡ã®ä»£ããã«åŠçããŠããŸãããã®ãããªãããã€ããŒãšã¯ããããã€ããŒãç§ãã¡ã®æ瀺ã«åŸã£ãŠå人ããŒã¿ãåŠçããããšãå¥çŽäžçŸ©åä»ããããååãªæè¡çãã€çµç¹çãªã»ãã¥ãªãã£å¯Ÿçãå®æœãããŠããããšã確èªããããã®ãã¥ãŒããªãžã§ã³ã¹ãå®æœããå¥çŽé¢ä¿ãç· çµããããŸãã¯ããããç· çµããããšããæåããããŸãã
åœç€Ÿã¯ã欧å·ã®é»åããŒã±ãã£ã³ã°ããã³ã¯ãããŒã«é¢ãããã©ã€ãã·ãŒæ³åŸã®é²åã«ãé©çšãããŸããEUã¯ãèŠå¶ã®åœ¢ããšãæ°ããèŠåã«ãã£ãŠe-Privacyæ什ïŒ2002/58/ECïŒã眮ãæããéçšã«ãããå欧å·é£åå çåœã®æ³åŸã«çŽæ¥å®è£
ããããããªãå¶å®ã®å¿
èŠã¯ãªããªããŸããe-PrivacyèŠå¶ã¯ãå
ã
ã¯2018幎5æ25æ¥ã«ïŒGDPRãšãšãã«ïŒæ¡æãããããšãäºå®ãããŠããŸããããçŸåšã欧å·ç«æ³éçšã§å¯©è°äžã§ããèæ¡èŠå¶ã¯ã2019幎11æ22æ¥ã®EUçäºäŒåžžä»»ä»£è¡šå§å¡äŒã«ãã£ãŠæåŠãããæ°ããèŠå¶ããã€æ¡çšããããããããã¯æ¡çšããããã©ããã¯äžæã§ããæã
ã¯ãŸããã«ãããªã©ã®ä»ã®å€åœã®çŸè¡ããã³é²åäžã®ãã©ã€ãã·ãŒæ³åŸã®å¯Ÿè±¡ã§ããããŸãã
ç±³åœããã³åœéçãªããŒã¿ä¿è·æ³ããã³èŠå¶ã®éµå®ã«ãããå¥çŽã«ãããŠå³ãã矩åãè² ããããŒã¿ã®åéã䜿çšãé瀺ã®èœåãå¶éãããå Žåã«ãã£ãŠã¯ç¹å®ã®ç®¡èœåºåã§ã®äºæ¥æŽ»åã«åœ±é¿ãäžããããå¯èœæ§ããããŸãããããã®æ³åŸãèŠå¶ã«éåãããšãæ¿åºã«ããå·è¡æªçœ®ïŒæ°äºãåäºãããã³è¡æ¿åŠåãå«ãïŒãæ°äºèšŽèšãæªã宣äŒãçºçãã䜿çšçµæãšããžãã¹ã«åŠå®çãªåœ±é¿ãäžããå¯èœæ§ããããŸãããŸããèšåºè©Šéšã®è¢«éšè
ãåŸæ¥å¡ããã®ä»ã®å人ïŒç§ãã¡ãæœåšçãªååè
ãå人æ
å ±ãååŸããããšãããå ŽåïŒãããã³ç§ãã¡ãšãã®æ
å ±ãå
±æããæäŸè
ã¯ãæ
å ±ã®åéã䜿çšãé瀺ã®èœåãå¶éããå¯èœæ§ããããŸããå人ã®ãã©ã€ãã·ãŒæš©ã䟵害ãããããŒã¿ä¿è·æ³ã«éåããããŸãã¯å¥çŽçŸ©åã«éåãããšäž»åŒµãããå Žåã§ããç§ãã¡ã責任ãè² ãå¿
èŠããªããŠãããã®èšŽèšã«å¯ŸåŠããã®ã«æéãšè²»çšãããããæªã宣äŒãæããããžãã¹ãå·ã€ããå¯èœæ§ããããŸãã
é£éŠæ¿åºã®æ¯åºãå
Œ
±ãµãŒãã¹ã®åæžã«ããããµãŒãã¹ãæãæ»ããè³é調éãåŸãèœåã圱é¿ãåããå¯èœæ§ããããŸãããŸããåœç€Ÿããã®ãããªå€åã«å¹æçã«é©å¿ã§ããªãå Žåãåœç€Ÿã®ããžãã¹ãèŠéããæ¥çžŸã財åç¶æ³ã«é倧ãªåœ±é¿ãäžããå¯èœæ§ããããŸãã
2011幎ã®äºç®ç®¡çæ³ã«ããã2013幎ãã2021幎ãŸã§ã®èµ€ååæžæªçœ®ãè°äŒãå¶å®ããªãã£ãå Žåãã»ãšãã©ã®é£éŠããã°ã©ã ã«èªåçã«åæžæªçœ®ãçºåãããŸãããããã®åæžæªçœ®ã«ã¯ã2013幎ããéå§ããã1äŒèšå¹ŽåºŠãããæ倧2ïŒ
ã®åæžãå«ãå»çè
ãžã®ã¡ãã£ã±ã¢æ¯æãã®ç·åæžãå«ãŸããŸãããããã®èªååæžæªçœ®ã®ãã¡ãäžéšãå°å
¥ãããããšã«ãããå»åž«ãç
é¢ããã®ä»ã®å»çè
ã«å¯Ÿããã¡ãã£ã±ã¢æ¯æãã®åæžãå®æœãããŸããããã€ããŒã¶ã³äºç®æ³ãå«ãæ³åŸãæ¹æ£ãããããããããã®åæžæªçœ®ã¯ãè¿œå ã®è°äŒæªçœ®ããšãããªãéãã2030幎ãŸã§æå¹ã§ããããšã«ãªããŸãããã³ãããŠã€ã«ã¹æå©ãææŽåã³çµæžå®å®åæ³ã«ãããããã³ãã®åŸã®æ³åŸã«ãããCOVID-19ãã³ãããã¯ã®ããããããã®åæžæªçœ®ã¯ã2020幎5æ1æ¥ãã2021幎12æ31æ¥ãŸã§åæ¢ãããŸãããäŒæ¢æéåŸã2022幎4æ1æ¥ãã6æ30æ¥ãŸã§ã®éã1ïŒ
æ¯æãåæžãéå§ãããŸããã2ïŒ
ã®æ¯æãåæžã¯ã2022幎7æ1æ¥ã«åéãããŸããã2012幎ã®ã¢ã¡ãªã«çŽçšè
ææžæ³ã¯ãè€æ°ã®å»çè
ãžã®ã¡ãã£ã±ã¢æ¯æããåæžããæ¿åºãæäŸè
ããã®è¶
éæ¯æããååããããã®æå¹æéã3幎ãã5幎ã«å»¶é·ããŸããããããã®æ°ããæ³åŸã¯ãã¡ãã£ã±ã¢ããã³ãã®ä»ã®å»çè²»ãããã«åæžããããšããããåœç€Ÿã®æ¿èªæžã¿è£œåãŸãã¯ããããã®è£œååè£ã®äŸ¡æ Œã«åœ±é¿ãåãŒãå¯èœæ§ããããŸãã
åœç€Ÿã®è£œåãŸãã¯å°æ¥ã®è£œåãåŠæ¹ãããé »åºŠããŸãã¯èŠå¶æ¿èªãååŸã§ããå¯èœæ§ã
è°äŒãæ¯åºåæžãè¡ã£ã以åã®è¡åãæ¿åºè³éã¬ãã«ã«é¢ããè°äŒã®æèŠã®äžäžèŽãé«ãæ¿åºã®åµåãçŸç¶ã®åœ¢æ
ã§ã®æç¶å¯èœæ§ã«é¢ããã¡ãã£ã±ã¢çäºäŒã®èŠåãªã©ãããé¢é£ããã°ã©ã ã®è³éå²ãåœãŠã®äžæ/ç¶ç¶çãªæé·ã¯ä¿èšŒãããŠããªããšèããããŸããé£éŠæ¿åºã®ã°ã©ã³ããå¥çŽã«å²ãåœãŠãããéé¡ã¯åæžããããæã¡åãããå¯èœæ§ããããããããåæžã«ãã£ãŠé¢é£æ©é¢ã®èœåãäœäžããæ¿èªãé
ããå¯èœæ§ããããŸããããã¯ãæ¿èªãããåœç€Ÿã®è£œåãããã³éçºäžã®ãã®ä»ã®è£œåã®éçºã販売ã«æ¯éããããå¯èœæ§ããããŸãã
3400ååã®è¬äŸ¡åºæºå¶åºŠããã®ä»ã®ã¢ã¡ãªã«æ¿åºã®äŸ¡æ Œå¶åºŠã®çŸ©åãå±¥è¡ããªãã£ãå Žåãè¿œå ã®æãæ»ãèŠä»¶ã眰éãå¶è£ã眰åã課ããããããžãã¹ãèŠéããæ¥çžŸåã³è²¡åç¶æ³ã«æ·±å»ãªåœ±é¿ãåãŒãå¯èœæ§ããããŸãã
åœç€Ÿã¯ãç±³åœã®æ¿åºä¿å¥å»çããã°ã©ã ã®äžéšãšãªã3400åãã«ã®è¬äŸ¡ããã°ã©ã ãã¡ãã£ã±ã€ãè¬å€å²åŒããã°ã©ã ãããã³ãã®ä»ã®é£éŠããã³å·æ¿åºã®äŸ¡æ Œããã°ã©ã ã«åå ããåœç€Ÿã®è£œåããããã®ããã°ã©ã ã®åçè
ã«æäŸãããå Žåãç¹å®ã®æ¿åºä¿å¥å»çããã°ã©ã ã«ãã補åã®ã«ãã¬ããžãååŸããããšãã§ããŸãããããã®ããã°ã©ã ã§ã¯ãéåžžãç¹å®ã®æ¯æ人ã«å¯ŸããŠå²åŒããªããŒããæäŸããããšãæ±ããŠããŸãããããã®ããã°ã©ã ã«ã¯ãç¹å®ã®äŸ¡æ Œå ±åèŠä»¶ãå«ãããã®ä»ã®èŠä»¶ã課ããããå ŽåããããŸãããããã®æ¿åºäŸ¡æ Œããã°ã©ã ã«å¯Ÿãã矩åã®å€æŽãé »ç¹ã«çºçããããã°ã©ã ã®èŠä»¶ã¯ãã°ãã°ææ§ã§ãããããã®ããã°ã©ã ã«éåããå Žåãé©æãã€æ£ç¢ºãªæ
å ±ãæ¿åºã«æäŸããªãã£ãå Žåãæ£ãããªããŒããæ¯æããªãã£ãå ŽåããŸãã¯æ£ããå²åŒäŸ¡æ ŒãæäŸããªãã£ãå Žåãåœç€Ÿã¯çœ°éã®å¯Ÿè±¡ã«ãªãããšããããŸãããããã®ããã°ã©ã ã«æºæ ãããããã®ããã°ã©ã ã®å°æ¥ã®å€æŽã«å¯Ÿå¿ããããšã¯ãã³ã¹ããšãªãœãŒã¹ãå€ãå¿
èŠãšãªãããšããããåœç€Ÿã®ããžãã¹ãå±æãæ¥çžŸããã³è²¡åç¶æ³ã«é倧ãªåœ±é¿ãåãŒãå¯èœæ§ããããŸãã
ç§ãã¡ã®ããžãã¹ã«ã¯è£œå責任蚎èšã®é倧ãªãªã¹ã¯ããããŸããååãªä¿éºãåããããªãå Žåãç§ãã¡ã«å¯Ÿãã補å責任è«æ±ãããžãã¹ãèŠéããéå¶çµæã財åç¶æ³ã«æªåœ±é¿ãåãŒãå¯èœæ§ããããŸãã
åœç€Ÿã®ããžãã¹ã¯ã人éã®æ²»ç補åã®éçºãè©Šéšã補é ãããŒã±ãã£ã³ã°ã«åºæã®é倧ãªè£œå責任ãªã¹ã¯ã«ãããããŠããŸãã補å責任è«æ±ãç§ãã¡ã®èšåºéçºããã°ã©ã ã®å®äºãé
ãããããé²æ¢ãããããå¯èœæ§ããããŸãããã®ãããªè«æ±ã補å責任ä¿éºã«ãã£ãŠå®å
šã«ã«ããŒãããªãå ŽåããããŸãããŸãã補å責任è«æ±ã«ãããæ¿èªããã補åã®å®å
šæ§ãæå¹æ§ã補é ããã»ã¹ãæœèšããŸãã¯ããŒã±ãã£ã³ã°ããã°ã©ã ãFDAã«ãã£ãŠèª¿æ»ããã補åã®ååãããé倧ãªå·è¡æªçœ®ã䜿çšãèš±å¯ãããæ¿èªæ瀺ã®å¶éããŸãã¯æ¿èªã®åæ¢ãŸãã¯åãæ¶ãã®å¯èœæ§ããããŸããçµæã«é¢ãããã責任è«æ±ã¯è£œåã®éèŠã®æžå°ãåœç€Ÿã®è©å€ãžã®æå·ãé¢é£èšŽèšã®é²åŸ¡è²»çšããããžã¡ã³ãã®æéãšãªãœãŒã¹ã®è»¢çšãè©Šéšåå è
ãŸãã¯æ£è
ãžã®è«å€§ãªééçæ¯æããæ ªäŸ¡ã®äžèœãããããå¯èœæ§ããããŸããçŸåšãåœç€Ÿã¯ãåœç€Ÿã®éçºæ®µéãããã³æ¿èªããã補åã®ããŒã±ãã£ã³ã°ããã³è²©å£²ã«é©ããŠãããšèããŠãã補å責任ä¿éºãä¿æããŠããŸããåœç€Ÿãä¿æããä¿éºã¯ãæœåšçãªè²¬ä»»ã«å¯Ÿããååãªã«ãã¬ããžãæäŸããŠããªãå ŽåããããŸããããã«ãèšåºè©Šéšããã³è£œå責任ä¿éºããŸããŸãé«äŸ¡ã«ãªã£ãŠããŸãããã®ãããæœåšçãªè²¬ä»»è«æ±ã«ããæ倱ããåœç€Ÿãä¿è·ããååãªä¿éºãé©åãªã³ã¹ãã§ååŸããããšãã§ããªãå Žåããããåœç€Ÿã®ããžãã¹ã«é倧ãªäžå©çãããããå¯èœæ§ããããŸãã
åœç€Ÿã®åŸæ¥å¡ã¯ãèŠå¶åºæºãèŠä»¶ã®ééµå®ãå
éšååŒéåãå«ãäžæ£è¡çºã«é¢äžããå¯èœæ§ããããããã«ãã£ãŠåœç€Ÿã®ããžãã¹ãèŠéããæ¥çžŸåã³è²¡åç¶æ³ã«é倧ãªæ害ãããããããšããããŸãã
åŸæ¥å¡ã«ããè©æ¬ºããã®ä»ã®äžæ£è¡çºã®ãªã¹ã¯ã«ãããããŠããŸããåŸæ¥å¡ã«ããäžæ£è¡çºã«ã¯ãç±³åœããã³æµ·å€ã«ãããå»çè©æ¬ºã»ä¹±çšãåæ±è·æ³åŸããã³èŠå¶ã®éåããŸãã¯æ£ç¢ºãªè²¡åæ
å ±ãããŒã¿ã®å ±åã®äžé©åãããèš±å¯ãããŠããªã掻åã®é瀺ãå«ãŸããå ŽåããããŸããç¹ã«ãå»çæ¥çã®è²©å£²ãããŒã±ãã£ã³ã°ãããžãã¹ååŒã¯ãè©æ¬ºãäžæ£è¡çºãããã¯ããã¯ãèªå·±ååŒããã®ä»ã®æªè³ªãªååŒæ
£è¡ãé²æ¢ããããšãç®çãšããæ³åŸããã³èŠå¶ã®ç¯å²å
ã«ãããŸãããåŒç€Ÿããããã¯åŒç€Ÿã®å
±åç 究è
ãïŒïŒ¯ããµãŒãã¹ ãããã€ããŒãªã©ãå»çæ³èŠããã©ã€ãã·ãŒãããŒã¿ä¿è·ããã³æ
å ±ã»ãã¥ãªãã£ã«é¢ããæ³ç矩åã«éåããå ŽåãåŒç€Ÿã®è£œåã®éçºã販売ãããŒã±ãã£ã³ã°ã«åŠå®çãªåœ±é¿ãåãŒãå¯èœæ§ããããåœç€Ÿã®è©å€ã«æ害ãäžããæããããããšãããªã¹ã¯ãã¡ã¯ã¿ãŒã«èšèŒãããŠããããã«ããããã®æ³åŸããã³èŠå¶ã¯ãåºç¯ãªäŸ¡æ Œèšå®ãå²åŒãããŒã±ãã£ã³ã°ããã³ããã¢ãŒã·ã§ã³ã販売ææ°æã顧客ã€ã³ã»ã³ãã£ãããã°ã©ã ããã³ãã®ä»ã®ããžãã¹ååŒãå¶éãŸãã¯çŠæ¢ããå¯èœæ§ããããŸããåŸæ¥å¡ã«ããäžæ£è¡çºã«ã¯ãã¯ãªãã«ã«ãã©ã€ã¢ã«ã®éçšã§åŸãæ
å ±ã®äžé©åãªäœ¿çšïŒååŒãè¡ãçïŒãå«ãŸããå Žåããããããã¯èŠå¶åœå±ããã®å¶è£ãåœç€Ÿã®è©å€ã«æ·±å»ãªæ害ãããããããšã«ãªããŸããåœç€Ÿã¯ã°ããŒãã«ãªã³ã³ãã©ã€ã¢ã³ã¹ããã°ã©ã ãç¶æãããã®é²åãšåŒ·åã«æ³šåããŠããŸããåœç€Ÿã®ããã°ã©ã ã«ã¯ããªã¹ã¯è©äŸ¡ãšç£èŠãåŸæ¥å¡ã第äžè
ãè¯å¿çãªè³ªåãæžå¿µãæèµ·ããããšã奚å±ãã話ãåãæåã®è²æãåçºãæžå¿µäºé
ã®å¯©æ»ãšæ¯æ£ã®ããã®å®çŸ©ãããããã»ã¹ãã·ã¹ãã ãªã©ã®åãçµã¿ãå«ãŸããŠããŸããããããªãããåŸæ¥å¡ã«ããäžæ£è¡çºãç¹å®ããé²æ¢ããããšã¯åžžã«å¯èœã§ã¯ãªãããã®ãããªæŽ»åãæ€åºããé²æ¢ããããã«ç§ãã¡ãåãäºé²çãæªç¥ãŸãã¯æªç®¡çã®ãªã¹ã¯ãŸãã¯æ倱ãã³ã³ãããŒã«ããããã«å¹æçã§ã¯ãªãããšããŸãã¯æ¿åºã®èª¿æ»ããã®ä»ã®è¡åãŸãã¯èšŽèšããç§ãã¡ãä¿è·ããããšã«å¹æçã§ã¯ãªãããšããããŸãã
ãããã®æ³åŸãèŠå¶ã«åŸããªãã£ãããã«çºçããã ããããã®ãããªè¡çºãæã
ã«å¯ŸããŠè¡ãããæã
ãèªå·±ã®æš©å©ã䞻匵ã§ããªãã£ãå Žåããã®è¡çºã¯æã
ã®ããžãã¹ãèŠéããæ¥çžŸåã³è²¡åç¶æ³ã«é倧ãªåœ±é¿ãäžããå Žåããããé倧ãªçœ°éããã®ä»ã®å¶è£ãç§ããããå¯èœæ§ãããã
ç°å¢ãå¥åº·ã»äººã®å®å
šä¿è·ã«é¢ããæ³åŸãéµå®ããªãå Žåãããžãã¹ãèŠéããæ¥çžŸã財åç¶æ³ã«æªåœ±é¿ãäžããå¯èœæ§ããããŸãã
ç§ãã¡ã®ç 究éçºããã³è£œé ã«ã¯ãå±éºç©è³ªãååŠç©è³ªãããã³æ§ã
ãªæŸå°æ§ååç©ã䜿çšãããŸãã ç§ãã¡ã¯ãã±ã³ããªããžããã³ããŒãã³ã®åœç€Ÿæœèšã§ãç 究éçºããã³è£œé 掻åã«å¿
èŠãªæ§ã
ãªå¯çæ§ããã³ææ¯ååŠç©è³ªãéç£ããŠããŸãã ãããã®å±éºç©è³ªã®äœ¿çšã補é ã貯èµãåãæ±ããããã³å»æ£ã«é¢ããé£éŠãå·ãããã³å°æ¹ã®æ³åŸããã³èŠå¶ã«å¯Ÿå¿ããŠããŸãã ç§ãã¡ã¯ãåœç€Ÿã®ã±ã³ããªããžããã³ããŒãã³æœèšã§ãããã®ç©è³ªã貯èµãåãæ±ããããã³å»æ£ããããã®æé ããã±ã³ããªããžåžãããŒãã³çºãããµãã¥ãŒã»ããå·ã®é¢é£ã¬ã€ãã©ã€ã³ãããã³ç±³åœåŽåçã®åŽåå®å
šè¡ç管çå±ã«ãã£ãŠæå³ãããåºæºã«æºæ ããŠãããšä¿¡ããŠããŸãã ãããã®ç©è³ªã®åãæ±ããšå»æ£ã«é¢ããå®å
šå¯Ÿçããé©çšèŠå¶ã«ãã£ãŠç€ºãããåºæºã«æºæ ããŠãããšä¿¡ããŠãããã®ã®ããããã®ç©è³ªã«ããå¶çºçãªæ±æãŸãã¯æå·ã®ãªã¹ã¯ã¯å®å
šã«æé€ããããšã¯ã§ããŸããã ããäºæ
ãèµ·ããã°ãç§ãã¡ã¯çµæçãªæå·ã«ã€ããŠè²¬ä»»ãè² ãããšã«ãªããŸãã ãã®è²¬ä»»ã¯å€§ããªãã®ã«ãªãå¯èœæ§ããããŸãã ç§ãã¡ã¯ãå®éšå®€ã®æé ãè¡æ¶²åªä»æ§ç
åäœãžã®æé²ãããã³çç©å±éºç©è³ªã®åãæ±ããå«ããå€æ°ã®ç°å¢ãå¥åº·ãããã³è·å Žå®å
šã«é¢ããæ³åŸããã³èŠå¶ã®å¯Ÿè±¡ãšãªã£ãŠããŸãã
ãããã®ææã®äœ¿çšã«ãã£ãŠåŸæ¥å¡ã®è² å·ããçããè²»çšãçµè²»ã«å¯ŸåŠããããã«åŽåçœå®³ä¿éºã«å å
¥ããŠããŸããããã®ä¿éºãæœåšçãªè²¬ä»»ã«å¯ŸããŠååãªä¿éãæäŸããããã§ã¯ãããŸãããç§ãã¡ã¯ãçç©ãæ害ç©è³ªãæŸå°æ§ç©è³ªã®è²¯èµãŸãã¯åŠåã«é¢é£ããŠç§ãã¡ã«å¯ŸããŠäž»åŒµãããå¯èœæ§ã®ããç°å¢ç責任ãŸãã¯æ害蚎èšã®ããã®ä¿éºãä¿æããŠããŸãããä»åŸæ¡æãããé£éŠãå·å°æ¹ã®æ³åŸããã³èŠå¶ãç§ãã¡ã®æŽ»åã«åœ±é¿ãäžããå ŽåããããŸãããããã®æ³åŸãŸãã¯èŠå¶ã«éåããå Žåãç§ãã¡ã¯é倧ãªã³ã¹ããè² æ
ããããšããããéèŠãªçœ°éãŸãã¯çœ°åãåããå¯èœæ§ããããŸãã
ç¹èš±ãã©ã€ã»ã³ã¹ãååŒç§å¯ã«é¢é£ãããªã¹ã¯
ç§ãã¡ã®çºèŠã«ç¹èš±ä¿è·ãåŸãããã匷å¶ã§ããªãå Žåã補ååè£ã®éçºãšåååèœåãæãªãããå¯èœæ§ããããŸãã
ç§ãã¡ã®æåã¯ãç±³åœããã³ä»ã®åœã®ç¹èš±ããã³ç¥ç財ç£æ³ã«åºã¥ãç¹èš±ããã³ãã®ä»ã®æè¡ããç§ãã¡ã®çºæãšç¬å æ
å ±ãäžæ³ã«äœ¿çšããä»ã®è
ãé²æ¢ããããšãã§ããããã«ä¿è·ããèœåã«éšåçã«äŸåããŠããŸãããã ããç§ãã¡ã¯ãææ¡ããã補åã®è£œé ããã³åååã«å¿
èŠãªäžéšã®ç¹èš±ã®å°ææš©ãæã£ãŠããªãå ŽåããããŸããç¹å®ã®ç±³åœã®ç¹èš±åºé¡ã¯ãç¹èš±ãçºè¡ããããŸã§æ©å¯ã«ä¿ãããããã2000幎11æ29æ¥ä»¥åã«æåºãããåºé¡ããŸãã¯ãã®åŸæåºãããåºé¡ã§å€åœã«åºé¡ãããªããã®ã該åœããŸãããã®ããã第äžè
ããç§ãã¡ããã®åºé¡ã«æ°ä»ããªããŸãŸãç§ãã¡ã®æªæ±ºè£åºé¡ãã«ããŒããäž»é¡ã«ã€ããŠç¹èš±åºé¡ãè¡ã£ãŠããå¯èœæ§ããããç§ãã¡ã®ç¹èš±åºé¡ããã®åºé¡ãããåªå
ããªãå¯èœæ§ããããŸãããããã®çç±ããã³ãã®ä»ã®çç±ã«ãããç§ãã¡ã¯ææã®ç¹èš±æš©ã確ä¿ã§ããªãå Žåããããææã®æä»æš©ã倱ãããšããããŸããããã«ãç§ãã¡ãŸãã¯ååè
ã¯ãæ¿èªããã1ã€ãŸãã¯è€æ°ã®è£œåãåžå Žåããããã«ããŸãã¯å°æ¥ã®è£œåãéçºããã³åååãããŸãã¯ç§ãã¡ãŸãã¯ååè
ã«ãã£ãŠéçºãããåœç€Ÿã®ãã€ãã©ã€ã³å
ã®è£œååè£ãåŒãç¶ãéçºããããã«ã第äžè
ç¹èš±ã®ã©ã€ã»ã³ã¹ãååŸããå¿
èŠãããå ŽåããããŸããã©ã€ã»ã³ã¹ãå©çšã§ããªãå Žåãåççãªæ¡ä»¶ã§å©çšã§ããªãå Žåãç§ãã¡ãŸãã¯ã©ã€ã»ã³ã·ãŒã¯ã圱é¿ãåãã補åãåžå Žåããããææã®æŽ»åãè¡ãããšãã§ããªãå ŽåããããŸãã
åœç€Ÿã®æŠç¥ã¯ãè¿
éã«çºèŠãç¹å®ããç¹èš±ä¿è·ãæ±ããããšã«äŸåããŠããŸããããã«ãå
±åç 究ã®äžç°ãšããŠå
±åéçºããç¬èªæè¡ã«é¢é£ããç¹èš±åºé¡ã第äžè
ã®å
±åéçºè
ã«å§ä»»ããããšããããŸããç¹èš±ä¿è·ãååŸããããã»ã¹ã¯é«é¡ã§æéãããããŸããåå¿
èŠãã€æãŸããç¹èš±åºé¡ãåççãªè²»çšãã€ã¿ã€ã ãªãŒã«è¡ããªãã£ãå Žåãåœç€Ÿã®ããžãã¹ã«æªåœ±é¿ãåãŒãå¯èœæ§ããããŸããç¬èªæš©å©ãä¿è·ããããã®åœç€Ÿããã³å
±åéçºè
ã®åªåã«ãããããããäžæ£ãªããŒãã£ãŒã¯ãåœç€Ÿãç¬èªæš©å©ãšã¿ãªãæ
å ±ãååŸããŠäœ¿çšããããšãã§ããå¯èœæ§ããããŸããçºè¡ãããç¹èš±ã¯æå¹ãšãããŠããŸãããããã¯ç¹èš±ãæå¹æ§ã®ãã£ã¬ã³ãžãçãæ®ã£ããã匷å¶åãäžãããããããããšãä¿èšŒãããã®ã§ã¯ãããŸãããåœç€Ÿãä»åŸååŸããå¯èœæ§ã®ããç¹èš±ã¯ã第äžè
ãæã
ã®ç¥ç財ç£ãåé¿ããããšããæã«ããã£ã¬ã³ãžãããããç¡å¹åãããããé©çšã§ããªãããããããå¯èœæ§ããããŸããããã«ã第äžè
ãŸãã¯ç±³åœç¹èš±åæšåºïŒUSPTOïŒã¯ãåœç€Ÿã®ç¹èš±ãŸãã¯ç¹èš±åºé¡ã«é¢ããå¹²æžæç¶ããéå§ããå¯èœæ§ããããŸããåœç€Ÿã®ç¹èš±ãŸãã¯ç¹èš±åºé¡ã«å¯ŸãããããªãææŠãå·è¡äžèœã®çºèŠãç¡å¹åãŸãã¯åé¿ããè²»çšãããããåœç€Ÿã®çµå¶é£ã®éèŠãªæéãšæ³šæãå¿
èŠãšãã第äžè
ã®èš±å¯è
ããã®ãã€ã«ã¹ããŒã³ããã³/ãŸãã¯ãã€ã€ã«ãã£æ¯æããæžå°ãŸãã¯å»æ¢ããåœç€Ÿã®ããžãã¹ã«é倧ãªæªåœ±é¿ãåãŒãå¯èœæ§ããããŸãã
ç§ãã¡ã®ä¿çäžã®ç¹èš±ç³è«ã¯ãçºè¡ç¹èš±ã«çµã³ã€ããšã¯éããŸãããå»è¬åãŸãã¯ãã€ãªãã¯ãããžãŒäŒæ¥ã®ç¹èš±äœçœ®ãå«ãæã
ã®ãã®ã¯äžè¬çã«äžç¢ºå®ã§ãè€éãªæ³çããã³äºå®äžã®èæ
®äºé
ãé¢ä¿ããŠããŸããç±³åœç¹èš±åæšåºããã³å€åœã®ç¹èš±åºãç¹èš±ãäžããããã«äœ¿çšããèŠæ Œã¯ãåžžã«äºæž¬å¯èœãŸãã¯åäžã«é©çšããããšã¯éãããå€æŽãããå¯èœæ§ããããŸããåæ§ã«ããã€ãªãã¯ãããžãŒçºæåãæã
ãå«ãããã®ããç±³åœããã³å€åœã®ãããªãåœã§ã©ã®çšåºŠã®ä¿è·ãæäŸããããã¯äžç¢ºå®ã§ãããç¹èš±åºãè£å€æããã³ç«æ³è
ã決å®ããä¿è·ç¯å²ã«äŸåããããšã«ãªããŸããããã«ãç±³åœè°äŒããã³åœéçãªç®¡èœåºåã§ãå®æçãªè°è«ãè¡ãããŠããããšããããŸãã
ç¹èš±æ³ã®ããŸããŸãªåŽé¢ãä¿®æ£ããŸããããšãã°ãã¢ã¡ãªã«åè¡åœã®ç¹èš±æ³ã«ããã€ãã®å€æŽãå«ããã¢ã¡ãªã«çºææ³ïŒAIAïŒãæ¡çšããŸãããæ¡æãããå€æŽã®ããããããçºèŠã®é©åãªä¿è·ãæäŸããªãå Žåãç¹èš±æš©äŸµå®³è
ã«å¯ŸããŠé倧ãªæå®³è³ åãè«æ±ã§ããªããªããããããžãã¹ã«æªåœ±é¿ãäžããå¯èœæ§ããããŸãã AIAã®äž»èŠãªèŠå®ã®1ã€ã§ããã2013幎3æã«çºå¹ãããã®ã¯ãç±³åœã®ç¹èš±ã®å®åããæåã«çºæãããã®ã§ã¯ãªããæåã«åºé¡ãã人ãæš©å©ãåŸãæ¹åŒã«å€æŽããŸããã競åä»ç€Ÿãåãçºæã«ã€ããŠåºé¡ããåã«çºæãç³è«ããªãå Žåãåœç€Ÿã¯ç«¶åä»ç€Ÿã®åºé¡æ¥åã«çºæç©ãä¿æããŠããããšã蚌æã§ããªããªãããããã£ãŠåœç€Ÿã®çºæã«å¯Ÿããç¹èš±ä¿è·ãåŸãããšãã§ããªããªããŸãããŸããäžççã«å»è¬åããã€ãªãã¯ãããžãŒã®ç¹èš±ã«ãããŠä»äžãããè«æ±ã®äž»é¡ãç¯å²ã«ã€ããŠãäžè¬çãªåæã¯ãããŸããã
åŸã£ãŠãç§ãã¡ã¯å°æ¥çãªç¬èªã®æš©å©ã®ä¿è·ã®çšåºŠãç¹èš±ã®çºè¡ã«èš±å¯ãããè«æ±ã®å¹
ãç¥ãããšãã§ããŸããããŸããç¹èš±ã§ä¿è·ãããŠããªãç§å¯ä¿æãããŠããŠããã¯ãããžãŒã«ããçšåºŠäŸåããŠããã競äºåãç¶æããŠããŸããç¹èš±ã§ä¿è·ãããŠããªãååŒç§å¯ãããŠããŠããŸãã¯ãã®ä»ã®æè¡ã競åä»ç€Ÿã«é瀺ãããå ŽåããŸãã¯ç«¶åä»ç€Ÿã«ãã£ãŠç¬èªã«éçºãããå Žåãç§ãã¡ã®ããžãã¹ãèŠéããéå¶çµæãããã³è²¡åç¶æ³ã«é倧ãªäžå©çãäžããå¯èœæ§ããããŸãã
補ååè£ç©ã補åãã«ããŒããç¹èš±ã®åºç¯ãªç¯å²ã®ååŸãšç¶æãšå©çšå¯èœãªãã¹ãŠã®èŠå¶ã®æä»çæš©å©ãšç¹èš±æéå埩ãŸãã¯å»¶é·ãæ倧åã§ããªãå Žåãåžå Žã·ã§ã¢ãš/ãŸãã¯å£²äžé«ã®åªå€±ãããã³ãžã§ããªãã¯ã®ãšã³ããªãŒãåŒãèµ·ããå¯èœæ§ããããŸãã
ç§ãã¡ã¯ããµãŒãããŒãã£ã®ãªãŒããŒããç¹èš±æš©ãã©ã€ã»ã³ã¹ååŸããŠããŸãããã®ãããªææè
ãããããã®ã©ã€ã»ã³ã¹ã®åºç€ãšãªãç¹èš±ãé©åã«ååŸãç¶æããŸãã¯æœè¡ã§ããªãå Žåãç§ãã¡ã®ç«¶äºåãšããžãã¹ãèŠéããéå¶çµæãããã³è²¡åç¶æ
ã«æ害ãäžããããšããããŸãã
ç§ãã¡ã¯ãããžãã¹ã«å¿
èŠãŸãã¯äŸ¿å©ãªãµãŒãããŒãã£ã®ç¥çæææš©ã«é¢ããæš©å©ãäžããå€æ°ã®ã©ã€ã»ã³ã¹ã®åœäºè
ã§ããç¹ã«ãIonisãArbutusãDicernaãå«ãé¢ä¿è
ããã©ã€ã»ã³ã¹ãååŸããŠããŸãããŸããå°æ¥çã«ã¯ãµãŒãããŒãã£ã®ç¥çæææš©ã«é¢ããè¿œå ã®ã©ã€ã»ã³ã¹ã«ãåå ããäºå®ã§ãã
ç§ãã¡ã®æåã¯ãã©ã€ã»ã³ã·ãŒãã©ã€ã»ã³ã¹ãããç¥ç財ç£æš©ã«å¯ŸããŠç¹èš±ä¿è·ãååŸãç¶æã匷å¶ããèœåã«éšåçã«äŸåããå¯èœæ§ããããŸããç¹ã«ãç¬å çãªæš©å©ã確ä¿ããç¹èš±ã«é¢ãããã®ã§ããç§ãã¡ãã©ã€ã»ã³ã¹ããç¹èš±ç³è«ãååã«åŠçã§ããªãå¯èœæ§ããããŸãããããã®ç¹èš±ç³è«ã«å¯ŸããŠç¹èš±ãçºå¹ããŠããç§ãã¡ã®ã©ã€ã»ã³ã·ãŒã¯ãããã®ç¹èš±ãç¶æã§ããªãããããã®ç¹èš±ã«äŸµå®³ããŠããä»ã®äŒæ¥ã«å¯ŸããŠèšŽèšãèµ·ãããªãããšã決å®ããããŸãã¯ç§ãã¡ãããæ§ããã«ãã®ãããªèšŽèšãèµ·ããå¯èœæ§ããããŸããã©ã€ã»ã³ã¹ããç¥ç財ç£æš©ã«ä¿è·ããªãå Žåãä»ã®äŒæ¥ã¯å®è³ªçã«åäžã®è£œåã販売ããããšãã§ããç§ãã¡ã®ç«¶äºåã®ããããžãã¹ããžã·ã§ã³ã«æªåœ±é¿ãäžããããžãã¹ãèŠéããéå¶çµæãããã³è²¡åç¶æ
ã«æ害ãäžããå¯èœæ§ããããŸããããã«ãç§ãã¡ã¯ç¬¬äžè
ã©ã€ã»ã³ã¹ããµãã©ã€ã»ã³ã¹ããå
±åç 究è
ã«æš©å©ãäžããŠããŸãããããã®ãµãã©ã€ã»ã³ã¹ãããæš©å©ã®æ倱ã¯ãå
±åç 究å¥çŽã§ã®åå
¥æžå°ã«ã€ãªããå¯èœæ§ãããããŸãã1人以äžã®å
±åç 究è
ã«ããå¥çŽã®çµäºã«ã€ãªããå¯èœæ§ããããŸãã
ãã®ä»ã®äŒæ¥ãå£äœããç¹èš±æš©ãäºãã補åã®éçºãåååã劚ããå¯èœæ§ããããŸãã
RNAiã¯æ¯èŒçæ°ããç§åŠåéã§ãããåæ¥åã«äŒŽãããã®åéã§ç¹èš±ä¿è·ãåŸãããšæãçµç¹ãå人ããå€æ°ã®ç¹èš±ãšç¹èš±åºé¡ãåºãããŠããŸããç§ãã¡ã¯RNAiã®ç¹èš±ãåãåããã©ã€ã»ã³ã¹ãéçºè
ããç¬å çã«ååŸããŠããŸããç±³åœããã³äžççãªäž»èŠåžå Žã«ãããçºå¹ç¹èš±ããã³ä¿çäžã®ç¹èš±åºé¡ã«é¢ãããåœç€ŸãææãŸãã¯ã©ã€ã»ã³ã¹ãåããæ¹æ³ãæ§æãããã³ããã»ã¹ãå€æ°ãããRNAiæ²»çè¬ã®éçºã補é ãåæ¥åã«é¢ãããã®ã§ãã
å
·äœçã«ã¯ãç¹èš±ãç¹èš±åºé¡ãããã³ãã®ä»ã®ç¥ç財ç£ããsiRNAã®æ§é ããã³çšéã®åºæ¬çãªåŽé¢ãRNAié¢é£ã®ã¡ã«ããºã ãæ²»çè¬ãšããŠã®äœ¿çšãããã³ååŠä¿®é£Ÿã«ãããæ²»çããã³ãã®ä»ã®çšéã®é©æ§ãåäžããsiRNAãç¹å®ã®æšçã«åããsiRNAãç¹å®ã®çŸæ£ã®æ²»çè¬ãšããŠã®siRNAãçæ°Žåç©å
±åœ¹äœããã³éœã€ãªã³æ§ãªããœãŒã ãªã©ã®é
éæè¡ãããã³ç¹å®ã®éçºåè£ã®ãã¹ãŠã®åŽé¢ãã«ããŒããŠããŸãã
RNAiæ²»çã®åéãæçããã«ã€ããŠãäžçäžã®åœç«ç¹èš±åºãç¹èš±åºé¡ãå®å
šã«åŠçããŠããŸããã©ã®ç¹èš±ãçºè¡ããããããããŠçºè¡ãããå Žåã«ã€ããŠããã€ã誰ã«ãã©ã®ãããªæš©å©ã§ãããã«ã€ããŠã¯äžæ確ã§ããRNAiåéã®ç¹èš±æš©ã«é¢ããããŸããŸãªç¹èš±åºã«ãããå¹²æžãå審æ»ãç°è°ç³ç«ãŠæç¶ããããã³äºåããã³äºåŸã®å¯©æ»æç¶ããå«ããéèŠãªèšŽèšããã³ãã®ä»ã®æç¶ããè¡ãããå¯èœæ§ãããã§ããããããã«ã第äžè
ãæã
ã®ç¹èš±ã®æå¹æ§ãäºãããšããããŸããäŸãã°ã第äžè
ããRNAiçµæç©ããã³ANGPTL3ã®ãµã€ã¬ã³ã·ã³ã°æ¹æ³ã«é¢ãã䞻匵ãå«ãææç¹èš±EP 2723758ã«å¯ŸããŠãæ¬ æ Œã®äž»åŒµã§ãããšäž»åŒµããŠã欧å·ç¹èš±åºããŸãã¯EPOã«ç°è°ãç³ãç«ãŠãŸããã2021幎2æã®å£é åŒè«ã«ç¶ããŠãç¹èš±ã¯æ€åãããŸããã2021幎6æã«ã¯ãEPOã®æ±ºå®ã«å¯Ÿããæ§èšŽéç¥ãæåºããã2023幎11æã®å£é åŒè«ã«ç¶ããŠãæ§èšŽãæ£åŽãããç¹èš±ãæ€åããããŸãŸãšãªããŸããã2022幎3æã第äžè
ããã±ããããœãããŒãŒã®ãµã€ã¬ã³ã·ã³ã°ã®ããã®RNAiçµæç©ããã³æ¹æ³ã«æåãããææç¹èš±EP3105332ã«å¯ŸããŠãEPOã«ç°è°ãç³ãç«ãŠãç¹èš±ã®æ€åãæ±ããŸãããããã«ã2023幎2æã«ã¯ã第äžè
ãç°è°ç³ç«ãŠãè¡ãã
åŒç€ŸãææãããModified RNA Agentsããšããç¹èš±EP 3366775ã«å¯ŸããEPOããç°è°ç³ãç«ãŠããããŸããããã®æç¶ãã§å£é åŒè«ãäºå®ãããŠããŸãããŸããinclisiranã«é¢é£ãã2ã€ã®äžåœç¹èš±ïŒZL201380063930.5ããã³ZL201810143112.0ïŒã®æå¹æ§ãã第äžè
ã«ãã£ãŠäžåœåœå®¶ç¥ç財ç£å±ã«ç°è°ç³ãç«ãŠããããŸãããäžåœåœå®¶ç¥ç財ç£å±ã¯æè¿ãç¹èš±çªå·ZL201380063930.5ãå
šäœçã«æå¹ã§ããããšããããŠåŒç€Ÿãæåºããã¯ã¬ãŒã ã®ä¿®æ£çã«åºã¥ããç¹èš±çªå·ZL201810143112.0ãæå¹ã§ããããšã確èªãã決å®ãåºããŸãããEPOããã³ä»ã®æèœåºåã§è¿œå ã®ç°è°ç³ãç«ãŠãè¡ãããããšãäºæ³ãããããŒããã©ãªãªå
ã®ä»ã®ç¹èš±ããã³ç¹èš±åºé¡ã«é¢ãããã®ä»ã®ç°è°ç³ãç«ãŠãæèµ·ãããå¯èœæ§ããããŸããå€ãã®å Žåãåœäºè
ã®ã©ã¡ãããæ§èšŽã®å¯èœæ§ããããããç¹å®ã®ç®¡èœåºåã«ããããããã®ç¹èš±ã«é¢ããæçµçã§æ§èšŽäžå¯èœãªå€æ±ºãŸã§æ°å¹Žãããå¯èœæ§ããããŸãããããããã³ãã®ä»ã®æç¶ãã®ã¿ã€ãã³ã°ããã³çµæã¯äžç¢ºå®ã§ãããä¿çäžã®ç¹èš±ã¯ã¬ãŒã ã®ç¹èš±æ§ããã³ç¯å²ãå®ãããã«æåããªããã°ãããžãã¹ãèŠéããæ¥çžŸããã³è²¡åç¶æ³ã«äžå©ãªåœ±é¿ãäžããå¯èœæ§ããããŸããåŒç€Ÿã®æš©å©ãçŽæ¥çã«åé¡ã«ãªããªãå Žåã§ããçŽäºãç¥ç財ç£æš©ã匱ããå¯èœæ§ããããŸãã第äžè
ãç¥ç財ç£æš©ãåé¿ãŸãã¯ç¡å¹ã«ããè©Šã¿ã«å¯ŸããåŒç€Ÿã®é²åŸ¡çã¯ãåŒç€Ÿã«ãšã£ãŠè²»çšãããããçµå¶é£ã®é倧ãªæéãšæ³šæãèŠããããžãã¹ãèŠéããæ¥çžŸããã³è²¡åç¶æ³ã«é倧ãªæªåœ±é¿ãåãŒããRNAiåéã§ã®æåè£ã«ç«¶äºããèœåã«åœ±é¿ãäžããå¯èœæ§ããããŸãã
åœç€ŸãŸãã¯åœç€Ÿã®ã©ã€ã»ã³ã·ãŒã®siRNA補åãåœç€ŸãŸãã¯åœç€Ÿã®ååè
ãéçºäžã®ã¬ã€ãã¹ããŒãžã®æ²»çåè£è
ã§ããzilebesiranããã³fitusiranãããã³åœç€Ÿã®ãã®ä»ã®ãã€ãã©ã€ã³è£œåã«å¿
èŠãšãªãå¯èœæ§ããããªãªãŽãã¯ã¬ãªããååŠããã³ä¿®é£Ÿã®åŽé¢ã䞻匵ããçºè¡æžããã³ä¿çäžã®ç¹èš±ãå€æ°ãããŸãããŸããåœç€ŸãéçºãããsiRNAè¬å€ã«é¢é£ããéºäŒåãŸãã¯éºäŒåéšåãæšçãšããçºè¡æžç¹èš±ãå€æ°ãããŸããããã«ãåœç€ŸãéçºããŠãããŸãã¯åœç€Ÿã®ååè
ãéçºããŠãããã€ãã©ã€ã³ã§éçºåè£è
ãç¶ç¶çã«éçºããããã«ãç¹èš±ãå¿
èŠãšããå Žåããåœç€Ÿã®siRNAæ²»çåè£è
ãŸãã¯ããŒã±ãã£ã³ã°è£œåã«å¿
èŠãšããããå°æ¥ã®è£œåéçºããã³åæ¥åãä¿é²ããããã«ç¹èš±ãå¿
èŠãšãªãå ŽåããŸããç°è°ç³ç«ãŠã®å¯Ÿè±¡ãšãªãç¹èš±åºé¡ãããå ŽåããããŸãããã®ããã1ã€ãŸãã¯è€æ°ã®çµç¹ãåœç€Ÿãã©ã€ã»ã³ã¹ãå¿
èŠãšããç¹èš±æš©ãä¿æããŠããå¯èœæ§ãããããŸãã¯åœç€Ÿã«å¯ŸããŠäž»åŒµãããç¹èš±æš©ãä¿æããŠããå¯èœæ§ããããŸãããããã®çµç¹ãåœç€Ÿã«åççãªæ¡ä»¶ãŸãã¯å
šãã©ã€ã»ã³ã¹ãä»äžããªãããšããè£å€æãåœç€Ÿã䞻匵ãããç¹èš±æš©ãå¿
èŠãšãããšå€æ±ºãåºããšãONPATTROãAMVUTTRAãGIVLAARIããŸãã¯OXLUMOãªã©ã®è£œåãããŒã±ãã£ã³ã°ããããšãã§ããªããªãããŸãããã®ãããªç¹èš±ã«ãã£ãŠã«ããŒãããç 究éçºããã®ä»ã®æŽ»åãå®æœããããšãã§ããªããªãå¯èœæ§ããããŸããäŸãã°ã2017幎ãã2018幎ã«ãããŠãSilence Therapeutics plcãŸãã¯Silenceã¯ãã€ã³ã°ã©ã³ãããã³ãŠã§ãŒã«ãºé«çè£å€æãå«ãæ°å€ãã®ç®¡èœåºåã§ãåœç€Ÿããã³å®å
šåäŒç€Ÿã§ããAlnylam Uk Ltd.ãå
±å被åãšããŠåæãããONPATTROã1ã€ãŸãã¯è€æ°ã®Silenceç¹èš±ã䟵害ãããªã©ã®äž»åŒµãããŸããããã®ç¥ç財ç£çŽäºã«é¢é£ããæã
ãŸãã¯Silenceã«ããé¢é£ãã蚎èšãããã€ããããŸããã2018幎12æãåœç€Ÿã¯Silenceãšå解ããã³ã©ã€ã»ã³ã¹å¥çŽãç· çµããç¹èš±äŸµå®³ãç¹èš±ç¡å¹ããã³å¥çŽéåãªã©ãåœç€ŸãšSilenceã®éã®å
šãŠã®çŸè¡ã®äž»åŒµãè¡æ¿æç¶ããããã³äžçäžã®èŠå¶æç¶ãã解決ããŸããã
ç¥ç財ç£æš©ã®èšŽèšãæš©å©ã®å€æã«é¢é£ãããã®ä»ã®æç¶ãã«å·»ã蟌ãŸããå Žåãèšå€§ãªè²»çšãè²»çšãçºçããå¯èœæ§ããããç§ãã¡ã«å¯Ÿãã蚎èšãæç¶ãã®å Žåã¯ãèšå€§ãªæå®³è³ å責任ãè² ãå¯èœæ§ãããã補åéçºãšåååã®åªåãåæ¢ããå¿
èŠãããããšããããŸãã
第äžè
ã¯ç¹èš±æš©ã䟵害ãããšããŠãç§ãã¡ã蚎ããå¯èœæ§ããããŸããããšãã°ã2017幎10æã«Silenceãç§ãã¡ã蚎ããONPATTROããã³ãã®ä»ã®RNAiæ²»çè¬ã®éçºã«ãããŠç§ãã¡ãŸãã¯MDCOã1ã€ä»¥äžã®Silenceç¹èš±ã䟵害ãããšäž»åŒµããŸããã2018幎12æã«ç§ãã¡ã¯Silenceãšã®ãã¹ãŠã®èšŽèšã解決ããŸããã第äžè
ã¯ãŸããç§ãã¡ãæ©å¯æ
å ±ãäžé©åã«ååŸãŸãã¯äœ¿çšãããšäž»åŒµããå¯èœæ§ããããŸãã
ããã«ã第äžè
ã¯ãç¹èš±ãŸãã¯ã©ã€ã»ã³ã¹ç¹èš±ã®çºæè
ã«ç°è°ãå±ããå¯èœæ§ããããŸããäŸãã°ã2011幎3æããŠã¿å€§åŠïŒä»¥äžããŠã¿ïŒã¯ãç§ãã¡ãããã¯ã¹ã»ãã©ã³ã¯ç§åŠæ¯èåäŒãããã¯ã¹ã»ãã©ã³ã¯ã»ã€ãããŒã·ã§ã³ãããã³ãã¯ã€ãããããMItããã³ããµãã¥ãŒã»ãã倧åŠã«å¯ŸããŠããŠã¿å€§åŠã®ææãç§ãã¡ã®ã©ã€ã»ã³ã¹ååŸç¹èš±ã®åäžã®çºæè
ã§ãã£ããããŸãã¯ä»£æ¿ã§ãå
±åçºæè
ã§ãã£ãããšã䞻匵ãã蚎èšãèµ·ãããŸããããŠã¿ã¯ãTuschlç¹èš±ã®çºæè
è³æ Œã®ä¿®æ£ãæªæ瀺ã®æå®³è³ åããã³ãã®ä»ã®ææžãæ±ããŠããŸãããè£å€æã¯ãè£å€ææç¶ããšçºèŠã®æ°å¹ŽåŸãç§ãã¡ã®éšåå€æ±ºã®åè°ãèªãããŠã¿å·æ³ã«åºã¥ãæå®³è³ åè«æ±ãåŽäžããŸããããã®èšŽèšã®å¯©çäžãããã³ä»¥äžã«èª¬æãããã£ã»ã«ãã£èšŽèšäžãç§ãã¡ã¯èšå€§ãªè²»çšãè² æ
ããŸããããŸããåäºä»¶ã«ãããŠã蚎èšã¯ç§ãã¡ã®çµå¶é£ããã³ãã®ä»ã®ãªãœãŒã¹ã®æ³šç®ãããããä»ã®æŽ»åã«åŸäºããŠããã¯ãã®æ¥åãé»å®³ããŸããã
ç¹èš±çºè¡ãŸãã¯ç§ãã¡ã«ã©ã€ã»ã³ã¹ãããç¹èš±ã匷å¶ããããã®èšŽèšããä»ã®äººã®å°ææš©ã®ç¯å²ãšæå¹æ§ãå€æããããããŸãã¯ç§ãã¡ã®å°ææ
å ±ããã¬ãŒãã·ãŒã¯ã¬ãããä¿è·ããããã«èšŽèšã«èšŽããå¿
èŠãããå ŽåããããŸããããšãã°ã2015幎第2ååæã«ã¯ãMerck SharpïŒDohme Corp.ïŒMerckïŒãã賌å
¥ããRNAiè³ç£ã«ãããåœç€Ÿã®æš©å©ãä¿è·ããããããã€ã¯ãRNAã®ç§å¯ãççšãã蚎èšãDicernaã«å¯ŸããŠæèµ·ããŸããã 2018幎4æã«ãDicernaãšç§ãã¡ã¯ãç§ãã¡ã®éã®èšŽèšã«ããããã¹ãŠã®è«æ±ãå解ããŸããã2022幎3æãç§ãã¡ã¯ç±³åœç¹èš±ç¬¬11,246,933å·ïŒä»¥äžãã'933ç¹èš±ããšããŸãïŒã«å¯Ÿãã䟵害ã«ã€ããŠã®æå®³è³ åãæ±ãããããç±³åœãã©ãŠã§ã¢å°åºé£éŠè£å€æã«èšŽèšãæèµ·ããŸããããã®åŸãPfizerã¯BioNTech SEãŸãã¯BioNTechã«åå ããå蚎ãæèµ·ããŸããã2022幎7æãç§ãã¡ã¯ãç±³åœç¹èš±ç¬¬11,382,979å·ïŒä»¥äžãã'979ç¹èš±ããšããŸãïŒã«å¯Ÿãã䟵害ã«ã€ããŠãPfizer / BioNTechãšModernaã®äž¡æ¹ã«å¯ŸããŠãç±³åœãã©ãŠã§ã¢å°åºé£éŠè£å€æã«ããã«èšŽèšãèµ·ãããŸãã
â979ç¹èš±ãè£å€æã¯ãPfizer / BioNTechããŸãã¯2022幎蚎èšã®ããããã«å¯ŸããŠ2ã€ã®ç¹èš±ã1ã€ã®èšŽèšã«çµ±åããModernaã«ã€ããŠã¯2024幎11æã«ãããã審çæ¥çšãèšå®ããŠããŸãã2023幎5æ26æ¥ãç±³åœç¹èš±ç¬¬11,590,229å·ã䟵害ããŠããããšã«ããæå®³è³ åããã©ãŠã§ã¢å·ã®PfizerãšModernaã«å¯ŸããŠè¿œå ã®èšŽèšãæèµ·ããŸãããããã«ãPfizerãšModernaã®æè¿ã®èšŽèšã«ã¯ãç±³åœç¹èš±ç¬¬11,633,479å·ããã³ç¬¬11,633,480å·ãããã³Pfizerã®ã¿ã«å¯Ÿããç±³åœç¹èš±ç¬¬11,612,657å·ãè¿œå ãããŠããŸãã 2023幎8æ9æ¥ãç±³åœç¹èš±ç¬¬â933ããã³â979ç¹èš±ã«ãããŠäœ¿çšããã3ã€ã®äºãããçšèªã®æå³ãæ€èšããããã«ããã©ãŠã§ã¢å·å°åºé£éŠè£å€æã§ããŒã¯ãã³èŽèäŒãéå¬ããã2023幎8æ21æ¥ã«ã3ã€ã®çšèªã®ãã¡2ã€ã解éããããã®åœä»€ãè£å€æããçºè¡ãããæ®ãã®1ã€ã®çšèªã«ã€ããŠã¯èšŒæ 調ã¹ãè¡ãããšã延æãããããã¯2024幎1æ4æ¥ã«è¡ããããæçµçãªå€æã¯è¿œå ã®èŽèäŒã®çµæãåŸ
ã£ãŠå»¶æãããããã¯2024幎7æ12æ¥ã«éå¬ãããŸããã2023幎8æ21æ¥ã®åœä»€ã«ç¶ããŠãç§ãã¡ãšModernaã¯å
±åã§2ã€ã®ç¹èš±ã«ã€ããŠã®é䟵害ã®æçµå€æ±ºã«åæããè£å€æã¯2023幎8æ30æ¥ã«ãã®å€æãäžãã2023幎9æ7æ¥ã«ç§ãã¡ã¯Modernaã«å¯Ÿãã2022幎ã®èšŽèšã§ã®äž»åŒµã®è§£éã«é¢ããå€æãé£éŠå·¡åè£å€æã«æ§èšŽããŸããã䞻匵解éã®å€æã¯ã2023幎5æ26æ¥ã«Modernaã«å¯ŸããŠæèµ·ããã蚎èšã®1ã€ã«ã¯åœ±é¿ããªãã£ãããããã®äºä»¶ã¯2025幎åŸåã«äºå®ãããŠãã審çã¹ã±ãžã¥ãŒã«ã«åŸã£ãŠé²ããããŠããŸãã2023幎9æãç§ãã¡ãšPfizer / BioNTechã¯ã2022幎蚎èšãš2023幎蚎èšã1ã€ã®äºä»¶ã«çµ±åããããšã«åæããè£å€ã®äºå®æ¥ã2024幎11æãã2025幎ååã«å€æŽããå¿
èŠããããè£å€æã«ãã£ãŠæçµã¹ã±ãžã¥ãŒã«ã決å®ãããŸãã2024幎1æ4æ¥ã«ã¯ãçµ±åãããPfizer / BioNTechäºä»¶ã«ãããŠæçµçãªäž»åŒµçšèªã®è§£éã®ããã®èŽèäŒãè¡ãããæçµå€æãä¿çãããŸããã2024幎7æ12æ¥ãAcuitas Therapeuticsã¯ãç§ãã¡ã«å¯ŸããŠãã©ãŠã§ã¢å·å°åºé£éŠè£å€æã§äžææçå€æ±ºãæèµ·ããç§ãã¡ãPfizer / BioNTechãšModernaã«å¯ŸããŠèšŽèšã§äž»åŒµããŠããç¹èš±ã«ç¹å®ã®AcuitasåŸæ¥å¡ãå
±åçºæè
ãšããŠè¿œå ããå€æ±ºãæ±ããŠããŸãã åè¿°ã®ç¹èš±ã¯ãmRNA COVID-19ã¯ã¯ãã³ã®æåã®åºç€ãšãªãç§ãã¡ã®çå解æ§ã«ããªã³æ§ãªãããã«é¢ä¿ããŠããŸãã
ç¥ç財ç£ã®ç¹èš±æš©ã蚎èšãŸãã¯ãã®ä»ã®æ段ã§ä¿è·ããéã第äžè
ãäžåœã«æã
ãèªåãã¡ã®æš©å©ã䞻匵ãããšäž»åŒµããå¯èœæ§ããããŸããããšãã°ã2017幎8æã«ã¯ãDicerna瀟ããäžèšã®åæ¥ç§å¯ã®èšŽèšã«ãããŠãæã
ã®èšŽèšãéçšæ¿«çšãè¡šããå瀟ã®ããžãã¹ã«å¯Ÿããäžæ³è¡çºã®åŠšå®³ã䞻匵ããåè«ãæåè£ã«è¿œå ããŸãããããã«ã2017幎8æã«ã¯ãDicerna瀟ããç§ãã¡ã«å¯ŸããŠã·ã£ãŒãã³åãã©ã¹ãæ³ã«åºã¥ãç¬å çŠæ¢æ³éåã䞻匵ãã蚎èšãç±³åœããµãã¥ãŒã»ããå°åºé£éŠè£å€æã«æèµ·ããŸãããäžèšã®ããã«ã2018幎4æã«ã¯ãç§ãã¡ãšDicerna瀟ã¯ãåœç€Ÿéã®å
šãŠã®è«æ±ã«ã€ããŠå解ããããšãæèšãããŠããŸãã
ããã«ãç¹å®ã®ã©ã€ã»ã³ã¹å¥çŽããã³ã³ã©ãã¬ãŒã·ã§ã³å¥çŽã«é¢é£ããŠãç¥ç財ç£æš©ã«é¢é£ãã蚎èšãŸãã¯å¥çŽã®å¯Ÿè±¡ãšãªã蚎èšã«ãããç¹å®ã®è²»çšã«ã€ããŠãç¹å®ã®ç¬¬äžè
ãä¿éããããšã«åæããŸããããã®ãããªç¥ç財ç£æš©ã«é¢é£ãã蚎èšãŸãã¯ãã®ä»ã®èšŽèšã«é¢é£ããè²»çšã¯ãåœç€Ÿã«ãšã£ãŠé倧ãªãã®ãšãªãå ŽåããããŸããããã«ã蚎èšã¯åœç€Ÿã®çµå¶ã®åªåãããããã®ã§ãããã泚æãå¿
èŠã§ãã競åä»ç€Ÿã®äžã«ã¯ã倧å¹
ã«å€ãã®ãªãœãŒã¹ãæã£ãŠãããããè€éãªç¹èš±èšŽèšã®è²»çšãããå¹æçã«è² æ
ã§ããå¯èœæ§ããããŸãã蚎èšãæ³çæç¶ãã«é¢ããäžç¢ºå®æ§ããããã圱é¿ã¯ãç 究ãéçºãåååã®åªåã®é
延ããåœç€Ÿã®äºæ¥ãç¶ããèœåã®å¶éãšãªãå¯èœæ§ããããŸãã
åœç€Ÿã®ç¬å æè¡ã®åµé ã䜿çšããç¥ç財ç£æš©ã䟵害ããããéåãããšäž»åŒµããåœäºè
ãããå Žåãéåãæ
æã§ãã£ãå Žåãåœç€Ÿã¯å解éãå¯èœæ§ãšããŠã¯3åã«ãªãå解éãæ¯æãããšã匷ããããå¯èœæ§ããããŸããç§ãã¡ãæ¯æããªããã°ãªããªãè³ åéã«å ããè£å€æã¯ãéåè¡çºãåæ¢ããããç³ç«äººããã©ã€ã»ã³ã¹ãååŸããããåœããå·®æ¢åœä»€ãçºè¡ããããšãã§ããŸããç¹èš±ã«å¿
èŠãªã©ã€ã»ã³ã¹ã®ååŸãã§ããªãå ŽåããŸãç¹èš±ã®èšèšåé¿ãã§ããªãå Žåã¯ãç§ãã¡ã®æè¡ã補åã®ããŒã±ãã£ã³ã°ãããŸããããªãå Žåããããåçãçæããå©çãåŸãããšãå¶éãããäºæ¥ãç¶æããããã«å¿
èŠãªåçãåŸãããšãã§ããªããªãããšããããŸããããã«ãåœç€Ÿã®å€ãã®ã³ã©ãã¬ãŒã·ã§ã³ã§ã¯ãåœç€Ÿã®ç¥ç財ç£ã«å¯Ÿããã©ã€ã»ã³ã¹æã¯ãé¢é£åéã§ç«¶åãŸãã¯åªäœãªç¥ç財ç£æš©ã®ç«å Žãæã€ç¬¬äžè
ã«æ¯æãããéé¡ã«ãã£ãŠçžæ®ºãããããšããããããã³ã©ãã¬ãŒã·ã§ã³ãéããŠéçºããã補åããã®åå
¥ã倧å¹
ã«åæžãããå¯èœæ§ããããŸãã
åœç€Ÿãã©ã€ã»ã³ã¹å¥çŽãŸãã¯é¢é£å¥çŽã®çŸ©åãå±¥è¡ããªãã£ãå Žåãåœç€Ÿã¯æå®³è³ åéãæ¯æãããšãæ±ããããå¯èœæ§ããããŸãããã®å Žåãåœç€Ÿã¯RNAiãã¯ãããžãŒã®éçºãåååãä¿è·ã«å¿
èŠãªã©ã€ã»ã³ã¹ãã®ä»ã®æš©å©ã倱ãããšããããæ¿èªããã補åããã³è£œååè£ã«é¢ãããã®ãå«ãŸããŸãã
çŸåšã®ã©ã€ã»ã³ã¹ã«ã¯ãç§ãã¡ã«ããŸããŸãªéçºãåæ¥åãè³é調éããã€ã«ã¹ããŒã³ããã€ã€ãªãã£ãå€åããµãã©ã€ã»ã³ã·ã³ã°ãä¿éºãç¹èš±åºé¡ããã³å·è¡ãªã©ã®çŸ©åã課ããããŠãããå°æ¥çã«ç§ãã¡ãç· çµããã©ã€ã»ã³ã¹ã«ã€ããŠãåæ§ã§ãããããã®çŸ©åã®ãããããéåããå Žåããèš±å¯ãããŠããªãæ¹æ³ã§ç§ãã¡ã«ã©ã€ã»ã³ã¹ãããç¥ç財ç£ã䜿çšããå Žåãç§ãã¡ã¯æå®³è³ åãæ¯æãå¿
èŠããããã©ã€ã»ã³ãµãŒã¯ã©ã€ã»ã³ã¹ãçµäºãããæš©å©ãæããããã©ã€ã»ã³ã¹ãéç¬å çã«ããããšãã§ãããããã©ã€ã»ã³ã¹ãããæè¡ã«ãã£ãŠã«ããŒããã補åã®éçºã補é ã販売ããã³è²©å£²ãã§ããªããªãå¯èœæ§ãããã競åä»ç€Ÿãã©ã€ã»ã³ã¹ãããæè¡ã«ã¢ã¯ã»ã¹ã§ããå¯èœæ§ããããŸããããã«ãç§ãã¡ã¯ãã©ã€ã»ã³ãµãŒã«ãã£ãŠäž»åŒµããããã®ãããªã©ã€ã»ã³ã¹ã®éåã«å¯ŸããŠé²è¡ããããã«ãè«å€§ãªè²»çšãš/ãŸãã¯ããžãã¹ã®é倧ãªé害ãããã³ç®¡çé£ã®æ³šææ£æŒ«ã被ããããããŸãããäŸãã°ã2018幎6æã«ãã¢ã€ãªãã¹ã¯ã2åç®ã®ä¿®æ£ãšåç·šæãããæŠç¥çååããã³ã©ã€ã»ã³ã¹å¥çŽã®äžã§ã2018幎1æã®ãµããã£ãšã®åååå®ã®åæ§ç¯ãšé¢é£ããå°çšTTRã©ã€ã»ã³ã¹ããã³AT3ã©ã€ã»ã³ã¹æ¡é
ã®çµæãšããŠç§ãã¡ããæ¯æãããã¹ãæ¯æãããããšããéç¥ãç§ãã¡ã«éä¿¡ããŸãããã¢ã€ãªãã¹ã¯æè¡ãè«æ±ããŸãã
ãµããã£ã®ãªã¹ãã©ã«é¢é£ããç§ãã¡ãžã®æ¯æããšæš©å©ã«åºã¥ãã¢ã¯ã»ã¹æéãŸãã¯TAFãèšç®ãããIonisã¯ãå¥çŽéåãªã©ã䞻匵ããŠããã®åŸãAmerican Arbitration Associationã®ãã¹ãã³ãªãã£ã¹ã«ä»²è£ãæ±ããç³ãç«ãŠãè¡ã£ãã2020幎第2ååæã«ä»²è£æç¶ããå®äºãã2020幎10æã«ã仲è£å§å¡äŒããè¿œå æ
å ±ãèŠæ±ãããéšåçãªè³ãçºè¡ãããã仲è£å§å¡äŒã¯2020幎12æã«æçµå€æ±ºãäžããç§ãã¡ããµããã£ã®ãªã¹ãã©ã§åãåã£ãäžå®ã®æš©å©ã«é¢ããŠIonisã®TAFãæ¯æãããæ±ãã決å®ãäžããïŒãã ããIonisãæ±ããTAFé¡ã¯æåŠãããåããªã¹ãã©ã§ç§ãã¡ãåãåã£ããã€ã«ã¹ãã³æ¯æãã«é¢ããŠIonisã®TAFãæ±ããç³ãç«ãŠã¯èªããããªãã£ãïŒã仲è£å§å¡äŒã®æçµçãªè³ããIonisã®æ¯æãåå©åãåŒè·å£«è²»çšã®è«æ±ãæåŠããã仲è£å§å¡äŒã®æçµå€æ±ºã«åŸãã2021幎1æã«ç§ãã¡ã¯Ionisã«$ 41.2 millionãæ¯æã£ãã
ããã«ãåœç€Ÿã®ã©ã€ã»ã³ãµã¯ãåœç€Ÿã«ã©ã€ã»ã³ã¹ãããŠããªãç¥ç財ç£ãææãŸãã¯ç®¡çããå Žåãããããã®çµæãã©ã€ã»ã³ãµã®æš©å©ã䟵害ãŸãã¯éåããŠãããšäž»åŒµãããå¯èœæ§ããããŸããããã«ãæ¿èªãããåœç€Ÿã®è£œåãŸãã¯å°æ¥ã®è£œåã®è²©å£²ã«å¯Ÿãããã€ã€ã«ãã£è² æ
é¡ãçŸåšç¢ºå®ããããšã¯ã§ããªãããããã®é¡ã¯èãããªãå¯èœæ§ããããŸããå°æ¥ã®ãã€ã€ã«ãã£çŸ©åã®é¡ã¯ãåœç€Ÿããã®ãããªè£œåã«äœ¿çšããæè¡ãšç¥ç財ç£ã«äŸåãããããåœç€Ÿã補åãéçºããåæ¥åæåããŠããåçæ§ãéæãŸãã¯ç¶æã§ããªãããšããããŸãã
åŸæ¥å¡ããã®ä»ã®äººãšã®æ©å¯ä¿æå¥çŽã«ãã£ãŠã¯ãååŒã®ç§å¯ããã®ä»ã®å°ææ
å ±ã®é瀺ãååã«é²ãããšãã§ããªãå ŽåããããŸãã
åœç€Ÿã®å°ææè¡åã³ããã»ã¹ãä¿è·ããããã«ãååäŒç€ŸãåŸæ¥å¡ãã³ã³ãµã«ã¿ã³ããç§åŠçã¢ããã€ã¶ãŒãCMOãå€éšç§åŠååè
ãåã³ã¹ãã³ãµãŒãããç 究è
ããã®ä»ã®ã¢ããã€ã¶ãŒãªã©ãšã®æ©å¯ä¿æå¥çŽãäžéšé ŒããšããŠããŸãããããã®å¥çŽãæ©å¯æ
å ±ã®é瀺ãå¹æçã«é²æ¢ãããæ©å¯æ
å ±ãäžæ£ã«æŒæŽ©ããå Žåã«ååãªææžãæäŸããªãå¯èœæ§ããããŸãããŸãã第äžè
ãç¥ãåŸãååŒç§å¯ãç¬å æ
å ±ãç¬èªã«çºèŠããããšãã§ãããã®å Žåã«ã¯åœç€Ÿã¯ãã®ãããªè
ã«å¯ŸããŠååŒç§å¯æš©å©ã䞻匵ã§ããŸãããåœç€Ÿã®å°ææš©ã®ç¯å²ã確ç«ããå·è¡ããããã«ã¯ãé«é¡ãªèšŽèšã«å¿
èŠãšãããããæéãšã³ã¹ãããããããšããããååŒç§å¯ä¿è·ãç²åŸãŸãã¯ç¶æã§ããªãã£ãå Žåã¯ãåœç€Ÿã®ããžãã¹ãèŠéããæ¥çžŸã財åç¶æ³ã«æªåœ±é¿ãäžããå¯èœæ§ããããŸãã
競äºã«é¢é£ãããªã¹ã¯
å»è¬ååžå Žã¯æ¿ãã競äºçã§ããæã
ãŸãã¯å
±åç 究è
ãæ¢åã®è¬å€ãæ°ããæ²»çæ³ãæ°ããæè¡ã«åå競äºã§ããªãå Žåãéçºããããããè¬å€ãåæ¥åããããšãã§ããŸããã
å»è¬ååžå Žã¯ç«¶äºãæ¿ãããæ¥éã«å€åããŠããŸããç§ãã¡ãã¿ãŒã²ããã«ããŠããçŸæ£ã«å¯Ÿããæ°ããè¬ã®éçºãè¿œæ±ããå€ãã®å€§èŠæš¡ãªå»è¬åããã³ãã€ãªãã¯ãããžãŒäŒæ¥ãåŠè¡æ©é¢ãæ¿åºæ©é¢ããã®ä»ã®å
¬çããã³æ°éã®ç 究æ©é¢ãååšããŠããŸãã競åä»ç€Ÿã®å€ãã¯ã次ã®ãããªç¹åŸŽãæã£ãŠããŸãã
⢠ç§ãã¡ãæã€ãããé¥ãã«å€§ããªè²¡æ¿ãæè¡ã人çè³æºããã;
⢠補é æ¥ãè¬åã®è²©å£²ãšããŒã±ãã£ã³ã°ãèšåºè©Šéšã®å®æœãèŠå¶æ¿èªã®ååŸãªã©ãèšåºåè©Šéšã«ãããããåºç¯ãªçµéšãå¿
èŠã§ãã
⢠以åã«ãã¹ãããããŸãã¯æ¿èªãããæè¡ã«åºã¥ã補ååè£
⢠æ¿èªããããŸãã¯éçºã®åŸæ段éã«ããè€æ°ã®è£œåïŒãããŠ
⢠ç§ãã¡ã®ç®æšåžå Žã§äž»èŠãªäŒæ¥ãç 究æ©é¢ãšã®ååçãªåã決ãã
ç§ãã¡ã¯ãç§ãã¡ãéçºããè¬ã®æ²»çã«é¢ããŠãæ¢ã«æ¿èªãããå»çé¢é£ã³ãã¥ããã£ã§åãå
¥ããããè¬å€ããæ¿ãã競äºã«çŽé¢ããããšã«ãªãã§ããããããã«ãç§ãã¡ãéçºããããšãããç¶æ
ã«å¯Ÿããæ²»ççšè¬å€ã®åæ¥åå¯èœæ§ããããå°æ¥çã«åžå Žã«åºããããããªãå€ãã®è¬å€ããããŸãããããã®è¬å€ã«ã¯ãç§ãã¡ãéçºããŠåæ¥åãã補åãããå¹æçã§ãå®å
šã§ãè²»çšãå°ãªãããã䟿å©ãªæäžæ³ãæã¡ãããå¹æçã«è²©å£²ãããå¯èœæ§ããããŸãã
äŸãã°ãèŠå¶åœå±ã®èªå¯ãåæãšããŠãã«ã«ãžãªããªãããŒã䌎ãATTRã¢ããã€ããŒã·ã¹ã®æ²»ççšRNAiæ²»çè¬ã§ããvutrisiranã¯ãçŸåšãã®ç
æ°ã®æ²»çã«èªå¯ãããŠããtafamidisïŒãã©ã€ããã€ãªã¯2次çã«è²©å£²ïŒã«å¯Ÿæããããšã«ãªããŸãããããã«ããã©ã€ããã€ãªã¯ã2023幎7æã«acoramidisãšããTTRå®å®å€ã®ç¬¬3çžèšåºè©Šéšã§ATTRã¢ããã€ããŒã·ã¹ã®ã«ã«ãžãªããªãããŒã«ãããéœæ§çµæãçºè¡šãã2024幎2æã«PDUFAè¡åæ¥ã2024幎11æ29æ¥ã§ããNDAãFDAã«åçãããããšãçºè¡šããŸããããŸãããã©ã€ããã€ãªã¯ãEMAã2025幎ã®æ±ºå®ãäºå®ããŠããããŒã±ãã£ã³ã°æ¿èªç³è«ãæ¿èªããããšãããã«ã°ããŒãã«ãªèŠå¶åœå±ãžã®è¿œå æåºãäºå®ããŠããããšãçºè¡šããŸãããIntellia TherapeuticsãInc.ãšRegeneronã«ãã£ãŠéçºããã第3çžèšåºè©Šéšã«ããNTLA-2001ãNovo Nordiskã«ãã£ãŠéçºããã第2çžèšåºè©Šéšã«ããNNC-6019ãããã³Neurimmune AGãšã¢ã¹ãã©ãŒãã«ç€Ÿã«ãã£ãŠéçºããã第3çžèšåºè©Šéšã«ããNI006ãå«ããATTRã¢ããã€ããŒã·ã¹ã®ã«ã«ãžãªããªãããŒã®æ²»ççšã®ãã®ä»ã®åè£è£œåãããããšãèªèããŠããŸãã
éçºãATTRã¢ããã€ããŒã·ã¹æ§å¿ççãæ²»çããããã«åžå Žã«ç»å Žãããããã®æ°è¬ã®ã©ãããããã³æœåšçãªãã®ä»ã®è¿œå æ°è¬ãã競äºã«çŽé¢ããããšãäºæ³ããŠããŸãã
ONPATTROãšAMVUTTRAã¯ãããªãã¥ãŒããããŒã䌎ãhATTRã¢ããã€ããŒã·ã¹ã®ç¹å®æ£è
ã®æ²»çã«ãããŠãç¹å®ã®ç®¡èœåºåã§æ¿èªãããŠããŸããIonisãAstraZeneca plcãšææºããŠéçºããè¬å€ã§ããWAINUAïŒãšããã³ãã«ã»ã³ïŒãVYNDAQEL / VYNDAMAXïŒã¿ãã¡ããžã¹ïŒãIonisãéçºã販売ããŠããTEGSEDIïŒã€ããã«ã»ã³ïŒãªã©ããã®çŸæ£ãæ²»çããããã«æ¿èªããã補åãä»ã«ããããŸããããªãã¥ãŒããããŒã䌎ãhATTRã¢ããã€ããŒã·ã¹æ£è
ã®æ²»çã«ããããONPATTROãšAMVUTTRAã競ååã®ãã補åãããã¡ã€ã«ãæã€ãšä¿¡ããŠããŸããããããã®è£œåãåè£è£œåããã®ä»ã«ããæå©ã«ç«¶åããããšãå¯èœã§ããããã®çµæãåæ¥çãªæåãåããŸããå¯èœæ§ããããŸãã
ããæã
ãŸãã¯ååè
ã補ååè£ãæåè£ã«éçºããæ¿èªãåŸããªããæã
ãšååè
ã¯ä»¥äžã®å€æ§ãªèŠå ã«åºã¥ã競äºã«çŽé¢ããå¯èœæ§ããããŸããïŒ
⢠åœç€ŸãŸãã¯ååäŒç€Ÿã®è£œåã®å®å
šæ§ãšæå¹æ§ã¯ã代æ¿çæ³ãšæ¯èŒããŠã©ãã§ããïŒ;
⢠ç§ãã¡ãŸãã¯ç§ãã¡ã®ååè
ã®è£œåã管çããããããæ£è
ãæ¯èŒçæ°ããæäžçµè·¯ãåãå
¥ãã床åãã
⢠ãããã®è£œåã®èŠå¶æ¿èªã®ã¿ã€ãã³ã°ãšç¯å²ïŒ
⢠補é æ¥ãããŒã±ãã£ã³ã°ã販売èœåã®å¯çšæ§ãšã³ã¹ãïŒ
⢠åœç€ŸãŸãã¯ååäŒæ¥ã®è£œåã®äŸ¡æ Œã¯ãæ¿èªããã代æ¿çæ³ã«å¯ŸããŠçžå¯Ÿçã«ã§ãã
⢠æãæ»ãã®è£åç¯å²;ããã³
⢠ç¹èš±ã®ããžã·ã§ã³ã§ãã
åœç€Ÿã®RNAiæ²»çè¬ã§ããOXLUMOããç±³åœãšEUã§PH1ã®æ²»çã«æ¿èªããããã®ã®ããã®ç
æ°ã®æ²»çã«é¢ããŠãæ§ã
ãªèšåºéçºæ®µéã«ãã補ååè£ãååšããŠããã2023幎9æã«PH1ã®æ²»çã«æ¿èªããã2024幎ã«çºå£²ããããšäºæ³ãããããã»ãã«ãã£ã¹ã¯ã®è£œåã§ããRIVFLOZAïŒããã·ã©ã³ïŒãå«ã¿ãŸããRIVFLOZAã¯ãDicernaã«ãã£ãŠéçºãããç®äžæäžã®RNAiæ²»çè¬ã§ããã1ãæã«1åã®æäžãå¿
èŠã§ãããŸããBridgeBioãChinook TherapeuticsãInc.ãBioMarin PharmaceuticalãInc.ãå«ãããã€ãã®äŒæ¥ãPH1ã®æ²»çã®ããã«èšåºéçºäžã®è¬å€ãææããŠããŸããåœç€ŸãšDicernaã¯2020幎4æã«ãã«ãã·ã©ã³ãšDicernaã®ããã·ã©ã³ã«é¢é£ããããããã®ç¥ç財ç£ã«ã€ããŠãçžäºã«éæä»çãªã¯ãã¹ã©ã€ã»ã³ã¹ãä»äžããŸããã
äžèšã®èŠå ã®ããããã«åºã¥ããŠããŸãã¯ãã®ä»ã®èŠå ã«åºã¥ããŠãåœç€ŸãŸãã¯åœç€Ÿã®å
±åç 究è
ãéçºãã補åãããåªãã補åã競åä»ç€ŸãéçºãŸãã¯åååããå¯èœæ§ããããŸããããã«ã競åä»ç€Ÿã¯ããã倧ããªå»è¬åãŸãã¯ãã€ãªãã¯ãããžãŒäŒæ¥ãšã®ææºãéçºããããè³éæŽå©ãåãããããããšããããåœç€Ÿãšåœç€Ÿã®å
±åç 究è
ã«æ¯ã¹ãŠæå©ãªç«å Žã«ãããŸãããã®ããã競åä»ç€Ÿã¯åœç€Ÿããã³åœç€Ÿã®å
±åç 究è
ããã補åãåæ¥åããããšãããæåããå¯èœæ§ããããããã¯ãåœç€Ÿã®ç«¶äºåãããžãã¹ãèŠéããéå¶æ瞟ããã³è²¡åç¶æ³ã«äžå©ã«åœ±é¿ããå¯èœæ§ããããŸãã競å補åãåœç€ŸãŸãã¯åœç€Ÿã®å
±åç 究è
ãéçºãã補åãããåªããŠããããã«ãç§ãã¡ãŸãã¯åœç€Ÿã®å
±åç 究è
ã補ååè£ã®éçºãšåååã®è²»çšãååããåã«ãç§ãã¡ãéçºãã補åããã§ã«æ代é
ãã«ãªãå¯èœæ§ããããŸãããŸãããã®ãããªç«¶åä»ç€Ÿãç§ãã¡ã®åŸæ¥å¡ãæ¡çšããããšããããããã¯ç§ãã¡ã®å°éç¥èã®ã¬ãã«ãšããžãã¹ãã©ã³ã®å®è¡èœåã«åŠå®çãªåœ±é¿ãäžããå¯èœæ§ããããŸããããã«ãç§ãã¡ãšç§ãã¡ã®å
±åç 究è
ã¯ãé²æ©ããå»çæ©åšã®äœ¿çšãªã©ãè¬å€ã®äœ¿çšãæžãããŸãã¯æé€ããæ¢åã®æ²»çæ¹æ³ãæ°ããæ²»çæ¹æ³ãšã®ç«¶äºãçŽé¢ããŠããŸããç§ãã¡ãŸãã¯ç§ãã¡ã®å
±åç 究è
ãã¿ãŒã²ããã«ããŠããçŸæ£åãã®æ°ããå»çæ©åšãŸãã¯æ²»çæ¹æ³ã®éçºã«ãããåœç€ŸãŸãã¯åœç€Ÿã®å
±åç 究è
ã®è£œååè£ãåçãããå£ã£ãããæ代é
ãã«ãªãããšããããŸãã
ãããããååè
ã¯ããããããšé¡äŒŒã®æè¡ã䜿çšããŠæ°è¬ããã¯ãããžãŒãã©ãããã©ãŒã ãéçºããä»ç€Ÿãããã³æ°èæè¡ãå©çšããäŒæ¥ãã競åãåããŠããŸãããããã®äŒæ¥ããããå¹æçãªèŒžéæè¡ãå«ãããããããååè
ããéãè¬å€ãéçºããå Žåããããããååè
ãšããŠè£œåãæåè£ã«åæ¥åããèœåãæãªãããå¯èœæ§ããããŸãã
競åããè¬å€ãšã®ç«¶äºã«å ããŠãç§ãã¡ãååè
ã¯ãããçŽæ¥èªç€Ÿã®æè¡ãšç«¶åããæè¡ãçšããç»æçãªè¬ãéçºããããã«åããŠããä»ç€Ÿããã®ç«¶åã«ãçŽé¢ããŠããŸããæã
ã¯ãRNAiæ²»çè¬ã®éçºãè¡ã£ãŠããããã€ãã®ä»ç€Ÿãç¥ã£ãŠããŸãããããã®äŒæ¥ã®äžã«ã¯ãååŠçã«åæãããsiRNAãè¬å€ãšããŠéçºããããšãããã®ããããŸããäžæ¹ã现èå
ã§siRNAã®ãããªååãç£çããããã«ãåæçã«å°å
¥ãããéºäŒåãæ²»çã®ç®çãšããéºäŒåæ²»çã¢ãããŒãã«åŸãäŒæ¥ããããŸããååŠçã«åæãããsiRNAãéçºããŠããäŒæ¥ã«ã¯ãArrowheadãšãã®ååè
ãã¿ã±ããã¡ãŒãã·ã¥ãŒãã£ã«ã«ãºãJanssen Pharma IncãGSKãAdamãžã§ã³ãªã©ãããŸããQuark Pharmaceuticals Inc.ãRocheãSilence Therapeutics瀟ããã³ãã®ååè
ãã¢ã¹ãã©ãŒãã«ãæ±èæ±æ¶å¶è¬éå£æéå
¬åžãMallinckrodt plcãArbutusãSylentisãNovo Nordiskããã³Boehringer IngelheimãEli Lillyããã³Companyãšã®ååè
ãªã©ãRNAiæ²»çè¬ãéçºããããã«åããŠããŸããããã«ãç§ãã¡ã¯IonisãBenitec Biopharma Ltd.ãArrowheadãArbutusãQuarkãSylentisããã³ãã®ä»ã®äŒæ¥ã«ã©ã€ã»ã³ã¹ãŸãã¯ãªãã·ã§ã³ã®ã©ã€ã»ã³ã¹ãä»äžãããããã®äŒæ¥ãç¬èªã«RNAiæ²»çè¬ãéçºããããšãã§ããããã«ããŠããŸãã
ã¿ãŒã²ããã®æ°ã«å¶éããããŸãããããã®äŒæ¥ã®ããããããæã
ãããè¿
éãã€å¹æçã«RNAiãã¯ãããžãŒãéçºããå¯èœæ§ããããŸããããã«ãç§ãã¡ãç· çµããåæã®çµæãæŠç°ã¯éæä»çã©ã€ã»ã³ã¹ãååŸããã¢ããŒãããã¯ããã«ãã£ã¹ã®è²å人ãšããŠãç¹å®ã®30ã®éºäŒåã¿ãŒã²ããã«å¯ŸããŠç¬å çãªã©ã€ã»ã³ã¹ãååŸããŠãããããã«ã¯ãåœç€Ÿã®æè¡ã®äžéšãžã®ã¢ã¯ã»ã¹ãå«ãŸããŠããŸãã
ç§ãã¡ãšå
±åç 究è
ããã¢ã³ãã»ã³ã¹ããŒã¹ã®å»è¬åã®éçºãè¡ã£ãŠããäŒæ¥ãšç«¶åããŠããŸããRNAiæ²»çè¬ãšåæ§ã«ãã¢ã³ãã»ã³ã¹è¬ã¯mRNAãæšçãšããŠãç¹å®ã®éºäŒåã®æŽ»åãæå¶ããããã«äœ¿çšãããŸããIonisã®å®å
šåäŒç€Ÿã§ããAkcea Therapeutics, Inc.ã¯ãæ人hATTRã¢ããã€ããŒã·ã¹æ£è
ã®ã¹ããŒãž1ãŸãã¯ã¹ããŒãž2ããªãã¥ãŒããããŒã®æ²»çã®ããã®ã¢ã³ãã»ã³ã¹è¬ãinotersenã®è²©å£²æ¿èªãåããŠããŸããIonisãéçºããããã€ãã®ã¢ã³ãã»ã³ã¹è¬ã¯æ¿èªãåããçŸåšåžè²©ãããŠãããWAINUAïŒeplontersenïŒãå«ãå€æ°ã®ã¢ã³ãã»ã³ã¹è£œååè£ãèšåºè©Šéšäžã§ããIonisã¯ãç§ãã¡ããã©ã€ã»ã³ã¹å¥çŽãåãããªã¬ã³ãçµååGalNAcæè¡ã䜿çšããŠã¢ã³ãã»ã³ã¹è¬ãéçºããŠããããããã®è¬å€ã¯èšåºè©Šéšããã³èšåºåç 究ã§ããã®ãããªã©ã€ã»ã³ã¹ãããGalNAcæè¡ã䜿çšããªãã¢ã³ãã»ã³ã¹è¬ãããäœçšéã§ããé«ãå¹åãçºæ®ããããšã瀺ãããŠããŸããã¢ã³ãã»ã³ã¹è¬ããã³ã¢ã³ãã»ã³ã¹æè¡ã®éçºã¯ãç¹å®ã®éºäŒåãæ²é»ãããããã«mRNAãæšçã«ããå»è¬åã®åªå
æè¡ã«ãªãå¯èœæ§ããããŸãã
RNAiãç¹å®ã®è£œåã«é¢ããŠã®ç«¶äºã«å ããé©åãªçŽ°èçš®ãçµç¹ã«siRNAãå®å
šãã€å¹æçã«æäžããæ段ãçºèŠããéçºããããšã«ãããŠã倧ããªç«¶äºããããŸãã競åä»ç€Ÿãé©åãªçŽ°èçš®ãçµç¹ã«siRNAãå®å
šãã€å¹æçã«æäžããæ段ãçºèŠããéçºããå Žåã競å補åãåæ¥åããå¯èœæ§ãçå€ãã«ãªãããšããããŸããå ããŠãç§ç«äŒæ¥ã倧åŠç 究æãªã©ã第äžè
ã倧ããªãªãœãŒã¹ã泚ãã§ãsiRNAãé©åãªçŽ°èçš®ãçµç¹ã«å®å
šãã€å¹æçã«æäžããæ段ãçºèŠããéçºããŠããŸãã競åä»ç€Ÿã®äžã«ã¯ãç§ãã¡ããã倧ããªãªãœãŒã¹ãæã£ãŠããè
ãããã競åä»ç€Ÿã第äžè
ã«ãã£ãŠéçºãããçŽå
¥ãœãªã¥ãŒã·ã§ã³ãç¬å çã«ååŸããå Žåãç§ãã¡ã¯è£œååè£ãåæ¥åããããšãã§ããªããããããŸããã
åœç€Ÿã®æ®éæ ªåŒã«é¢ãããªã¹ã¯
åœç€Ÿã®æ ªäŸ¡ã¯éå»ã«äžå®å®ã§ãããä»åŸãäžå®å®ãšãªãå¯èœæ§ããããŸããåœç€Ÿã®æ®éæ ªåŒãžã®æè³ã¯äŸ¡å€ã®äžèœã被ãå¯èœæ§ããããŸãã
åœç€Ÿã®æ ªäŸ¡ã¯éå»ã«å€åããŠãããä»åŸãå€åããå¯èœæ§ããããŸããäžè¬çãªæ ªåŒåžå Žããç¹ã«ãã€ãªãã¯ãããžãŒäŒæ¥åžå Žã¯ãç¹å®ã®äŒæ¥ã®æ¥çžŸãšã¯ç¡é¢ä¿ãªäŸ¡æ Œãåºæ¥é«ã®æ¥µç«¯ãªå€åãçµéšããŠããŸãããå°æ¥çã«åœç€Ÿã®æ®éæ ªåŒã®åžå ŽäŸ¡æ Œã¯ãå€ãã®èŠå ã«ãã£ãŠèããäžå©ãªåœ±é¿ãåããå¯èœæ§ããããŸãããããã®èŠå ã«ã¯ã以äžãå«ãŸããŸãïŒ
⢠ç§ãã¡ã®ååæããšã®åççºè¡šã«å«ãŸããæ
å ±ã«ã¯ãç§ãã¡ãŸãã¯å
±åäœæ¥è
ãåæ¥åãã補åãŸãã¯è£œååè£ã«é¢ããæŽæ°ãç§ãã¡ã®çŽè£œåããã³å
±åæ¥ååçãéå»ã®æéããã³å°æ¥ã®æéã«é¢ãã財åã¬ã€ãã³ã¹ãå«ã¿ãŸããå¶æ¥è²»çšãå«ã¿ãŸãã
⢠æ¢å補åãŸãã¯æ°ãã競äºè£œåãæè¡ã®æå;
⢠åœç€ŸãŸãã¯å
±åç 究è
ã®è£œåãŸãã¯è£œååè£ã«é¢ããèŠå¶åœå±ã®æªçœ®ïŒ
⢠ç§ãã¡ãŸãã¯ç«¶åä»ç€Ÿã«ããéèŠãªååŸãææºãååŒäºæ¥ãã³ã©ãã¬ãŒã·ã§ã³ããŸãã¯è³æ¬æ¯åºã®çºè¡šïŒ
⢠ç§ãã¡ã®ãŸãã¯ç§ãã¡ã®å
±åç 究è
ã®ãã®ä»ã®è£œååè£ã®èšåºè©Šéšã®ã¿ã€ãã³ã°ãšçµæïŒ
⢠æã
ã®éçºããã°ã©ã ã«ãããååé¢ä¿ã®éå§ãŸãã¯çµäºïŒ
⢠ç§ãã¡ãŸãã¯ç§ãã¡ã®å
±åç 究è
ã®éçºããã°ã©ã ã®å€±æãŸãã¯äžæ¢;
⢠競åä»ç€Ÿã®è£œååè£ã®èšåºè©ŠéšçµæïŒ
⢠米åœããã³ä»ã®åœã§ã®èŠå¶ãæ³åŸäžã®é²å±ïŒ
⢠ç¹èš±åºé¡ãçºè¡ç¹èš±ãŸãã¯ãã®ä»ã®ç¬å çæš©å©ã«é¢ããéçºãŸãã¯çŽäº;
⢠䞻èŠäººå¡ã®æ¡çšãŸãã¯éä»»ïŒ
⢠åœç€Ÿã®è£œååè£ãŸãã¯èšåºéçºããã°ã©ã ã«é¢é£ããè²»çšã®ã¬ãã«ïŒ
⢠ç§ãã¡ãŸãã¯ååè
ãè¿œå ã®è£œååè£ãŸãã¯è£œåãéçºããããã®åªåã®çµæ;
⢠財åçµæãéçºã¿ã€ã ã©ã€ã³ã®å®éãŸãã¯äºæ³ãããå€æŽ
⢠远å ã®è³é調éã®çºè¡šãŸãã¯æåŸ
ïŒ
⢠ç§ãã¡ãç§ãã¡ã®é¢ä¿è
ããŸãã¯ä»ã®æ ªäž»ã«ããæ®éæ ªåŒã®è²©å£²ïŒ
⢠ç§ãã¡ã®è²¡åçµæãŸãã¯ç§ãã¡ãšé¡äŒŒããŠãããšèªèãããŠããäŒæ¥ã®çµæã®å€å;
⢠ç§ãã¡ãã«ããŒãã蚌åžã¢ããªã¹ãã®èŠç©ããæšå¥šäºé
ã®å€æŽïŒ
⢠å»çæ¯æãã·ã¹ãã ã®æ§é ã®å€åïŒ
⢠å»è¬åããã³ãã€ãªãã¯ãããžãŒæ¥çã®åžå Žç°å¢ïŒ
⢠äžè¬çãªçµæžãæ¥çš®ãåžå Žã®ç¶æ³; ããã³
⢠ãã®ããªã¹ã¯ãã¡ã¯ã¿ãŒãã»ã¯ã·ã§ã³ã«èšèŒãããä»ã®èŠå ã
éå»ã«ãããŠã蚌åžé¡ã®éå£èšŽèšã¯ãèªç€Ÿã®èšŒåžã®åžå ŽäŸ¡æ Œã®äžèœã«ç¶ããŠèµ·ããããšãå€ãã£ãããã®ãªã¹ã¯ã¯ãè¿å¹Žã倧å¹
ãªæ ªäŸ¡å€åãçµéšããŠãããã€ãªå»è¬åäŒæ¥ã«ãšã£ãŠç¹ã«é¢é£æ§ããããäŸãã°ã2019幎9æã«ãåœç€ŸãšçŸåšããã³å
ã®åœ¹å¡ã»åç· åœ¹ãããã³2017幎11æã®åœç€Ÿæ ªåŒå
¬éã®ã¢ã³ããŒã©ã€ã¿ãŒã«å¯ŸããŠãé£éŠèšŒåžæ³ã®éåã䞻匵ãã蚎èšã®ä»®æ³éå£èšŽèšãæèµ·ãããããã®åé¡ã¯æçµçã«å解ããããä»åŸåæ§ã®èšŽèšã®æšçã«ãªãå¯èœæ§ããããåœç€Ÿã«å¯Ÿãã蚌åžèšŽèšã¯ãéèŠãªã³ã¹ãã䌎ããåœç€Ÿã®çµå¶é£ã®é¢å¿ãšãªãœãŒã¹ããããå¯èœæ§ããããåœç€Ÿã®ããžãã¹ãèŠéããæ¥çžŸã財åç¶æ³ã«é倧ãªæ害ãäžããå¯èœæ§ããããåœç€Ÿã¯è²¬ä»»ä¿éºã«å å
¥ããŠãããã蚎èšã«é¢é£ããããããã³ã¹ããè²»çšãåœç€Ÿã®ä¿éºé©çšé¡ãè¶
ããå Žåãåœç€Ÿã¯çŽæ¥ãã®è²»çšãã³ã¹ããè² æ
ããããšãäœåãªããããå¯èœæ§ããããããã¯è«å€§ãªãã®ã«ãªãå¯èœæ§ãããããŸããåœç€Ÿã¯ãåœç€Ÿã®åœ¹å¡ããã³åç· åœ¹ã蚌åžå
¬éã®ã¢ã³ããŒã©ã€ã¿ãŒãå«ã第äžè
ããç¹å®ã®èšŽèšã«é¢é£ããŠå
責ãã矩åãè² ã£ãŠããããããã®çŸ©åã«å¯ŸããŠä¿éºãé©çšãããªãå Žåãããã
ç§ãã¡ã圹å¡ãåç· åœ¹ããããã¯äž»èŠãªæ ªäž»ãå«ããã倧éã®æ®éæ ªåŒã®å
¬éåžå Žãžã®å£²åŽã¯ãç§ãã¡ã®æ®éæ ªåŒã®äŸ¡æ Œãäžèœãããå¯èœæ§ããããŸãã
ç§ãã¡ã®å°æ°æ ªäž»ãç§ãã¡ã®æ®éæ ªåŒã®å®è³ªçæ°éãææããŠããŸãã2024幎6æ30æ¥çŸåšãç§ãã¡ã®8人ã®æ倧ã®æ ªäž»ããç§ãã¡ã®çºè¡æžã¿æ®éæ ªåŒã®50ïŒ
ãè¶
ããæ°éãææããŠããŸããç§ãã¡ã圹å¡ãåç· åœ¹ããŸãã¯äž»èŠæ ªäž»ãå
Œ
±åžå Žã§å€§éã®æ®éæ ªåŒã売åŽãããããã®ãããªè²©å£²ãè¡ãããå¯èœæ§ããããšã®èªèãããå Žåãç§ãã¡ã®æ®éæ ªåŒã®åžå ŽäŸ¡æ Œãäžå©ã«åœ±é¿ãåããå¯èœæ§ããããŸããäž»èŠæ ªäž»ã«ããæ®éæ ªåŒã®å£²åŽã¯ãç§ãã¡ãå°æ¥çã«é©åãšå€æããæç¹ããã³äŸ¡æ Œã§ãæ ªåŒãŸãã¯æ ªåŒé¢é£èšŒåžã®å£²åŽã«ããè³é調éãããå°é£ã«ããå¯èœæ§ããããŸãããã¹ãŠæä¿¡ã売åŽããããšããããŸãã
統治ææžããã³ãã©ãŠã§ã¢æ³ã«ãããæµå¯Ÿçè²·åé²æ¢çã¯ãåœç€Ÿã®æ ªäž»ã«ãšã£ãŠæçãããããªãè²·åãå°é£ã«ããããšããããçŸåšã®çµå¶é£ãåç· åœ¹äŒã®ã¡ã³ããŒã亀代ãããæ ªäž»ã®è©Šã¿ãé²æ¢ããå¯èœæ§ããããŸãã
ç§ãã¡ã®å®æ¬Ÿããã³äŒç€ŸèŠçšã«å®ããããèŠå®ã«ãããç§ãã¡ã®è²·åãŸãã¯çŸåšã®çµå¶é£ãŸãã¯åç· åœ¹äŒã®ã¡ã³ããŒã®å€æŽãé
ãããããŸãã¯é²æ¢ãããå¯èœæ§ããããŸãããã®äžã«ã¯ã次ã®èŠå®ãå«ãŸããŸãïŒ
⢠å
šã»ã¯ã¿ãŒãäžåºŠã«éžåºãããªãããã«ãç§å¯ç®¡çå§å¡äŒãèšçœ®ããããšã
â¢ æ ªäž»ã®æžé¢ã«ããåæã«ããè¡çºãçŠæ¢ããèŠå®ãå¶å®ããããšïŒ
⢠åç· åœ¹äŒã«æ ªäž»æ¿èªãªãã«åªå
æ ªåŒãçºè¡ããæš©éãäžããæµå¯Ÿçãªè²·åè
ã®æ ªåŒææãåžéãããâãã€ãºã³ã»ãã«âãå°å
¥ããå¯èœæ§ããããããåç· åœ¹äŒã®æ¿èªãåŸãŠããªãè²·åãå¹æçã«é²æ¢ããããšãã§ããŸãã
⢠åç· åœ¹äŒã®æ±ºè°ã«ããã®ã¿ãåŒç€Ÿã®åœ¹å¡ã®æ¿èªäººæ°ã®å€æŽãèš±å¯ããŸãã
â¢ æ ªäž»ç·äŒã®ç¹å¥äŒè°ãåŒã³åºãããšãã§ãã人ãå¶éããïŒ
⢠ç§ãã¡ã®æ²ç« ãŸãã¯èŠçŽã®äžéšãä¿®æ£ãŸãã¯æ€åããããã«ãç§ãã¡ã®å
šæ ªäž»ãæ祚ããããã«äžããããæ祚ã®75ïŒ
以äžã®æ¿èªãå¿
èŠã§ãã
⢠åœç€Ÿã®åç· åœ¹äŒããåç· åœ¹ã解任ã§ããæ¹æ³ãå¶éããããšã§ãã
⢠åœç€Ÿã®åç· åœ¹äŒãžã®éžæã«å
ç«ã€éç¥èŠä»¶ãããã³æ ªäž»ç·äŒã§æ±ºè°å¯èœãªäºé
ãææ¡ããããã®èŠä»¶ãèšå®ããã
ããã«ãåœç€Ÿã¯ãã©ãŠã§ã¢å·ã«çµã¿èŸŒãŸããŠããããããã©ãŠã§ã¢å·ç·äŒç€Ÿæ³203æ¡ã®èŠå®ã«ãã£ãŠçµ±æ²»ãããŠããŸãããã®æ³åŸã¯ãç§ãã¡ã®çºè¡æžã¿è°æ±ºæš©æ ªåŒã®15ïŒ
ãè¶
ããŠææãã人ãããã®æææš©ãååŸããååŒæ¥ãã3幎éãå䜵ãŸãã¯çµ±åãè¡ãããšãçŠæ¢ããŠããŸãããã ããå䜵ãŸãã¯çµ±åãäžå®ã®æ¹æ³ã§æ¿èªãããå Žåã¯ããã®èŠå®ãé©çšãããŸãããããã®èŠå®ã¯ãææ¡ãããå䜵ãŸãã¯è²·åãäžéšã®æ ªäž»ã«ãšã£ãŠæçã§ãããšèããããå Žåã§ãé©çšãããŸãã
ç§ãã¡ã¯ãç§ãã¡èªèº«ãå
±åç 究è
ã®èšåºéçºæŽ»åã競åä»ç€Ÿã®èšåºéçºæŽ»åãããå®æçã«çµæãçºè¡šãããç§ãã¡ã®æ®éæ ªåŒã®äŸ¡æ Œã«å€§ããªå€åãããããå¯èœæ§ãããããšãäºæ³ããŠããŸãã
ç§ãã¡ãå
±åç 究è
ã®è£œåã補ååè£ã競å補åãæœåšçãªç«¶å補åã«é¢ããæ°ããæ
å ±ãããå Žåãæè³å®¶ã®å°æ¥ã®èŠéãã«å¯Ÿããæè³å®¶ã®èªèã«é倧ãªåœ±é¿ãäžããå¯èœæ§ããããŸããç§ãã¡ãå
±åç 究è
ãããã³ç«¶åä»ç€Ÿã¯é©æã«è¬å€éçºããã°ã©ã ã«é¢ããæŽæ°ãæäŸããå ŽåããããŸããããã®æ¹æ³ã¯ãããããã®ã«ãªããŸãã
å»çé¢é£ã®ã«ã³ãã¡ã¬ã³ã¹ããã¬ã¹ãªãªãŒã¹ãåã³çºè¡šè³æã«ãããŠãæã
ã競åä»ç€Ÿã«ããèšåºè©Šéšã®äžéããããã¯æçµçµæã®ã»ããèŠå¶ç³è«ãæåºã補åéçºã競å補åããããŠæœåšç«¶åè
ã«é¢ããŠãæ
å ±ãå«ãŸããŠããå ŽåããããŸããæã
ã®è£œè¬ããã°ã©ã ã«é¢ããæ
å ±é瀺ã®ã¿ã€ãã³ã°ã¯ãæã
ãèšåºè©Šéšããã®ããŒã¿ãåé ããã¿ã€ãã³ã°ãã補è¬äŒæ¥ãå»çã«ã³ãã¡ã¬ã³ã¹ã«ãããŠèšåºããŒã¿ãé瀺ããåŸåã«åœ±é¿ãåããããšããããæã
ã®å¶åŸ¡ãè¶
ããããšããããŸããæã
ã®èšåºè©Šéšããããã¯ç«¶åä»ç€Ÿã®èšåºè©Šéšã«é¢ããæ
å ±ããäžéããŒã¿ã«åºã¥ããŠé瀺ãããããšãããã解éã®é£ãããæçµçãªçµæãæ£ç¢ºã«äºæž¬ã§ããªãå¯èœæ§ããããŸãããã®ãããªæ
å ±é瀺ã¯ãæã
ã®æ®éæ ªåŒäŸ¡æ Œã®å€åãåŒãèµ·ããããšããããŸããäŸãã°ã2021幎æ«ã«ãBridgeBio瀟ã®ATTRã¢ããã€ããŒã·ã¹ã«å¯Ÿããã«ã«ãã©ããžã³ç¬¬3çžèšåºè©ŠéšPart Aã®çµæãå
¬è¡šãããåŸãåœç€Ÿã®æ ªäŸ¡ã¯è² ã®åœ±é¿ãåããŸããã
ç§ãã¡ã®è»¢æ瀟åµã«é¢é£ãããªã¹ã¯
ç§ãã¡ã®ããžãã¹ããã®ååãªãã£ãã·ã¥ãããŒããªããããããªããããç§ãã¡ã¯åµåãæ¯æãããšãã§ããªããããããŸããã
2024幎6æ30æ¥çŸåšãåœç€Ÿã¯çºè¡æžã¿ã®åµåžã®å
æ¬ç·é¡ã10.4åãã«ãããŸããåµåžã®å©çã¯å¹Ž1ïŒ
ã®åºå®éå©ã§ãããæ¯å¹Ž5æ15æ¥ããã³9æ15æ¥ã«å幎ããšã«æ¯æãããŸããæåã®æ¯æãã¯2023幎3æ15æ¥ã«è¡ãããŸããåœç€Ÿãåœç€Ÿã®æªæ¥ã®æ¥çžŸã«äŸåããŠãåµåãåµåžãå«ãçŸéæ¯æããè¡ãèœåããããã©ããã¯ãçµæžã財åã競äºãªã©åœç€Ÿã®ææ¡äžèœãªèŠå ã«åœ±é¿ãããŸããåœç€Ÿã®äºæ¥ãå°æ¥ã®éå¶è³éãå¿
èŠãšããè³æ¬æ¯åºãããªããçŸéãããŒãçã¿åºããªãå Žåãåœç€Ÿã¯è³ç£å£²åŽãåµååç·šæãè¿œå ã®åµåãŸãã¯è³æ¬é調éãªã©ã1ã€ä»¥äžã®ä»£æ¿æ段ãæ¡çšããå¿
èŠããããŸããããããã®æŽ»åã«åå ã§ããªãå¯èœæ§ããããããæãŸããæ¡ä»¶ã§ãããã®æŽ»åã«åå ã§ããªãããšããããŸãããã®çµæãåœç€Ÿã®åµåäžå±¥è¡ã«ã€ãªããããšããããŸããå°æ¥ã®åµåã®åèè³èœåã¯ãè³æ¬åžå Žãšåœç€Ÿã®è²¡åç¶æ³ã«äŸåããŸããå°æ¥ã®åµåã®åèè³èœåã¯ãè³æ¬åžå Žãšåœç€Ÿã®è²¡åç¶æ³ã«äŸåããŸãããããã®æŽ»åã®ããããã«åå ã§ããªãããšãããããããŸãã¯åžæããæ¡ä»¶ã§ãããã®æŽ»åã«åå ã§ããªãããšããããããåœç€Ÿã®åµåäžå±¥è¡ã«ã€ãªããããšããããŸãã
ãŸããåœç€Ÿã®è² åµã¯ããã®ä»ã®è²¡åäžã®çŸ©åããã³å¥çŽäžã®çŸ©åãšçµã¿åãããããšãéèŠãªåœ±é¿ãåãŒãå¯èœæ§ããããŸããããšãã°ã以äžã®ãããªãã®ãèããããŸãïŒ
⢠米åœåã³äžççµæžãæ¥çš®ã競äºæ¡ä»¶åã³èŠå¶ã®äžå©ãªå€åã«å¯ŸããŠãç§ãã¡ã¯ããå·ã€ãããããªãå¯èœæ§ãããã
⢠ããžãã¹ãæ¥çš®ã®å€åã«å¯Ÿå¿ããããã®æè»æ§ãå¶éããå¯èœæ§ããã;
â¢ è² åµãå°ãªã競åä»ç€Ÿãšæ¯èŒããŠãç§ãã¡ã¯äžå©ãªç«å Žã«çœ®ãããããšã«ãªããŸãã
⢠ãã®ä»ã®äžè¬äŒæ¥ç®çãè¿œå è²·åè³éãããã³é転è³é調éé¡ã®äžéãèšããããŸãã
⢠åœç€Ÿã®è²·åãé
åçã«ããªãããŸãã¯ããå°é£ã«ããã
ãããã®èŠå ã®ãããããç§ãã¡ã®ããžãã¹ãèŠéããéå¶çµæãããã³è²¡åç¶æ³ã«æ害ãäžããå¯èœæ§ããããŸããããã«ãç§ãã¡ãè¿œå ã®åµåãè² ãå Žåãããžãã¹ãšåµåã®è¿æžèœåã«é¢é£ãããªã¹ã¯ãå¢å€§ããŸãã
ãã¹ãŠæä¿¡ãéããèœåããªãå ŽåããŸãã¯æ ¹æ¬çãªå€åã«ããçŸéåã®ããã«ããŒããå賌å
¥ããèœåããªãå ŽåããããŸãã
ããŒãã®ä¿æè
ã¯ãããŒãã®å¥çŽã«å®çŸ©ãããåºæ¬çãªå€æŽãçºçããå ŽåãåéäŸ¡æ Œãæªåå©æ¯ãå«ããé¡é¢ç·é¡ã®100ïŒ
ã«çžåœããéé¡ã§ç§ãã¡ã«ããŒãã®åéãèŠæ±ããæš©å©ããããŸããããŒããæéãããå Žåãæ®éæ ªåŒã®ã¿ãé
åœããããšãéžæããªãéãïŒåå²æ ªã®ä»£ããã«çŸéæ¯æããè¡ãïŒãæéãããããŒãã«é¢ããŠçŸéæ¯æããè¡ãå¿
èŠããããŸããããŒãã®éäŒãŸãã¯æéã«å¿
èŠãªè¿æžãè¡ãããã®ååãªçŸéããªãå ŽåããŸãã¯ãã®ãããªããŒãã®åéãŸãã¯æéã«å¿
èŠãªçŸéã調éã§ããªãå ŽåããããŸããããã«ãããŒãã®è²·ãæ»ããŸãã¯ããŒãã®æéæã«çŸéãæ¯æãããšãã§ããèœåã¯ãæ³åŸãèŠå¶åœå±ããŸãã¯ç§ãã¡ã®å°æ¥ã®åµåã®åã決ãã«ãã£ãŠå¶éãããå¯èœæ§ããããŸããç§ãã¡ãããŒããæéå
ã«è²·ãæ»ã矩åãããå Žåã«ããŒããè²·ãæ»ããªãå ŽåããŸãã¯ãã®ãããªå¥çŽã«åŸã£ãŠããŒãã®å°æ¥ã®æéæã«æ¯æãããçŸéãæ¯æããªãå Žåããã®å¥çŽã®ããã©ã«ããæ§æããŸããããŒãã®å¥çŽãŸãã¯åºæ¬çãªå€æŽèªäœã®ããã©ã«ãã¯ãå°æ¥ã®åµåèŠå®ã«é¢ããå¥çŽã®ããã©ã«ããåŒãèµ·ããå¯èœæ§ããããŸãã察å¿ããåµåã®åéãé©çšå¯èœãªéç¥ãŸãã¯ç¶äºæéã®åŸã«å éãããå Žåãç§ãã¡ã¯åµåã®è¿æžãšããŒãã®è²·ãæ»ããŸãã¯æéæã®çŸéæ¯æãã«ååãªè³éãæã£ãŠããªãå ŽåããããŸãã
ããŒãã®æ¡ä»¶ä»æç®æ©èœãããªã¬ãŒããããšãæµåæ§ã«æªåœ±é¿ãäžããå¯èœæ§ããããŸãã
ããŒãã®æ¡ä»¶ä»ãæéæ©èœãããªã¬ãŒãããå ŽåãããŒãã®ä¿æè
ã¯æå®ãããæéäžã«ãã€ã§ãããŒããèªå·±ã®éžæã«åºã¥ããŠæéããæš©å©ãæã¡ãŸãã1人以äžã®ä¿æè
ãããŒããæéããããšãéžæããå Žåãåœç€Ÿãæ®éæ ªåŒä»¥å€ã®çŸéãæ¯æãããšãªãæ®éæ ªåŒã®ã¿ãæäŸããŠæé矩åãæºããããšãéžæããªãéãã
ããïŒå
šã»ã¯ã¿ãŒã§ïŒåæ°ã§ã·ã§ã¢ãææããŠããå ŽåãçŸéæ¯æãã«ããåµåã®æž
ç®ãå¿
èŠã«ãªãããšããããŸããããã¯åœç€Ÿã®æµåæ§ã«æªåœ±é¿ãäžããå¯èœæ§ããããŸãããŸããããŒãä¿æè
ãããŒãã転æããªããŠããé©çšãããäŒèšèŠåã«ãããããŒãã®æªæãååå
šäœãŸãã¯äžéšããé·æè² åµã§ã¯ãªãçæè² åµãšããŠååé¡ããå¿
èŠãããå¯èœæ§ããããããåœç€Ÿã®çŽé転è³æ¬ã倧å¹
ã«æžå°ããããšã«ãªããŸãã
ããŒãã«é¢ããååŒã¯ãåœç€Ÿã®æ®éæ ªåŒã®äŸ¡å€ã«åœ±é¿ããå¯èœæ§ããããŸãã
å
šã»ã¯ã¿ãŒäžã®äžéšããŸãã¯å
šãŠã®ããŒãã®å€æã¯ãåœç€Ÿããã®ãããªããŒããå€æããå Žåã«ãæ®éæ ªåŒã®æ ªäž»ã®æææš©å©çãåžèåããå¯èœæ§ããããŸããããŒãã¯å°æ¥ãç¹å®ã®ç¶æ³äžã§ãã®ææè
ã®éžæã«ããå€æå¯èœã«ãªãå ŽåããããŸããããŒãã®ææè
ãããŒããå€æããããšãéžæããå Žåãåœç€Ÿã¯åœŒãã«å€§éã®æ®éæ ªåŒãæäŸããããšã§å€æ矩åãå±¥è¡ããããšãã§ããŸããããã«ãã£ãŠãæ¢åã®æ ªäž»ã«æ ªåŒã®åžèåãèµ·ããå¯èœæ§ããããŸãã
ããã«ãããŒãã®çºè¡ã«é¢é£ããŠãç§ãã¡ã¯ãã¡ã€ãã³ã·ã£ã«ã€ã³ã¹ãã£ãã¥ãŒã·ã§ã³ãºã®äžéšãšãã£ãããã³ãŒã«å¥çŽãç· çµããŸããã ãã£ãããã³ãŒã«ã¯ãããŒãã®å€æãŸãã¯ç²Ÿç®æã«æ®éæ ªåŒã®æœåšçãªåžéãç·©åããå€ææžã¿ããŒãã®å
æ¬é¡ãè¶
ããçŸéæ¯æããçžæ®ºããããšãäžè¬çã«æåŸ
ãããŠããŸããããã®ç·©åããã³/ãŸãã¯çžæ®ºã¯ãã£ããã«åŸå±ããŸãã
ãã£ãããã»ã³ãŒã«ã®åæãããžã確ç«ããããããªãã·ã§ã³ã®ååŒå
ãŸãã¯ãããã®é¢é£äŒç€Ÿã¯ãæ®éæ ªåŒã«é¢ããŠæ§ã
ãªæŽŸçååŒãè¡ãããŸãã¯ããŒãã®äŸ¡æ Œèšå®ãšåæã«ããŸãã¯ãã®çŽåŸã«æ®éæ ªåŒã®æ ªåŒã賌å
¥ããŸããã
ãªãã·ã§ã³ã®çžææ¹ãŸãã¯ãã®é¢ä¿äŒç€Ÿããåœç€Ÿã®æ®éæ ªåŒã«é¢é£ããããŸããŸãªæŽŸçååŒãè¡ã£ãã解æ¶ãããããããŸãã¯äžå Žåžå Žã§åœç€Ÿã®æ®éæ ªåŒãŸãã¯ãã®ä»ã®èšŒåžã売買ããããšã§ãããŒãã®æºæåã«ãããžããžã·ã§ã³ãå€æŽããå ŽåããããŸãïŒãããŠãåœç€Ÿããã£ãããã³ãŒã«ã®é¢é£éšåãçµäºããããªãã·ã§ã³ãè¡äœ¿ããå ŽåããŸãããŒãã®æéãåœç€Ÿã«ããåºæ¬çãªå€æŽã®è²·æ»ãæ¥ãåéæ¥ããŸãã¯ä»ã®åéæ¥ã«ãããŠãåœç€ŸãããŒããåéããå Žåãè¡äœ¿ããããšãå€ãã§ãïŒããã®ãããªæŽ»åãåœç€Ÿã®æ®éæ ªåŒã®åžå ŽäŸ¡æ Œã®æžå°ãå€åãªã©ãåŒãèµ·ããããšããããŸãã
äžèšã®ååŒãããŒãã®äŸ¡æ ŒãŸãã¯æ®éæ ªåŒã®äŸ¡æ Œã«äžããå¯èœæ§ã®ãã圱é¿ã®æ¹åã倧ããã«ã€ããŠã¯ãåœç€Ÿã¯äœãè¡šæãŸãã¯äºæž¬ããŠããŸãããããã«ãåœç€Ÿã¯ããªãã·ã§ã³å¥çŽã®å¯Ÿæ¥µåŽããããã®ååŒãè¡ããšã¯éãããäžåºŠéå§ãããååŒãäºåãªãäžæ¢ãããå¯èœæ§ãããããšããäœãè¡šæããŠããŸããã
ç§ãã¡ã¯ãã£ãããã³ãŒã«ã«é¢ããååŒçžæãªã¹ã¯ã«ãããããŠããŸãã
ãªãã·ã§ã³ã®çžæå
ã¯ããã¡ã€ãã³ã·ã£ã«ã€ã³ã¹ãã£ãã¥ãŒã·ã§ã³ãºã§ããããããã®ãããããCapped Callsã®äžã§ããã©ã«ããããªã¹ã¯ãè² ã£ãŠããŸããç§ãã¡ã®ãªãã·ã§ã³çžææ¹ã®ã¯ã¬ãžãããªã¹ã¯ãžã®é²åºã¯ãã©ã®ãããªæ
ä¿ã«ããã£ãŠã¯ä¿è·ãããŸãããéå»ã®ã°ããŒãã«ãªçµæžç¶æ³ã¯ãå€ãã®ãã¡ã€ãã³ã·ã£ã«ã€ã³ã¹ãã£ãã¥ãŒã·ã§ã³ã®å®éäžãŸãã¯æ³å®äžã®å€±æãŸãã¯è²¡æ¿çå°é£ãåŒãèµ·ãããŠããŸãããªãã·ã§ã³çžææ¹ãç Žç£æç¶ãã«é¥ã£ãå Žåãç§ãã¡ã¯ãã®ãããªãªãã·ã§ã³çžææ¹ãšã®Capped Callsã®äžã§ã®åœæã®ç§ãã¡ã®é²åºã«çããè«æ±æš©ãæã€åµæš©è
ãšããŠç Žç£æç¶ãã«åå ããããšã«ãªããŸããç§ãã¡ã®é²åºã¯å€ãã®èŠå ã«äŸåããŸãããäžè¬çã«ãç§ãã¡ã®é²åºã®å¢å ã¯ãåžå ŽäŸ¡æ Œããã³æ®éæ ªåŒã®å€åã®äžæã«çžé¢ããã§ããããããã«ããªãã·ã§ã³çžææ¹ãããã©ã«ãããå Žåãç§ãã¡ã¯çŸåšæ³å®ããŠãã以äžã®äžå©ãªçšç圱é¿ãæ®éæ ªåŒã«å¯Ÿããããå€ãã®åžéãåããå¯èœæ§ããããŸãããªãã·ã§ã³çžææ¹ã®è²¡æ¿çå®å
šæ§ãŸãã¯çååã«ã€ããŠãç§ãã¡ã¯äœãä¿èšŒãæäŸããããšã¯ã§ããŸããã
åµåžã»åµå蚌åžã®äŒèšåŠçæ¹æ³ã¯ãããŒããªã©çŸéã§æž
ç®å¯èœãªãã®ã«å¯ŸããŠãåœç€Ÿã®è²¡åè«žè¡šã«é倧ãªåœ±é¿ãäžããå¯èœæ§ããããŸãã
åœç€Ÿã®åžèååŸçŽå©çã«ãããåéæ圢ãå©æ¯è²»çšãããã³æ®éæ ªåŒã®æ ªåŒååã³å ±åãããåžèå調æŽçŽå©çã«åœ±é¿ãäžããå¯èœæ§ããããŸãã
2020幎8æãFASbã¯äŒèšåºæºã®ããã€ããç°¡çŽ åããããã«ãASU 2020-06ãšããŠèšåãããäŒèšåºæºæ¹èšæ¡ãå
¬è¡šããŸããã ASU 2020-06ã¯ã2022幎1æ1æ¥ä»¥éãç§ãã¡ã«é©çšãããŸãã
ASUïŒAccounting Standards UpdateïŒ2020-06ã«åºã¥ããããŒãã¯çºè¡è²»çšãå·®ãåŒããå
æ¬ãšããŠè³ç£è² åµèšç®æžã«è² åµãšããŠåæ ãããŸããçºè¡è²»çšã¯äŒèšäžåµåå²åŒãšããŠæ±ãããããŒãã®æéäžã«å©æ¯è²»çšã«ååŽãããŸãããã®ååŽã«ãããäŒèšäžèªèãããããŒãã®å©æ¯è²»çšã¯ãçŸéã§æ¯æãå©æ¯é¡ãã倧ãããªããããå ±åãããåœæçŽå©çã¯äœããªããããããã¯åœæçŽæ倱ã¯é«ããªãããšãäºæ³ãããŸãã
ãŸããããŒãã«åºã¥ãæ®éæ ªåŒã®æ ªåŒã¯ãASU 2020-06ã«åŸã£ãŠããæç®ããã°ãæ³ã䜿çšããŠåžèååŸã®1æ ªãããå©çã«åæ ãããŸãããã®æ¹æ³ã«åºã¥ããåžèååŸã®1æ ªãããå©çã¯äžè¬ã«èšç®ãããŸãã
å ±åæåã«ããã¹ãŠã®åµåžãåžèåããããšãªãæ®éæ ªåŒã«æç®ãããå Žåãé€å€çãªãã®ã§ã¯ãªãéããæç®æ³ãé©çšãããŸããæç®ãé©çšãããå Žåãä»åŸå©çãäžããå¯èœæ§ãããå Žåãåœç€Ÿã®åžèæ ªäŸ¡åççã¯å ±åããããã®ããäœããªãå ŽåããããŸããå°æ¥ãäŒèšåºæºãå€æŽãããåžèæ ªäŸ¡åççãäžå©ã«åœ±é¿ãåããå¯èœæ§ããããŸãã
ããã«ãåµåžã®æéæ¡ä»¶ã®ãããããæºããããå Žåãåœç€Ÿã¯ãå®éã«åµåžãæéããªããŠããåœç€Ÿã®å ±åãããé転è³æ¬ãå®è³ªçã«æžå°ãããå¯èœæ§ãããçŸåšã®åµåãšããŠãåµåžã®è² åµäŸ¡å€ãååé¡ããããšããé©çšäŒèšåºæºã«åŸã£ãŠå¿
èŠã«ãªãå ŽåããããŸãããã®ååé¡ã¯ãåµåžã®ä¿æè
ãå®éã«åµåžãæéããªããŠããå¿
èŠã«ãªãå Žåããããåœç€Ÿã®å ±åãããé転è³æ¬ãå®è³ªçã«æžå°ãããããšããããŸãã
é
ç®5ããã®ä»ã®æ
å ±ã
10b5-1æ¡çš ååŒèšç» 圹å¡ããã³åç· åœ¹ã®æ¡çš
2024幎6æ30æ¥ã«çµäºããåœç€Ÿã®è²¡åååæäžãåœç€Ÿã®åœ¹å¡ïŒãååŒæ³ã«åºã¥ãã«ãŒã«16a-1ïŒfïŒã«å®çŸ©ããããã®ïŒããã³åç· åœ¹ã®äžéšã¯ãéå
¬éæ
å ±ã«åºã¥ãæ䟡蚌åžååŒã®è²¬ä»»ã«å¯Ÿããè¯å®çãªé²åŸ¡çãšããŠRule 10b5-1ïŒcïŒäžã«æå®ãããæ¡ä»¶ãæºããããšãæå³ããæ䟡蚌åžã®å£²è²·ã®ããã«ãå¥çŽãæ瀺ãŸãã¯æžé¢ã«ããèšç»ã«å
¥ããŸããããããã®å¥çŽãæ瀺ãããã³æžé¢ã«ããèšç»ããRule 10b5-1ååŒèšç»ããšåŒã³ãããããããRule 10b5-1ååŒèšç»ããšåŒã³ãŸãããããã®Rule 10b5-1ååŒèšç»ã®éèŠãªæ¡ä»¶ã説æããŸãã 以äžã
ã±ãã³ã»ãã£ãããžã§ã©ã«ã ãPh.D.ã Executive Vice President, Chief Scientific Officer
2024幎4æ1æ¥ãYield10 Bioscience, Inc. ã¯ã2023幎12æ31æ¥ã«çµäºããååæããã³è²¡æ¿å¹ŽåºŠã®è²¡åçµæãçºè¡šãããã¬ã¹ãªãªãŒã¹ãçºè¡ããŸããããã¬ã¹ãªãªãŒã¹ã®ã³ããŒã¯ã Exhiebition99.1ãšããŠæ·»ä»ãããŠããŸãããããã®æ
å ±ãExhiebition99.1ãå«ããæ¬æžé¡ã«èšèŒããããã®ã¯ã1934幎蚌åžååŒæ³18æ¡ã®ç®çã§ããã¡ã€ã«ããããã®ããšèŠãªããããã®ã§ã¯ãªãã1933幎蚌åžæ³ãŸãã¯èšŒåžååŒæ³ã®ããããã«åºã¥ãç³è«æžã«åç
§ãããå Žåãé€ããåç
§ããããã®ãšã¯æ瀺çã«æå®ãããŠããªããã°ãªããŸããã2024幎5æ10æ¥ åœç€Ÿã®ãšã°ãŒã¯ãã£ããã€ã¹ãã¬ãžãã³ããããŒããµã€ãšã³ãã£ãã£ãã¯ãªãã£ãµãŒã®ã±ãã³ã»ãã£ããžã§ã©ã«ãå士ã¯ãRule 10b5-1ååŒèšç»ã«åå ããŸããã ãã®ååŒèšç»ã§ã¯ããã£ãããžã§ã©ã«ãå士ããã®ãããŒã«ãŒãéããŠãæ ªåŒåå²ãæ ªåŒçµ±åãæ ªåŒé
åœãã®ä»åœç€Ÿã®æ®éæ ªåŒã«å¯Ÿããé¡äŒŒããå€æŽã«å¿ãããèªå·±è³æ¬å ±é
¬ãšããŠãã£ãããžã§ã©ã«ãæ°ã«æäžãããè³ã®æ±ºæžã«ããåãåã£ãåœç€Ÿã®æ®éæ ªåŒãåèšããŠå£²åŽã§ããããã«ãªã£ãŠããŸãã æ¬ååŒèšç»ã«ãããæ ªåŒå£²åŽã¯ã2024幎8æ11æ¥ãã2025幎5æ10æ¥ãŸã§ã®éã«ã®ã¿è¡ãããããšãã§ããŸãã åœç€Ÿã®æ®éæ ªåŒ50,634æ ªãå«ããã¹ãŠã®æ ªåŒã売åŽãããæããã£ãããžã§ã©ã«ãå士ãŸãã¯ãããŒã«ãŒã«ããååŒèšç»ã®å²ãåœãŠã®ãããããçµäºããããšããååŒèšç»ãã®ãã®ãå®ããæ¡ä»¶ã«åŸã£ãŠãããçµäºããããšãé€ããæ¬ååŒèšç»ã¯2025幎5æ10æ¥ã«çµäºããäºå®ã§ãã æ ªåŒåå²ãæ ªåŒçµ±åãæ ªåŒé
åœãã®ä»åœç€Ÿã®æ®éæ ªåŒã«å¯Ÿããé¡äŒŒããå€æŽã«å¿ããŠèª¿æŽãããŸãã 2025幎5æ10æ¥ çµäºæ¥ã¯2025幎5æ10æ¥ã§ããããã£ãããžã§ã©ã«ãå士ãŸãã¯ãããŒã«ãŒã«ããååŒèšç»ã®å²ãåœãŠã®ãããããçµäºããããšããååŒèšç»ãã®ãã®ãå®ããæ¡ä»¶ã«åŸã£ãŠãããçµäºããããšãé€ãããã以åã«ãã€ã§ãçµäºããå¯èœæ§ããããŸããå
šã»ã¯ã¿ãŒã«ããã売ã泚æãæåŸ
ãããè¡çºã¯ãååŒã®éæ³æäœã«åœããå¯èœæ§ããããŸãã
ããã¹ã»ã¢ãŠãžã§ã ãM.D.ãåç· åœ¹
2024幎4æ1æ¥ãYield10 Bioscience, Inc. ã¯ã2023幎12æ31æ¥ã«çµäºããååæããã³è²¡æ¿å¹ŽåºŠã®è²¡åçµæãçºè¡šãããã¬ã¹ãªãªãŒã¹ãçºè¡ããŸããããã¬ã¹ãªãªãŒã¹ã®ã³ããŒã¯ã Exhiebition99.1ãšããŠæ·»ä»ãããŠããŸãããããã®æ
å ±ãExhiebition99.1ãå«ããæ¬æžé¡ã«èšèŒããããã®ã¯ã1934幎蚌åžååŒæ³18æ¡ã®ç®çã§ããã¡ã€ã«ããããã®ããšèŠãªããããã®ã§ã¯ãªãã1933幎蚌åžæ³ãŸãã¯èšŒåžååŒæ³ã®ããããã«åºã¥ãç³è«æžã«åç
§ãããå Žåãé€ããåç
§ããããã®ãšã¯æ瀺çã«æå®ãããŠããªããã°ãªããŸããã2024幎5æ3æ¥ åœç€Ÿåç· åœ¹äŒã®ã¡ã³ããŒã§ããDennis A. Ausielloå士ã¯ãã«ãŒã«10b5-1ååŒèšç»ã«åå ããŸããã ãã®èšç»ã§ã¯ã仲ä»æ¥è
ãéããŠãAusielloå士ã¯ãåœç€Ÿã®æ®éæ ªåŒã売åŽããããšãã§ããŸãã ãã®èšç»ã§ã¯ã調æŽãããæ ªåŒåå²ãæ ªåŒäœµåãæ ªåŒé
åœãã®ä»ã®åæ§ã®åœç€Ÿã®æ®éæ ªåŒã«å¯Ÿããå€æŽãå å³ããäžã§ãAusielloå士ã«ãªãã·ã§ã³ãšããŠä»äžãããåœç€Ÿã®æ®éæ ªåŒã®äžéšãæ倧ã§å£²åŽããããšãã§ããŸãã 20,250 ãã®èšç»ã®äžã§ã¯ã2024幎8æ5æ¥ãã2025幎5æ20æ¥ãŸã§ã®æéäžãåœç€Ÿã®æ®éæ ªåŒã®åžå ŽäŸ¡æ Œãç¹å®ã®äŸ¡æ Œãäžåã£ãŠããå Žåã«éããæ ªåŒã売åŽã§ããŸãã 2025幎5æ20æ¥ã èšç»ã¯2025幎5æ20æ¥ã«çµäºããäºå®ã§ãããAusielloå士ãŸãã¯ä»²ä»æ¥è
ã«ããèšç»çµäºæã«èšç»å¯Ÿè±¡ã®å
šæ ªåŒã売åŽãããå ŽåããŸãã¯èšç»ã§å®ããããä»ã®äºæ
ãããå Žåã¯ãæ©æã«çµäºããããšãã§ããŸãã
2025幎ã®å¹Žæ¬¡ç·äŒã«å¯Ÿããæ ªäž»ææ¡
åŒç€Ÿã¯2024å¹Žæ ªäž»ç·äŒã®éç¥ããã³ãããã·å£°ææžïŒã¹ã±ãžã¥ãŒã«14AïŒã2024幎4æ1æ¥ã«èšŒåžååŒå§å¡äŒã«æåºããŸãããããè¿œå æ
å ±ããã³ãã®ä»ã®äºé
ãŒæ ªäž»ææ¡ããšããã»ã¯ã·ã§ã³ã«ãããŠãæ ªäž»ã2025å¹Žæ ªäž»ç·äŒã®ãããã·å£°ææžïŒ2025 Proxy StatementïŒã«å¯èœæ§ãå«ããããã«ãããã¯2025å¹Žæ ªäž»ç·äŒã§æ ªäž»ãããžãã¹ãæåºããå Žåã«ãåŒç€Ÿã«éç¥ãè¡ãå¿
èŠãããæéã«é¢ãã誀åããããŸãããæ£ããã»ã¯ã·ã§ã³ã¯ä»¥äžã®éãã§ãã
æ ªäž»ææ¡
2025å¹Žæ ªäž»ç·äŒã®è°æ±ºè³æã«æ²èŒãããããã«ã¯ãæ ªäž»ææ¡ã¯2024幎12æ2æ¥ãŸã§ã«ãåœç€Ÿã®æ¬ç€Ÿãã«ããªããžãããµãã¥ãŒã»ããå·ããã³ãªã»Aã»ãã«ãã¢åºå ŽããŠã§ã¹ãã»ã±ã³ãã«ã»ã¹ããªãŒã675çªå°å®ã«å°çããªããã°ãªããŸãããæè°è
ã«ã¯ãåœç€Ÿã®äŒæ¥ç§æžå®ã«ãè¿ä¿¡ã䌎ãå
¬èªéµäŸ¿ã§ææ¡ãæåºããããšãææ¡ããŸããå ããŠãç§ãã¡ã®èŠçŽã§ã¯ãæ ªäž»ãåç· åœ¹äŒã®æ ªäž»éžåºã«é¢ããå
é²éç¥åã³ãããã·ã¹ããŒãã¡ã³ãã«å«ãŸããªãæ ªäž»æè°ãé瀺ããããã®å
é²éç¥ãåãåãå¿
èŠããããŸããå¿
èŠãªéç¥ã¯ã2025幎2æ15æ¥ïŒ2024å¹Žæ ªäž»ç·äŒã®1åšå¹Žåã®90æ¥ïŒãŸã§ã«ãäŒæ¥ç§æžãåœç€Ÿæ¬ç€Ÿã«æžé¢ã§åé ããå¿
èŠãããã2025幎1æ16æ¥ïŒ2024å¹Žæ ªäž»ç·äŒã®1åšå¹Žåã®120æ¥ïŒãããåã«å°çããªããã°ãªããŸããããã ãã2025å¹Žæ ªäž»ç·äŒã2024å¹Žæ ªäž»ç·äŒã®1åšå¹Žæ¥ãã20æ¥ä»¥äžååãããŸãã¯60æ¥ä»¥äžå»¶æãããå Žåã¯ãéç¥ããã®å¹Žã®äŒè°ã®120æ¥åãããæ©ãåä¿¡ãããªãããã«ããïŒ1ïŒãã®å¹Žã®æ ªäž»ç·äŒã®90æ¥åãïŒ2ïŒãã®å¹Žã®æ ªäž»ç·äŒã®æ¥ä»ã®éç¥ãéä¿¡ãããæ¥ä»ã®10æ¥ä»¥å
ã®ããããåŸã«éäŒããããã«éç¥ãåä¿¡ããå¿
èŠããããŸãã
ç§ãã¡ã®èŠçŽã¯ãæ ªäž»ã2025å¹Žæ ªäž»ç·äŒã§æ£ããæåºããããã«å¿
èŠãªå
容ã«é¢ããèŠä»¶ãã€ãŸãåç· åœ¹äŒéžæã«åããæ ªäž»ã®æšèŠãå«ããéç¥ã®å
容ãæå®ããŠããŸããåç· åœ¹äŒã«ãã£ãŠæ±ãããã代çæ祚暩ã¯ããã®æš©éã®è¡äœ¿ã«é¢ããSECã®èŠåã«åŸãéãããããã®ææ¡ã«é¢ããè£éæ祚暩ãäžããŸãã
æ®éçãªå§ä»»ç¶ã«ãŒã«ã«æºæ ããããã«ãååŒææ³ã®èŠå14a-19ã«åŸã£ãŠå¿
èŠãšãããæ
å ±ãèšèŒããéç¥ã2025幎3æ17æ¥ãŸã§ã«æäŸããå¿
èŠããããäŒæ¥ã®åè£è
ã§ã¯ãªãåç· åœ¹åè£ã®ããã«å§ä»»ç¶ãåéããæ ªäž»ã¯ãã®æšéç¥ããå¿
èŠããããŸãã
é
ç® 6. å±ç€ºç©
10.1ïŒ**
10.2ïŒ**
10.3ïŒ**
10.4ïŒ**
31.1ïŒ 31.2ïŒ 32.1ïŒ+ 32.2ïŒ+ 101.SCH ã€ã³ã©ã€ã³XBRLã¿ã¯ãœããæ¡åŒµã¹ããŒãããã¥ã¡ã³ã 101.CAL ã€ã³ã©ã€ã³XBRLã¿ã¯ãœããæ¡åŒµèšç®ãªã³ã¯ããŒã¹ããã¥ã¡ã³ã 101.LAB ã€ã³ã©ã€ã³XBRLã¿ã¯ãœããæ¡åŒµã©ãã«ãªã³ã¯ããŒã¹ããã¥ã¡ã³ã 101.PRE ã€ã³ã©ã€ã³XBRLã¿ã¯ãœããæ¡åŒµãã¬ãŒã³ããŒã·ã§ã³ãªã³ã¯ããŒã¹ããã¥ã¡ã³ã 101.DEF ã€ã³ã©ã€ã³XBRLã¿ã¯ãœããæ¡åŒµå®çŸ©ãªã³ã¯ããŒã¹ããã¥ã¡ã³ã 104 ã«ããŒããŒãžã€ã³ã¿ã©ã¯ãã£ãããŒã¿ãã¡ã€ã«ïŒExhibit 101ã«å«ãŸããé©çšå¯èœãªã¿ã¯ãœãããŒæ¡åŒµæ
å ±ãã€ã³ã©ã€ã³XBRLãšããŠãã©ãŒããããããŠããïŒ
# ããã«æåºãããã **
管çå¥çŽãè£åãã©ã³ãŸãã¯å¥çŽã
+ ãã®èªèšŒã¯ãæ¹æ£ããã1934幎蚌åžååŒæ³ïŒExchange ActïŒç¬¬18æ¡ã®ç®çã«ãããŠãæåºãããããšã¿ãªããããããã®ã»ã¯ã·ã§ã³ã®è²¬ä»»ãè² ããã®ã§ã¯ãããŸããããã®èªèšŒã¯ãæ¹æ£ããã1933幎蚌åžæ³ïŒSecurities ActïŒãŸãã¯Exchange Actã®ããããã®å ±åæžã«ãæ瀺çã«ãã®å ±åæžã«åã蟌ãŸããå Žåãé€ããŠãåç
§ããããšã¯ãããŸããã
眲å
蚌åžååŒæ³ïŒ1934幎ïŒã®èŠä»¶ã«åºã¥ããæ¬å ±åæžã®çœ²åã«ã€ããŠãç»é²è
ã¯äžèšã«ä»£ç人ãä»»åœããæ¬å ±åæžã«çœ²åãããã
ã¢ã«ãã€ã©ã ã»ãã¡ãŒãã·ã¥ãŒãã£ã«ã«ãºæ ªåŒäŒç€Ÿ æ¥ä»ïŒ2024幎8æ1æ¥ /s/ ã€ãã³ãã»Lã»ã°ãªãŒã³ã¹ããªãŒããMBChBãMBA ã€ãã³ãã»Lã»ã°ãªãŒã³ã¹ããªãŒããMBChBãMBA æé«çµå¶è²¬ä»»è
(æé«å·è¡åœ¹å¡) æ¥ä»ïŒ2024幎8æ1æ¥ /s/ ãžã§ããªãŒã»Vã»ããŒã«ãã³ ãžã§ããªãŒã»Vã»ããŒã«ãã³ å·è¡å¯ç€Ÿé·ãæé«è²¡å責任è
(æé«è²¡åäŒèšè²¬ä»»è
)